



# Passion for Life

2024 Annual Report

At some point in life, everyone needs to seek care. We have a long tradition of creating innovations that improve people's quality of life – and save lives. It is one of the most important jobs in the world.

**About the report**

Getinge AB (publ)'s formal Annual Report and consolidated financial statements comprise the section Financial statements on pages 55–126, except for the Remuneration Report on pages 64–67, and have been audited by the company's auditor. The Corporate Governance Report comprises the section "Corporate Governance" on 32–54 and has been examined by the company's auditor. Sustainability information is integrated in the section "Strategy" on pages 12–31 and in the Sustainability Report on pages 127–168. The statutory Sustainability Report is defined on page 128. The auditor's report on the limited assurance of Getinge's Sustainability Report and statement on the statutory Sustainability Report is presented on page 168. Getinge has used artificial intelligence (AI) as a tool to assist in text production in parts of this Annual Report. Final review and approval is carried out by company employees to ensure accuracy and relevance.

# Contents

**Introduction | 1–11**

- 3 This is Getinge
- 4–5 2024 in brief
- 6–7 Words from the CEO
- 8 Global value creation
- 9 Getinge as an investment
- 10–11 External trends

**Strategy | 12–31**

- 13–15 Getinge's strategy and vision beyond 2030
- 16 Targets 2024–2028
- 17 Growing market for Getinge products
- 18–19 Business areas
- 20–23 Acute Care Therapies
- 24–27 Life Science
- 28–31 Surgical Workflows

**Corporate Governance Report | 32–54**

- 34–48 Corporate governance structure
- 39–41 Board of Directors
- 42–44 President & CEO and Getinge Executive Team
- 45–46 Building blocks in the Getinge corporate governance model
- 47–52 Assurance framework, risks and risk management
- 53–54 Internal control over the financial reporting
- 54 Auditor's report on the Corporate Governance Report

**Financial statements | 55–126**

- 56–60 Administration Report
- 61–63 Guidelines for remuneration
- 64–67 Remuneration Report 2024
- 68 Proposed appropriation of profit
- 69–73 Group financial statements
- 74–111 Group notes
- 112–115 Parent Company financial statements
- 116–122 Parent Company notes
- 123–126 Auditor's report

**Sustainability Report | 127–168**

- 128 About the Report
- 129 Sustainability at Getinge
- 130–134 Materiality and stakeholders
- 135–137 Sustainability governance and management
- 138–149 Environment
- 150–159 Social responsibility
- 160–161 Governance
- 162–163 Reporting principles
- 164–167 GRI content index
- 168 Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

**Other information | 169–185**

- 170–171 The Getinge share
- 172–175 Multi-year overview
- 176–178 Reconciliation of alternative performance measures
- 179–181 Group companies
- 182–183 Definitions
- 184 Annual General Meeting and Nomination Committee
- 184 Financial information
- 185 Reading guide and distribution policy
- 185 Contact

**Introduction**

**This is Getinge**

2024 in brief

Words from the CEO

Global value creation

Getinge as an investment

External trends

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

# This is Getinge

As the world's population grows and ages, and the number of people with multiple illnesses increases, so do the challenges in healthcare. Lifestyle diseases, such as cardiovascular diseases remain among the leading causes of death globally, requiring more effective and comprehensive solutions.

At Getinge, we work globally with a shared belief that all people and societies should have access to the best possible care, with as little impact on the environment as possible.

By offering hospitals and life science institutions advanced technological solutions and expertise, we not only contribute to improved clinical outcomes, but also more efficient workflows and reduced resource utilization.

Ultimately, our work involves saving and improving lives, by making life-saving technology accessible for more people.

**~12,000**

Employees

**~30,000**

Customers

**34.8** billion

Net sales 2024

**>135**

Sales to no. of countries



**Introduction**

This is Getinge

**2024 in brief**

Words from the CEO

Global value creation

Getinge as an investment

External trends

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

# 2024 in brief

|   |   |  |  |
|---|---|--|--|
| <p><b>Q1</b></p>  |   | <p><b>Q2</b></p>   |  |
| <p>JAN 9</p> <p><b>Maquet Ezea</b> launched – an easy-to-use and robust surgical light</p>  | <p>JAN 11</p> <p><b>The Heart Surgeon's Cookbook</b> – a world-first collaboration to help heart surgeons improve their dexterity</p>  | <p>APR 11</p> <p>Our covered stent system <b>Advanta V12</b> receives <b>EU MDR approval</b> for use for patients with renal artery stenosis and/or aortoiliac occlusive disease (AIOD)</p>        | <p>APR 25</p> <p>With <b>compact design and sustainable performance</b> our cGMP washer redefines cleanroom efficiency</p>  |
| <p>FEB 6</p> <p>Servo ventilators get a <b>virtual twin, TwinView</b></p>  | <p>MAR 1</p> <p><b>TÜV SÜD</b> temporarily suspends the CE certificate for <b>Cardiosave</b></p>  | <p>MAR 7</p> <p><b>Aquadis Index</b> is launched – an intuitive high-performance multi-chamber washer-disinfector</p>  | <p>MAY 21</p> <p>We introduce <b>DPTE-BetaBag®</b> with material from renewable sources</p>  |
| <p>MAR 21</p> <p><b>120 years</b><br/>We celebrate 120 years in medtech</p>   | <p>MAR 7</p> <p>We take a <b>giant leap forward in cardiovascular surgery</b> with 510(k) clearance for <b>Vasoview Hemopro 3</b></p>  | <p>MAR 8</p> <p><b>FDA sends a letter</b> to US healthcare providers about <b>Cardiosave, Cardiohelp</b> and <b>HLS sets</b></p>   | <p>MAY 28</p> <p>Our new lab sterilizer <b>Lancer LSS</b></p>    |
| <p>MAR 28</p> <p><b>We donate</b> life-saving medical equipment to Ukraine</p>  | <p>MAR 31</p> <p>Agneta Palmér appointed <b>new CFO</b></p>    | <p>MAY 14</p> <p><b>12%</b><br/>Getinge's financial targets 2024–2028: Adjusted EPS growth of above 12% on average</p>   | <p>MAY 28</p> <p>Our new lab sterilizer <b>Lancer LSS</b></p>  |
| <p>MAR 28</p> <p>We extend the bioreactor portfolio with <b>SUPR</b> – a <b>larger single-use systems</b></p>   | <p>MAR 28</p> <p>We extend the bioreactor portfolio with <b>SUPR</b> – a <b>larger single-use systems</b></p>   | <p>JUN 3</p> <p>We introduce <b>Poladus 150</b> – the latest innovation in low-temperature sterilization</p>  | <p>JUNE 12</p> <p>We receive FDA 510(k) <b>clearance from the US</b> for <b>Talis + ACG Clinical Decision Support software</b></p>   |

**Introduction**

- This is Getinge
- 2024 in brief**
- Words from the CEO
- Global value creation
- Getinge as an investment
- External trends

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**


**Other information**

# 2024 in brief

**Q3**

**JUL 2**

We launch **Pulsiocare** – the next generation in hemodynamic monitoring



**AUG 22**

We acquire **Paragonix Technologies**, a leading organ transport products and services company in the US

**SEP 1**

We make a provision of **SEK 482 M** related to Brazilian investigation

**SEP 25**

Our **CE certificate** for ECLS consumables is reinstated

**JUL 5**

We extend and elevate our partnership with **Universeum**



**Q4**

**OCT 9**

**FleetView** is introduced – a web application that elevates service with connected devices

**DEC 19**

We partner with **908 Devices** to enhance bioreactor capabilities for continuous monitoring of key cell culture parameters

**OCT 28**

Paragonix Technologies receives FDA 510(k) clearance for **KidneyVault** portable renal perfusion system

**NOV 7**

Alexandra Holland appointed as **EVP Brand & Communications**



**DEC 5**

We open our new **Experience Center** in Mumbai, India



**Introduction**

This is Getinge

2024 in brief

**Words from the CEO**

Global value creation

Getinge as an investment

External trends

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

**Interview with Mattias Perjos, President and CEO of Getinge**

# “A record-breaking year for Getinge”

2024 was a record-breaking year with strong growth, more satisfied customers and successful product launches.

**What are Getinge’s greatest achievements this year, and what has been the key to them?**

In terms of sales, 2024 was a record-breaking year for Getinge. We are continuing to grow, have more satisfied customers, our acquisitions have performed strongly and we have launched in-demand products in all business areas. This was possible due to a long-term focus on innovation, a customer-first approach and strong collaboration.

**What challenges have you faced, and what have you learned from them?**

During the year, we worked very intensely on continuing to improve quality, which we have regularly provided information about. These experiences have further strengthened our focus on continuous improvement and on the need to adapt quickly to meet both regulatory requirements and market expectations.

At the same time, we see the great appreciation showed by many customers for our products and employees, which can be seen in, for example, higher sales of these products. It has been impressive to see how our customers and employees have worked together to solve these challenges.

**What trends are affecting medtech right now, and how are you preparing?**

An ageing population, a worldwide lack of resources and economic pressures are increasing the need for cost-effective and sustainable care. We are tackling these challenges by working closely with customers, offering solutions that improve both patient care flows



**Introduction**

This is Getinge

2024 in brief

**Words from the CEO**

Global value creation

Getinge as an investment

External trends

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

and the work environment. Our digital solutions, such as Servo TwinView, enable healthcare professionals to monitor ventilators remotely and reduce disruption to critically ill patients. With T-DOC, hospitals can automate the traceability and utilization of surgical instruments, saving time and reducing the risk of manual errors in central sterile supply departments and operating rooms. Digitalization and personalized medicines present considerable opportunities but require innovative technologies and sustainable processes, something that we are working on throughout our value chain.

**How are you leveraging innovation to strengthen your position and create long-term value?**

Innovation is a central part of our DNA and essential for remaining relevant to our customers. We are continuously developing new therapies and solutions and improving existing products to meet future healthcare needs and ensure long-term sustainability. Our strategy extends beyond 2030, and means that we will help double the number of lives saved, enable at least one additional surgery per OR per day, and ensure that medicines for complex diseases reach patients 25% faster. This requires advanced development of technologies, business models and digital solutions, which create higher customer value and provide us with competitive advantages. One example is our Torin OR management solution that uses AI optimization to help hospitals maximize their capacity through better scheduling and resource utilization. By automating and streamlining planning, more surgeries can be performed, leading to shorter waiting times and better access to care.

We are also open to making supplementary acquisitions that will enable us to make even more of a difference.

**How is Getinge contributing to a more sustainable future?**

Sustainability is the core of our vision for a future of better and more accessible care. We are working actively to reduce our environmental impact through energy efficiency and sustainable choices of materials, while helping to strengthen society by supporting healthcare providers and increasing access to life-saving technologies globally. Our strategy focuses on sustainable

innovation for better health and responsible business conduct, with engaged co-workers as a foundation.

**What are the main priorities moving forward?**

We are continuing to focus on creating value for our customers in their important work to deliver better healthcare to more patients. A critical part of this is that we must resolve our quality challenges. In addition, we will strengthen our leading position in acute cardiopulmonary support, organ transplantation and cardiovascular surgery through continuous product development, clinical partnerships and strategic investments. We are also strengthening our position in the OR and central sterile supply departments by digitizing and optimizing workflows, increasing productivity and minimizing the risk of healthcare-acquired infections. At the same time, we are developing our capacity to support and collaborate with customers working on the vital issue of finding solutions to complex and currently incurable diseases.

**What message do you want to send shareholders and other stakeholders about the future of Getinge?**

We stand strong for the future with a clear direction toward sustainability, innovation and global growth. Our long-standing customer relationships and leading positions mean we are well equipped to meet the healthcare needs of the future.

Despite geopolitical uncertainty and increased protectionism, our industry has historically been resilient. Trade barriers are impacting the entire market but ultimately pose the greatest risks for patients and tax payers, a realization I hope policymakers will also arrive at. At the same time, there is a constant growing need for care, and we have already shown in 2024 that we have a strong position in our prioritized categories. With the continued willingness of hospitals and pharmaceutical companies to invest, and our strong market presence, we see many opportunities for continuing to create long-term value and make life-saving technology available for more people.

“With the continued willingness of hospitals and pharmaceutical companies to invest, and our strong market presence, we see many opportunities for continuing to create long-term value and make life-saving technology available to more people.”

**Introduction**

- This is Getinge
- 2024 in brief
- Words from the CEO
- Global value creation**
- Getinge as an investment
- External trends

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

# We exist to make life-saving technology accessible for more people

At Getinge we strive to contribute to a more sustainable healthcare with optimized use of resources, improved medical results and reduced waiting times. Our ambition is for everyone to have access to the best possible care.

**WE USE RESOURCES...**



Resources & suppliers

Depending on the product, we either purchase raw materials (mainly metals and minerals), processed materials (such as plastics and electronics) or parts of products. When developing our supplier base, we evaluate a wide range of factors including impacts, opportunities and risks.

**Environmental impact**

Carbon emissions arise throughout the life cycle of our products, from raw materials and sourcing to production and use. Energy consumption, water use, material extraction, use, and waste also account for negative impacts to the environment in our value chain.

**TO CONDUCT OUR BUSINESS...**



Own operations

For our business to evolve and to achieve our financial and sustainability targets, we depend on the expertise and diverse perspectives provided by our ~12,000 employees worldwide. By ensuring employee engagement and an inclusive culture, we can unlock their expertise and dedication to continue delivering the products that lead to improved outcomes and resource efficiency within the healthcare sector.

**AND CREATE VALUE FOR CUSTOMERS AND SOCIETY**



Customers & society

**Healthcare**

By supplying products and solutions to hospitals and life science institutions in over 135 countries, we help improve efficiency and reduce the use of resources, which benefits customers and patients.

**Patient**

We work actively to increase the number of lives saved, the number of operations performed per day per hospital and to reduce the time it takes to bring new medicines to market.

**Society**

Our products and service offerings are part of the healthcare sector's important mission to save and improve people's lives, which benefits both patients and society as a whole.

As a large global company, we also create jobs and develop skills of many employees and professionals. We comply with laws and regulations in the countries where we operate and tax income from our operations helps build and develop societies.

**Employees**

Engaged employees are critical to our company's success. This means that we work to create the best possible conditions for coworkers to thrive and reach their highest potential. We offer skills development and have a global approach to family leave, which set out a minimum standard offering for paid parental and caregiver leave.

**For owners and lenders**

It is important for us that the capital contributed by owners and lenders leads to a reasonable return on investment in relation to risk. With good potential for growth and long, close customer relationships, we create value for our owners and lenders.

**Environment**

We work actively to reduce negative environmental impact by setting ambitious targets, implementing improvement activities and collaborating across the value chain with suppliers, customers and other stakeholders in the pharmaceutical and healthcare industry.

**Introduction**

This is Getinge

2024 in brief

Words from the CEO

Global value creation

**Getinge as an investment**

External trends

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

# Getinge as an investment

**3,837%**

Total return from the initial public offering in May 1993

**2,885%**

The total return on the Stockholm Stock Exchange over the same period

**11.6%**

Return on invested capital (ROIC\*)

**MARKET LEADING POSITION AND CLOSE CUSTOMER RELATIONSHIPS**

Since the company was founded 120 years ago, we have built up close customer relationships and developed innovative healthcare technologies. This has resulted in leading positions in most product segments, a high level of customer loyalty and strong competitiveness.

**GROWTH POTENTIAL IN A STABLE MARKET**

Demographic factors indicate a rising need for effective healthcare worldwide. Our growth strategy focuses on the product areas that have favorable prospects and includes both organic and acquired growth. The healthcare market is relatively unaffected by economic fluctuations, which provides stability for underlying growth.

**FOCUS ON IMPROVEMENTS AND SUSTAINABILITY**

Continuous improvement activities are being made to increase customer value, sales, margins and cash flow. Sustainability has top priority, focusing on quality, business conduct, engaged employees and sustainable innovations.

**LONG-TERM OWNERSHIP AND VALUE CREATION**

We have a stable shareholder base with a long-term perspective, with the largest shareholder holding more than 50% of the votes. This lends stability and creates the conditions for continuous value creation for our shareholders, customers, patients and society as a whole.

The total return includes both price growth and dividends. An investor who bought shares for SEK 10,000 in connection with the 1993 listing and reinvested the dividends had increased the value of their investment to SEK 393,700 by the end of the year.

It is important for us that the capital contributed by owners and lenders leads to a return that is higher than the cost of the same capital (e.g. interest expense for loans). Our return for 2024 was higher than the cost of capital, which means that we generate added value for our owners and increase our scope for action thanks to a financially stronger position.

\* Rolling 12 months adjusted EBIT/invested capital. Invested capital is defined as Equity + Net debt (excluding pension commitments) and is calculated as (opening balance + closing balance of operating capital) divided by 2.



**Introduction**

- This is Getinge
- 2024 in brief
- Words from the CEO
- Global value creation
- Getinge as an investment

**External trends**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

**External trends**

# Agility in a changing world

We operate globally, and although the conditions between markets may differ, many of the external influences are the same.



**Market requirements**

**MORE COST EFFICIENT HEALTHCARE**

The need for accessible and sustainable healthcare is increasing with a growing global population and longer life expectancy. Technological and digital innovations are crucial for meeting demand, yet can also be costly. Global challenges such as conflict, supply chain problems and inflation are putting further pressure on funding for the healthcare sector.

**ATTRACT AND RETAIN SKILLED HEALTHCARE STAFF**

Staff shortages in the healthcare sector are growing and burnout is a challenge. Attracting and retaining skilled staff requires efficient workflows and a sustainable working environment.

**Our solutions**

We are addressing these needs in close cooperation with our customers to create effective care solutions. We support purchasing organizations and hospitals by offering attractive procurement terms, larger purchase volumes and customized financial solutions. This facilitates both improved quality of care and lower costs – without compromising patient safety. By also promoting out-of-hospital care solutions, such as ambulatory care centers, we are helping the healthcare system to become more efficient and increase accessibility.

Our Hospital Transformational Partnerships and Digital Health Solutions initiatives offer verified solutions to increase employee productivity and job satisfaction. Our innovative products and services relieve the burden on healthcare professionals, contributing to a sustainable work environment and reducing the risk of burnout. We aim to create conditions for healthcare professionals to do their job safely and effectively.

**Introduction**

- This is Getinge
- 2024 in brief
- Words from the CEO
- Global value creation
- Getinge as an investment

**External trends**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**



**DIGITALIZING HEALTHCARE**

Digitalization is revolutionizing healthcare with technologies such as telecare, AI, 3D printing and robotics. These innovations are paving the way for new business models and personalized care solutions that make healthcare more efficient and accessible.

We are developing digital ecosystems for healthcare of the future together with partners, focusing on integrated solutions for advanced care. Examples of this are our systems for controlling and streamlining hospital flows of equipment and patients, as well as connected products that enable staff to monitor patient vital signs remotely.



**NEW CUSTOMIZED DRUGS**

Biopharmaceutical innovation is rapidly progressing towards personalized medicines, which requires specialized manufacturing processes that can be adapted to the unique needs of patients.

We are contributing to this development through solutions that ensure biopharmaceutical processes and prevent contamination. Our advanced bioprocessing and cell and gene therapy technology support pharmaceutical manufacturers in meeting strict regulations and optimizing production. We aim to be a key partner in the ongoing development of next generation of medicines.



**SUSTAINABLE SOLUTIONS IN MEDTECH**

The world is facing increasing demands for resource efficiency and sustainability. One of the most critical challenges is creating a more sustainable and resource-efficient healthcare system.

We have integrated sustainability throughout our value chain, from research and development to recycling. Our operations are founded on environmental, social and ethical responsibility, with clearly defined environmental, social and governance (ESG) standpoints and policies. We aim to be a long-term and responsible player in the industry by delivering high-quality products and solutions with sustainability as a core component.

**Introduction**

**Strategy**

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

Business Areas

Acute Care Therapies

Life Science

Surgical Workflows

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

# Strategy

During the year, we continued to develop our strategic focus areas to create value for all stakeholders.

**Introduction**

**Strategy**

**Strategy for sustainable growth**

Targets 2024–2028

Growing market for Getinge products

Business Areas

Acute Care Therapies

Life Science

Surgical Workflows

**Corporate Governance Report**


**Financial statements**

**Sustainability Report**

**Other information**

# Strategy and vision beyond 2030

Our ambition is to ensure long-term profitable growth. This is only possible if our customers believe that we have an offering that enables the best possible care. Our strategy to achieve this is based on the three focus areas of quality, customers and innovation. These in turn are enabled by our people, sustainability, productivity and financial performance.



Our **vision** beyond 2030

|   |   |  |
|---|---|--|
| <p><b>Acute Care Therapies</b></p> <p style="font-size: 2em; font-weight: bold;">&gt;38</p> <p>lives saved per minute*</p> <p>By strengthening our leading offering in acute advanced heart &amp; lung therapy and cardio-vascular surgery.</p> | <p><b>Life Science</b></p> <p style="font-size: 2em; font-weight: bold;">25%</p> <p>shorter time to market for new, complex medicines</p> <p>By being a key partner to the institutions focused on developing solutions to complex and previously incurable diseases.</p> | <p><b>Surgical Workflows</b></p> <p style="font-size: 2em; font-weight: bold;">&gt;1</p> <p>additional surgeries per OR per day</p> <p>By strengthening our offering for the operating room and in the central sterile supply department, we help increase productivity and reduce the risk of healthcare-acquired infections.</p> |
|---|---|--|

\* Lives of critically ill patients saved.

**Introduction**

**Strategy**

**Strategy for sustainable growth**

Targets 2024–2028

Growing market for Getinge products

Business Areas

Acute Care Therapies

Life Science

Surgical Workflows

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**



**QUALITY**

The highest level of quality is not only a prerequisite for us to operate – we are working hard for, and are convinced, that it will be a competitive advantage for us in the future.

Quality beyond 2030 includes:

- We no longer have a Consent Decree with the FDA, we deliver high-quality products that benefit patients, and we work closely with authorities to set the standards for the future
- Our extensive quality efforts make us one of the most reliable medtech suppliers, resulting in productivity gains for us and our customers



**CUSTOMERS**

We already hold a leading position in the majority of our product categories. Our solutions reach approximately 30,000 customers globally, and are represented in the top ten largest hospitals in all markets. We are endeavoring to advance our position further.

Customers and patients beyond 2030 include:

- We are an acknowledged and preferred partner for our customers thanks to our comprehensive offering and our first-rate service and advisory support
- We have successfully launched new offerings, leveraged our global reach, satisfied needs in our main markets and served many of the needs in emerging markets



**INNOVATION**

We remain relevant to our customers through continuous innovation. This ranges from optimizing internal processes to developing revolutionary new therapies and solutions. Our historically important product launches such as Servo ventilators and DPTE-BetaBag® clearly demonstrate that innovation is part of our company's DNA.

Accordingly, innovation beyond 2030 includes:

- We carried out successful launches under our innovation and sustainability strategy and are continuously adding new projects
- Attractive digital solutions are an integral part of our offering and provide us with competitive advantages
- We have intensified our proactive M&A strategy to further strengthen our innovativeness

**Introduction**

**Strategy**

**Strategy for sustainable growth**

Targets 2024–2028

Growing market for Getinge products

Business Areas

Acute Care Therapies

Life Science


Surgical Workflows

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**



**ENABLERS**

| <b>EMPLOYEES</b>  | <b>SUSTAINABILITY</b>   | <b>PRODUCTIVITY</b>   | <b>FINANCIAL PERFORMANCE</b>  |
|---|---|---|---|
| <p>Our approximately 12,000 employees are our most important asset. Therefore, their well-being and dedication is critical to our success.</p> <p>Employees beyond 2030 includes:</p> <ul style="list-style-type: none"> <li>• We are regarded as an attractive workplace that manages to attract top talent and continues to score highly in regular employee surveys</li> <li>• We act based on three key principles: Team players, Forward thinkers and Game changers</li> </ul> | <p>Sustainability is a central aspect of our goal to contribute to a future of better, more efficient and more accessible healthcare.</p> <p>Sustainability beyond 2030 includes:</p> <ul style="list-style-type: none"> <li>• A focus on quality, responsible business and engaged employees are the backbone of everything we do</li> <li>• Sustainable innovations for better health are the driving force and pave the way for our sustainability activities</li> </ul> | <p>Increasing productivity has been necessary to handle high levels of inflation in recent years. Our customers are under more pressure than ever to deliver more and better care with limited resources. This is where we play an important role.</p> <p>Productivity beyond 2030 includes:</p> <ul style="list-style-type: none"> <li>• Continuously improve our operating model and processes to become the most customer-centric and profitable business possible</li> <li>• Continue to help our customers achieve more cost-efficient patient flows based on the leading clinical performance of our solutions and enabling resource savings</li> </ul> | <p>This is the consequence of how we manage the other elements of our strategy. If we implement it well, the results will follow.</p> <p>Financial performance beyond 2030 thus includes:</p> <ul style="list-style-type: none"> <li>• Having average growth and profitability at least in line with the market</li> <li>• We have an efficient capital structure that facilitates attractive growth and profitability at reasonable risk</li> <li>• We are considered an attractive investment in both the stock and bond markets</li> </ul> |

**Introduction**

**Strategy**

Strategy for sustainable growth

**Targets 2024–2028**

Growing market for Getinge products

Business Areas

Acute Care Therapies

Life Science

Surgical Workflows

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

# Targets 2024–2028

## Sustainability targets

|                    |   |   |
|--------------------|---|---|
| <b>Social</b>      | <b>&gt;70%</b><br>Employee engagement   | <b>&lt;1.5</b><br>Audit findings /quality system audits                     |
| <b>Environment</b> | <b>-90%</b><br>Reduce Scope 1 and 2 emissions by 90% by 2030*                       | <b>-25%</b><br>Reduce Scope 3 emissions by 25% by 2030, and by 90% by 2050* |
| <b>Governance</b>  | <b>&gt;90%</b><br>Percentage of employees who completed training in business ethics |   |

\*Base year 2021

## Financial targets

**>12%**  
Average adjusted EPS growth

Adjusted earnings per share increased 27.6% during the year, mainly as a result of stronger underlying earnings in all business areas.

Dividend policy  
**30–50%**  
of net profit for the year

Dividend for 2023 fiscal year  
**SEK 4.40**  
per share  
(49% of net profit)

Proposed dividend for 2024 fiscal year  
**SEK 4.60**  
per share  
(76% of net profit)

\*The Board's proposed dividend for 2024 represents a departure from the policy of distributing 30–50% of net profit. The proposal is based on the favorable cash flow generated by the operations.

**Introduction**

**Strategy**

Strategy for sustainable growth

Targets 2024–2028

**Growing market for Getinge products**

Business Areas

Acute Care Therapies

Life Science

Surgical Workflows

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

# Growing market for our products

With a broad portfolio and a leading position in a number of product categories, we are working together with customers and partners to provide all people and societies with access to the best possible healthcare.

**Available in the top ten hospitals in all markets**



The market’s annual growth is deemed to be 4–6% and the need to increase productivity and create more sustainable healthcare is greater than ever. Our company is well equipped to address these challenges with a broad portfolio in which solutions are becoming increasingly connected to facilitate the care of the future. We have a leading position in most product categories of our three business areas. These solutions reach approximately 30,000 customers in 135 countries globally, and are represented in the top ten largest hospitals in all markets. By capitalizing on our unique position in many growing segments, we have many opportunities to continue to expand the business.

**Ambition to continue to grow in the US**

Competition differs between each business area and product category. Just like us, most of these competitors have long experience in the industry, substantial size and market presence for their specific product segments. Some competitors primarily operate in the US market, which is a relative strength given that the price levels and margins in general are higher there. This concentration to the US is largely due to historical reasons, since several of them have their roots there. Getinge was founded in Europe, but has been growing faster in the US than in Europe for a long period of time and the ambition is to continue on the established track.

**Our largest sales markets 2024**

Our ten largest markets represented >70% of total sales in 2024.



**Introduction**

**Strategy**

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

**Business areas**

Acute Care Therapies

Life Science

Surgical Workflows

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

# Three business areas with world-leading positions

Our operations are organized into three business areas: Acute Care Therapies, Life Science and Surgical Workflows. Each business area has world-leading positions in most product categories. They operate in a market with annual sales of more than SEK 200 billion.

## Acute Care Therapies



Our solutions in Acute Care Therapies helps save the lives of 10 million critically ill patients each year, the majority of whom have problems with the most fundamental aspect of body function – the circulation of oxygenated blood. The business area has a world-leading position and provides key products, therapies and training to make this possible.

- Life support during intensive care and surgery
- Cardiovascular surgery and effective management of organs for transplantation
- Comprehensive range of services, training and digital solutions

## Life Science



In Life Science, we partner with scientists and engineers to develop and manufacture better pharmaceutical solutions. The focus is on bioprocesses and reducing the risk of contamination through tailored, compliant and effective solutions to prevent, mitigate and cure diseases – and save lives.

- Future-proofed products and systems for efficient development and manufacturing of more advanced medicines
- Reduce the risk of contamination by using washer-disinfectors, sterilizers, isolators and sterile transfers
- Service and user support

## Surgical Workflows



In Surgical Workflows, we have a leading position in the global market for products and services for hospital operating rooms and central sterile supply departments.

- High quality operating room equipment such as operating tables and lights
- Products for sterile reprocessing of surgical instruments
- Digital solutions for increased efficiency, quality and safety before, during and after surgery
- Service and project management

**Introduction**

**Strategy**

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

**Business areas**

Acute Care Therapies

Life Science

Surgical Workflows

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**


**Other information**

**Percentage distribution of sales in 2024**



● Acute Care Therapies, 51.6%  
 ● Life Science, 13.1%  
 ● Surgical Workflows, 35.3%

**Net sales, SEK billion**



● Acute Care Therapies ● Life Science ● Surgical Workflows


**Percentage distribution of adjusted EBITA in 2024, %<sup>1</sup>**



● Acute Care Therapies, 67.7%  
 ● Life Science, 11.6%  
 ● Surgical Workflows, 20.8%

<sup>1</sup> Excluding Group functions and other

**Adjusted EBITA margin, %**



— Acute Care Therapies — Life Science — Surgical Workflows

**Introduction**

**Strategy**

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

Business Areas

**Acute Care Therapies**

Life Science

Surgical Workflows

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**


**Other information**

**ACUTE CARE THERAPIES CASE**

# Innovative solutions for the future of intensive care

With our renowned Servo ventilators, we are showcasing our long-term commitment to meeting the growing demands of healthcare and creating safer, more efficient workflows. One of this year's milestones was the launch of Servo TwinView – our ventilators have a virtual twin that provides medical staff with near real-time view of the data, without having to step inside the sensitive environment of the intensive care unit.

Servo TwinView enhances both patient safety and workflows by allowing staff to monitor therapies remotely, reducing disruption to critically ill patients and improving introduction and training outside the ICU. In addition, the solution enables faster and more informed decisions by enabling remote second opinions and contributes to a more sustainable work environment by relieving healthcare professionals. Our Servo ventilators are here to stay, and we are continuing to develop them to help our customers shape the care of the future.



Introduction

Strategy

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

Business Areas

**Acute Care Therapies**

Life Science

Surgical Workflows

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

Acute Care Therapies

# Helping to double the number of lives saved among critically ill patients



**QUALITY**

Very high quality requirements apply to our products and we operate our business in accordance with the current regulations. Regulators around the world monitor to ensure proper implementation.

**Activities in 2024**

In 2024, we focused on Cardiopulmonary and Cardiac Assist, where we have experienced quality challenges originating from previous years. We have worked to increase the pace of critical product care, strengthen dialogue with regulators and ensure updates in quality registers. An analysis concluded that there are no additional systemic problems besides those already announced. The action plan has been shared with the authorities and will be implemented in 2024–2026.

During the year, we received FDA 510(k) clearance for Vasoview Hemopro 3 for endoscopic vessel harvesting, Talis’ innovative digital clinical decision support software and KidneyVault, Paragonix’s first perfusion technology for safe and effective kidney transport for organ transplantation. We have also made extensive progress in the EU MDR process, with all product categories having approved EU MDD extensions and ten product categories have now been approved under the EU MDR.



**CUSTOMERS**

Our customers work with advanced intensive care, cardiovascular surgery and organ transportation, among other things. They need to be able to rely on the safety, ease of use and advanced productivity of our products and services.

**Activities in 2024**

We continued our work to increase brand awareness and customer satisfaction, which generated positive results in this year’s survey. We also focused on restoring customer confidence following quality challenges in Cardiopulmonary and Cardiac Assist. In parallel, we focused on the deployment of attractive technologies and addressing profitable markets, as well as launching digital offerings that help increase customer value.



**INNOVATION**

Our customers demand medical technologies that increase clinical efficiency and productivity, enabling more patients to be saved in a cost-effective way. This requires innovation in a variety of areas.

**Activities in 2024**

In 2024, we focused on product development and implementing the digital strategy, while also ensuring successful product launches in terms of customer value, regulatory requirements and growth agenda.

Launches during the year include Servo TwinView, which allows medical teams to analyze data from ventilators remotely, and Pulsiocare, which offers advanced hemodynamic monitoring with a high degree of user-friendliness.

We also acquired the US company Paragonix, which offers unique solutions for the safe transportation and storage of organs for transplantation, which fits perfectly with our portfolio from a strategic perspective. Paragonix has made significant progress after the acquisition, for example, by receiving FDA 510(k) clearance for the KidneyVault portable renal perfusion system.

**Introduction**

**Strategy**

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

Business Areas

**Acute Care Therapies**

Life Science

Surgical Workflows

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**



**ENABLERS**

**EMPLOYEES**

Thousands of dedicated employees in Acute Care Therapies work side by side to save lives every day. From sales and product development to production and support functions, everyone plays a crucial role in empowering healthcare professionals to make a difference.

**Activities in 2024**

We have set performance targets for all employees to strengthen key skills and increase commitment. This is achieved through transparent communication, improved decision-making, leadership accountability and promoting a growth mindset.

**SUSTAINABILITY**

Healthcare as a whole accounts for about 5% of carbon emissions worldwide and also generates hazardous waste. We are working intensively to reduce this impact while also improving clinical efficiency, which is positive for patients, hospital productivity and the finances of the healthcare system.

**Activities in 2024**

We continued to take action to achieve our sustainability targets, which also increases our competitiveness and ensures regulatory compliance. Alongside capitalizing on environmental effects, we place great importance on the contribution of our products to social and economic sustainable development. These include our new Vasoview Hemopro 3, which allows for faster treatment, shorter recovery and reduced risk of infection.

CO<sub>2</sub> emissions from our own production (Scope 1 & 2) for the year was reduced by 4%.

**PRODUCTIVITY**

We have a responsibility to our customers, investors and society around the world to conduct our operations cost efficient and to develop products and services that enhance productivity. In doing so, more patients can be helped without undermining the finances of the healthcare system.

**Activities in 2024**

The focus has been on reducing operating expenses to offset the effects of temporary increases in quality costs and inflation. At the same time, we have implemented improvements by making structural changes for long-term productivity.

For example, we carried out initiatives to improve the stability of purchasing and production, which increases productivity and delivery reliability, an important factor for customer satisfaction.

**PRIORITIES FOR 2025**

- Take the next step toward excellence in quality
- Increase customer confidence through delivery stability
- Drive productivity and continuous improvements
- Accelerate the pace of innovation and implement the digital plan
- Drive employee development and commitment
- Continue to implement the sustainability approach

**Introduction**

**Strategy**

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

Business Areas

**Acute Care Therapies**

Life Science

Surgical Workflows

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**



**ENABLERS**


Getinge's addressable market amounts to SEK

**100**


billion with an anticipated growth of 4–6% per year.

**FINANCIAL PERFORMANCE**

**Business area's share of Group sales**



**Business area's regional distribution of sales**



**Net sales and adjusted EBITA margin**



**Market dynamics**

|  | <b>Advanced cardiopulmonary therapy</b>  | <b>Cardiovascular surgery</b>   | <b>Endovascular therapies</b>   |
|--|--|---|---|
| Products   | Life-support therapies for intensive care and the OR, in the form of ECMO, heart-lung machines <sup>1</sup> , ventilators, anesthesia systems, hemodynamic monitoring, intra-aortic balloon pumps, organ preservation and transportation <sup>2</sup> and digital solutions. | Products for advanced cardiac surgery in the form of endoscopic vessel harvesting products, beating heart surgery, vascular grafts and thoracic drainage systems. | Products for peripheral vascular diseases, which includes covered stents. |
| Share of sales within Acute Care Therapies (average 3 years) | <b>69%</b>   | <b>27%</b>  | <b>4%</b>   |
| Market growth per year                                       | <b>6–8%</b>  | <b>0–1%</b>   | <b>8–10%</b>  |
| Our position   | <b>1</b>   | <b>1</b>  | <b>2</b>  |
| Our market share   | <b>~20%</b>  | <b>40–45%</b>   | <b>15–20%</b>   |
| Main competitors   | Dräger, Mindray, GE Healthcare, BD, LivaNova, Medtronic, Teleflex, Transmedics, XVIVO  | WL Gore, Terumo, Artivion, Medtronic  | WL Gore, Bentley, BD  |

<sup>1</sup> Expected to be phased out in 2025, therefore included in 2024 figures but excluded from future market growth. <sup>2</sup> Paragonix was acquired in September 2024, therefore excluded from 2024 figures but included in future market growth.

**Introduction**

**Strategy**

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

Business Areas

Acute Care Therapies

**Life Science**

Surgical Workflows

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**



**LIFE SCIENCE, CASE**

# Innovative solutions for sterile transfer with renewable materials

Our latest DPTE-BetaBag® demonstrates our commitment to sterile transfer by integrating renewable materials. The newly launched Tyvek bag includes a Beta part primarily made of plastics derived from biomass waste and biological residues. This shift reduces the bag's carbon footprint while maintaining its essential functions. The new DPTE-BetaBag® has been rigorously tested to meet strict performance requirements, including sterilizing and gamma irradiation processes. In line with our EcoDesign initiatives, we have conducted a Life Cycle Assessment (LCA) of the DPTE-BetaBag® to evaluate its environmental impact and confirm a reduced carbon footprint, meeting customers' growing demand for sustainable innovations.

**Introduction**

**Strategy**

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

Business Areas

Acute Care Therapies

**Life Science**

Surgical Workflows

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

**Life Science**

# Enabling 25% more rapid development of advanced medicines



**QUALITY**

Our life science customers are engaged in the development and production of medicines, which means that they are subject to very strict quality requirements. Being both a supplier and partner, we are indirectly subject to the same high standards.

**Activities in 2024**

We continued our cultural shift to a more proactive approach, focusing on the preventive identification of potential shortcomings in products and production processes. We have restructured our quality organization by adopting a holistic approach to quality throughout the entire product life cycle. We have also implemented increased testing in production and preventive maintenance to ensure that the products and services we supply are of the highest quality. This enables a more efficient and reliable supply chain for our customers and ourselves.



**CUSTOMERS**

Our customers develop, manufacture and distribute medicines. These customers include some of the largest global companies, as well as many newer and fast-growing companies active in biopharma.

**Activities in 2024**

During the year, we worked intensively to meet the demand from companies who are expanding their capacity. Biopharma customers have started to generate higher order intakes again after a long period of focusing on reducing their inventory levels. This is most noticeable in Europe and North America and in Sterile Transfer, where we have also broadened our customer base.



**INNOVATION**

Our customers are seeking technologies and services that provide safer, faster and more economically efficient development production and distribution of medicines. The aim of our ongoing development activities is to help achieve this.

**Activities in 2024**

A great deal of our innovation takes place together with our customers. More widespread use of AI is an example of this. We launched several new products in 2024, including the GEW 888 neo – a washer that consumes up to 32% less water depending on configuration, the Lancer LSS lab sterilizer and a new version of the DPTE-BetaBag® made from renewable plastics. We also acquired INTACT™, an ecosystem of patents to create simpler and more cost-effective aseptic handling throughout the value chain. The performance of HPNE, which was acquired at the end of 2023, has also strengthened our position.

**Introduction**

**Strategy**

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

Business Areas

Acute Care Therapies

**Life Science**

Surgical Workflows

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**



**ENABLERS**

**EMPLOYEES**

Customers greatly appreciate our commitment to customer focus, innovation and collaboration. Therefore, these aspects are naturally integrated into the development of our employees and the organization as a whole.

**Activities in 2024**

During the year, we carried out activities to increase commitment by defining roles and responsibilities and strengthening our initiative, cooperation and decision-making ability. We also improved the technical and business proficiency of the sales organization.

**SUSTAINABILITY**

Our customers' commitment to sustainable development and manufacturing of medicines has increased considerably in recent years. This presents new opportunities that inspire us to develop.

**Activities in 2024**

We continued to identify and take sustainability action to achieve our sustainability targets and strengthen our competitiveness. This is based on a detailed roadmap and the development of EcoDesign guidelines, as well as specific activities and development efforts. Examples of this are the launch of the new Lancer LSS lab sterilizer that reduces energy consumption by up to 17% through improved control, and the cGMP washer GEW 888 neo that, depending on configuration, reduces water consumption by up to 32% and utility consumption by up to 25% compared with the product it replaces.

Emissions from our own production (Scope 1 & 2) for the year decreased with 36%.

**PRODUCTIVITY**

To enhance our competitiveness, we are striving to work cost-effectively and create products and services that improve productivity for our customers.

**Activities in 2024**

As a result of declining demand in biopharma in recent years, we have made capacity and cost adjustments to increase earnings capacity ahead of expected growth. This encompasses structural improvements that include consolidating the supplier base, reducing the cost of existing products and improving the quality of production.

**PRIORITIES FOR 2025**

- Drive growth through continued focus on innovation and acquisitions
- Integration and expansion of acquired companies HPNE and INTACT™
- Manufacturing Excellence that drives productivity and profitability
- Releasing capital for investments in value-adding growth
- Driving operations toward our sustainability targets
- Create high engagement among employees

**Introduction**

**Strategy**

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

Business Areas

Acute Care Therapies

**Life Science**

Surgical Workflows

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**



**ENABLERS**


Getinge's addressable market amounts to SEK

**35**


billion with an anticipated underlying growth of 9–11% per year.

**FINANCIAL PERFORMANCE**


**Business area's share of Group sales**



**Business area's regional distribution of sales**



**Net sales and adjusted EBITA margin**



**Market dynamics**

|                                | Pharma production   | Medical research   |
|--------------------------------|---|--|
| Products                       | Solutions for aseptic/sterile transfers, GMP sterilizers, GMP washers, bioreactors, automated logistics, isolators, disposables for liquid handling, pumps. | Lab washers, sterilizers and bioreactors, as well as cage washers and logistic automation. |
| Share of sales in Life Science | <b>70%</b>  | <b>30%</b>   |
| Market growth per year         | <b>10–12%</b>   | <b>8–10%</b>   |
| Our position                   | <b>1–4</b>  | <b>2–3</b>   |
| Our market share               | <b>10–15%</b>   | <b>10–15%</b>  |
| Main competitors               | Fedegari, Steris, Steelco, Sartorius, GE, Thermo Fisher   | Steris, Steelco/Miele, IWT, Sartorius, Eppendorf   |

**Introduction**

**Strategy**

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

Business Areas

Acute Care Therapies

Life Science

**Surgical Workflows**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

**SURGICAL WORKFLOWS CASE**

# Efficient throughput and resource savings with Aquadis Index

With Aquadis Index, our new multi-chamber washer-disinfector, we combine high capacity with low resource consumption to help Central Sterile Supply Departments (CSSDs) worldwide achieve both productivity and sustainability goals. Designed for ease of use, it handles large loads efficiently, ensuring smooth throughput for CSSD teams at all experience levels. Our resource-saving technology significantly reduces water, energy, and detergent consumption. Features such as reuse tanks, dynamic water filling, optimized detergent dosing, and heat/energy recovery enhance resource efficiency while maintaining premium cleaning performance. With full connectivity, Aquadis Index enables CSSD staff to maximize uptime and ensure that the washer-disinfector is always ready for use.



**Introduction**

**Strategy**

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

Business Areas

Acute Care Therapies

Life Science

**Surgical Workflows**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

**Surgical Workflows**

# One more surgery per day per OR

|  |   |  |
|--|---|--|
|  <p><b>QUALITY</b></p>  |  <p><b>CUSTOMERS</b></p>   |  <p><b>INNOVATION</b></p>   |
| <p>Our Surgical Workflows products are the backbone of a hospital’s surgical operations. Accordingly, it is essential that our products and services are of the highest quality. Otherwise, the operations risk coming to a standstill.</p> <p><b>Activities in 2024</b><br/>During the year, we strengthened our processes for customer feedback, field actions, reporting to regulators and product development. Our Quality Value Engineering efforts have raised quality and reduced costs and our First Time Pass ratio has increased significantly during the year, reducing the need for post-processing. This in turn entails faster delivery to the customer.</p> | <p>Our customers are hospitals and clinics offering surgery and sterilization of surgical instruments. High utilization rates, productivity and quality in these operations are essential to the financial performance of the hospitals.</p> <p><b>Activities in 2024</b><br/>We want to be a partner to our customers and contribute to efficient workflows and high productivity. As a result, we offer infrastructure, machinery, consumables, service and digital tools. During the year we saw solid growth in such areas as infection control consumables and Digital Health Solutions, thanks to our leading digital tools for managing sterile reprocessing, ORs and patient flows.</p> | <p>Our customers want technology and services that make surgical workflows safer, faster and more cost effective. Our efforts strive to meet these needs.</p> <p><b>Activities in 2024</b><br/>During the year, we launched a large number of new features to existing offerings and some completely new products and services. These include the user-friendly and robust Maquet Ezea surgical light, the intuitive and high-performance Aquadis Index washer-disinfector and the Poladus 150 low-temperature sterilizer. At the end of 2023, we completed the acquisition of US-based Healthmark Industries, significantly strengthening our offering in Infection Control consumables and services.</p> |

**Introduction**

**Strategy**


- Strategy for sustainable growth
- Targets 2024–2028
- Growing market for Getinge products
- Business Areas
- Acute Care Therapies
- Life Science
- Surgical Workflows**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**



**ENABLERS**

**EMPLOYEES**

Meeting customer needs requires strong customer focus, innovation and collaboration. That is why we are prioritizing the development of both our employees and the entire organization.

**Activities in 2024**

We have a high level of employee engagement, which we aim to maintain. During the year, we accelerated our Responsible Leadership program, explained and discussed the strategy behind our priorities, and developed local action plans where necessary.

**SUSTAINABILITY**

Sterile reprocessing and surgery have a negative impact on the environment, which is why our customers demand products and services that minimize these effects. This is something we have been working on for a long time, which has resulted in a leading position.

**Activities in 2024**

During the year, we analyzed the environmental impact of selected consumables and established product environmental profiles (PEPs) for key products. We continued to map the impact of raw material and component sourcing and accelerated product development to reduce electricity and water consumption.

CO<sub>2</sub> emissions from our own production (Scope 1 & 2) for the year reduced with 48%.

**PRODUCTIVITY**

To enhance our competitiveness, we will conduct cost efficient operations and develop products and services that increase customer productivity.

**Activities in 2024**

We are continuing to focus intensely on reducing product costs through more efficient manufacturing and procurement. Efficient procurement helped bring about net savings in 2024 and Quality Value Engineering, which involves redesigning and replacing components, also made a positive contribution. These initiatives will continue.

**PRIORITIES FOR 2025**

- Continue the structured efforts to ensure high quality in products and processes
- Strengthen our position in Infection Control and become a leading full-service supplier with the help of Healthmark-industries
- Launch new products and assume a stronger position in fast growing segments such as Digital Health Solutions, endoscope reprocessing and low temperature sterilization
- Increase productivity through efficient manufacturing, procurement and service processes
- Improvements in line with our sustainability targets

**Introduction**

**Strategy**

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

Business Areas

Acute Care Therapies

Life Science

**Surgical Workflows**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**



**ENABLERS**

Getinge's addressable market amounts to SEK

**67**


billion with an anticipated growth of 4–6% per year.

**FINANCIAL PERFORMANCE**


**Business area's share of Group sales**



**Business area's regional distribution of sales**



**Net sales and adjusted EBITA margin**



**Market dynamics**

|                                      | <b>Sterile reprocessing department</b>  | <b>Operating room equipment</b>   | <b>Digital solutions for increased efficiency</b>   |
|--------------------------------------|---|---|---|
| Products                             | Complete solutions for instrument and endoscope reprocessing, including steam and low-temperature sterilizers, washer-disinfectors, endoscope cleaners, automation solutions and consumable supplies, as well as service and clinical training. | Complete operating room solutions including modern hybrid operating rooms in combination with imaging partners, advanced operating tables, surgical lights and ceiling supply units, as well as consulting on layouts, workflows and technical service. | Advanced digital solutions to optimize hospital workflows and ensure efficiency in sterile supply chains, operating room integration and OR management. |
| Share of sales in Surgical Workflows | <b>50%</b>  | <b>44%</b>  | <b>6%</b>   |
| Market growth per year               | <b>3–5%</b>   | <b>4–6%</b>   | <b>7–15%</b>  |
| Our position                         | <b>1–2</b>  | <b>1</b>  | <b>1–5</b>  |
| Our market share                     | <b>20–25%</b>   | <b>15–20%</b>   | <b>5–10%</b>  |
| Main competitors                     | Steris, SteelcoBelimed, Shinva, ASP   | Baxter, Steris, Stryker, Mindray, Dräger  | Steris, Karl Storz, Teletracking, Censis and local IT companies   |

**Introduction**

**Strategy**

**Corporate Governance Report**

Corporate governance structure

Board of Directors

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

Assurance framework, risks and risk management

Internal control over the financial reporting

Auditor's report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

# Corporate Governance Report



**Introduction**

**Strategy**

**Corporate Governance Report**

- Corporate governance structure
- Board of Directors
- President & CEO and Getinge Executive Team
- Building blocks in the Getinge corporate governance model
- Assurance framework, risks and risk management
- Internal control over the financial reporting
- Auditor’s report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

## Contents

|       |   |
|-------|---|
| 33    | About the report  |
| 34    | Corporate governance structure                            |
| 35    | General Meeting   |
| 35–36 | Nomination Committee                                      |
| 36    | External auditor  |
| 36–41 | Board of Directors  |
| 42–44 | President & CEO and Getinge Executive Team                |
| 45–46 | Building blocks in the Getinge corporate governance model |
| 47–52 | Assurance framework, risks and risk management            |
| 53–54 | Internal control over the financial reporting             |
| 54    | Auditor’s report on the Corporate Governance Report       |

## About the report

This Corporate Governance Report has been prepared and adopted by Getinge AB (publ)’s Board of Directors in accordance with the provisions of the Swedish Annual Accounts Act and the Swedish Corporate Governance Code. The Corporate Governance Report presents an overview of Getinge’s corporate governance, including a description of the system for internal control over the financial reporting.

Information on Getinge’s corporate governance is also available at [www.getinge.com/int/company/corporate-governance/overview/](http://www.getinge.com/int/company/corporate-governance/overview/). Information on the website does not comprise part of this Corporate Governance Report.

# Responsibly, sustainably and efficiently

Getinge AB (publ) hereby submits its 2024 Corporate Governance Report that summarizes how the corporate governance is structured, how it has been carried out and how it has been developed in the Group during the 2024 fiscal year. This Corporate Governance Report is reviewed by the company’s auditors. The auditor’s report can be found on page 54.

Getinge always strives to ensure effective management, social and environmental responsibility, ethical business practices and optimal use of resources. As part of the efforts to continuously improve corporate governance, two of the primary focus areas during the year remained the further development of sustainability governance and the regulatory area of product quality.

In the area of sustainability, Getinge continued its work to strengthen governance during the year to ensure that the Group meets the expectations and requirements set. The overall focus has been to integrate sustainability dimensions throughout the operations and to increase cooperation on the matters between different functions in the Group. Part of this work was implementing a Sustainability Advisory Group, which works to ensure coordination between the different functions and that the varying characteristics of the business areas are taken into account in decision-making. The process of fine tuning the responsibilities and tasks of the newly established Ethics and Sustainability Committee continued during the year.

Getinge continued to work actively on ensuring proactivity, good product quality and integrated operational quality responsibility during the year, and adjustments to the Quality Compliance, Regulatory & Medical Affairs function. Examples of such measures are initiating a new process for management review and developing way of working using the global quality management system that was implemented in 2023.

During the year, the structure of the Acute Care Therapies business area was updated with the creation of the Transplant Care product segment as a direct result of the acquisition of Paragonix Technologies, an organ transport products and services company.

» As part of the efforts to continuously improve corporate governance, two of the primary focus areas during the year remained the further development of sustainability governance and the regulatory area of product quality. «

**Introduction**

**Strategy**

**Corporate Governance Report**

**Corporate governance structure**

Board of Directors

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

Assurance framework, risks and risk management

Internal control over the financial reporting


Auditor’s report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

Main governing bodies within Getinge



**Corporate governance structure**

**Getinge as a company**

The company is a Swedish public limited liability company with the business name Getinge AB (publ). The Board of Directors is domiciled in the municipality of Gothenburg, Västra Götaland County, Sweden. The objects of the company’s operations shall be to, directly or indirectly through subsidiaries, engage in the manufacturing and sale of medical technical equipment, and in any other activities compatible therewith.

The complete Articles of Association are available on [www.getinge.com](http://www.getinge.com). The Articles of Association contain no specific provisions for the appointment or dismissal of Board members or on amendments to the Articles of Association.

**External regulations**

Getinge’s corporate governance is based on applicable laws, regulations, good practice on the stock market and the Nasdaq Rulebook for Issuers. In addition, the Group’s corporate governance is based on the Swedish Corporate Governance Code (the “Code”). Getinge follows the Code’s “comply or explain” principle.

Getinge’s only deviation from the Code’s regulations in 2024 was from the Code’s rule 2.4, that the Chairman of the Board or any other Board member is not to be Chairman of the Nomination Committee. The Nomination Committee appointed Carl Bennet (Board member and owner of the company’s largest shareholder, Carl Bennet AB) as Chairman of the Nomination Committee, since the Nomination Committee found it important to have a representative of the largest shareholder to serve as Chairman of the Nomination Committee.

There were no violations of the stock market rules and no violations of good practice on the stock market reported by Nasdaq Stockholm’s Disciplinary Committee or the Swedish Securities Council.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Corporate governance structure**

Board of Directors

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

Assurance framework, risks and risk management

Internal control over the financial reporting

Auditor’s report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

**A SHARES AND SHAREHOLDERS**

The total number of shares in the company amounts to 272,369,573, of which 18,217,200 are Class A shares, each share carrying entitlement to ten votes and 254,152,373 are Class B shares, each share carrying entitlement to one vote. All shares carry the same dividend entitlement, and the Articles of Association contain no limitation on the number of votes each shareholder can cast at a General Meeting of Shareholders.

The largest shareholder, Carl Bennet AB, held 20.20% of the shares outstanding and 50.19% of all votes in the company at the end of the 2024 fiscal year, making him the only direct or indirect shareholder with a holding in the company representing over one tenth of the number of votes for all of the shares in the company.

For information about shareholders and the Getinge share, see pages 170–171 and [www.getinge.com](http://www.getinge.com).

**B GENERAL MEETING OF SHAREHOLDERS**

The General Meeting of Shareholders is Getinge’s highest decision-making body. Shareholders can exert their influence at the Annual General Meeting (“AGM”) and, when applicable, at an Extraordinary General Meeting. The AGM, where shareholders exercise their voting rights in key issues for the company, is held within six months of the end of the fiscal year.

General Meetings of Shareholders are convened by publishing of a notice in Post- och Inrikes Tidningar (the Swedish Official Gazette) and on the company’s website. An announcement is to be made in Svenska Dagbladet that the notice of the Meeting has been published. Shareholders, who want to participate in the discussions at the Meeting, must give notice of attendance to the company not later than the date provided in the notice of the Meeting. The Articles of Association also prescribe a possibility for the Board of Directors to resolve on collection of powers of attorney and to resolve that shareholders can exercise their voting rights by post. A shareholder who wishes to have a matter put forward at the General Meeting of Shareholders must submit a written proposal to the Board in a timely manner so that the proposal can be included in the notice of the Meeting.

**2025 Annual General Meeting**

The AGM will be held on April 22, 2025 at Kongresshallen at Hotel Tylösand in Halmstad, Sweden. Shareholders are also offered the possibility of taking part through postal voting.

Information about how shareholders can register their attendance at the AGM is available at [www.getinge.com](http://www.getinge.com). The notice of the AGM is also available on the website, together with proposals and other relevant documentation for the AGM.

**2024 Annual General Meeting**

The 2024 AGM was held on April 22, 2024 in Halmstad, both physically and through postal voting. All of the members of the Board, the Nomination Committee’s representatives and the auditor in charge attended the AGM. A total of 1,128 shareholders were represented at the AGM, representing approximately 82% of the votes in the company. The minutes from the AGM are available on [www.getinge.com](http://www.getinge.com).

The decisions made by the AGM include:

- Dividend of SEK 4.40 per share for the 2023 fiscal year
- Re-election of all Board members available for re-election and the Chairman
- Re-election of Öhrlings PricewaterhouseCoopers AB as the company’s auditor
- Approval of the remuneration report

**C NOMINATION COMMITTEE**

The Nomination Committee’s task is to put forward proposals ahead of the AGM regarding the election of the Chairman of the AGM, the Chairman of the Board and other members of the Board, election of auditors, as well as fees for Board members and auditors.

At the 2020 AGM, principles were adopted for the appointment of the Nomination Committee and the instruction for the Nomination Committee, to apply until further notice. Ahead of each AGM, the Nomination Committee shall be composed of members appointed by the four largest shareholders in terms of voting rights as of August 31 of each year, and the Chairman of the Board. In addition, if the Chairman of the Board in consultation with the member appointed by the largest shareholder in terms of voting rights deems it appropriate, it shall include an, in relation to the company and its major shareholders, independent representative of the minority shareholders. The instruction for the Nomination Committee is available in its entirety at: [www.getinge.com/int/company/corporate-governance/](http://www.getinge.com/int/company/corporate-governance/).

**Nomination Committee ahead of the 2025 Annual General Meeting**

Following changes in the ownership structure of the company, Getinge’s Nomination Committee ahead of the 2025 AGM comprises the company’s Chairman of the Board Johan Malmquist, and representatives from the following five owners, listed by size:

- Carl Bennet AB: Carl Bennet
- Fourth Swedish National Pension Fund: Jannis Kitsakis
- AMF Pension & Fonder: Dick Bergqvist
- Carnegie fonder: Simon Blecher
- Swedbank Robur: Marianne Nilsson

Carl Bennet was appointed Chairman of the Nomination Committee ahead of the 2025 AGM (see also the section “External regulations” for information about deviation from the Code). No remuneration is paid to members of the Nomination Committee, and the members have affirmed that there are no conflicts of interest that affect their assignment on the Committee.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Corporate governance structure**

Board of Directors

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

Assurance framework, risks and risk management

Internal control over the financial reporting

Auditor's report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

**C NOMINATION COMMITTEE cont.**

The Nomination Committee has addressed all the matters that the Nomination Committee must address in accordance with the Code. As a basis for its work, the Nomination Committee studied the financial statements for the company's operations in 2024, the completed Board evaluation and proposals received.

When preparing its proposals on the composition of the Board, the Nomination Committee takes into account the individual expertise and experience of the proposed Board members, how well the Board will work as a whole and whether it possesses the necessary breadth in terms of background and expertise. The Nomination Committee pays particular attention to the value of diversity and the balance between the need for renewal and continuity in the Board. In its efforts to achieve diversity, the Nomination Committee gives special consideration to an even gender distribution. The Nomination Committee applies rule 4.1 of the Code as its diversity policy in preparing proposals of Board members. The aim of the policy is that the Board is to have a composition appropriate to the company's operations, phase of development and other relevant circumstances and to exhibit diversity and breadth of qualifications, experience and background, and strive for an equal gender distribution. Ahead of the 2024 AGM, the Nomination Committee stated that the gender balance is not satisfactory and expressed an intention to strive toward a more even gender balance.

The Nomination Committee has, in its own assessment, concluded that the Board is well functioning and that the Board members together hold the diversity and extensive competence, experience and background required, and are suitable with respect to the company's operations, phase of development and other circumstances, including sustainability aspects.

The proposals of the Nomination Committee ahead of the 2025 Annual General Meeting are submitted in the notice of the Meeting.

**D EXTERNAL AUDITOR**

Getinge AB (publ)'s auditor is elected at the AGM. The auditor performs an audit of the Annual Report, financial statements and the consolidated financial statements as well as the management by the Board and President & CEO in accordance with generally accepted auditing standards. After each fiscal year an auditor's report for the Parent Company and a Group auditor's report are presented to the General Meeting. The auditor also reviews Getinge's nine-months report. The auditor in charge and co-auditor participate in all of the Audit and Risk Committee meetings, as well as relevant Ethics and Sustainability Committee meetings, and report to the relevant committees and Board of Directors on their audit.

**External auditors in 2024**

At the 2024 AGM, the registered auditing firm Öhrlings PricewaterhouseCoopers AB was re-elected auditor until the 2025 AGM, which the firm has been since 2008. Authorized Public Accountant Cecilia Andrén Dorselius has been Auditor in Charge since the 2024 AGM and Authorized Public Accountant Karin Olsson was the co-signing auditor.

In addition to standard audit assignments, Öhrlings PricewaterhouseCoopers AB provides advisory services and performs assessments. Such assignments take place in accordance with the regulations determined by the Audit and Risk Committee for approval of the nature and scope of the services and the fees for such services. The performed assignments are not deemed to have given rise to any conflict of interest. Details about the amounts of remuneration paid to auditors are presented in Note 5 of the Annual Report.

**E BOARD OF DIRECTORS**

**Composition of the Board of Directors**

In 2024, Getinge AB (publ)'s Board comprised eight members elected at the AGM, of whom one is Getinge's President & CEO, as well as two members appointed by employee representative organizations and two deputy members for the employee representatives. Out of the Board members elected at the AGM, two are women and six are men (corresponding to 25% and 75%, respectively).

**Independence of Board members**

The Nomination Committee deemed that the composition of the Board during 2024 met the requirements for independence as stipulated by the Code. The Nomination Committee has observed that Mattias Perjos, in his capacity as President & CEO, is to be regarded as dependent in relation to the company and executive management, and that Carl Bennet and Dan Frohm, as Board members of Getinge's principal owner Carl Bennet AB, are to be regarded as dependent in relation to the major shareholders. Other Board members are deemed to be independent in relation to the company, executive management and major shareholders. A total of seven out of eight Board members are deemed to be independent in relation to the company and executive management (87.5%) and six out of eight are deemed to be independent in relation to major shareholders (75%).

**Expertise of the Board**

Ahead of the 2024 AGM, the Nomination Committee concluded that the Board functions well and that the Board members possess broad expertise and solid industry knowledge. For example, the Board members jointly possess solid financial background and extensive financial know-how, among other, through Board members' previous operative assignments within fields of economics and finance and other Board assignments, including work in Audit Committees. The Board also jointly possess competence and experience from the sustainability field, for example through one Board member's previous assignment as chairman of a Sustainability Committee but also through other Board members' operational assignments in

**Introduction**

**Strategy**

**Corporate Governance Report**

**Corporate governance structure**

Board of Directors

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

Assurance framework, risks and risk management

Internal control over the financial reporting

Auditor’s report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

**E BOARD OF DIRECTORS, cont.**

executive positions. Through certain Board members’ previous and/or current operational assignments for Getinge and other companies, the Board members jointly possess sound knowledge of the industry and market where the company operates and of areas of relevance for the operations, such as artificial intelligence. Within the Board, there is also competence and experience from operational work within hospitals and clinical activity. In addition, the Board has solid experience from international relations and Board work, in broad sense, through Board members’ previous and current operational assignments as well as Board assignments in other companies.

**Responsibilities and work of the Board of Directors**

Primarily, the Board is responsible for the organization of the company and the management of its affairs. In carrying out its duties, the Board must safeguard the interest of all its shareholders. The Board of Directors is to maintain and promote a good corporate culture and ensure that Getinge – on behalf of its shareholders – is led in the most sustainable, responsible and effective manner possible.

The guidelines for the Board’s work are described in greater detail in the Board’s rules of procedure and annual plan, which are reviewed and adopted each year. The rules of procedure include provisions on preventing disqualification and conflicts of interests for Board members, and a process for handling any transactions between Getinge and related parties.<sup>1</sup>

The Chairman is responsible for leading and managing the Board’s work and ensuring that it is conducted in an organized and efficient manner. The President & CEO acts as rapporteur at the Board’s meetings. In addition, the Group’s Chief Financial Officer serves as rapporteur and the Group’s Head of Corporate Legal serves as Secretary of the Board, with the exception of instances where it is inappropriate for them to attend. Other senior executives also participate when needed. The rules of procedure also contain guidelines for the work of the Board’s committees. The Board decides on the members of the committees, with the aim of the committee members possessing the relevant experience and skills for the committee’s work.

**Board of Directors’ work in 2024**

In 2024, the Board held a total of 13 meetings, with an attendance rate of 97% of the members elected by the AGM.

At its ordinary meetings, the Board has addressed fixed agenda items in accordance with the Board’s rules of procedure and annual plan. Accordingly, the Board has addressed the Group’s long-term objectives and strategy, risks and risk management,

**The Board of Directors of Getinge AB (publ) is responsible for, among other things:**

- Overall strategy, targets and organization
- That procedures are in place for financial reporting and that financial reporting is conducted in accordance with applicable rules and regulations
- An overview of the financial plan, earnings, forecasts and forward-looking statements as well as the adoption of the financial statements
- Ensuring that there are effective systems for follow ups and control of operations, financial position and risks, and well-functioning internal control
- Identifying how sustainability issues affect risks and business opportunities
- Approving guidelines and general policies for conduct in society with the aim of securing long-term value creation
- Ensuring that there are sufficient control mechanisms in place for compliance with applicable rules and regulations, as well as with internal policies and guidelines
- Ensuring that external disclosures (incl. financial reporting) are characterized by openness and objectivity, and are correct, reliable and have a high level of relevance, and that there are appropriate processes, controls and systems in place

sustainability matters, financial and investment plan, financial reports and corporate governance documents. The Board has continuously addressed its business situation and financial matters, ethics and compliance, quality and regulatory matters, succession planning and talent development, as well as organizational matters. During the year, the Board also addressed legal proceedings and acquisitions.

During the year, the Board worked in particular on matters related to:

- quality work and remediation of the communicated challenges in the area and implementation of robust processes and systems;
- sustainability efforts and ensuring that these are integrated throughout operations; and
- the Group’s acquisition agenda and, in particular, the acquisition of Paragonix Technologies.

At one of its meetings, the Board met with the company’s auditor without the presence of the President & CEO or any other individual from executive management. The Board also continuously evaluated the work of the President & CEO and addressed to this matter at one meeting without the presence of executive management.

**Board of Directors’ evaluation of its work**

The Board carries out an annual evaluation of its work for the purpose of developing its methods and effectiveness. The evaluation in 2024 was, as in previous years, based on a survey and a tool provided by an external party. Additionally, the Chairman of the Board carried out individual interviews with the Board members. The results and analysis of this have been reported to the Board and followed up on with discussions and identification of focus areas moving forward. The Nomination Committee has taken part of the evaluation in its entirety as well as the Board’s conclusions.

<sup>1</sup> Board member’s shareholdings and other assignments can be found on pages 39–41. Getinge does not collect shareholding information from suppliers or other stakeholders. Information on any transactions with related parties are presented in Note 28.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Corporate governance structure**

Board of Directors

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

Assurance framework, risks and risk management

Internal control over the financial reporting

Auditor’s report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

**BOARD COMMITTEES**

The Board has established three committees – to focus on remuneration, audit and risk and ethics and sustainability

**F REMUNERATION COMMITTEE**

**Responsibilities and work**

The Remuneration Committee is responsible for:

- preparing the Board’s resolutions concerning remuneration principles, remuneration and other employment terms and conditions for executive management;
- monitoring and evaluating variable remuneration programs for executive management;
- assisting in the preparation of the company’s remuneration report;
- preparing proposals on guidelines for the remuneration to senior executives that the Board will propose to the AGM;
- monitoring and evaluating the application of the guidelines for remuneration;
- evaluating the current remuneration structures and levels in the company; and
- preparing resolutions related to succession planning and talent development.

The Committee held four meetings in 2024, and remained in contact as required. A particular area of focus was evaluating and ensuring that current remuneration levels and structures are in line with market terms.

**Composition**

In 2024, the Committee comprised the Board members Johan Malmquist (Chairman), Carl Bennet and Dan Frohm. The members of the Remuneration Committee are independent in relation to the company and executive management, and Johan Malmquist is also independent in relation to the company’s major shareholders.

**G AUDIT AND RISK COMMITTEE**

**Responsibilities and work**

The Audit and Risk Committee is responsible for:

- meeting the requirements of the Swedish Companies Act, the Code and the EU Audit Regulation;
- contact between the Board and the auditors;
- preparing matters relating to the election of auditors and remuneration;
- monitoring the company’s accounting;
- preparing the company’s financial statements;
- preparing the company’s finance policy;
- monitoring the effectiveness of the company’s internal control, financial risk management and internal audit;
- monitoring legal disputes, internal investigations and whistleblowing cases;
- monitoring the Group’s work on information and cyber security matters; and
- monitoring sustainability reporting matters that have been delegated to the Ethics and Sustainability Committee

The Committee held seven meetings in 2024, and remained in contact as required. The company’s auditors participated in all meetings. Particular focus areas were internal control, monitoring remediation programs, the Group’s long-term financing, procurement of audit services and digital compliance.

**Composition**

In 2024, the Committee comprised the Board members Johan Bygge (Chairman), Cecilia Daun Wennborg, Dan Frohm and Kristian Samuelsson. The members of the Committee are independent in relation to the company, executive management and the company’s major shareholders, with the exception of Dan Frohm, who is not considered to be independent in relation to the company’s major shareholders. The composition of the Committee meets the qualification criteria that is placed on accounting or auditing expertise.

**H ETHICS AND SUSTAINABILITY COMMITTEE**

**Responsibilities and work**

The Ethics and Sustainability Committee is responsible for:

- preparing strategic matters regarding the company’s work on areas defined by Getinge as key areas for sustainable development;
- preparing the sustainability-related matters that the Board is required to address under the Code;
- monitoring the work of the Sustainability function;
- monitoring the work of the Ethics & Compliance function and monitoring the implementation of an effective Ethics & Compliance program;
- monitoring the work of the Quality Compliance, Regulatory & Medical Affairs function, and monitoring the implementation of the quality organization.

The Committee held six meetings in 2024, and remained in contact as required. Particular focus areas for the year were the work on the Group’s materiality assessment and sustainability strategy, monitoring the process of sustainability reporting and product quality activities. Furthermore, the Committee particularly monitored the Group’s work on human rights compliance programs, integration of sustainability dimensions in the acquisition process and due diligence in the supply chain.

**Composition**

Since the 2024 AGM, the Committee comprised the Board members Cecilia Daun Wennborg (Chairman), Malin Persson and Dan Frohm. The members of the Committee are independent in relation to the company, executive management and the company’s major shareholders, with the exception of Dan Frohm, who is not considered to be independent in relation to the company’s major shareholders.

Introduction

Strategy

Corporate Governance Report

Corporate governance structure

Board of Directors

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

Assurance framework, risks and risk management

Internal control over the financial reporting

Auditor's report on the Corporate Governance Report

Financial statements

Sustainability Report

Other information

# Board of Directors



| Name  | Johan Malmquist   | Carl Bennet   | Johan Bygge   | Cecilia Daun Wennborg   |
|---|---|---|---|---|
| <b>Position</b>   | Board member elected by the AGM, Chairman of the Board. Board member since 2016. Chairman of the Remuneration Committee.  | Board member elected by the AGM, Vice Chairman of the Board. Board member since 1989. Member of the Remuneration Committee.   | Board member elected by the AGM. Board member since 2007. Chairman of the Audit and Risk Committee.   | Board member elected by the AGM. Board member since 2010. Chairman of the Ethics and Sustainability Committee. Member of the Audit and Risk Committee.  |
| <b>Year of birth, education and nationality</b>   | 1961, B.Sc. in Business Administration, Swedish.  | 1951, B.Sc. in Business Administration, med. Dr. h.c., tech. Dr. h.c., honorary doctorate in economics, Swedish.  | 1956, B.Sc. in Business Administration, Swedish.  | 1963, B.Sc. in Business Administration, Swedish.  |
| <b>Core expertise</b>   | Industry know-how, Business management, International industry  | Industry know-how, Business management, International industry  | Business management, Mergers and acquisition, Finance   | Medical and healthcare, Business management, Sustainability   |
| <b>Board assignments</b>  | Chairman of Arjo AB (publ) and Trelleborg AB (publ). Board member of Mölnlycke Health Care AB, Stena Adactum AB and Chalmers University of Technology Foundation.   | Chairman of Lifco AB (publ). Vice Chairman of Arjo AB (publ) and Elanders AB (publ). Board member of L E Lundbergsföretagen AB (publ).  | Chairman of Scandi Standard AB (publ), Guard Therapeutics AB (publ), Yangi AB, Arevo AB and AB Regin. Vice Chairman of Third Swedish Pension Fund (AP3). Board member of Lantmännen Ek.För CapMan OYJ and Riksbankens Jubileumsfond Foundation.   | Chairman of Almi AB. Board member of Loomis AB (publ), Bravida Holding AB (publ), Oncopeptides AB (publ), Atvexa AB, Social Initiative Norden AB, Gränges AB (publ), and member of Swedish Securities Council.  |
| <b>Professional experience, previous assignments and other information</b>                                      | President & CEO of Getinge 1997–2015. Former Business Area Director within Getinge, President of Getinge's French subsidiary, President of subsidiaries in the Electrolux Group. Former Chairman of the Board of Tingstad Pappers AB, and Board member of Elekta AB (publ), SCA AB (publ) and the Dunker Foundations. | CEO and Chairman of Carl Bennet AB. Former President & CEO of Getinge 1989–1997. Chairman of Getinge's Board of Directors 1997–2019. Former Board member of Holmen AB (publ). | Former Chairman of PSM International China and Nobina AB (publ), Chairman of EQT Asia Pacific, Venture Partner of Prorsum AG Venture Fund, COO of EQT, Board member of Anticimex, I-Med Ltd and Praktikertjänst AB, CFO of Investor AB, Executive Vice President of Electrolux and CFO of Electrolux. | Former deputy CEO of Ambea AB, CEO of Carema Vård och Omsorg AB, acting CEO of Skandiabanken, Head of Swedish Operations at Skandia, President of Skandia Link, and Board member of Atos Medical Holding AB (publ), Hoist Finance AB (publ), Sophiahemmet, ICA Gruppen AB (publ), Hotell Diplomat AB, Eleda TopCo AB and the Oxfam Sweden Foundation. |
| <b>Attendance at meetings*</b>  |   |   |   |   |
| Board meetings  | 13/13   | 11/13   | 13/13   | 13/13   |
| Remuneration Committee  | 4/4   | 4/4   | –   | –   |
| Audit and Risk Committee  | –   | –   | 7/7   | 7/7   |
| Ethics and Sustainability Committee   | –   | –   | –   | 6/6   |
| <b>Independence<sup>1)</sup></b>  |   |   |   |   |
| Dependent/independent in relation to the company and executive management and in relation to major shareholders | Independent in relation to the company, executive management and major shareholders.  | Dependent in relation to major shareholders, owner and Chairman of Getinge's principal owner Carl Bennet AB. Independent in relation to the company and executive management. | Independent in relation to the company, executive management and major shareholders.  | Independent in relation to the company, executive management and major shareholders.  |
| <b>Remuneration and holdings</b>  |   |   |   |   |
| Total remuneration in 2024, SEK   | 1,806,200, of which 156,800 comprises fees for the Remuneration Committee.  | 816,600, of which 113,600 comprises fees for the Remuneration Committee.  | 1,016,700, of which 313,700 comprises fees for the Audit and Risk Committee.  | 1,013,400, of which 153,600 comprises fees for the Audit and Risk Committee and 156,800 comprises fees for the Ethics and Sustainability Committee.   |
| Holdings in Getinge AB (publ) (own and related parties <sup>2)</sup> )  | 160,000 Class B shares.   | Holds 18,217,200 Class A shares and 36,802,969 Class B shares through companies.  | 30,600 Class B shares.  | 18,500 Class B shares.  |

\* Barbro Fridén stepped down as a Board member at the 2024 AGM and attended 5/5 Board meetings and 1/1 Remuneration Committee meeting prior to that.  
 1) See further on the independence of the Board on page 36. 2) See definition of related parties on page 41.

Introduction

Strategy

Corporate Governance Report

Corporate governance structure

Board of Directors

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

Assurance framework, risks and risk management

Internal control over the financial reporting

Auditor's report on the Corporate Governance Report

Financial statements

Sustainability Report

Other information

## Board of Directors, cont.



| Name   | Dan Frohm  | Mattias Perjos   | Malin Persson   | Kristian Samuelsson  |
|--|--|--|---|--|
| <b>Position</b>  | Board member elected by the AGM. Board member since 2017.<br>Member of the Audit and Risk Committee, the Remuneration Committee and the Ethics and Sustainability Committee (from 2024 AGM).               | Board member elected by the AGM. Board member since 2017.<br>President & CEO.  | Board member elected by the AGM. Board member since 2014.<br>Member of the Ethics and Sustainability Committee.   | Board member elected by the AGM. Board member since 2021.<br>Member of the Audit and Risk Committee.   |
| <b>Year of birth, education and nationality</b>                            | 1981, M.Sc. in Industrial Engineering and Management, Swedish.   | 1972, M.Sc. in Industrial Engineering and Management, Swedish.   | 1968, M.Sc. in Industrial Engineering and Management, Swedish.  | 1977, Professor, M.D., PhD., Swedish.  |
| <b>Core expertise</b>  | International industry, Strategy and business development  | Industry know-how, Business management, International industry   | Business management, Sustainability, Technological development, R&D, Strategy and business development  | Medical and healthcare, Technological development, R&D, AI/Digitalization  |
| <b>Board assignments</b>   | Chairman of Elanders AB (publ). Vice Chairman of Carl Bennet AB and Lifco AB (publ). Board member of Arjo AB (publ) and Swedish-American Chamber of Commerce, Inc.   | Board member of EUROAPI S.A. Member of International Chamber of Commerce (ICC) Sweden's Board.   | Chairman of Universeum AB. Board member of Hexpol AB (publ), Peab AB (publ), Beckers Group, Hydros cand Group AB, Stena Sessan AB, Absolent Air Care Group AB (publ) and AB Sigrid Rudebecks Skola.   | Member of the Faculty Board of Sahlgrenska Academy, University of Gothenburg.  |
| <b>Professional experience, previous assignments and other information</b> | CEO of DF Advisory LLC. Former management consultant at Applied Value LLC in New York.   | President & CEO of Getinge. Former CEO of Coesia Industrial Process Solutions (IPS) and head of Coesia International. Senior positions at FlexLink AB including the role of CEO. | CEO and owner of Accuracy AB. Former CEO of the Chalmers University of Technology Foundation and many years' experience in major Swedish industrial enterprises such as the Volvo Group. Former Board member of Hexatronic Group AB (publ), EVRY ASA, OX2 AB (publ), Oddwork Sweden AB and Ricardo PLC. | Professor of orthopaedic surgery at the University of Gothenburg and senior consultant in orthopaedic surgery at Sahlgrenska University Hospital. Experience from healthcare with evidence-based medical research and interdisciplinary research in areas such as artificial intelligence (AI) and digitization. |
| <b>Attendance at meetings</b>  |  |  |   |  |
| Board meetings   | 12/13  | 13/13  | 13/13   | 13/13  |
| Remuneration Committee   | 4/4  | –  | –   | –  |
| Audit and Risk Committee   | 7/7  | –  | –   | 7/7  |
| Ethics and Sustainability Committee  | 3/3  | –  | 6/6   | –  |
| <b>Independence<sup>1)</sup></b>   | Dependent/independent in relation to the company and executive management and in relation to major shareholders  | Dependent in relation to major shareholders, Board member of Getinge's principal owner Carl Bennet AB. Independent in relation to the company and executive management.          | Dependent in relation to the company and executive management in his capacity as President & CEO of Getinge. Independent in relation to major shareholders.   | Independent in relation to the company, executive management and major shareholders.   |
| <b>Remuneration and holdings</b>   |  |  |   |  |
| Total remuneration in 2024, SEK  | 1,083,800, of which 113,600 comprises fees for the Remuneration Committee, 153,600 comprises fees for the Audit and Risk Committee and 113,600 comprises fees for the Ethics and Sustainability Committee. | –  | 816,600, of which 113,600 comprises fees for the Ethics and Sustainability Committee.   | 856,600, of which 153,600 comprises fees for the Audit and Risk Committee.   |
| Holdings in Getinge AB (publ) (own and related parties <sup>2)</sup> )     | 154,999 Class B shares.  | 200,000 Class B shares.  | 18,112 Class B shares.  | 5,000 Class B shares.  |

1) See further on the independence of the Board on page 36. 2) See definition of related parties on page 41.

Introduction

Strategy

**Corporate Governance Report**

Corporate governance structure

**Board of Directors**

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

Assurance framework, risks and risk management

Internal control over the financial reporting

Auditor's report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

## Board of Directors, cont.



| Name  | Åke Larsson   | Fredrik Brattborn  | Ida Ekman   | Pontus Käll   |
|---|---|--|---|---|
| <b>Position</b>   | Ordinary Board member appointed by employee organization  | Ordinary Board member appointed by employee organization   | Deputy appointed by employee organization   | Deputy appointed by employee organization   |
| <b>Year of birth, education and nationality</b>   | 1966, M.Sc. in Electrical engineering, Swedish.   | 1976, Swedish.   | 1985, B.Eng. in Chemical engineering, Swedish.  | 1991, Swedish.  |
| <b>Board assignments</b>  | –   | –  | –   | –   |
| <b>Professional experience, previous assignments and other information</b>                                      | Specialist, Research & Development at Maquet Critical Care AB.<br>Assignments on Getinge's Board: Ordinary Board member 2016–2018, 2020–2022 and from October 2022. Deputy 2014–2016, 2018–2020 and 2022. | Workshop technician, Manufacturing at Getinge Disinfection AB.<br>Assignments on Getinge's Board: Deputy 2020–2021. Ordinary member from April 2022. | Manager Master Data Operations, IT at Getinge Business Support Services.<br>Assignments on Getinge's Board: Deputy representative since 2022. | Functional tester at Getinge Sterilization AB.<br>Assignments on Getinge's Board: Deputy representative since 2022. |
| <b>Attendance at meetings</b>   |   |  |   |   |
| Board meetings  | 13/13   | 13/13  | 13/13   | 13/13   |
| Remuneration Committee  | –   | –  | –   | –   |
| Audit and Risk Committee  | –   | –  | –   | –   |
| Ethics and Sustainability Committee   | –   | –  | –   | –   |
| <b>Independence<sup>1)</sup></b>  |   |  |   |   |
| Dependent/independent in relation to the company and executive management and in relation to major shareholders | –   | –  | –   | –   |
| <b>Remuneration and holdings</b>  |   |  |   |   |
| Total remuneration in 2024, SEK   | –   | –  | –   | –   |
| Holdings in Getinge AB (publ) (own and related parties <sup>2)</sup> )  | 100 Class B shares.   | Holds no shares.   | 45 Class B shares.  | Holds no shares.  |

**Definition of related parties, linked to shareholdings:**

Related parties are legal entities directly or indirectly controlled by the Board member or President & CEO or by his or her related parties. In the case of physical relatives, the spouse/cohabiting partner, children under custody and other relatives with whom households have been shared for at least one year are covered.

1) See further on the independence of the Board on page 36.

2) See also the definition of related parties above.

**Introduction**

**Strategy**

**Corporate Governance Report**

Corporate governance structure

Board of Directors

**President & CEO and Getinge Executive Team**

Building blocks in the Getinge corporate governance model

Assurance framework, risks and risk management

Internal control over the financial reporting

Auditor’s report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

**I PRESIDENT & CEO AND GETINGE EXECUTIVE TEAM**

**President & CEO**

The Board of Directors has delegated the day-to-day management of Getinge and the overall management of the Group’s operations to the President & CEO, including an authorization to make decisions or govern all matters that are not exclusively under the authority of the Board of Directors.

It is the President & CEO’s responsibility to implement and ensure that the strategies, business plans and operational objectives that the Board adopts are carried out and that effective internal governance and control are maintained. The President & CEO also reports at Board meetings and keeps the Board of Directors and its Chairman up to date on Getinge’s financial position, development, risks and opportunities, and the progress of sustainability activities. The President & CEO’s role, areas of responsibility and authorizations are described in more detail in the instruction for the CEO and for financial reporting.

**Getinge Executive Team**

The President & CEO is supported by the Getinge Executive Team in conducting Getinge’s operations. The Getinge Executive Team comprises the business area presidents, the head of the Global Sales and Service organization, the CFO and heads of the Group support functions.

The President & CEO delegates roles and responsibilities to the Executive Team, which then structures its own management teams and ensures that strategic matters, leadership, product quality, ethics and compliance, and sustainability matters are integrated into the business.

**Forum at Getinge Executive Team level**

Internally, Getinge has a continuous need for coordination and interaction between various functions and competencies in the global organization. Cross functional forums and meeting structures have been established at the Group level to ensure acceptance and coordination and to assist the President & CEO and the Getinge Executive Team in making well-informed decisions, and also to provide a defined structure for escalation to the Getinge Executive Team and the Board of Directors.

**Getinge Executive Team 2024**

At year-end 2024, Getinge Executive Team comprised ten individuals. The Getinge Executive Team held six ordinary meetings in 2024 and remained in continuous contact and alignment between meetings. The primary focus of the meetings was the Group’s strategic and operational performance and monitoring of results. During the year the Getinge Executive Team addressed topics such as sustainability, the acquisition agenda, the changing global land-

scape and financial situation, challenges in the supply chain and other external factors. One of the major focus areas for 2024 has been the Group’s quality activities, both in terms of communicated challenges in quality and remediation activities related to this, but also in terms of proactive work to strengthen processes and refine relevant systems.

**Forum at Getinge Executive Team level**

| Forum                             | Responsibilities  |
|-----------------------------------|---|
| Sustainability Board              | Governance across all sustainability-related areas. This includes preparing proposals, initiatives and guiding principles for the Executive Team, the Ethics and Sustainability Committee and the Board of Directors. |
| Sponsorship & Donations Committee | Pre-approval of sponsorships and donations.   |
| IT Board                          | Prioritizing coordination and decisions on IT activities and proposing decisions on IT investments to the Executive Team.   |
| Ethics Committee                  | Follow ups of internal investigations and compliance issues and measures taken as a result. Also has decision-making powers regarding relations with third parties where specific risks have been identified.         |
| Disclosure Committee              | Previews proposed disclosures in financial reports, and makes recommendations to the Audit and Risk Committee and the Board of Directors on these.  |
| Insider Committee                 | Supports the President & CEO in managing insider information issues and the disclosure of these.  |
| STIP Steering Committee           | Prepares – in relation to non-executives – the annual variable remuneration process, performance targets and any deviations or adjustments.   |

**Introduction**

**Strategy**

**Corporate Governance Report**

Corporate governance structure

Board of Directors

**President & CEO and Getinge Executive Team**

Building blocks in the Getinge corporate governance model

Assurance framework, risks and risk management

Internal control over the financial reporting

Auditor’s report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

# Executive Team



| Mattias Perjos (1972)   | Agneta Palmér (1978)   | Carsten Blecker (1966)   | Elin Frostehav (1982)   | Stéphane Le Roy (1977)  | Eric Honroth (1971)  |
|---|--|--|---|---|--|
| President & CEO   | Chief Financial Officer  | Chief Commercial Officer   | President, Acute Care Therapies   | President, Surgical Workflows   | President, Life Science  |
| M.Sc. in Industrial Engineering and Management  | M.Sc. in Economics   | PhD in Dentistry; Doctorate in Business Administration, Bachelor in Medicine   | Master of Science Program in Industrial Engineering and Management  | M.Sc. in Industrial Engineering   | B.Sc. in Business and Marketing  |
| Swedish citizen   | Swedish citizen  | German citizen   | Swedish citizen   | French citizen  | US citizen   |
| Employed at Getinge since 2017  | Employed at Getinge since 2018   | Employed at Getinge since 2014   | Employed at Getinge since 2019  | Employed at Getinge since 2012  | Employed at Getinge since 2018   |
| Shareholdings (own and related parties): 200,000 Class B shares   | Shareholdings (own and related parties): 2,800 Class B shares  | Shareholdings (own and related parties): 7,200 Class B shares  | Shareholdings (own and related parties): 4,000 Class B shares   | Shareholdings (own and related parties): 5,300 Class B shares   | Shareholdings (own and related parties): 1,025 Class B shares  |
| <p>Previous experience:</p> <p>Mattias Perjos has held senior positions at Coesia 2012–2017, including CEO of Coesia IPS Division and Coesia International. Previously he was CEO of Flexlink 2006–2016 where he started his career in 1998 and served as business area manager 2003–2006.</p> <p>Other assignments: Board member of EUROAPI S.A. Member of International Chamber of Commerce (ICC) Sweden’s Board.</p> | <p>Previous experience:</p> <p>Until March 2024, Agneta Palmér held the position of Executive Vice President Operational Services and prior to that was Vice President Corporate Control at Getinge. She has previously held leading positions in finance in the Volvo Group and before that worked as a management consultant with a focus on business development, process optimization and financial control.</p> | <p>Previous experience:</p> <p>Carsten Blecker previously served as President EMEA, responsible for all of Getinge’s country organizations in the region. Before that, he was Head of Biomet’s Dental business for EMEA. Prior to that, Carsten was with Palex Medical as Business Unit Director. Carsten also worked for McKinsey &amp; Company, Kimberly-Clark Healthcare EMEA and Medtronic EMEA.</p> | <p>Previous experience:</p> <p>Until March 2022, Elin Frostehav was Vice President of Critical Care, a product segment in Acute Care Therapies at Getinge. She has previously held leading global positions within Semcon in the areas of product development and digitalization. Prior to Semcon, Elin held various positions at FlexLink.</p> | <p>Previous experience:</p> <p>Stéphane Le Roy most recently served as the Regional President of South West Europe in Getinge’s Global Sales organization. He joined Getinge in 2012 as country manager for Infection Control in France. Between 2006 and 2012, he was business unit manager for CT Scanners for Siemens Healthcare in France. Before that, he held several product management positions and supply chain assignments within the field of medical imaging at GE Healthcare.</p> | <p>Previous experience:</p> <p>Until March 2022, Eric Honroth was President of the North America sales region in Getinge’s Global Sales organization. He has more than 20 years of experience in global leadership roles in the medical devices industry, including roles at Becton Dickinson, CareFusion and Abbott Vascular.</p> |

**Introduction**

**Strategy**

**Corporate Governance Report**

Corporate governance structure

Board of Directors

**President & CEO and Getinge Executive Team**

Building blocks in the Getinge corporate governance model

Assurance framework, risks and risk management

Internal control over the financial reporting

Auditor's report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

**Getinge Executive Team cont.**



| <b>Joanna Engelke (1960)</b>   | <b>Magnus Lundbäck (1969)</b>   | <b>Anna Romberg (1979)</b>  | <b>Alexandra Holland (1986)</b>  |
|--|---|---|--|
| Executive Vice President, Quality Compliance, Regulatory & Medical Affairs   | Executive Vice President, Human Resources   | Executive Vice President, Sustainability, Legal & Compliance  | Executive Vice President, Communications   |
| MBA, B.A. in Political Science   | PhD in Strategy and Organization and Technology Licentiate  | PhD in Corporate Governance and Compliance, M.Sc. in Economics and Business Administration  | Bachelor of Science in Communications  |
| US citizen   | Swedish citizen   | Finnish citizen   | US citizen   |
| Employed at Getinge since 2022   | Employed at Getinge since 2017  | Employed at Getinge since 2020  | Employed at Getinge since 2024   |
| Shareholdings (own and related parties): Holds no shares.  | Shareholdings (own and related parties): 7,842 Class B shares   | Shareholdings (own and related parties): 7,100 Class B shares   | Shareholdings (own and related parties): Holds no shares.  |
| <p>Previous experience:</p> <p>Joanna Engelke has solid experience from areas of regulatory healthcare in international companies. She has previously held leading positions as Head of New Ventures &amp; Chief Quality Officer for JUUL Labs, Senior Vice President Global Quality &amp; Regulatory Affairs at Boston Scientific Corporation, Managing Director at Holloran Consulting Group and Portfolio CEO, Biospecific at PureTech Ventures among others.</p> | <p>Previous experience:</p> <p>Magnus Lundbäck was previously SVP Human Resources &amp; Sustainability at Gunnebo Group. He has previously served as Executive Vice President Human Resources and Sustainability at Getinge and as Vice President Human Resources at Volvo Car Corporation.</p> | <p>Previous experience:</p> <p>Anna Romberg has served as VP Ethics and Compliance for Cargotec Oyj, and in various governance and compliance roles at Telia Company AB. She has also supported numerous global companies, with regards to governance and compliance matters, on a consultancy basis. She is one of the founders of the Nordic Business Ethics Initiative.</p> <p>Other assignments: Chairman of the Board of North House AB.</p> | <p>Previous experience:</p> <p>Until November 2024, Alexandra Holland was Vice President, Business and Culture Communications, Johnson &amp; Johnson MedTech. She has more than 15 years of leadership experience in healthcare communications working across the consumer, medtech and corporate sectors.</p> |

**Introduction**

**Strategy**

**Corporate Governance Report**

Corporate governance structure

Board of Directors

President & CEO and Getinge Executive Team

**Building blocks in the Getinge corporate governance model**

Assurance framework, risks and risk management

Internal control over the financial reporting

Auditor’s report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

## Building blocks in the Getinge corporate governance model

Getinge’s operational corporate governance model consists of three main components: governing principles and documents, operational governance and legal entity governance.

Combined, these components form the building blocks for Getinge’s corporate governance model and conditions for meeting targets, monitoring and control, which supports the Board’s agenda.



Framework for Getinge’s corporate governance.

**Getinge guiding principles and steering documents**

**Guiding principles**

Getinge’s expressed vision, purpose, goals, brand promise and cultural core values are used as guiding principles for its operations. The Board of Directors establishes the general long-term strategy, which sets the direction for the coming years, as well as annual operational and financial targets. The Board also evaluates the strategy for all business areas and the Global Sales and Service organization once per year.

The President & CEO establishes the operational targets for the business, based on decisions by, and guidance from, the Board.

**Steering documents – framework**

The Code of Conduct – Responsible leadership – provides guidelines for how Getinge works. It can be summarized in the six principles in the figure on this page.

The Code of Conduct is based on Getinge’s global policies adopted by the Board and revised at least every two years.

For each of the policy documents, more detailed and guiding directives and guidelines are issued (where appropriate) that are decided upon by the CEO or member of the Executive Team responsible for the area.

The Code of Conduct and all policy documents, directives and guidelines as well as quality steering documents are available to all employees. The Code of Conduct and several global policies are also available on Getinge’s website.

**GETINGE’S CODE OF CONDUCT**

-   
 Always act with honesty, fairness and integrity
-   
 Act respectfully to protect confidentiality, privacy and information
-   
 Take care of each other
-   
 Take care of the world
-   
 Stand up and speak up when something isn't right
-   
 Act together to protect our stakeholders

 Read more at the link below:  
<https://www.getinge.com/int/company/business-ethics/code-of-conduct/>

**Introduction**

**Strategy**

**Corporate Governance Report**

Corporate governance structure

Board of Directors

President & CEO and Getinge Executive Team

**Building blocks in the Getinge corporate governance model**

Assurance framework, risks and risk management

Internal control over the financial reporting

Auditor's report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

**Getinge's operating model**

Getinge's operating model aims to create a clear structure and distribution of roles within the Group. It is based on what and how Getinge develops, manufactures, serves and sells to customers and capitalizes on the differences between the business areas. The operating model is based on decentralized decision-making under the established Group-wide frameworks and strategies.

**Business areas**

The operational business areas are Acute Care Therapies, Life Science and Surgical Workflows. The business areas are responsible for (i) their daily operations and integrated financial results, (ii) developing their product portfolios and offerings, and (iii) their strategic agendas. They are also responsible for ensuring that the operations are conducted in accordance with laws and rules, and for ensuring that quality and regulatory requirements are met and that sustainability topics are integrated into operations.

**Global Sales and Service organization**

The operational business also includes a Group-wide Global Sales and Service organization to capitalize on synergies in sales. The function coordinates larger strategic decisions with the business areas and assumes the ultimate responsibility for ensuring that sales are conducted in accordance with laws and rules and that quality and regulatory requirements are met.

**Competence and support functions**


Getinge has certain shared competence and support functions that are organized into two categories. Corporate functions provide steering in areas at Group level and are responsible for developing policies, guidance, processes and structures. Getinge has a centralized Ethics & Compliance function that is responsible for designing the compliance programs, providing support for

implementing and monitoring such implementation. Getinge also has a separate Corporate Internal Audit function. See also page 48 for information about these supervisory functions. The group support functions are competence and support functions for coordination of a variety of areas and are more active operationally in daily activities.

**Legal entity governance**

Getinge comprises a large number of separate legal entities globally. Each legal entity within Getinge functions as part of an operational business area, the Global Sales and Service organization, the corporate functions or the Group support functions.

Governance of the legal entities must be effective and designed to ensure compliance with rules and intra-Group requirements.



1) Includes Strategy, M&A and Investor Relations  
 2) Also includes Treasury, Tax, Corporate Control, Risk Management, IT and Supply Chain Services.  
 3) Reports directly to the Audit and Risk Committee.

**Introduction**

**Strategy**

**Corporate Governance Report**

Corporate governance structure

Board of Directors

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

**Assurance framework, risks and risk management**

Internal control over the financial reporting

Auditor’s report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

## Assurance framework, risks and risk management

### Risk management framework

Getinge actively and systematically manages the risks that the Group is exposed to. In accordance with this, the Getinge Executive Team conducts an annual evaluation of material risks and effects. Based on this evaluation, the Executive Team decides and acts on measures to reduce risks and their effects. The risk evaluation is reported to the Board of Directors and serves as a key basis in determining the focus areas for Corporate Internal Audit.

Risks at Getinge are managed in accordance with the Group’s decentralized structure. The three business areas and the Global Sales and Service organization are responsible for risk management in their respective areas and have their own structures for this purpose. The corporate and Group support functions support these units by providing governance, developing processes and promoting synergies in their specific areas of competence. Several established forums that focus on specific types of risks conduct regular evaluations and monitoring to ensure correct coordination and management from a Group perspective. Examples of these forums are the Ethics Committee, Sustainability Board and the Group’s risk manager forum. To manage cyber risks, Getinge also has a Chief Information Security Officer (CISO) who coordinates this work via, inter alia, a Security Advisory Board and a Getinge Centre of Excellence for cyber security linked to the Group’s products.

### Risk assessment

By conducting quantitative and qualitative risk analyses focusing on the customer offering and operations, Getinge identifies the key risks that could prevent the achievement of business and financial targets. In addition, several of the Group’s units are analyzed to gain a more detailed understanding of how existing regulations are applied in practice. The overall responsibility for identifying and managing potential risk areas lies with the Getinge Executive Team and the operations. The Ethics & Compliance function and Corporate Internal Audit assist with support, ongoing monitoring, investigations and internal audit, which help to identify risk.

In 2024, Getinge continued its efforts to strengthen the process for risk identification, preventive action and risk management in the Corporate Risk Management function, with support from Corporate Internal Audit. The risk identification process was, as in previous years, carried out as a Group-wide analysis based on consolidated input data from the three business areas, the Global Sales and Service Organization and support functions. Financial risks and opportunities from a sustainability perspective are evaluated in Getinge’s double materiality assessment (DMA) process and then incorporated into the overall process. The most relevant identified risks are presented on the following pages, but do not comprise a complete account of all of the risks to which the Group is exposed. The risks are divided into three categories:

- External – risks that cannot be controlled, but that are monitored and prepared for in order to optimize outcomes and turn risks into opportunities;
- Operational – risks that can be controlled and are to be managed in a cost-efficient manner to minimize negative effects, where the company has a direct impact on the root causes; and
- Strategic – risks and opportunities that the company is exposed to and are to be managed by balancing risks and the potential for maximizing advantages.

Efforts to identify specific risks in each category and develop plans to prevent risks and mitigate the potential effects were continually conducted during the year.

### Getinge’s insurance program

#### Strategy

Getinge works actively with loss prevention activities, for example, through its extensive quality activities and by preventing interruption risks in the operations. The starting point is for Getinge to act as if the Group was uninsured. That means that Getinge continuously considers risk factors and manage them as part of the daily work. Actively monitoring incidents and correcting underlying causes means that claims related to product liability can be prevented.

#### Group-wide insurance program

Getinge has a Group-wide insurance program that encompasses the global operations. The program aims to protect the assets in the consolidated balance sheet and to counteract fluctuations in earnings. The aim is to cover insurable risks with adequate limits based on current risk exposure levels. Insurance policies have been entered into with insurance companies with high credit ratings and a documented ability to provide claims assistance. The joint insurance programs create economies of scale, ensure a harmonized approach to limits and deductibles and is the foundation of balanced and cost-efficient insurance policies.

#### Customer value

A stable and standardized insurance coverage for the Group’s global operations also adds customer value since it is required in many tender and procurement processes and when commercial contracts are signed.

**Introduction**

**Strategy**

**Corporate Governance Report**

Corporate governance structure

Board of Directors

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

**Assurance framework, risks and risk management**

Internal control over the financial reporting

Auditor's report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

**Ethics & Compliance**


The risk identification system and management process is supplemented by the Ethics & Compliance function. The function is responsible for the global Ethics & Compliance program, sets standards and processes, and monitors the use and implementation of these. The function also manages the Group's Speak-Up Line (whistleblower function) and performs risk assessments and internal investigations. Internal investigations and whistleblowing cases are reported to the Audit and Risk Committee, other work is reported to the Ethics and Sustainability Committee. An update is also presented to the Board in its entirety once a year. More information on the Ethics & Compliance function is presented in the Sustainability Report on page 136.

**Corporate Internal Audit**

Getinge's internal audit function, Corporate Internal Audit, aims to provide independent audit of operational governance in selected areas, with a focus on effectiveness and risk management. The annual internal audit plan is based on identified risks and function-specific and industry-related risk assessments. Each year, priority is assigned to a number of units, Group-wide processes or thematic areas for auditing, in which improvement areas are identified and graded based on their potential business impact. The areas are based on the annual plan but can also be adapted to issues that arise during the year. For all observations, an action plan is prepared in collaboration with each business owner. The Corporate Internal Audit function follows up on and ensures that actions plans are conducted within defined time periods.

In 2024, the work to develop the internal Corporate Internal Audit function continued under the Head of Internal Audit who reports directly to the Audit and Risk Committee, but belongs to the management team for Sustainability, Legal & Compliance.

**GETINGE'S GOVERNANCE AND ASSURANCE FRAMEWORK**



1) The first pillar's control activities include: quality systems audit (at certificate level), management control self-assessment and remediation of audit and investigations findings.  
 2) The second pillar's control activities include: The Ethics & Compliance function's risk monitoring and risk assessment, internal controls (management testing) and Corporate Quality Audit.

**Introduction**

**Strategy**

**Corporate Governance Report**

Corporate governance structure

Board of Directors

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

**Assurance framework, risks and risk management**

Internal control over the financial reporting

Auditor’s report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

**GETINGE’S PRIMARY RISKS, CONSEQUENCES AND MANAGEMENT**

| EXTERNAL RISKS  | Description   | Potential consequences  | Management   |
|---|---|---|--|
| <b>External shocks, such as geopolitical risks, natural disasters, terrorism, pandemics, etc.</b> | Rapidly emerging situations, which could affect large geographical areas, a single country, a region or a specific facility.  | The primary risk of such events is that employees could be injured. In addition, operations can be disrupted, which could have a negative impact on sales and earnings.   | Active business intelligence can identify some of these risks at an early stage, which enables the Group to adapt to the changed circumstances. The process of further strengthening the Group’s management of continuity risks continued in 2024. This also includes scenarios based on external shocks as part of Getinge’s proactive risk management.<br><br>Getinge conducts operations in Russia in accordance with international sanctions and regulations via a small sales company. The activities in the country are currently limited to fulfilling existing customer commitments. However, the circumstances for conducting operations in the country have gradually deteriorated. Getinge does not conduct any manufacturing operations in either Russia or Ukraine and has no major suppliers in these countries. When Russia invaded Ukraine in 2022, the Group’s sales in Russia and Ukraine represented less than 1% of the Group’s total net sales and equity. Despite the limited direct impact that the invasion has had on Getinge’s operations in Russia and Ukraine, the Russian invasion of Ukraine may nevertheless have a negative impact on the development of the Group’s earnings and position. However, it is difficult at the current time to assess the future consequences of the conflict and its impact on the Group.<br><br>Getinge is actively monitoring the current debate on trade barriers such as tariffs. Getinge has a geographically diversified purchasing and production strategy which partly can help to mitigate any negative consequences. |
| <b>Interruptions in supply chains / dependence on external suppliers</b>                          | Critical components manufactured by external suppliers are a vital part of Getinge’s production chain. Serious production disruptions may arise if these components are not supplied on schedule. | As a consequence, vital equipment may not be delivered to customers, which may make it difficult or impossible to provide necessary healthcare.   | Getinge actively monitors critical suppliers, starting as early as when the partnership is established and continuing with routine evaluations. The Purchasing organization has tools for assessing risk and receives regular training in this area. The Group also works on ensuring that it has adequate levels of critical components in stock, in its own operations or with the relevant supplier. Interruptions of critical deliveries are also managed as an important part of activities related to business continuity risks. See "Business interruptions."   |
| <b>Risks related to healthcare reimbursement systems</b>  | Political decisions can change the conditions for healthcare through changed reimbursement models for healthcare providers.   | Changes to reimbursement systems could have significant effects on specific markets, with budget cuts or deferred funding potentially impacting the operations.   | Although it is difficult to influence this risk directly, since decisions are outside the Group’s control, it is mitigated by the presence in a large number of markets, which reduces the overall impact of individual changes.   |
| <b>New competitors and new technologies</b>   | Certain markets and product segments have niche players who offer solutions outside customary market behavior.  | These competitors could capture market shares from established companies, including Getinge, which could result in lower sales and earnings.  | Through continuous innovative development and market analysis, Getinge strives to be at the forefront, identify potential competitors and adapt to technological changes. The industry is also considered to have high barriers to entry since medical devices are subject to extensive regulatory requirements.   |
| <b>Increased expectations and new laws and regulations related to sustainability</b>              | The sustainability requirements and expectations placed on Getinge as a company are changing, and the scope is increasing rapidly.  | Getinge’s failure to meet the ever-more stringent environmental, social and governance requirements could have negative consequences on the company’s reputation, operations and financial earnings. It may also impact the company’s ability to recruit and retain competent staff, and risk disqualifying the company from participating in tenders with specific requirements. | By engaging with stakeholders and improving its materiality assessment and ERM process, Getinge increases its understanding of the expectations placed on the company. It also helps that the company is adopting the focus areas that are to be prioritized moving forward.<br><br>In addition, the company has developed its sustainability framework, focusing on the products and solutions placed on the market to ensure quality and corporate responsibility. This also leads to employee engagement. The company reports annually on its performance in sustainability in a transparent manner in accordance with the GRI standards and is making preparations ahead of the forthcoming CSRD regulation.   |
| <b>Increasing competition for public funds</b>  | Reduced public budgets for investing in medical devices impacts the total market potential.   | Increased competition for limited public funds may lead to reduced funding for medical device investments, which in turn negatively impacts Getinge’s sales figures.  | Getinge works actively to offer solutions that improve the efficiency of healthcare, which is believed to generate healthy demand even where budgets are constrained.  |

**Introduction**

**Strategy**

**Corporate Governance Report**

Corporate governance structure

Board of Directors

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

**Assurance framework, risks and risk management**

Internal control over the financial reporting

Auditor’s report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

| OPERATIONAL RISKS                                  | Description   | Potential consequences   | Management  |
|--|---|--|---|
| <b>Quality risks from a regulatory perspective</b> | A large part of Getinge’s product range is subject to strict legislation requiring extensive assessments, quality controls and detailed documentation.  | It cannot be ruled out that Getinge’s operations, financial position and earnings may be negatively impacted in the future if the company is unable to comply with regulatory requirements or if these requirements change.                              | <p>To limit these risks, Getinge conducts extensive quality and regulatory activities. The Quality Compliance, Regulatory &amp; Medical Affairs function has a representative in the Getinge Executive Team and also on the management teams of each business area, and in all R&amp;D and production units. In addition, Getinge’s sales force and service technicians receive quality and regulatory training every other year, and then have their certification renewed, which is a requirement for representing the company. Getinge conducts extensive research and development to ensure that the product portfolio meets all existing and future quality and regulatory requirements.</p> <p>The majority of the production facilities have ISO 13485 and/or ISO 9001 certification. In summary, Getinge invests significant resources in quality and regulatory matters, which is a top priority of the Group’s strategy.</p> <p>As previously reported in the first quarter of 2023, the notifying body TÜV SÜD decided to temporarily suspend the CE certificate for Getinge’s HLS and PLS sets for ECLS therapy and for Getinge’s intra-aortic balloon pumps. As a result, the company initiated corrective actions to regain CE certification for these products. At the end of September 2024, TÜV SÜD reinstated Getinge’s CE certificate for HLS and PLS sets, with certain conditions. The temporary suspension of Getinge’s Cardiosave intra-aortic balloon pump, effective from March 2024, was extended until July 1, 2025. On May 8, the FDA sent a letter to healthcare providers in the US. The letter does not refer to any new field actions, but healthcare providers are encouraged to move from using Getinge’s Cardiosave, Cardiohelp and HLS sets to alternative products and to continue to use Getinge’s products only if no other options are available. As a result of the FDA’s letter, Getinge has decided to suspend marketing activities for the relevant products in the US until outstanding actions related to quality improvements have been taken and approved. Sales of these products are restricted to customers who do not have any other alternatives.</p> <p>On November 15, 2024, the FDA published a Letter to Health Care Providers on its website, reminding them of the voluntary medical device removal and supply concerns related to all of Getinge’s VasoView Hemopro endoscopic vessel harvesting (EVH). Actions are being taken as agreed with the FDA.</p> |
| <b>Product quality from a customer perspective</b> | In certain cases, Getinge’s products do not meet customer expectations.   | Product quality shortcomings could lead to customer seeking out alternative suppliers, which in turn could negatively impact sales and profitability over time.  | Getinge applies a comprehensive quality process to ensure a high and even level of quality, which is an ongoing process that results in continuous improvements. When quality fails, it is important to rapidly rectify the fault during the first service visit. Getinge closely monitors the “first-time fix” factor of its services operations and works actively to make improvements.  |
| <b>Product liability risks</b>                     | Healthcare suppliers run a risk, like other players in the healthcare industry, of being subject to product liability and other legal claims.   | Such claims can involve large amounts and significant legal expenses. Getinge carries the customary indemnity and product liability insurances, but there is a risk that this insurance coverage may not fully cover product liability and other claims. | <p>The most important way of managing these risks is the extensive quality-related and regulatory activities performed by the Group. Sources of potential future liability claims are monitored through active incident reporting. Corrective and protective action (CAPA) is initiated when necessary to investigate the underlying cause, after which the product design may be corrected to remedy the fault.</p> <p>The settlement process regarding the Multidistrict Litigation (MDL) for surgical mesh implants, which Getinge announced previously, has been completed and payment of the majority of the settlement amount was made in the first quarter of 2023. The settlement is not an admission of liability or wrongdoing by the company. Getinge will continue to defend against any litigation that cannot be resolved under the final agreement. Costs for such processes are not expected to be material.</p>  |
| <b>Information and data security</b>               | Leaks of confidential information or hacking into the Group’s IT system resulting in restricted availability or interruptions of business-critical systems. In this context, extortion or sabotage cannot be excluded either. | Hacking into IT systems could lead to business interruptions. A loss of sensitive information may adversely affect confidence in the company. Leaks of personal data could lead to high fines.   | Getinge’s IT structure in production is largely decentralized, which reduces the consequences of any unauthorized access by spreading the risks across different systems. At the same time, a shared infrastructure for central services ensures efficiency and coordination where necessary. During the year, the Group improved authentication processes to prevent hacking, and this process will continue in the years ahead. Getinge conducts extensive surveillance and monitoring of the central infrastructure to quickly detect and counteract security threats.   |

**Introduction**

**Strategy**

**Corporate Governance Report**

Corporate governance structure

Board of Directors

President & CEO and Getinge

Executive Team

Building blocks in the Getinge corporate governance model

**Assurance framework, risks and risk management**

Internal control over the financial reporting

Auditor’s report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

| OPERATIONAL RISKS                               | Description   | Potential consequences  | Management   |
|---|---|---|--|
| <b>Deficiencies in cybersecurity</b>            | Security deficiencies in the Group’s digital offering, such as connected machines at customer sites and stricter legal requirements for processing personal data. In this context, extortion or sabotage cannot be excluded either.   | Restricted availability of equipment delivered by Getinge to its customers, which could result in interruptions to the hospital operations and it not being possible to offer patients sufficient care in critical situations.  | Getinge works diligently and systematically, following a risk-based approach, to ensure the integrity of its connected equipment. By continuously evaluating and prioritizing security risks, we can effectively protect both our systems and customers’ data. Comprehensive access testing is carried out before these solutions are offered to the Group’s customers so as to identify and rectify potential vulnerabilities.  |
| <b>Business interruptions</b>                   | Unforeseen events, such as natural disasters or fires, etc. can cause disruptions to production or the supply chain.  | Such events may result in costly, delayed or non-delivery of products to Getinge’s customers, which may adversely affect the Group’s earnings.  | There is a risk of temporary business interruptions, for example, due to supply constraints for key components such as semi-conductors, as a result of the uncertain global security situation. Getinge takes continuous preventive action to ensure a high level of availability and delivery reliability, including regular inspections of the production facilities with the help of external expertise.  |
| <b>Non-compliance with laws and regulations</b> | Breaches of laws and regulations related to, for example, competition, anti-corruption, AI, cyber security, data protection or trade restrictions.  | Breaches of these regulations could lead to fines, sanctions and have a negative impact on the Getinge brand.   | Getinge has previously provided information about ongoing investigations and agreements with the authorities regarding anti-competitive procedures in the sale of medical devices in Brazil. The process with the Brazilian federal authority, Comptroller General of the Union (CGU), is still ongoing. During the third quarter of 2024, Getinge made, in line with applicable accounting standards, a provision of SEK 482 M related to anticipated costs related to this process. The provision is the result of an ongoing constructive dialogue to reach a conclusion in the negotiations with the CGU. The final and definitive costs will be determined once the negotiations have been concluded, and such an amount could be lower or higher than the provision that has now been made. No information emerged in the fourth quarter of 2024 that would cause a change in the provision.<br><br>In addition to the investigations with CGU, Getinge has previously communicated that settlement agreements have been reached with the Brazilian Federal Prosecutor’s Office (Ministério Público Federal) in 2018 and the competition authority, Administrative Council for Economic Defense (CADE) in 2019, both related to anti-competitive practices relating to the sale of medical devices. It cannot be ruled out that any further agreements with authorities may have a material impact on the company’s financial earnings and position, but cannot currently be estimated neither in terms of amount nor timing. Getinge has a zero tolerance policy when it comes to breaches of these regulations. The Group’s Code of Conduct is very clear in this respect.<br><br>The EVP Sustainability, Legal & Compliance represents the Ethics & Compliance function in the Getinge Executive Team, which highlights the high priority of these issues. A training program in business ethics is provided on an ongoing basis and the aim is for all employees to undergo such training at least once a year. The regulations also apply to external distributors who sell Getinge products. |
| <b>Dependence on meeting climate targets</b>    | Getinge is dependent on meeting the climate targets set to reach net-zero emissions by 2050 that were approved by the SBTi. Getinge’s analysis shows that the majority of emissions come from the purchases of goods, logistics and the use of sold products. As a result, the company does not have full control over its emissions and cannot therefore directly control their reduction. | If Getinge does not meet its climate targets, it could have a significant negative impact on the company’s reputation and operations, in addition to negative climate impacts.  | In 2024, Getinge continued to focus on the actions that will be required to meet its Scope 3 emissions target (25% reduction by 2030) such as reducing air freight, improving energy efficiency for products introduced to market and replacing materials with high emissions. At the same time, the company is preparing for dialog both upstream and downstream in the value chain to increase the use of renewable electricity and energy.  |
| <b>Lack of future skills</b>                    | Risk of dependency on key people including lack of succession planning and ineffective processes to identify and spread critical know-how within the organization. Also the risk of being unable to attract and retain the right talent and skills.   | A lack of future skills could lead to higher staff turnover, operational disruptions and damage the Getinge brand. In the future, it may have a negative impact on Getinge’s long-term sustainability and growth, and ultimately affect Getinge’s ability to attract and retain talent. | Getinge is continuously improving the succession planning process to ensure the global development of talent. Getinge is focusing on talent mobility and knowledge sharing and strives to create a culture and leadership that attracts both new and existing talent. Getinge’s aim is to be a company where everyone can thrive and grow.   |

**Introduction**

**Strategy**

**Corporate Governance Report**

Corporate governance structure

Board of Directors

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

**Assurance framework, risks and risk management**

Internal control over the financial reporting

Auditor’s report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

| STRATEGIC RISKS  | Description   | Potential consequences   | Management  |
|--|---|--|---|
| <b>Digitalization and innovation</b>                           | Getinge’s future growth depends on successful product development, particularly in digitalization. Innovation is crucial for maintaining and strengthening the company’s leading position.  | Innovation efforts are costly and it is not possible to guarantee that developed products will be commercially successful, which could result in impairment. In the long term, the Group’s market position could be negatively affected if Getinge is unsuccessful in this area. | As means of maximizing the return on investments in research and development, the Group applies a structured selection and planning process that includes careful analyses of the market, technological progress, choice of production method and selection of subcontractors. The actual development work is also conducted in a structured manner and each project undergoes a number of fixed controls. Getinge is particularly concerned with ensuring access to the right skills, retaining key individuals, being an attractive employer to recruit talent externally, and identifying and developing talent within the organization. |
| <b>Fragmented product portfolio</b>                            | Getinge’s product portfolio consists, to a certain extent, of a large number of acquisitions that were made throughout the years within a variety of product categories.  | An offering to our customers that, in certain parts, is too diverse could lead to Getinge lacking the critical mass needed to conduct fully efficient operations in all product categories.  | Efforts are being made to enhance the efficiency of the customer offering under the framework of the ongoing strategic activities in each business area. The introduction of the EU Medical Device Regulation means priorities need to be made regarding the certification of products under the new regulatory framework. Products have been selected that, over the long term, will be a part of the customer offering, which will lead to increased concentration as well as streamlining.   |
| <b>Risks related to intellectual property rights</b>           | Getinge’s leading positions in many product segments are based on patent and trademark rights, which could lead to disputes with competitors.   | Costly disputes over intellectual property rights could reduce the return on investment in research and development.   | Getinge closely monitors the activities of its competitors and actively defends its intellectual property rights through legal processes if necessary.  |
| <b>Financial risks</b>   | Getinge is exposed to a number of financial risks in its operations. Financial risks principally pertain to currency risks, interest-rate risks, and credit and counterparty risks.   | Fluctuations in exchange rates and interest rates and changes in counterparties’ credit profiles could adversely affect the Group’s income statement and balance sheet.  | Risk management is regulated by the finance policy adopted by the Board and a Treasury Directive approved by the Getinge Executive Team based on the finance policy. The ultimate responsibility for managing the Group’s financial risks and developing methods and principles of financial risk management lies with the Getinge Executive Team and the Treasury function. For more detailed information concerning these risks, refer to Note 18 of the Annual Report.   |
| <b>Profitability dependent on certain products and markets</b> | Some products and markets contribute more to overall profitability.   | If sales volumes in these markets were to decrease, it could have a negative impact on the Group’s profitability.  | Getinge works actively to monitor profitability per product and market in order to ensure profitability over time. To reduce the sensitivity of profitability, the Group actively works on ensuring that it has the right cost level in relation to the current price levels in the market. Getinge also works actively to establish itself in new markets.   |
| <b>Transferring the product portfolio</b>                      | Long lead times in research and development due to comprehensive regulations and long validation processes are hampering rapid development to more sustainable product and packaging solutions. The medical device market is strictly regulated, partly to ensure patient safety, which can affect how quickly Getinge’s products can become sustainable. | If it is not possible to transfer Getinge’s product and packaging solutions to more sustainable solutions quickly enough, there is a risk that Getinge’s reputation and competitiveness could decline.   | Getinge will always prioritize patient safety and follow applicable regulations. Without impacting Getinge’s fundamental approach, the company has expanded the implementation of eco-design principles in its development process and has begun to carry out life cycle assessments of its product and packaging solutions to ensure that advances can be made when the opportunity arises.  |

**Introduction**

**Strategy**

**Corporate Governance Report**

Corporate governance structure

Board of Directors

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

Assurance framework, risks and risk management

**Internal control over the financial reporting**

Auditor’s report on the Corporate Governance Report

**Financial statements**

**Sustainability Report**

**Other information**

## Internal control over the financial reporting

At Getinge, internal control over the financial reporting is an integrated part of the corporate governance. It comprises processes and methods to safeguard the accuracy in the financial reporting, and in this manner, is aimed to protect the shareholders’ investment in the company.

**Control environment**

The basis of the internal control over the financial reporting comprises the control environment, including the organization, decision-making channels, authorities and the responsibilities that are documented and communicated in steering documents. The Audit and Risk Committee’s responsibilities include monitoring the effectiveness of the company’s internal control, financial reporting and risk management. Each business area and the Global Sales and Service organization are responsible for continuous transaction management and accounting. Getinge’s Shared Service Center in Krakow, Poland, conducts this management on behalf of the business areas and the Global Sales and Service organization for most of the companies in Europe and North America, primarily regarding customer invoicing, supplier invoices and payment and work duties in the annual accounting process. Each business area and the Global Sales and Service organization has a financial manager, who is responsible for the financial control and for ensuring that the financial statements are accurate, complete and submitted in good time prior to consolidated reporting. In 2024, the finance functions for the larger countries were divided into a financial and a business-oriented function with the aim of streamlining work in accounting and in the business organization. The financial control function is divided into the geographic areas of responsibility of France, the Nordic region, North America, DACH/BNL and East Asia.

**Control activities**

The most material risks identified relating to financial reporting are handled by the company’s control activities. For example, there are automated controls in IT-based systems that manage authority levels and attestation rights, as well as key control elements, such as duality in the day-to-day accounting and closing entries. Detailed financial analyses of results and follow-ups against plan and forecasts supplement the operation-specific controls and provide overall confirmation of the quality of the financial reporting. The Group follows standardized templates and models to document controls.

During the year, an internal framework for general IT controls was defined and implemented in systems and applications that have the greatest impact on the financial reporting. These controls include maintenance, development and authorization management processes. System and application owners have carried out self-assessments of the control environment, which were then evaluated internally and subsequently by the external auditors. The process is similar to the annual assessment of financial controls.

**Information and communication**

The Group has information and communication procedures to promote completeness and accuracy in the financial reporting. Steering documents and work descriptions are available on the company’s internal digital platform. Information regarding the efficiency of the internal controls in the Group is regularly reported to the relevant financial manager for the Global Sales and Service organization and the business areas, as well as to the internal control function, the finance function, the Getinge Executive Team and the Audit and Risk Committee.

**Follow-up and monitoring**

Each financial manager and the Getinge Executive Team perform monthly analyses of the financial reporting at a detailed level. The Audit and Risk Committee follows up the financial reporting at its meetings and the company’s auditors report on their observations

and provide recommendations. The Board of Directors receives financial reports on a monthly basis and the company’s financial position is discussed at every Board meeting. The efficiency of the internal control activities for the financial reporting is followed up by the internal control function every year using a risk-based random sampling model. This comprises an assessment of the formulation and operative function of key control elements that have been identified and documented. The external auditors perform an annual evaluation of key controls in the internal assurance framework and report the results to the Audit and Risk Committee.

**Self-assessment and validation**

Getinge has worked for several years with a formalized process for the follow-up and evaluation of the documentation of key control elements. The internal assurance framework is revised every year based on the results of, for example, self-assessments and auditing activities. The validations are performed by each financial manager and the person with the main responsibility for the geographic financial controller function, or the person delegated in the Global Sales and Service organization or the business area, supported by the central internal control function.

The purpose of self-assessment is to proactively identify any weaknesses in the internal control environment, jointly develop improvement measures, but also to ensure the maintenance of the achieved good internal control environment. Another purpose is to enhance the efficiency of the local control activities in Group companies by identifying shared work methods and transferring knowledge between the companies to raise the general quality of the control environment.

In 2024, just over two-thirds of the active companies, jointly totaling just over 90% of the sales in the Group, conducted a self-assessment. In conjunction with the standard Group audit, the auditors conducted an in-depth validation of the internal control environment. The self-assessment includes the following business processes: corporate governance (such as assignment of authority for financial IT systems), financial reporting, production and

**Introduction****Strategy****Corporate Governance Report**

Corporate governance structure

Board of Directors

President & CEO and Getinge Executive Team

Building blocks in the Getinge corporate governance model

Assurance framework, risks and risk management

Internal control over the financial reporting

**Auditor's report on the Corporate Governance Report**

**Financial statements****Sustainability Report****Other information**

inventories, tangible and intangible assets, sourcing of and revenues from products and services, salary and remuneration procedures and tax management. The auditors' assessment includes a sample of these processes.

**Outcome 2024**

The follow-up of the internal control in 2024 indicated that documentation and control activities over the financial reporting were, in all material respects, established at the validated companies. A couple of areas identified as having the largest potential for improvement are further training for the organization in internal control with a focus on documenting controls and their outcomes, and identifying the automated key controls in the Group's financial system.

**Follow-on work**

The focus in 2025 will be on continuing to harmonize ways of working in the business processes, thus optimizing the use of the common system environment. Uniform business processes also allow for a higher degree of standardized and automated controls, and enhance efficiency. The outcome from the year's validation and evaluation, and from the various company audits, will be used as a basis for the continuous improvement work on internal control via financial reporting.

## Auditor's report on the Corporate Governance Report

To the annual general meeting of the shareholders in Getinge AB (publ), Corporate Identity Number 556408-5032

**Engagement and responsibility**

It is the Board of Directors who is responsible for the Corporate Governance Report for the year 2024 on pages 32–54 and that it has been prepared in accordance with the Annual Accounts Act.

**The scope of the audit**

Our examination has been conducted in accordance with FAR's auditing standard RevR 16 The auditor's examination of the corporate governance statement. This means that our examination of the corporate governance statement is different and substantially less in scope than an audit conducted in accordance with International Standards on Auditing and generally accepted auditing standards in Sweden. We believe that the examination has provided us with sufficient basis for our opinions.

**Opinions**

A Corporate Governance Report has been prepared. Disclosures in accordance with chapter 6 section 6 the second paragraph points 2–6 the Annual Accounts Act and chapter 7 section 31 the second paragraph the same law are consistent with the annual accounts and the consolidated accounts and are in accordance with the Annual Accounts Act.

*This is a translation of the Swedish language original. In the event of any differences between this translation and the Swedish language original, the latter shall prevail.*

Gothenburg, March 27, 2025

Öhrlings PricewaterhouseCoopers AB

Cecilia Andrén Dorselius

Auditor in charge

Authorized Public Accountant

Karin Olsson

Authorized Public Accountant

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

# Financial statements

## Contents

|         |                                     |
|---------|-------------------------------------|
| 56–60   | Administration Report               |
| 61–63   | Guidelines for remuneration         |
| 64–67   | Remuneration Report 2024            |
| 68      | Proposed appropriation of profit    |
| 69–73   | Group financial statements          |
| 74–111  | Group notes                         |
| 112–115 | Parent Company financial statements |
| 116–122 | Parent Company notes                |
| 123–126 | Auditor's report                    |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Administration Report**

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

# Administration Report

**Ownership and Legal form**

Getinge AB (publ) with corporate identity no 556408-5032 is a limited liability company and its Class B shares are listed on Nasdaq Stockholm. Getinge AB with registered office at Box 8861, 402 72 Gothenburg, Sweden, is the Parent Company of the Getinge Group and is headquartered in Gothenburg, Sweden. The largest shareholder in Getinge AB (publ) is Carl Bennet AB.

**Operation and structure**

Getinge is a global provider of products and solutions for operating rooms, intensive-care units and sterilization departments serving 40 countries and with proprietary production in nine countries. Operations are conducted in three business areas – Acute Care Therapies, Life Science and Surgical Workflows.

Sales take place through our own subsidiaries and distributors in more than 135 countries. Approximately 72% of the sales are conducted through the Group's sales companies and the remaining 28% are sold by agents and distributors in markets where Getinge often lacks its own representation. Americas represented the Group's largest market, accounting for 45% (41) of sales, followed by EMEA at 35% (37). APAC accounted for 20% (22) of sales.

Production is conducted at a total of 25 facilities in France, China, the Netherlands, Poland, the UK, Sweden, Türkiye, Germany and the US.

**Financial overview**

**Net sales**

Net sales increased 9.2% during the year to SEK 34,759 M (31,827). Organically, sales increased by 4.9%. In Acute Care Therapies, sales amounted to SEK 17,948 M (16,529), corresponding to an organic increase of 8.2%. Life Science's sales decreased organically by 1.9% and amounted to SEK 4,552 M (4,325). Surgical Workflows' sales in 2024 amounted to SEK 12,258 M (10,974). Sales increased organically by 2.6%.

**Adjusted EBITA**

EBITA adjusted for restructuring and acquisition costs and other items affecting comparability amounted to SEK 4,869 M (3,887).

**Operating profit**

The Group's operating profit amounted to SEK 2,854 M (3,736). Adjusted for restructuring and acquisition costs and other items affecting comparability, operating profit amounted to SEK 4,549 M (3,653), corresponding to 13.1% (11.5) of net sales. The Group's adjusted EBITDA amounted to SEK 6,646 M (5,574), corresponding to 19.1% (17.5) of net sales.

**Net financial items**

Net financial items amounted to SEK -571 M (-393), of which net interest items comprised SEK -539 M (-346).

**Profit before tax**

The Group's profit before tax amounted to SEK 2,282 M (3,343).

**Taxes**

The Group's tax expense amounted to SEK -628 M (-915), entailing a tax rate of 27.5% (27.4).

**Tied-up capital**

Inventories amounted to SEK 6,590 M (6,416) and accounts receivable to SEK 6,348 M (5,739). The return on equity was 5.2% (7.8). Goodwill totaled SEK 30,088 M (24,869) at the end of the fiscal year.

**Investments**

Investments in intangible assets and tangible assets amounted to SEK 1,309 M (1,353). Investments primarily pertained to product development, production facilities, production tools and IT projects. Investments related to acquisitions of businesses amounted to SEK 3,256 M (5,209), primarily relating to the acquisition of Paragonix Technologies, Inc.

**Financial position and equity/assets ratio**

Consolidated net interest-bearing debt increased to SEK 10,467 M (8,012). The equity/assets ratio amounted to 52.0% (56.7) and the net debt/equity ratio to 0.32 (0.26). The Group's debt ratio (net debt in relation to adjusted EBITDA) amounted to 1.6 (1.4). Equity at year-end amounted to SEK 33,210 M (30,403).

**Cash flow**

Cash flow from operating activities amounted to SEK 4,577 M (2,957).

**Restructuring activities**

In 2024, restructuring costs amounted to SEK 848 M (75), which were mainly attributable to impairment of fixed assets and inventory related to the communicated phase-out of the Surgical Perfusion product category and the warranty provisions for planned field actions relating to Cardiosave.

**Class of shares and share data**

Net profit for 2024 amounted to SEK 1,654 M (2,428). Earnings per share, before and after dilution, amounted to SEK 6.01 (8.86).

For information regarding trading of shares in the company, the number of shares, shareholders, classes of shares and the rights associated with these classes, refer to Getinge as an investment on page 9 and Other information on pages 170–171.

**Significant events during the year**

**Governance of quality**

During the year, work continued on the improved global quality management system implemented in 2023. The aim of the system is to enhance focus and establish a well-defined Group-wide quality strategy in order to deliver an even higher level of quality. The quality management system is used to ensure safety, efficiency and compliance for Getinge's products. The system defines the processes, controls and documentation necessary to meet regulatory requirements, manage risks and deliver high-quality products to customers.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Administration Report**

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**Adjustments to EU Medical Device Regulation**

Work on meeting the requirements of the new EU Medical Device Regulation (EU MDR) continued during the year. At the end of 2024, 17 of 18 manufacturing sites had received their EU MDR certificates.

**CE certificates for HLS and PLS sets and Cardiosave**

At the end of September 2024, the notified body, TÜV SÜD, reinstated Getinge's CE certificate for HLS and PLS consumables, used for ECLS therapy, with certain conditions after Getinge developed a new packing solution. Deliveries of the products were resumed during the fourth quarter of 2024. In September 2024, TÜV SÜD announced that the temporary suspension of Getinge's Cardiosave intra-aortic balloon pump had been extended until July 1, 2025. This decision does not affect the previously installed base of Cardiosave, and means that products already on the market can continue to be used. Consumables, service and spare parts for the pumps are not affected.

**FDA letter regarding Cardiosave, Cardiohelp and HLS sets**

In May 2024, the US Food and Drug Administration (FDA) sent a Letter to Health Care Providers encouraging them to move from using Getinge's Cardiosave, Cardiohelp and HLS sets to alternative products and to continue to use Getinge's products only if no other options are available. As a result of the letter, Getinge decided to immediately suspend marketing activities for Cardiohelp and Cardiosave in the US until outstanding actions related to quality improvements have been addressed and approved, and to limit sales to those customers who have no other options. The installed base for intra-aortic balloon pumps and HLS sets was supplied and serviced. For markets outside the US, Getinge made product improvements and will continue to sell Cardiosave and Cardiohelp and continue to provide intra-aortic balloon pumps and HLS sets in markets where they are permitted and approved for use. At the same time, Getinge accelerated the development of the next generation of Cardiohelp and Cardiosave, and the company expects to submit applications for clearance in the US by the end of H1 to the

end of H2 2025, followed by an update and application for clearance of the HLS sets in H2 2026.

**FDA letter regarding Getinge's VasoView Hemopro Endoscopic Vessel Harvesting (EVH) system**

On November 15, the FDA published a Letter to Health Care Providers on its website, repeating information about the voluntary medical device recall and supply concerns related to all of Getinge's VasoView Hemopro Endoscopic Vessel Harvesting (EVH) Systems. Actions are being taken as agreed with the FDA.

**Changes to Getinge Executive Team**

Agneta Palmér replaced Lars Sandström as Getinge's CFO on March 31, 2024. Agneta Palmér previously served as Executive Vice President Operational Services and a member of the Executive Team.

Alexandra Holland was appointed as new Executive Vice President Communications, taking up her role on November 11, 2024. She is a member of the Executive Team and based in Wayne, US. Alexandra joins Getinge from Johnson & Johnson where she held the role of Vice President, Business and Culture Communications, MedTech.

**Acquisitions of operations**

**Acquisition of assets from Intact Solutions**

In July 2024, Getinge's subsidiary Aseptic Solutions LLC acquired technology and intellectual property rights from Intact Solutions LLC, a company in Connecticut, USA. This technology makes aseptic processing simpler, safer and more efficient, and addresses the entire bioprocessing value chain. The acquisition was consolidated into the Getinge Group on the acquisition date and is included in the business area Life Science.

Getinge paid approximately SEK 128 M (USD 12 M) upon completion of the acquisition. Furthermore, additional earn-out payments may be made between 2027 and 2030 if agreed upon regulatory and financial performance milestones are achieved.

**Paragonix Technologies, Inc.**

In September 2024, Getinge carried out the acquisition of 100% of the shares in Paragonix Technologies, Inc., a leading US company in organ transport products and services. The company, which was founded in 2010, employs approximately 100 people and is headquartered in Waltham, Massachusetts, USA. The acquisition aligns with Getinge's broader strategy to expand its portfolio into high growth markets that complement and enhance its acute heart and lung support offering already being used in connection with transplantation, positioning the company at the forefront of the fast-growing organ preservation and transportation market. The acquisition was consolidated into the Getinge Group on the acquisition date and is included in the business area Acute Care Therapies. Getinge paid approximately SEK 2,619 M (USD 253 M) in cash upon completion of the acquisition. Furthermore, additional earn-out payments may be made up until 2026 if agreed upon regulatory and financial performance milestones are achieved.

**Other**

In 2024, additional purchase price of SEK 325 M were paid relating to Talis Clinical LLC.

For further information on this year's acquisitions and contingent considerations, refer to Note 19 Financial instruments and Note 27 Acquisition of operations.

**Dispute**

**Settlement agreements with authorities in Brazil – ongoing**

As a consequence of ongoing government investigations regarding anti-competitive practices relating to the sale of medical devices between 2004 and 2017, mainly to public hospitals, Getinge has previously entered into Settlement Agreements with the Brazilian Federal Prosecutor's Office (Ministério Público Federal) and the competition authority, the Administrative Council for Economic Defense (CADE). The negotiations with the federal agency for internal control, public transparency and counter-corruption,

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Administration Report**

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

Comptroller General of the Union (CGU), are still pending and in Q3 2024 Getinge made a provision of SEK 482 M related to these negotiations (refer to Note 15 Other provisions for further information).

**Consent Decree with FDA – ongoing**

Getinge signed the original Consent Decree with the FDA in 2015 which encompassed four production units in the US and Germany and pertained to certain identified quality concerns. Previous remediation plans have already been implemented and the work at the production units in Hechingen was completed in 2021. In addition, Getinge's production units in Fairfield and Mahwah received warning letters from the FDA in 2018–2019, resulting from observations from inspections in 2018. These observations, which Getinge had also identified, pertain to procedures and processes linked to demands for supplier checks, processes for the approval of design changes and incident reporting. Getinge has subsequently worked to remedy these concerns and submitted an action plan to the FDA and improvements are proceeding according to this plan.

In 2022, the FDA announced that Getinge's subsidiary Datascope would be included in the existing Consent Decree due to observations made at inspections between 2021 and 2022 at the site in Wayne. These observations pertained to Datascope failing to fully comply with the Quality Management System and related processes. Datascope is enforcing the ongoing actions to address the findings and to ensure full compliance with the Quality Management System, including via the new quality organization. A work plan has been submitted to the FDA and dialogue and improvements are continuing.

**Getinge's financial targets 2024–2028 and dividend policy**

Getinge updated its financial targets in May 2024 as follows:

- Average adjusted earnings per share growth: >12%
- Getinge's dividend policy is to pay dividends of 30–50% of net profit to shareholders

**Innovation and product development**

Innovation and product development are a cornerstone of the Group's strategy to strengthen the customer offering and ensure future organic growth. The Group uses innovation and product renewal to manufacture products, systems and solutions with a documented ability to deliver high-quality clinical results and economic benefits. The Group's research and development costs amounted to SEK 2,091 M (1,821) in 2024. Of this amount, SEK 660 M (629) was capitalized as intangible assets.

**New products during the year**

*Surgical Workflows*

- Maquet Ezea – a versatile and robust surgical light
- Aquadis Index – a multi-chamber washer-disinfector that combines high capacity with low utility consumption
- FleetView – a web application with data-driven device lifecycle management, offering healthcare providers and life science companies a tool to navigate large amounts of service data and statistical insights
- Poladus 150 – a low-temperature sterilizer, designed for heat-sensitive surgical instruments

*Acute Care Therapies*

- Servo TwinView – a virtual twin of the Servo ventilators that enables clinics to analyze near real-time data from the ventilators, without having to step inside the intensive care unit
- Pulsiocare – an advanced hemodynamic monitoring platform that recently received its CE certificate

*Life Science*

- Livit ACE – a continuous cell processing platform developed together with bioprocessing company CellRev
- SUPR – an extension of the bioreactor portfolio by introducing the Single-Use Production Reactor (SUPR) system, which initially is available in 50-liter and 250-liter sizes that helps operators to bring life-saving medicines to market faster

- GEW 888 neo – cGMP washer designed to develop cleanroom efficiency and meet the strictest demands of the biopharmaceutical industry
- DPTE-BetaBag® – a new version with material from renewable sources
- Lancer LSS – an innovative lab sterilizer where cutting-edge technology meets refined design

**Approval and certifications**

In the first quarter, Getinge took a giant leap forward in cardiovascular surgery with 510(k) clearance for Vasoview Hemopro 3. In the same quarter, the notified body, TÜV SÜD, temporarily suspended the CE certificate for Getinge's intra-aortic balloon pump, Cardio-save, and this suspension was extended later in the year until 2025. Early in the second quarter, Getinge's covered stent system Advanta V12 received EU MDR approval for use for patients with renal artery stenosis and/or aortoiliac occlusive disease (AIOD). Getinge was also granted FDA 510(k) clearance for its innovative clinical decision support software Talis +ACG (+Advanced Clinical Guidance). After having been suspended since March 2023, Getinge's CE certificate for HLS and PLS consumables, used for ECLS therapy, was reinstated by TÜV SÜD in September with certain conditions. In October, Paragonix Technologies, Getinge's most recent acquisition, received FDA clearance for KidneyVault, an innovative device to optimize the protection of donor kidneys during transport.

**Personnel**

At December 31, 2024, there were 11,791 (11,739) employees, of whom 1,296 (1,263) were employed in Sweden. The number of employees increased by 121 in connection with the acquisitions of Paragonix Technologies and Aseptic Solutions. In 2024, Getinge continued its extensive efforts to strengthen the Group's personnel and management development. The Group also carried out activities intended to further strengthen the commitment of its employees and implemented digital tools for personnel development. Since early 2023, all Getinge units offer at least 16 weeks paid parental leave applicable to birth, adoption and surrogacy, and four weeks

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Administration Report**

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

paid caregiver leave to care for a close family member. In 2024, the Group also continued its long-term endeavors to increase diversity and collaboration. Getinge has a previously implemented policy to ensure that all employees are given equal opportunity to develop and receive equal pay for equal work, regardless of such factors as gender, ethnicity or religion.

**Annual General Meeting's guidelines for remuneration to Senior Executives**

The guidelines for remuneration to senior executives adopted at the 2023 AGM are presented on pages 61–63. During 2024, the company complied with these guidelines. No deviations from the guidelines nor any derogations from the procedure for resolution on remuneration, established by the remuneration guidelines, have been made. Total remuneration to senior executives amounted to SEK 144 M (106) in 2024, see Note 22 for more information. The total cost for remuneration and benefits to the Getinge Executive Team amounted to SEK 165 M (170) and pertains to base salaries, variable short-term and long-term remuneration, other benefits and pensions. It also includes social security expenses on salaries and benefits and special payroll tax on pensions.

**Sustainability Report**

In accordance with Chapter 6, Section 11 of the Annual Accounts Act, Getinge has chosen to prepare the Sustainability Report as a part of the Annual Report. The statutory Sustainability Report is defined on page 128. A description of diversity on the Board can be found on page 36. Refer to page 153–154 for a more detailed description of the work with diversity.

**Environmental accounting**

Getinge's environmental activities are based on the Group's sustainability policy, environmental policy and the international ISO 14001 environmental management standard. The 2019–2025 sustainability program has been based on a materiality assessment which anchors KPIs within the entire organization. All manufacturing units have or will implement and certify environmental management

systems that meet the standard. For acquisitions, the management system is to be introduced and certified within 24 months.

The management system ensures structured environmental work and provides a basis for the reporting of environmental performance that Getinge's manufacturing units submit every quarter. Through the targeted activities related to environmentally compatible product development, EcoDesign, the aim is to reduce the environmental impact from manufacturing and product usage, and offer customers sustainable market offerings.

One facility in Sweden conducts operations requiring permits or declaration under the Swedish Environmental Code. This facility holds the necessary permits. The operations were conducted in accordance with applicable permits and conditions during the year.

Getinge's climate target of reaching net-zero greenhouse gas emissions across the value chain by 2050 was validated by the SBTi. Further information concerning Getinge's environmental work and its sustainability targets is presented in the section Strategy and in the Sustainability Report.

**Risks and uncertainties**

Getinge actively and systematically manages the risks that the Group is exposed to. In accordance with this, the Getinge Executive Team conducts an annual evaluation of material risks and effects, and decides and acts on measures to reduce risks and their potential effects. The risk evaluation is reported to the Board of Directors and serves as a key starting point in determining the focus areas for Corporate Internal Audit. At the end of September 2024, the notified body, TÜV SÜD, reinstated Getinge's CE certificate for HLS and PLS consumables, used for ECLS therapy, with certain conditions after Getinge developed a new packing solution. Deliveries of the products were resumed during the fourth quarter of 2024. In September 2024, TÜV SÜD announced that the temporary suspension of Getinge's Cardiosave intra-aortic balloon pump had been extended until July 1, 2025. This decision does not affect the previously installed base of Cardiosave, and means that products already on the market can continue to be used. Consumables, service and spare parts for the pumps are not affected.

In addition, Getinge is exposed to risk related to other external events, such as geopolitical risks, natural disasters, terrorism, pandemics, etc. Active business intelligence can detect some of these risks at an early stage and the Group will then have the chance to adapt to the new situation. The process of further enhancing the Group's work on continuity risks continued in 2024.

External factors such as geopolitical tensions and possible associated sanctions are risks that could affect Getinge's ability to expand in markets that have significant needs for the Group's products and solutions. It can also not be ruled out that Getinge could be exposed to conflicting trade sanctions as a result of the geopolitical situation. Getinge actively follows the ongoing debate on increased trade barriers such as tariffs. Getinge has a geographically diversified purchasing and manufacturing strategy, which can partially limit any potential negative consequences. Technological advances are currently being made at a very fast pace, which is affecting the competitive situation in the market. The Group assigns considerable resources to developing its customer offering, such as in the form of a higher degree of connected products. In this way, information about how the products are used clinically can be transferred from the customers back to Getinge, and this information will then form the basis of the next stage of product development. There is a certain risk that new, or existing, players could develop transformative technology more successfully than Getinge and thus gain an advantage in the market.

Cyber-related risks are a focal point for the Group in terms of both IT infrastructure and connected equipment with customers. In both of these areas, Getinge carries out active and extensive measures to manage these risks. A circumstance that reduces exposure related to infrastructure is that this can be considered to be decentralized. In addition, the Group also closely monitors critical systems to prevent these risks. In relation to the cyber security of the Group's customer offering, the company works diligently to ensure the integrity of its equipment that is connected to the Internet. Comprehensive access testing and other measures are also carried out before these solutions are offered to the Group's customers.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Administration Report**

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

Furthermore, Getinge is also exposed to risks related to non-compliance with laws and regulations, mainly pertaining to business ethics. Corruption in particular remains a risk in many markets in which Getinge operates and has ambitions to grow. The Group has a zero tolerance policy when it comes to deviations in this area and takes extensive action in business ethics such as the responsible leadership training program and other training courses. The aim is for all employees to undergo training in business ethics every year. Business ethics regulations also apply to external distributors who sell the Group's products in markets in which it does not have its own presence. Further information about the Group's financial risk management can be found on pages 47–52.

**Financial risk management**

Getinge is exposed to a number of financial risks in its operations. Financial risks principally pertain to risks related to currency risks, interest-rate risks, financing and liquidity risks and credit and counterparty risks. Risk management is regulated by the finance policy adopted by the Board and a Treasury directive decided by the Getinge Executive Team that supplements the finance policy. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with the Getinge Executive Team and the finance function. For more detailed information concerning these risks, refer to Note 18 Financial risk management.

**Sensitivity analysis**

Getinge's earnings are affected by a series of external factors. The following table shows how changes to some of the key factors that are important to Getinge could have affected the Group's profit before tax in 2024.

| <b>Change in profit before tax</b> | <b>SEK M</b> |        |
|------------------------------------|--------------|--------|
| Price change                       | +/-1%        | +/-348 |
| Cost of goods sold                 | +/-1%        | +/-186 |
| Salary costs                       | +/-1%        | +/-132 |

**Outlook**

Organic sales growth is expected to be in the range of 2–5% for the full-year 2025.

**Significant events after the end of the reporting period**

Getinge has announced its intention to phase out the Surgical Perfusion product portfolio, which is part of the Cardiopulmonary product segment in Acute Care Therapies, in 2025. The intention is to reallocate resources to areas of more profitable growth, mainly in ECLS and Transplant Care. The Surgical Perfusion market has experienced low growth and Getinge has continuously lost market share to the current level of 7% outside the US, which is the largest market globally.

The products intended to be phased out are the HL40 heart-lung machine and the HCU40 heater-cooler unit, as well as consumables used in Surgical Perfusion. The production facilities concerned are located in Hechingen and Rastatt in Germany and in Antalya, Türkiye.

Introduction

Strategy

Corporate Governance Report

**Financial statements**

Administration Report

**Guidelines for remuneration**

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

Sustainability Report

Other information

# Current guidelines for remuneration to senior executives

Adopted at the 2023 Annual General Meeting

## 1. Scope of the guidelines, etc.

These guidelines cover the individuals who, during the validity period of the guidelines, are included in the group management of Getinge AB (publ), below referred to as "Senior Executives". The guidelines shall apply for remuneration agreed and amendments in any remunerations already agreed, as of the adoption of the guidelines by the 2023 Annual General Meeting. The guidelines are not applicable on any remuneration resolved by the General Meeting.

## 2. Promotion of Getinge's business strategy, long-term interests and sustainability, etc.

A prerequisite for successful implementation of the company's business strategy and safeguarding of the company's long-term interests is that the company is able to recruit and retain qualified personnel. The main principle is that remuneration and other employment conditions for Senior Executives, shall be in line with market terms and competitive on every market where Getinge operates, to ensure that competent and skilled personnel can be attracted, motivated and retained. Individual levels of remuneration shall be based on experience, competence, level of responsibility and performance, and also the country where the Senior Executive is employed. These guidelines promote the company's business strategy, long-term interests and sustainability as described in the below section regarding criteria for variable remuneration, and contribute to the company's ability to, on a long-term basis, retain qualified personnel.

For information regarding Getinge's business strategy, please see the company's annual reports and the website (<https://www.getinge.com>).

## 3. Principles for various types of remuneration, etc.

The total remuneration to Senior Executives shall be in line with market terms and consist of base salary (fixed cash remuneration),

variable cash remuneration, any other variable remuneration, pension benefits and other benefits. In addition, the General Meeting may – irrespective of these guidelines – resolve on, for instance, share- or share price-related remunerations.

### Fixed remuneration

The fixed remuneration, meaning the base salary, shall be based on the individual employee's area of responsibility, authority, competence, experience and performance.

### Variable remuneration

The allocation between base salary and variable remuneration shall be in proportion with the area of responsibility and authority of the executive. The variable remuneration shall always be pre-limited to a maximum amount and related to predetermined and measurable criteria, designed to contribute to the business strategy and long-term added value of the company.

The annual variable remuneration is designed to promote the company's strategy to produce and offer products that can support in making health care more efficient in the long-term and to provide better health care for the people who need Getinge's products. If the above-mentioned activities are performed in an efficient and sustainable way, one outcome is improved financial results and increased capital efficiency, which constitutes the foundation of the variable remuneration. The sustainability work is integrated in the company's day-to-day operations. If the company's principles for sustainability or ethical guidelines are not complied with, the company has the possibility to withhold any variable remuneration or reclaim already awarded remuneration.

### Annual variable remuneration

For Senior Executives, the annual variable remuneration (annual bonus) shall be capped at 70% and, in specific cases, were the

nature of the position, the competitive situation and the country of employment so require, capped at 90% of the fixed annual base salary. The variable remuneration shall be based on objectives set by the Board of Directors. These objectives are related to (i) earnings, (ii) organic growth, (iii) working capital and cash flow, and (iv) sustainability. In order to promote the interest of the shareholders, the company's values and collectively strive to achieve the business strategy, long-term interests and sustainable development of the company, all members of the group management have the same targets for annual variable remuneration.

### Variable long-term cash bonus (LTI-bonus)

In addition to base salary and annual variable remuneration as described above, Senior Executives can obtain a variable long-term bonus (LTI-bonus). The target that forms the basis for the LTI-bonus is adjusted earnings per share for a three year period, adjusted for the category of adjustment items decided at implementation of the program by the Board of Directors at the recommendation by the Remuneration Committee. By connecting the performance target to the shareholders' objective, a common interest to promote Getinge's business strategy, long-term interests and value creation is created. Payment is subject to continued employment at the end of the vesting period for the LTI-bonus (with some customary exceptions).

The vesting period for the LTI-bonus shall be not less than three financial years. The payment of LTI-bonus per each three-year program shall be capped to 33% of one year's base salary. A new LTI-bonus program can be set up every year with a duration period of three years. Senior Executives of the group management shall invest not less than 50% of the received LTI-bonus (net, after taxes paid) in Getinge shares, until the Senior Executive's own total holdings of shares correspond to one year's salary (gross). The Senior Executive shall keep these shares for at least three years.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

**Guidelines for remuneration**

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**Limitation of total variable remuneration for the CEO**

For the CEO, the total payment of variable remuneration (annual variable remuneration and LTI-bonus), in addition to what is previously mentioned, annually be limited so that the total variable remuneration does not exceed 100% of the fixed salary. This applies to variable remuneration that is paid 2022 or later.

**Determination of result for variable remuneration, etc.**

When the measuring period for achievement of the criteria for payment of the variable remuneration has expired, the Board of Directors shall, based on proposal by the Remuneration Committee, establish to which extent the criteria are achieved. In their assessment on whether the criteria are achieved or not, the Board of Directors may, in accordance with proposal by the Remuneration Committee, allow exception from the established targets on the conditions set out in the below item 5. The assessment of achievement of the financial targets shall be based on the company's most recent published financial information, with any adjustments predetermined by the Board of Directors when implementing the program. Variable cash payment can be awarded after the expiration of the measuring period (annual variable remuneration) or be subject to postponed payment (LTI-bonus).

Getinge is actively working to ensure that the company is managed in the most sustainable, responsible and efficient way possible, and that applicable legislations and regulations are complied with. Getinge also apply internal rules, including a code of conduct and different group-wide steering documents (policies, instructions and guidelines) within a range of different areas. Variable remuneration shall not be awarded, and can be reclaimed, if the Senior Executive has acted contrary to these rules, principles or the company's code of conduct. Variable remuneration shall not be awarded if the earnings before tax is negative. The Board of Directors shall also have the possibility to, in accordance with legislation or agreement, in whole or partly, reclaim any variable wrongly awarded remuneration.

1) Pension contributions may, exceptionally, exceed this limit if required to comply with mandatory law, collective bargaining agreements or other applicable rules or established local practice, taking into consideration, to the extent possible, the overall purpose of these guidelines.

**Other variable remuneration**

Additional variable cash remuneration can be awarded in case of extraordinary circumstances, provided such extraordinary arrangements are only conducted for the purpose of recruiting or retaining executives. Such remuneration may not exceed an amount corresponding to 100% of the base salary and only be awarded once a year per individual. Resolution on such remuneration shall be made by the Board of Directors and based on a proposal by the Remuneration Committee. In addition to variable remuneration, resolutions on share- or share price related incentive programs, in accordance with the above, can from time to time be made.

**Pension and insurance**

The CEO has right to retire from the age of 62 and other Senior Executives has right to retire in accordance with applicable local regulations.

Pension contributions for the CEO shall amount to no more than 40% of the fixed base salary on a defined contribution basis. Variable cash remuneration shall not qualify for pension benefits.

Pension contributions for other Senior Executives shall amount to a maximum of 40%<sup>1)</sup> of the pensionable salary and shall be on a defined contribution basis. Variable cash remuneration shall not qualify for pension benefits in general, except where mandatory by collective bargaining agreement provisions applicable for the executive. In such case, this shall be considered when creating the total benefits package. In addition to the above, Senior Executives may be covered by an additional health income insurance (sw. *sjukinkomstförsäkring*).

For employments governed by other than Swedish regulations, pension benefits and other insurances may be duly amended to comply with mandatory rules or established local regulations, taking into consideration, to the extent possible, the overall purpose of these guidelines.

**Other benefits**

Other benefits such as company car, additional medical insurance (sw. *sjukvårdsförsäkring*) and company health care (sw. *företagshälsovård*), may be provided to the extent this is considered to be in line with market terms for Senior Executives on similar positions on that local market. The total value of such benefits may not exceed 10% of the fixed base salary.

**Conditions for termination**

Senior Executives shall have a permanent employment. If the company terminates the employment, the notice period shall not exceed twelve months. Upon termination of employment, the total of the fixed salary during the notice period together with severance pay may not exceed an amount equivalent to two years fixed base salary for the CEO, and one year for other executives. If the executive terminates the employment, the notice period shall not exceed six months and be without any right to severance pay.

Senior Executives may be entitled to compensation for any competition restrictions after the termination of employment, however, only to the extent severance pay for the corresponding period is not awarded. The purpose of such compensation is to compensate the executive for any gap between the monthly base salary at the notice of termination and (lower) monthly income received, or that could be received, by a new employment, assignment or own business. The compensation can be awarded during the period of the competition restriction, however, not more than for 12 months after the termination of employment.

**Salary and employment conditions for employees**

When preparing the Board of Director's proposal for these remuneration guidelines, salary and employment conditions for the company's employees have been considered. This have been made by including information of the total income of the employees, the components of the remuneration and the increase and growth rate over time, as part of the Remuneration Committee's and the Board of Directors' basis for decision when evaluating whether the guidelines and the limitations set out herein are reasonable.

**Introduction****Strategy****Corporate Governance Report****Financial statements**

Administration Report

**Guidelines for remuneration**

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report****Other information**

The development of the gap between the remuneration to Senior Executives and remuneration to other employees will be disclosed in the remuneration report.

**4. The resolution process to determine, review and implement the guidelines**

The Board of Directors has established a Remuneration Committee. The Committee's tasks include preparing the Board of Directors' decision to propose guidelines for Senior Executive remuneration. These are reviewed annually and new proposals for guidelines shall be drafted by the Board at least every fourth year and presented to the Annual General Meeting for resolution. The guidelines shall be in force until new guidelines are adopted by the Annual General Meeting.

The Remuneration Committee shall also monitor and evaluate programs for variable remuneration to Senior Executives, the guidelines for remuneration to Senior Executives, as well as the current remuneration structures and compensation levels in the company, and provide recommendations to the Board of Directors in relation to remuneration to the CEO. Regarding resolution on remuneration to other Senior Executives in accordance with the guidelines (other than the specifically regulated above) the CEO shall consult with the Remuneration Committee.

The CEO and other members of the group management do not participate in the Board of Directors' processing of, and resolutions on, remuneration-related matters when such matters concern them.

The Board of Directors shall annually draw up a remuneration report that shall be presented to the Annual General Meeting for approval.

**5. Deviations from the guidelines**

The Board of Directors may temporarily resolve to deviate from the guidelines, entirely or partly, if in a specific case there is special cause for the deviation and a deviation is necessary to serve the company's long-term interests, a sustainable development of the company or to ensure the company's financial viability. As set out above, the Remuneration Committee's tasks include preparing the Board of Directors' resolutions in remuneration-related matters. This includes any resolutions to deviate from the guidelines.

**Introduction****Strategy****Corporate Governance Report****Financial statements**

Administration Report

Guidelines for remuneration

**Remuneration Report 2024**

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report****Other information**

# Remuneration Report 2024

**Introduction**

This report reflects how the guidelines for remuneration to Senior Executives, adopted at the 2023 Annual General Meeting ("AGM"), have been implemented and applied during 2024. The report also provide details on the remuneration to the President & CEO, how the performance targets for variable remuneration have been applied, and information that the company has not implemented any share- or share price-related incentive programs. This report has been prepared in compliance with the Swedish Companies Act and the *Rules on remuneration of the Board and Executive Management and Incentive programs* issued by the Stock Market Self-Regulation Committee (the Remuneration Rules).

Further information on remuneration to Senior Executives is available in Note 22 on pages 105–106 of the 2024 Annual Report. Information on the work by the Remuneration Committee in 2024 is set out in the Corporate Governance Report, which can be found on pages 32–54 of the 2024 Annual Report.

Remuneration of the Board of Directors is not covered by this report, but is resolved annually by the AGM. Information about remuneration to the Board of Directors is disclosed in Note 22 on page 105 and the Corporate Governance Report on pages 32–54 of the 2024 Annual Report.

The company has not received any comments on the 2023 Remuneration Report.

**The group's overall performance 2024**

The President & CEO summarizes the Group's result and overall performance in his statement, which is included on pages 6–7 of the 2024 Annual Report.

**The company's remuneration guidelines**

A prerequisite for successful implementation of the company's business strategy and safeguarding of its long-term interests and sustainability is that the company is able to recruit, motivate and retain qualified personnel. By offering Senior Executives a competitive total compensation, the remuneration guidelines enable the company, on a long-term basis, to attract qualified personnel to the business.

The total remuneration to Senior Executives shall be in line with market terms and consist of base salary (fixed cash remuneration), variable cash remuneration, any other variable remuneration, pension benefits and other benefits. The remuneration, and other employment conditions, shall be on market terms and competitive on every market where Getinge operates. In addition, the General Meeting can decide on share- or share price-related remunerations.

The current guidelines for remuneration, adopted at the 2023 AGM, are presented on pages 61–63 of the 2024 Annual Report.

**Application and deviations from the remuneration guidelines**

In 2024, the company has complied with the guidelines adopted at the 2023 AGM. No deviations have been made from the guidelines nor any derogations from the procedure for resolution on remuneration, established by the remuneration guidelines.

The auditors' statement regarding the company's compliance with the guidelines is available on [www.getinge.com/int/company/corporate-governance/general-meetings/](http://www.getinge.com/int/company/corporate-governance/general-meetings/) under the tab 2025 Annual General Meeting. No paid remuneration has been reclaimed during 2024.

**Share based remuneration**

The General Meeting has not resolved on implementation of any share- or share price-related incentive programs.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

**Remuneration Report 2024**

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**


**Total remuneration to the President & CEO during 2024**

SEK 000s

| Executive                       | Fixed remuneration         |                              | Variable remuneration                          |   |        | Pension expenses <sup>5)</sup> | Total | Share of fixed and variable remuneration (%) <sup>6)</sup> |
|---------------------------------|----------------------------|------------------------------|--|---|--------|--------------------------------|-------|--|
|                                 | Fixed salary <sup>1)</sup> | Other benefits <sup>2)</sup> | Short-term variable remuneration <sup>3)</sup> | Long-term variable remuneration <sup>4)</sup> |        |                                |       |  |
| Mattias Perjos, President & CEO | 27,141                     | 790                          | 21,088   | –   | 10,826 | 59,845                         | 65/35 |  |

- 1) Fixed salary refer to base salary, including holiday pay.
- 2) Other benefits refer to benefits such as company car, medical insurance (sw: sjukvårdsförsäkring), health income insurance (sw: sjukinkomstförsäkring) etc.
- 3) Short-term variable remuneration refers to bonus accrued during the 2024 fiscal year and to be paid during 2025.
- 4) Long-term variable remuneration refers to bonus accrued for expired long-term incentive program. During 2024, the program for 2022–2024 expired without reaching the performance target, why no long-term bonus has been accrued.
- 5) Pension expense for the President & CEO is based on a defined contribution basis and amounts to 40% of the base salary.
- 6) The pension expense for the President & CEO is based on the fixed base salary and is included in its entirety in the fixed remuneration.

**Total remuneration to the President & CEO in 2024**



**Percentage of fixed and variable remuneration in 2024**



**Principles for the application of performance targets for variable remuneration**

Selection of performance targets and resolution to determine the variable remuneration has been prepared by the Remuneration Committee and resolved by the Board of Directors. The variable remuneration is pre-limited to a maximum amount and related to predetermined and measurable criteria, designed to contribute to the interests of shareholders and the company's core values and creates an incentive for joint efforts to achieve the company's

business strategy, long-term added value and the sustainable development of the company. The sustainability work is integrated in the company's day-to-day operations. If the company's principles for sustainability or ethical guidelines are not complied with, the company has the possibility to withhold any variable remuneration or reclaim already awarded remuneration.

After the end of the fiscal year and based on a proposal by the Remuneration Committee, the Board of Directors has resolved to which extent the criteria for payment of the short- and long-

term variable remuneration have been fulfilled. The assessment if the financial targets have been reached has been based on the company's most recent published financial information, with any adjustments approved by the Board of Directors at the proposal of the Remuneration Committee.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

**Remuneration Report 2024**

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**Application of the performance targets for short-term variable remuneration**

The variable short-term remuneration to the President & CEO is limited to 80% of the fixed annual base salary. The targets for the 2024

fiscal year were related to earnings, organic growth, tied-up working capital and sustainability. All five performance targets were fully or partly achieved in 2024, resulting in a degree of target fulfillment of 98.7% and a corresponding bonus payout.

**The performance by the President & CEO during the reported fiscal year: short-term variable cash remuneration**

**Criteria for determination of short-term variable remuneration for the President & CEO and outcome**

| Executive                       | Performance target   | Weighting of performance target | Outcome of performance target | Variable remuneration per performance target (SEK 000s) |
|---------------------------------|--|---------------------------------|-------------------------------|---|
| Mattias Perjos, President & CEO | Adjusted EBITA (SEK M) <sup>1)</sup>   | 50%                             | SEK 4,874 M                   | 10,686  |
|                                 | Net sales – organic growth (%) <sup>2)</sup>   | 20%                             | 4.9%                          | 4,224   |
|                                 | Tied-up working capital – no. of days  | 20%                             | 89 days                       | 4,275   |
|                                 | Sustainability – reduction of CO <sub>2</sub> emissions in Scope 1 and Scope 2 <sup>3)</sup> | 5%                              | -13.4%                        | 834   |
|                                 | Sustainability – implementation of process for supplier ESG qualification                    | 5%                              | Achieved                      | 1,069   |
|                                 |  |                                 |                               | <b>21,088</b>   |


1) Adjusted EBITA refers to the operating profit adjusted for exchange rate changes, acquisitions, divestments, restructuring costs and other material items affecting comparability.  
 2) Refers to the Group's organic net sales growth.  
 3) Scope 1 includes emissions from the consumption of oil and gas, and Scope 2 includes emissions from the consumption of electricity, heating and cooling.

**Set performance target**



- Adjusted EBITA, 50%
- Net sales – organic growth, 20%
- Tied-up working capital – no. of days, 20%
- Sustainability – reduction of CO<sub>2</sub> emissions in Scope 1 and Scope 2, 5%
- Sustainability – implementation of process for supplier ESG qualification, 5%

**Distribution of outcome of short-term variable remuneration per performance target 2024**



**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

**Remuneration Report 2024**

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**Applying the performance targets for the variable long-term remuneration**

The long-term variable remuneration ("LTI-bonus") for the President & CEO is capped for a three-year period at an amount corresponding to one-year base salary and is subject to continued employment at the end of the vesting period (with some customary

exceptions). The vesting period for the LTI-bonus is three fiscal years.

The performance target for LTI 2022–2024, LTI 2023–2025 and LTI 2024–2026 is development of earnings per share over a three-year period adjusted for the categories of adjustment items that the Board of Directors determines at the recommendation of the

Remuneration Committee at the implementation of each program.

The incentive program LTI 2022–2024 expired at the end of the 2024 fiscal year and the performance targets was not achieved, which resulted in that there is no bonus payout.

**The performance by the President & CEO during the reported fiscal year – long-term variable remuneration**

**Criteria for determination of long-term variable remuneration for the President & CEO and outcome, SEK 000s**

| Executive                       | Long-term incentive program (LTI) | Performance target <sup>1)</sup>                     | Outcome of performance target                | Variable remuneration per performance target <sup>2)</sup> |
|---------------------------------|-----------------------------------|--|--|--|
| Mattias Perjos, President & CEO | LTI 2022–2024                     | Development of adjusted earnings per share 2022–2024 | SEK 11.73 (adjusted earnings per share 2024) | –  |
|                                 | LTI 2023–2025                     | Development of adjusted earnings per share 2023–2025 | –  | – <sup>3)</sup>  |
|                                 | LTI 2024–2026                     | Development of adjusted earnings per share 2024–2026 | –  | – <sup>4)</sup>  |

- 1) The performance targets in the group's long-term variable remuneration schemes are earnings per share, adjusted for acquisitions, divestments, restructuring costs and other material non-recurrent costs.
- 2) At the end of the year, there was no provision for earned LTI-bonus to the President & CEO as LTI 2022–2024 has expired and the performance target was not met. The vesting period for the group's long-term incentive scheme is three years and the remuneration is conditioned by the President & CEO remaining an employee at the end of the vesting period.
- 3) Since the three-year performance period for the performance target for the incentive program LTI 2023–2025 has not ended, there is no earned compensation for the incentive program and therefore no outcome for the performance target is reported.
- 4) Since the three-year performance period for the performance target for the incentive program LTI 2024–2026 has not ended, there is no earned compensation for the incentive program and therefore no outcome for the performance target is reported.

**Comparative information regarding the company's result and changes in remuneration**

**Changes in remuneration and company performance over the last five reported fiscal years<sup>1)</sup>**


|  | 2020 compared with 2019 | 2021 compared with 2020 | 2022 compared with 2021 | 2023 compared with 2022 | 2024 compared with 2023 | 2024 <sup>4)</sup> |
|--|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|--------------------|
| Changes in remuneration to the President & CEO, SEK 000s <sup>2)</sup>             | 20,663 (44.9%)          | -7,082 (-10.6%)         | -16,378 (-27.5%)        | 3,143 (7.3%)            | 13,457 (29.0%)          | 59,845             |
| Changes in average remuneration to employees of Getinge AB, SEK 000s <sup>3)</sup> | -34 (-2.1%)             | -340 (-21.1%)           | -244 (-19.2%)           | 356 (34.6%)             | -34 (-2.4%)             | 1,352              |
| Changes in operating profit for the group, SEK M                                   | 2,412 (101.7%)          | -413 (-8.6%)            | -745 (-17.0%)           | 110 (3.0%)              | -882 (-23.6%)           | 2,854              |

- 1) In the above table, changes in remuneration and result between the years are presented. The changes are presented in both absolute terms and as a percentage.
- 2) Remuneration to the President & CEO relates to the total remuneration including fixed salary, short- and long-term variable remuneration, pension expenses and other benefits.
- 3) Remuneration to the Senior Executives excluded.
- 4) Refers to the outcome for year 2024.

Gothenburg in March 2025

**The Board of Directors of Getinge AB (publ)**

**Relative changes in remuneration and profit**



- Remuneration to the President & CEO (SEK 000s)
- Operating profit for the group (SEK M)
- Adjusted EBITA for the group (SEK M)

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

**Proposed appropriation of profit**

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

# Proposed appropriation of profit

Getinge AB (publ), Corp. ID No. 556408-5032

**The following non-restricted equity in the Parent Company is at the disposal of the Annual General Meeting, SEK M:**

|                         |               |
|-------------------------|---------------|
| Share premium reserve   | 4,264         |
| Retained earnings       | 17,117        |
| Net profit for the year | 1,627         |
| <b>Total</b>            | <b>23,008</b> |

|  |               |
|--|---------------|
| The Board and CEO propose that a dividend of SEK 4.60 per share shall be distributed to shareholders | 1,253         |
| to be carried forward  | 21,755        |
| <b>Total</b>   | <b>23,008</b> |

The Board of Directors deems the proposed dividend to be justified in relation to requirements that the nature of the business, scope and risks impose on consolidated equity and the group's consolidation requirements, liquidity and financial position.

The Board of Directors and CEO affirm that the consolidated financial statements have been prepared in accordance with international financial reporting standards IFRS, as adopted by the EU, and provide a true and fair view of the group's financial position and profit. This Financial statements was prepared in accordance with generally accepted accounting policies and provides a true and fair view of the Parent Company's financial position and profit.

The Administration Report for the group and Parent Company provides a fair and accurate overview of the performance of the Parent Company and the group's operations, financial position and earnings and describes the material risks and uncertainties faced by the Parent Company and companies belonging to the group.

Gothenburg, March 26, 2025

**Johan Malmquist**  
Chairman  
AGM-elected Board member

**Carl Bennet**  
Vice Chairman  
AGM-elected Board member

**Johan Bygge**  
AGM-elected Board member

**Cecilia Daun Wennborg**  
AGM-elected Board member

**Dan Frohm**  
AGM-elected Board member

**Mattias Perjos**  
President & CEO,  
AGM-elected Board member

**Malin Persson**  
AGM-elected Board member

**Kristian Samuelsson**  
AGM-elected Board member

**Fredrik Brattborn**  
Board member  
Representative of the Swedish  
Metalworkers' Union

**Åke Larsson**  
Board member  
Representative of the Swedish  
Association of Graduate Engineers

**Our auditor's report was submitted on March 27, 2025**  
**Öhrlings PricewaterhouseCoopers AB**

**Cecilia Andrén Dorselius**  
Authorized Public Accountant  
Auditor in Charge

**Karin Olsson**  
Authorized Public Accountant

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

**Group financial statements**

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

# Consolidated income statement

| SEK M  | Note       | 2024          | 2023          |
|--|------------|---------------|---------------|
| Net sales  | 2, 3       | 34,759        | 31,827        |
| Cost of goods sold   | 4          | -18,606       | -17,332       |
| <b>Gross profit</b>  |            | <b>16,153</b> | <b>14,495</b> |
| Selling expenses   | 4          | -5,979        | -5,366        |
| Administrative expenses  | 4          | -4,654        | -4,315        |
| Research and development costs   | 4, 9       | -1,431        | -1,192        |
| Acquisition expenses   | 4          | -50           | -167          |
| Restructuring costs  | 4          | -848          | -75           |
| Other operating income   | 4          | 672           | 1,030         |
| Other operating expenses   | 4          | -1,008        | -673          |
| <b>Operating profit (EBIT)</b>   | 3, 4, 5, 6 | <b>2,854</b>  | <b>3,736</b>  |
| Interest income and other similar income   | 6, 7       | 107           | 167           |
| Interest expenses and other similar expenses   | 6, 7       | -678          | -560          |
| <b>Profit after financial items</b>  |            | <b>2,282</b>  | <b>3,343</b>  |
| Taxes  | 8          | -628          | -915          |
| <b>Net profit for the year</b>   |            | <b>1,654</b>  | <b>2,428</b>  |
| <b>Net profit for the year attributable to:</b>  |            |               |               |
| Parent Company's shareholders  |            | 1,638         | 2,412         |
| Non-controlling interests  |            | 16            | 16            |
| <b>Earnings per share, SEK<sup>1)</sup></b>  | 17         | <b>6.01</b>   | <b>8.86</b>   |
| Weighted average number of outstanding shares for calculation of earnings per share (000s) | 17         | 272,370       | 272,370       |

1) Before and after dilution.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

**Group financial statements**

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

# Consolidated statement of comprehensive income

| SEK M  | Note | 2024         | 2023          |
|--|------|--------------|---------------|
| <b>Net profit for the year</b>                                     |      | <b>1,654</b> | <b>2,428</b>  |
| <b>Other comprehensive income</b>                                  |      |              |               |
| <b>Items that cannot be restated in profit</b>                     |      |              |               |
| Actuarial gains/losses pertaining to defined-benefit pension plans |      | 31           | -258          |
| Tax attributable to items that cannot be restated in profit        |      | -3           | 68            |
| <b>Items that can later be restated in profit</b>                  |      |              |               |
| Translation differences  |      | 2,063        | -743          |
| Hedging of net investments   |      | 393          | -276          |
| Cash flow hedges   | 19   | 12           | 30            |
| Tax attributable to items that can be restated in profit           |      | -83          | 50            |
| <b>Other comprehensive income for the year, net after tax</b>      |      | <b>2,412</b> | <b>-1,128</b> |
| <b>Comprehensive income for the year</b>                           |      | <b>4,066</b> | <b>1,301</b>  |
| <b>Comprehensive income for the year attributable to:</b>          |      |              |               |
| Parent Company's shareholders                                      |      | 4,038        | 1,285         |
| Non-controlling interests  |      | 28           | 15            |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

**Group financial statements**

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

# Consolidated balance sheet

| SEK M                               | Note       | 2024          | 2023          |
|-------------------------------------|------------|---------------|---------------|
| <b>ASSETS</b>                       |            |               |               |
| <b>Non-current assets</b>           |            |               |               |
| Intangible assets                   | 3, 9       | 39,242        | 30,670        |
| Tangible assets                     | 3, 10      | 3,902         | 3,723         |
| Right-of-use assets                 | 11         | 1,795         | 1,486         |
| Financial instruments, long-term    | 19         | 15            | –             |
| Financial receivables, long-term    | 19         | 33            | 61            |
| Deferred tax assets                 | 8          | 770           | 1,000         |
| <b>Total non-current assets</b>     |            | <b>45,757</b> | <b>36,939</b> |
| <b>Current assets</b>               |            |               |               |
| Inventories                         | 12         | 6,590         | 6,416         |
| Accounts receivable                 | 13, 19     | 6,348         | 5,739         |
| Contract assets                     | 14         | 926           | 625           |
| Current tax assets                  |            | 73            | 135           |
| Financial instruments, current      | 19         | 3             | 36            |
| Other receivables                   | 19         | 806           | 581           |
| Prepaid expenses and accrued income | 16         | 455           | 386           |
| Cash and cash equivalents           | 19, 20, 26 | 2,961         | 2,728         |
| <b>Total current assets</b>         |            | <b>18,162</b> | <b>16,647</b> |
| <b>TOTAL ASSETS</b>                 |            | <b>63,918</b> | <b>53,586</b> |

| SEK M   | Note       | 2024          | 2023          |
|---|------------|---------------|---------------|
| <b>EQUITY AND LIABILITIES</b>   |            |               |               |
| <b>Equity</b>   |            |               |               |
| Share capital   | 17         | 136           | 136           |
| Other capital provided  |            | 6,789         | 6,789         |
| Other reserves  |            | 5,752         | 3,380         |
| Retained earnings   |            | 20,328        | 19,861        |
| <b>Equity attributable to the Parent Company's shareholders</b>       |            | <b>33,005</b> | <b>30,166</b> |
| Non-controlling interests   |            | 205           | 237           |
| <b>Total equity</b>   |            | <b>33,210</b> | <b>30,403</b> |
| <b>Long-term liabilities</b>  |            |               |               |
| Interest-bearing long-term liabilities                                | 19, 20     | 6,971         | 3,903         |
| Other long-term liabilities   | 19         | 1,892         | 185           |
| Provisions for pensions and similar obligations, interest-bearing     | 20, 21     | 2,700         | 2,664         |
| Provisions for pensions and similar obligations, non-interest-bearing | 21         | 86            | 120           |
| Leasing liabilities, long-term  | 11, 19, 20 | 1,309         | 1,057         |
| Deferred tax liabilities  | 8          | 2,172         | 1,681         |
| Restructuring reserves, long-term                                     | 15         | 19            | 6             |
| Other provisions, long-term   | 15         | 510           | 381           |
| <b>Total long-term liabilities</b>                                    |            | <b>15,660</b> | <b>9,998</b>  |
| <b>Current liabilities</b>  |            |               |               |
| Restructuring reserves, current                                       | 15         | 177           | 96            |
| Other provisions, current   | 15         | 1,537         | 960           |
| Interest-bearing current liabilities                                  | 19, 20     | 1,956         | 2,694         |
| Leasing liabilities, current  | 11, 19, 20 | 491           | 422           |
| Accounts payable  | 19         | 2,398         | 2,355         |
| Contract liabilities  | 14         | 2,464         | 2,453         |
| Current tax liabilities   |            | 444           | 387           |
| Financial instruments, current  | 19         | 13            | 60            |
| Other liabilities   | 19         | 2,046         | 840           |
| Accrued expenses and deferred income                                  | 16         | 3,522         | 2,919         |
| <b>Total current liabilities</b>                                      |            | <b>15,047</b> | <b>13,185</b> |
| <b>TOTAL EQUITY AND LIABILITIES</b>                                   |            | <b>63,918</b> | <b>53,586</b> |

Refer to Note 25 Pledge assets and contingent liabilities for information concerning Getinge Group's pledged assets and contingent liabilities.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

**Group financial statements**

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

# Changes in equity for the group

| SEK M                                       | Share capital | Other capital provided | Reserves <sup>1)</sup> | Retained earnings | Total  | Non-controlling interests | Total equity |
|---|---------------|------------------------|------------------------|-------------------|--------|---------------------------|--------------|
| <b>Opening balance 2024</b>                 | 136           | 6,789                  | 3,380                  | 19,861            | 30,166 | 237                       | 30,403       |
| Comprehensive income for the year           | –             | –                      | 2,372                  | 1,665             | 4,038  | 28                        | 4,066        |
| Dividend                                    | –             | –                      | –                      | -1,198            | -1,198 | -29                       | -1,228       |
| Transactions with non-controlling interests | –             | –                      | –                      | –                 | –      | -31                       | -31          |
| <b>Closing balance 2024</b>                 | 136           | 6,789                  | 5,752                  | 20,328            | 33,005 | 205                       | 33,210       |
| <b>Opening balance 2023</b>                 | 136           | 6,789                  | 4,317                  | 18,796            | 30,038 | 415                       | 30,453       |
| Comprehensive income for the year           | –             | –                      | -937                   | 2,223             | 1,285  | 15                        | 1,301        |
| Dividend                                    | –             | –                      | –                      | -1,158            | -1,158 | -23                       | -1,181       |
| Transactions with non-controlling interests | –             | –                      | –                      | –                 | –      | -170                      | -170         |
| <b>Closing balance 2023</b>                 | 136           | 6,789                  | 3,380                  | 19,861            | 30,166 | 237                       | 30,403       |

1) Reserves pertain to cash flow hedges, hedges of net investments and translation differences.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

**Group financial statements**

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

# Consolidated cash flow statement

| SEK M   | Note  | 2024          | 2023          | SEK M  | Note | 2024         | 2023          |
|---|-------|---------------|---------------|--|------|--------------|---------------|
| <b>Operating activities</b>                           |       |               |               | <b>Financing activities</b>                            |      |              |               |
| Operating profit (EBIT)                               |       | 2,854         | 3,736         | Raising of loans                                       |      | 7,736        | 3,133         |
| Add-back of amortization, depreciation and write-down |       | 2,421         | 2,093         | Repayment of loans                                     |      | -5,529       | -936          |
| Other non-cash items <sup>1)</sup>                    | 26    | 808           | 35            | Lease payments   |      | -506         | -476          |
| Add-back of restructuring costs <sup>2)</sup>         |       | 523           | 49            | Change in long-term receivables                        |      | 31           | -30           |
| Paid restructuring costs                              |       | -288          | -176          | Dividend paid  |      | -1,227       | -1,181        |
| Interest paid and received                            | 26    | -560          | -300          | <b>Cash flow from financing activities</b>             |      | <b>504</b>   | <b>511</b>    |
| Other financial items                                 |       | -24           | -24           | <b>Cash flow for the year</b>                          |      | <b>532</b>   | <b>-3,075</b> |
| Taxes paid  |       | -742          | -815          | Cash and cash equivalents at the beginning of the year |      | 2,728        | 5,676         |
| <b>Cash flow before changes in working capital</b>    |       | <b>4,993</b>  | <b>4,598</b>  | Cash flow for the year                                 |      | 532          | -3,075        |
| <b>Changes in working capital</b>                     |       |               |               | Translation differences                                |      | -299         | 127           |
| Inventories   |       | 46            | -202          | <b>Cash and cash equivalents at year-end</b>           | 26   | <b>2,961</b> | <b>2,728</b>  |
| Operating receivables                                 |       | -712          | -305          |  |      |              |               |
| Operating liabilities <sup>3)</sup>                   |       | 250           | -1,133        |  |      |              |               |
| <b>Cash flow from operating activities</b>            |       | <b>4,577</b>  | <b>2,957</b>  |  |      |              |               |
| <b>Investing activities</b>                           |       |               |               |  |      |              |               |
| Acquisition of operations                             | 27    | -3,256        | -5,209        |  |      |              |               |
| Investments in intangible assets and tangible assets  | 9, 10 | -1,309        | -1,353        |  |      |              |               |
| Divestment of non-current assets                      |       | 15            | 19            |  |      |              |               |
| <b>Cash flow from investing activities</b>            |       | <b>-4,549</b> | <b>-6,543</b> |  |      |              |               |

1) Provision for field actions for Cardiosave had an impact of SEK 297 M and negotiations with CGU in Brazil had an impact of SEK 482 M in 2024.

2) Excluding write-downs on fixed assets.

3) 2023 figures have been affected by payments related to the settlement regarding surgical mesh products.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 1** Accounting policies

**General information**

Getinge AB (publ), which is the Parent Company of Getinge Group, is a limited liability company with its registered offices in Gothenburg, Sweden. A description of the company's operations is included in the Administration Report on page 56–60. The consolidated financial statements for the fiscal year ending December 31, 2024 were approved by the Board on March 26, 2025 and will be presented to the AGM on April 22, 2025 for adoption.

**Accounting policies**

**Consolidation**

The consolidated financial statements for Getinge AB (publ) and its subsidiaries have been prepared in accordance with the International Financial Reporting Standards (IFRS), issued by the International Accounting Standards Board (IASB), as endorsed by the EU. This Annual Report has been prepared in accordance with IAS 1 Presentation of Financial Statements and the Swedish Annual Accounts Act. In addition, the Swedish Corporate Reporting Board's recommendation RFR 1 Supplementary Accounting Rules for Groups has been applied. Getinge presents the most material accounting policies in each note to provide a deeper understanding of each accounting area.

The consolidated financial statements include Getinge AB (publ) and its subsidiaries which are the companies (including structured entities) over which the Group exercises a controlling influence. The controlling influence is usually transferred at the acquisition date. The consolidated financial statements were prepared in accordance with the cost method.

The Parent Company applies the same accounting policies as the Group, except in the instances stated in the section Parent company Financial statements Note 1 Parent Company's accounting policies. The differences that arise between the Parent Company

and Group accounting policies are attributable to the limited opportunities for the application of IFRS in the Parent Company, as a result of the Swedish Annual Accounts Act and the Swedish Pension Obligations Vesting Act.

**Intra-Group transactions**

Intra-Group transactions and unrealized intercompany profits are eliminated in the consolidated financial statements, without respect of shares in non-controlling interests. In profit or loss, net profit is recognized without deductions for non-controlling interests in net profit for the year. Non-controlling interests are recognized as a separate item in consolidated equity in the balance sheet.

**Translation to SEK on consolidated of subsidiaries that have a different functional currency to the Group**

The Parent Company's functional currency is Swedish kronor (SEK), which is also the Parent Company's and Group's presentation currency. This means that the financial statements are presented in Swedish kronor (SEK). Getinge applies the current rate method, which means that when the consolidated financial statements are prepared, items in the income statements of foreign subsidiaries are translated to SEK at the average exchange rates for the fiscal year. Items in the balance sheet are translated to SEK using the exchange rates at the end of the reporting period (closing day rate). The exchange-rate fluctuations that arise are recognized as a separate component in other comprehensive income and are accumulated in equity. Getinge applies hedge accounting to external loans raised in order to reduce translation effects in exposed currencies. Exchange rate differences for these external loans are recognized directly in other comprehensive income for the Group.

Accumulated exchange-rate fluctuations attributable to a certain subsidiary are reversed to profit or loss as part of the gain or loss that arises on the divestment of this subsidiary.

**Receivables and liabilities in foreign currencies**

Each group company's functional currency is determined based on the primary economic environment in which the company operates. Transactions in foreign currencies are translated to the functional currency of the financial statements according to the exchange rate on the date of the transaction. Receivables and liabilities in currencies other than the functional currency of the reporting company (foreign currencies) are translated to the functional currency using the closing day rate, and unrealized currency gains and losses are included in profit or loss. Exchange-rate fluctuations on operating assets and liabilities are attributed to operating profit, while exchange-rate fluctuations on financial assets and liabilities are attributed to the Group's net financial items.

Unless otherwise stated, all amounts are given in millions of Swedish kronor (SEK M). For practical reasons, the figures in this Annual Report have not been rounded off, which is why notes and tables may not total correct amounts.

**Significant estimates and assessments**

To prepare the financial statements in accordance with IFRS Accounting Standards, the company management is required to make assessments and assumptions that affect the recognized amounts of assets and liabilities and other information in the financial statements as well as the revenues and expenses recognized during the period. Assumptions, assessments and estimates are reviewed on a regular basis. The actual outcome may diverge from these assumptions, assessments and estimates.

**Introduction****Strategy****Corporate Governance Report****Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report****Other information**

## Note 1 Accounting policies cont.

Getinge presents the most significant estimates and assessments made in each note to provide a deeper understanding.

The Board of Directors and Getinge Executive Team have deemed that the following areas may have a significant impact on Getinge's earnings and financial position in the year ahead:

- Measurement of identifiable assets, liabilities and additional purchase prices on acquisitions (Note 27 Acquisition of operations and Note 19 Financial instruments).
- Goodwill and intangible assets with an indefinite useful life and capitalized product development costs (Note 9 Intangible assets).
- Provisions for pensions and similar obligations (Note 21 Provisions for pensions and similar obligations).
- Write-down of inventories (Note 12 Inventories).
- Deferred tax (Note 8 Income taxes).
- Disputes and claims for damages (Note 15 Other provisions and Note 26 Pledged assets and contingent liabilities).

**New accounting policies applied by the Group in 2024**

No standards, amendments or interpretations effective from January 1, 2024 had a material impact on the consolidated financial statements.

**New and amended standards and interpretations that have not yet come into effect**

In 2024, the IASB presented the new standard IFRS 18 Presentation and Disclosure in Financial Statements. This standard includes requirements for changes to the structure of the financial statements and new requirements for the disclosure of information. Getinge has evaluated the impact on the Group's reporting and predicts minor changes to the presentation of the income statement and cash flow when IFRS 18 is implemented. The standard is effective from January 1, 2027 but has not yet been endorsed by the EU.

No other new or changed accounting standards and interpretations that have been published and take effect in 2025 or later are expected to have a material impact on Getinge's consolidated financial statements.

**Alternative performance measures and definitions**

In the Annual Report, alternative performance measures are used to facilitate analyses of the Group's operations, and the primary alternative performance measures that are presented are net debt/equity ratio, adjusted earnings per share, gross profit, EBIT, EBITA, EBITDA with add-back of acquisition and restructuring costs as well as other items affecting comparability. For reconciliations of the alternative performance measures and definitions, see pages 176–178 and 182–183.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 2** Net sales per revenue classification

**Accounting policies**

Sales are recognized according to IFRS15 and include products, services and rental, net after discounts, excluding indirect sales tax. Getinge's overall performance obligations can be divided into products and services, with services primarily comprising service/maintenance, installation and licenses/software but also including, to a certain extent, extended guarantees, training and revenue from the rental operations. Getinge's products comprise medical devices, spare parts and consumer goods, such as disposables and detergents. Getinge's customers generally conduct their operations in the healthcare sector and laboratory industry.

Revenue is mainly recognized when control of the sold product or service is passed to the buyer and the buyer is able to use or benefit from the product or service. Revenue recognition of a standardized product or equipment usually takes place at a point in time when the goods are delivered or installed and when collection of the receivable is reasonably assured. When delivered, the customer takes physical possession of the standardized product or equipment and Getinge, as a result, has a right to payment.

Revenue recognition from service agreements is adapted to the structure of the underlying customer contract. Getinge has ongoing service agreements with an unspecified number of service matters that take place at several undefined times during the year, and therefore revenue is recognized on a straight-line basis over the agreed contract period. Getinge also has more specific service agreements and revenue is then recognized at a point in time in the period when the specified service is provided.

For software licenses, revenue is recognized when the licenses are made available to the customer, which is usually at the time that the software is accepted and any training is given. Revenue from rental is allocated to a particular period over the term of the rental agreement.

For larger assignments that meet Getinge's and the regulatory criteria for revenue recognition over time, revenue and

expenses are recognized in relation to the degree of completion of the assignment on the closing date. Getinge applies stricter criteria for the possibility of recognizing projects on a percentage of completion basis than those criteria prescribed by the regulations. For example, Getinge requires that a specific stage of the project must have been reached, that the contract price of the performance obligation must be above a specific amount and that the project must have been completely customized and cover a period of at least three months.

The Group primarily recognizes revenue at one point in time. Revenues distributed over time are mainly referring to service agreements, which usually generate revenue over several years. Other revenue recognized over time refers to projects where revenue is recorded according to percentage of completion, revenues from rental of products and from sales of software and licenses.

Expected future revenue from existing customer contracts where the revenue is recognized over time amounts to SEK 1,610 M for 2025 and SEK 654 M for 2026, and primarily derives from multi-year service contracts in Surgical Workflows. Expected revenue for 2027 and beyond for existing customer contracts is not of a material value for the Group.

For information about Getinge's accounting policies for performance obligations that have not yet been invoiced or delivered, see Note 14 Contract assets and liabilities.

**Significant estimates and assessments**

The classification of contracts in performance obligations and determining when revenue for a performance obligation is recognized depends on a number of underlying factors in the contract, with Getinge considering, for example, time of delivery, the complexity and customization in the installation phase, delivery terms, how customized the entire product or service is, and how the terms for customer acceptance and option for the customer to terminate the contract are designed.

The degree of completion of an assignment to which percentage of completion is applied is established in a ratio between accrued assignment costs for work completed on the closing date and the calculated total assignment costs, except in those instances this does not correspond to the degree of completion. When the outcome of an assignment cannot be calculated in a reliable manner, only the amount corresponding to the accrued assignment costs that will probably be paid by the client is recognized as revenue. Other accrued assignment costs are recognized as costs in the period in which they occur. If it is probable that the total amount of accrued assignment costs will exceed total revenue from the assignment, the expected loss is promptly recognized as a cost in its entirety.

| Net sales, SEK M                      | 2024          | 2023          |
|---------------------------------------|---------------|---------------|
| <b>Capital goods</b>                  | <b>12,421</b> | <b>12,474</b> |
| <b>Recurring revenue</b>              |               |               |
| Product sales                         | 15,588        | 12,962        |
| Service assignments incl. spare parts | 6,750         | 6,391         |
| <b>Total recurring revenue</b>        | <b>22,338</b> | <b>19,353</b> |
| <b>Total</b>                          | <b>34,759</b> | <b>31,827</b> |

| Net sales, SEK M                               | 2024          | 2023          |
|--|---------------|---------------|
| <b>Revenue recognized at one point in time</b> | <b>30,791</b> | <b>28,000</b> |
| <b>Revenue recognized over time</b>            |               |               |
| Service  | 3,025         | 2,716         |
| Percentage of completion                       | 676           | 776           |
| Other revenue recognized over time             | 267           | 335           |
| <b>Total revenue recognized over time</b>      | <b>3,968</b>  | <b>3,828</b>  |
| <b>Total</b>                                   | <b>34,759</b> | <b>31,827</b> |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 3** Segment reporting

**Accounting policies**

Getinge's reporting of operating segments is in line with the internal reporting to the CEO, the chief operating decision maker. The group's operations are controlled and reported primarily by business area. Each segment is consolidated according to the same policies as for the group in its entirety and the earnings of the segments represent their contribution to the group's earnings. Assets in a segment include all operating assets used by the segment and primarily comprise intangible assets, tangible assets, inventories, external accounts receivable, other receivables and prepaid expenses and accrued income. Liabilities in a segment include all operating liabilities utilized by the segment and primarily comprise provisions excluding interest-bearing pension provisions and similar obligations, deferred tax liabilities, external accounts payable, other current liabilities and accrued expenses and deferred income. Non-distributed assets and liabilities include all tax items and all items of a financial interest-bearing nature.

The segment reporting has been prepared in accordance with the same policies as for the group in its entirety. Getinge's operations throughout the world are organized into three business areas – Acute Care Therapies, Life Science and Surgical Workflows. These business areas form the basis for the group's segment information. Business terms and conditions as well as market-regulated pricing apply for delivery of products and services between group companies. No sales are made between the different business areas. The group has no single customer that accounts for 10% or more of the group's sales.

**The reporting segments are active in the following operations**

**Acute Care Therapies** offers world-leading solutions for life support in acute health conditions. The offering includes solutions for cardiovascular procedures, efficient handling of organs for transplantation and a broad selection of products and therapies for intensive care.

**Life Science** offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in pharmaceutical and medical device production and with the aim to strengthen integrity of results in biomedical research.

**Surgical Workflows** offers products and solutions to serve as an end-to-end partner for optimizing the quality, safety and capacity usage of the sterile supply departments and operating rooms.

| SEK M  | Net sales     |               | Adjusted EBITA |              | Operating profit (EBIT) |              | Amortization, depreciation and write-downs |               |
|--|---------------|---------------|----------------|--------------|-------------------------|--------------|--|---------------|
|  | 2024          | 2023          | 2024           | 2023         | 2024                    | 2023         | 2024                                       | 2023          |
| Acute Care Therapies                         | 17,948        | 16,529        | 3,554          | 3,117        | 2,065                   | 3,215        | -1,415                                     | -1,214        |
| Life Science                                 | 4,552         | 4,325         | 608            | 430          | 526                     | 395          | -257                                       | -222          |
| Surgical Workflows                           | 12,258        | 10,974        | 1,090          | 721          | 703                     | 675          | -742                                       | -649          |
| Group functions                              | –             | –             | -383           | -381         | -440                    | -549         | -8   | -9            |
| <b>Total</b>                                 | <b>34,759</b> | <b>31,827</b> | <b>4,869</b>   | <b>3,887</b> | <b>2,854</b>            | <b>3,736</b> | <b>-2,421</b>                              | <b>-2,093</b> |
| Interest income and other similar income     |               |               |                |              | 107                     | 167          |  |               |
| Interest expenses and other similar expenses |               |               |                |              | -678                    | -560         |  |               |
| Tax on profit for the year                   |               |               |                |              | -628                    | -915         |  |               |
| <b>Net profit</b>                            |               |               |                |              | <b>1,654</b>            | <b>2,428</b> |  |               |

| SEK M                       | Assets        |               | Liabilities   |               | Investments  |              |
|-----------------------------|---------------|---------------|---------------|---------------|--------------|--------------|
|                             | 2024          | 2023          | 2024          | 2023          | 2024         | 2023         |
| Acute Care Therapies        | 39,769        | 32,919        | 9,762         | 6,666         | 894          | 914          |
| Life Science                | 5,201         | 4,159         | 1,636         | 1,057         | 105          | 105          |
| Surgical Workflows          | 15,169        | 12,719        | 3,696         | 2,979         | 309          | 333          |
| <b>Total business areas</b> | <b>60,139</b> | <b>49,797</b> | <b>15,094</b> | <b>10,702</b> | <b>1,308</b> | <b>1,353</b> |
| Undistributed               | 3,779         | 3,789         | 15,614        | 12,481        | 1            | –            |
| <b>Total</b>                | <b>63,918</b> | <b>53,586</b> | <b>30,708</b> | <b>23,183</b> | <b>1,309</b> | <b>1,353</b> |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

Note 3 Segment reporting cont.

| SEK M                   | Net sales     |               | Intangible assets, tangible assets and right-of-use assets |               |
|-------------------------|---------------|---------------|--|---------------|
|                         | 2024          | 2023          | 2024   | 2023          |
| EMEA                    | 12,182        | 11,739        | 11,814   | 11,903        |
| <i>of which, Sweden</i> | 617           | 632           | 2,308  | 2,345         |
| Americas                | 15,516        | 13,146        | 32,334   | 23,214        |
| <i>of which, USA</i>    | 13,929        | 11,697        | 32,234   | 23,107        |
| APAC                    | 7,061         | 6,943         | 791  | 761           |
| <b>Total</b>            | <b>34,759</b> | <b>31,827</b> | <b>44,939</b>  | <b>35,879</b> |

**Net sales per business area and region, 2024**

| SEK M        | Acute Care Therapies |              | Surgical Workflows | Total         |
|--------------|----------------------|--------------|--------------------|---------------|
|              | Life Science         |              |                    |               |
| EMEA         | 4,742                | 2,057        | 5,383              | 12,182        |
| Americas     | 9,223                | 1,937        | 4,356              | 15,516        |
| APAC         | 3,983                | 559          | 2,519              | 7,061         |
| <b>Total</b> | <b>17,948</b>        | <b>4,552</b> | <b>12,258</b>      | <b>34,759</b> |

**Net sales per business area and revenue type, 2024**

| SEK M             | Acute Care Therapies |              | Surgical Workflows | Total         |
|-------------------|----------------------|--------------|--------------------|---------------|
|                   | Life Science         |              |                    |               |
| Capital goods     | 4,318                | 1,970        | 6,133              | 12,421        |
| Recurring revenue | 13,631               | 2,582        | 6,125              | 22,338        |
| <b>Total</b>      | <b>17,948</b>        | <b>4,552</b> | <b>12,258</b>      | <b>34,759</b> |

**Net sales per business area and revenue stream, 2024**

| SEK M                                   | Acute Care Therapies |              | Surgical Workflows | Total         |
|---|----------------------|--------------|--------------------|---------------|
|   | Life Science         |              |                    |               |
| Revenue recognized at one point in time | 16,808               | 3,579        | 10,403             | 30,791        |
| Revenue recognized over time            | 1,140                | 973          | 1,855              | 3,968         |
| <b>Total</b>                            | <b>17,948</b>        | <b>4,552</b> | <b>12,258</b>      | <b>34,759</b> |

**Secondary reporting segment**

Getinge's operations are secondarily reported by geographic area. The US accounted for 40% (37) of the group's sales and was the only country that accounted for more than 10% of total sales.

Refer also to page 173 for a list of the group's 20 largest markets. The geographic areas' consolidation is conducted in accordance with the same policies as for the group in its entirety.

**Net sales per business area and region, 2023**

| SEK M        | Acute Care Therapies |              | Surgical Workflows | Total         |
|--------------|----------------------|--------------|--------------------|---------------|
|              | Life Science         |              |                    |               |
| EMEA         | 4,497                | 1,977        | 5,265              | 11,739        |
| Americas     | 8,288                | 1,607        | 3,251              | 13,146        |
| APAC         | 3,744                | 741          | 2,458              | 6,943         |
| <b>Total</b> | <b>16,529</b>        | <b>4,325</b> | <b>10,974</b>      | <b>31,827</b> |

**Net sales per business area and revenue type, 2023**

| SEK M             | Acute Care Therapies |              | Surgical Workflows | Total         |
|-------------------|----------------------|--------------|--------------------|---------------|
|                   | Life Science         |              |                    |               |
| Capital goods     | 4,011                | 2,230        | 6,233              | 12,474        |
| Recurring revenue | 12,517               | 2,095        | 4,741              | 19,353        |
| <b>Total</b>      | <b>16,529</b>        | <b>4,325</b> | <b>10,974</b>      | <b>31,827</b> |

**Net sales per business area and revenue stream, 2023**

| SEK M                                   | Acute Care Therapies |              | Surgical Workflows | Total         |
|---|----------------------|--------------|--------------------|---------------|
|   | Life Science         |              |                    |               |
| Revenue recognized at one point in time | 15,520               | 3,338        | 9,142              | 28,000        |
| Revenue recognized over time            | 1,008                | 987          | 1,832              | 3,828         |
| <b>Total</b>                            | <b>16,529</b>        | <b>4,325</b> | <b>10,974</b>      | <b>31,827</b> |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 4** Costs by cost category

| <b>Costs by cost category, SEK M</b>                            | <b>2024</b>    | <b>2023</b>    |
|---|----------------|----------------|
| Goods and services  | -15,918        | -14,557        |
| Salaries and remuneration                                       | -11,113        | -9,831         |
| Social security expenses  | -1,622         | -1,511         |
| Pension expenses  | -495           | -455           |
| Amortization and write-downs of intangible assets <sup>1)</sup> | -1,249         | -981           |
| Depreciation and write-downs of tangible assets <sup>2)</sup>   | -639           | -600           |
| Depreciation and write-downs of right-of-use assets             | -534           | -512           |
| Other operating income  | 672            | 1,030          |
| Other operating expenses  | -1,008         | -673           |
| <b>Total</b>  | <b>-31,905</b> | <b>-28,091</b> |

1) 2024 figure includes SEK -278 M phasing out of Surgical Perfusion product portfolio reported as restructuring costs in income statement.

2) 2024 figure includes SEK -46 M phasing out of Surgical Perfusion product portfolio reported as restructuring costs in income statement.

| <b>Amortization, depreciation and write-downs, SEK M</b> | <b>2024</b>   | <b>2023</b>   |
|--|---------------|---------------|
| Cost of goods sold                                       | -960          | -1,029        |
| Selling expenses   | -625          | -520          |
| Administrative expenses                                  | -414          | -457          |
| Research and development costs                           | -99           | -61           |
| Restructuring costs                                      | -325          | -26           |
| <b>Total</b>   | <b>-2,421</b> | <b>-2,093</b> |

| <b>Other operating income, SEK M</b> | <b>2024</b> | <b>2023</b>  |
|--------------------------------------|-------------|--------------|
| Currency gains                       | 518         | 445          |
| Capital gains                        | 1           | 2            |
| Other <sup>1)</sup>                  | 154         | 583          |
| <b>Total</b>                         | <b>672</b>  | <b>1,030</b> |

1) Other operating income in 2023 includes insurance compensation amounting to SEK 450 M.

| <b>Other operating expenses, SEK M</b> | <b>2024</b>   | <b>2023</b> |
|--|---------------|-------------|
| Currency losses                        | -461          | -610        |
| Capital losses                         | -10           | -7          |
| Other <sup>1)</sup>                    | -538          | -56         |
| <b>Total</b>                           | <b>-1,008</b> | <b>-673</b> |

1) Other operating expenses in 2024 includes provisions related to negotiations with CGU in Brazil amounting to SEK 482 M.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 5** Auditing

| Fee to PwC, SEK M                                   | 2024       | 2023       |
|---|------------|------------|
| Auditing assignment                                 | -41        | -39        |
| Auditing activities other than auditing assignments | -1         | -1         |
| Tax consultancy services                            | -6         | -3         |
| Other services                                      | -2         | -11        |
| <b>Total</b>  | <b>-50</b> | <b>-54</b> |

Total fees to PwC and its international network amounted to SEK 50 M (54) for the 2024 fiscal year. Fee to the Swedish auditing firm Öhrlings PricewaterhouseCoopers AB amounted to SEK 17 M (12), of which SEK 15 M (11) refers to the auditing assignment, SEK 1 M (1) to other statutory assignments and other auditing assignments and SEK 1 M (0) to tax consultancy and other services.

PwC has the auditing assignment for the entire group. Auditing assignments refer to auditing of the financial statements and statutory accounts and other required legal audit.

Auditing activities other than auditing assignments include review of sustainability report, review of interim reports as well as services in conjunction with the issuance of certificates and audit certificates. Tax consultancy services primarily pertain to general tax matters concerning corporate tax and internal pricing. Other services mainly pertain to services in connection with acquisitions.

**NOTE 6** Exchange-rate differences in income statement

| Recognized in income statement within, SEK M | 2024      | 2023        |
|--|-----------|-------------|
| Other operating income and expenses          | 57        | -166        |
| Financial items                              | -8        | -23         |
| <b>Total</b>                                 | <b>49</b> | <b>-188</b> |

**NOTE 7** Financial items

**Accounting policies**

Financial income and expenses include interest income on bank deposits and receivables, interest expenses on loans, income from dividends, unrealized and realized profits and losses on financial investments, exchange rate differences and the change in value of derivative instruments used in financial activities. Borrowing costs in conjunction with the raising of loans are recognized as part of the loan to which they pertain and are charged to profit or loss during the term of the loan.

| Interest income and other similar income, SEK M | 2024       | 2023       |
|---|------------|------------|
| Interest income                                 | 68         | 123        |
| Exchange rate gains                             | 39         | 44         |
| Other   | -          | 0          |
| <b>Total</b>                                    | <b>107</b> | <b>167</b> |

| Interest expense and other similar expenses, SEK M     | 2024        | 2023        |
|--|-------------|-------------|
| Interest expenses                                      | -410        | -299        |
| Interest expenses on lease liabilities <sup>1)</sup>   | -66         | -45         |
| Interest expenses on pension liabilities <sup>2)</sup> | -98         | -107        |
| Discounting of contingent considerations <sup>3)</sup> | -32         | -18         |
| Exchange rate losses                                   | -47         | -67         |
| Other  | -24         | -24         |
| <b>Total</b>   | <b>-678</b> | <b>-560</b> |

1) See Note 11 Leases

2) See Note 21 Provisions for pensions and other obligations

3) See Note 19 Financial instruments

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 8** Income taxes

**Accounting policies**

Getinge's income taxes include taxes on group companies' profits recognized during the accounting period and tax adjustments attributable to earlier periods and changes in deferred taxes. Measurement of all tax liabilities/receivables is conducted at nominal amounts and in accordance with enacted tax regulations and tax rates or those that have been announced and will almost certainly be adopted in the countries where the group companies operate. Tax is recognized directly in equity if the tax is attributable to items that are recognized directly in equity. Deferred tax is calculated to correspond to the tax effect arising when final tax is determined and corresponds to the net effect of tax on all existing differences between fiscal and carrying amounts of assets and liabilities by applying applicable tax rates. Tax loss carryforwards is recognized as an asset only to the extent that it is probable that these loss carryforwards will be matched by future taxable profits. Deferred tax liabilities pertaining to temporary differences that are attributable to investments in subsidiaries and affiliates are not recognized, since the Parent Company, in each instance, can control the point in time of reversal of the temporary differences and a reversal in the foreseeable future has been deemed improbable.

**Significant estimates and assessments**

*Deferred tax*

Getinge reports deferred tax assets related to loss carryforwards. The reporting of deferred tax assets is based on assessments of future taxable income in various tax jurisdictions, which includes assumptions about whether costs that have not yet been subject to taxation are deductible. The purpose of these assessments is to ensure that it is likely that the company's future taxable results will enable the utilization of reported loss carryforwards. Additionally, the offsetting possibilities of tax assets and tax liabilities are considered, as well as the fact that a significant portion of the loss carryforwards are attributable to countries with long or unlimited utilization periods.

The group's tax expense amounted to SEK -628 M (-915), entailing a tax rate of 27.5% (27.4).

| Taxes, SEK M | 2024        | 2023        |
|--------------|-------------|-------------|
| Current tax  | -848        | -678        |
| Deferred tax | 219         | -236        |
| <b>Total</b> | <b>-628</b> | <b>-915</b> |

**The relationship between the year's tax expense and the recognized profit before tax, SEK M**

|  | 2024         | 2023         |
|--|--------------|--------------|
| <b>Recognized profit before tax</b>              | <b>2,282</b> | <b>3,343</b> |
| Tax according to current tax rate in Sweden      | -470         | -689         |
| Adjustment for tax rates in foreign subsidiaries | -140         | -120         |
| Adjustment of tax expenses from earlier years    | 18           | -24          |
| Other tax effects <sup>1)</sup>                  | -36          | -82          |
| <b>Recognized tax expense</b>                    | <b>-628</b>  | <b>-915</b>  |

1) Mainly refers to foreign withholding tax and tax effects of non-deductible costs/non-taxable income.

**Deferred tax assets relate to the following temporary differences and loss carryforwards, SEK M**

|                            | 2024       | 2023         |
|----------------------------|------------|--------------|
| Non-current assets         | 391        | 160          |
| Leasing liabilities        | 452        | 369          |
| Current assets             | 567        | 545          |
| Provisions                 | 467        | 384          |
| Loss carryforwards         | 442        | 686          |
| Other                      | 408        | 369          |
| Offset                     | -1,957     | -1,513       |
| <b>Deferred tax assets</b> | <b>770</b> | <b>1,000</b> |

**Deferred tax liabilities relate to the following temporary differences, SEK M**

|                                 | 2024         | 2023         |
|---------------------------------|--------------|--------------|
| Non-current assets              | 3,219        | 2,289        |
| Right-of use assets             | 450          | 371          |
| Current assets                  | 72           | 73           |
| Other                           | 388          | 461          |
| Offset                          | -1,957       | -1,513       |
| <b>Deferred tax liabilities</b> | <b>2,172</b> | <b>1,681</b> |

**Maturity structure for loss carryforwards, SEK M**

|                    | 2024         | 2023         |
|--------------------|--------------|--------------|
| Due within 1 year  | -            | -            |
| Due within 2 years | -            | -            |
| Due within 3 years | -            | -            |
| Due within 4 years | 4            | 4            |
| Due within 5 years | -            | -            |
| Due after 5 years  | 17           | 16           |
| No due date        | 1,305        | 2,441        |
| <b>Total</b>       | <b>1,327</b> | <b>2,461</b> |

At year-end 2024, there were unrecognized deferred tax assets pertaining to loss carryforwards and unutilized interest deductions amounting to SEK 74 M (70).

**OECD global minimum tax model rules**

The group is subject to the Global Anti-Base Erosion (GloBE) rules. Legislation on global minimum tax has been adopted in Sweden, where Getinge AB (publ) has its registered offices, and came into effect on January 1, 2024. The group applies the exception to recognizing and disclosing information about deferred tax assets and liabilities related to OECD pillar two income taxes, as stipulated in IAS 12. As of the balance sheet date, the group has no significant tax exposure regarding Global Anti-Base Erosion rules.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**Accounting policies**

*Goodwill*

Goodwill comprises the portion of a purchase price for an acquisition that exceeds the market value of the identifiable assets, with deductions for liabilities and contingent liabilities, calculated on the acquisition date, on the share of the acquired company's assets acquired by the group. In a business acquisition whereby the acquisition costs are less than the net value of acquired assets, assumed liabilities and contingent liabilities, the difference is recognized directly in profit or loss. Goodwill arising in conjunction with the acquisition of a foreign entity is treated as an asset in the foreign entity and translated at the exchange rate on the closing date. Goodwill is recognised as an intangible asset with an indefinite useful life. For assets with an indefinite useful life such as goodwill, in addition to indications of impairment, an annual assessment of impairment needs is carried out. Goodwill is allocated and tested at the level of cash-generating units, which are identified as the Getinge Group's business areas. If the carrying amount of the tested cash-generating unit exceeds the estimated recoverable value, the difference is recognised as an impairment in the income statement. In 2024, the recoverable value of the Group's operations exceeded the carrying amount of all cash-generating units, thus no impairment has been recognized.

*Other intangible assets*

Other intangible assets comprise capitalized development costs, customer relations, technical know-how, trademarks, agreements and other assets. Intangible assets are recognized at cost with deductions for accumulated amortization and any impairment losses. Amortization is applied proportionally over the asset's anticipated useful life, which usually varies between three and 15 years. Acquired intangible assets are recognized separately from goodwill if they fulfill the criteria for qualifying as an asset, implying they can be separated or they are based on contractual or other legal rights and that their market value can be established in a reliable manner. Intangible assets that

are recognized separately from goodwill in acquisitions of operations include customer relations, technical know-how, trademarks, agreements, etc.

Acquired intangible assets are measured at market value and amortized on a straight-line basis over their anticipated useful life. The useful life can, in certain cases, be indefinite. These intangible assets are not amortized, instead they are tested for impairment every year or more often if there is an indication that there could have been a decrease in value. Costs for development, whereby research results or other knowledge is applied to produce new products, are recognized as an asset in the balance sheet to the extent that these products are expected to generate future financial benefits. These costs are capitalized when management deems that the product is technically and financially viable, which is usually when a product development project has reached a defined milestone in accordance with an established project model. The capitalized value includes expenses for material, direct expenses for salaries and indirect expenses that can be assigned to the asset in a reasonable and consistent manner. In other cases, development costs are expensed as they arise. Research costs are charged to earnings as they arise. Capitalized expenses are amortized on a straight-line basis from the point in time at which the asset is put into commercial operation and during the asset's estimated useful life. The amortization period is determined based on historical data and taking into consideration future changes in technology. For capitalized development costs, the amortization period is five to 15 years and for software three years.

*Depreciation and impairment of intangible assets with determinable useful life*

At the end of each accounting period, the carrying amount of the assets is assessed to determine whether there is any indication that impairment is required. If there is such an indication, the asset's recoverable amount is established. The recoverable amount is deemed to be the higher of the asset's net realizable value and its value in use, for which the impairment

loss is recognized as soon as the carrying amount exceeds the recoverable amount. Earlier recognized impairment losses on intangible assets and tangible assets are reversed if the recoverable amount is deemed to have increased, although the impairment losses are not reversed to an amount greater than what the carrying amount would have been if no impairment losses had been recognized in earlier years. Recognized impairments of goodwill are not reversed.

**Significant estimates and assessments**

*Goodwill and intangible assets with an indefinite useful life*

Each year Getinge evaluates whether there is an impairment of goodwill and other intangible assets with an indefinite useful life. In the impairment testing of goodwill and other intangible assets, estimates are made to determine the recoverable value of cash-generating units. The recoverable value for cash-generating units has been determined by calculating the value in use, which is based on management's estimate of future cash flows and is to varying degrees sensitive to changes in assumptions and external factors. Although management considers estimated future cash flows and other assumptions to be reasonable, there are uncertainties, which can significantly affect valuations.

*Capitalized product development costs*

Costs for product development projects are capitalized to the extent that the costs can be expected to generate financial benefits for the company. Capitalization starts when management assess the product to be technically or financially viable. This means that established criteria must be met before a development project is capitalized as an intangible asset. Capitalization ends and amortization of the capitalized development costs starts when the asset is ready for use. Capitalized development costs are tested for impairment when there are indications of a decline in value. Determining the amortization period and testing for impairment require management to make assessments.

Introduction

Strategy

Corporate Governance Report

Financial statements

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

Sustainability Report

Other information

Note 9 Intangible assets cont.

| Intangible assets, SEK M                                      | Goodwill      | Trademarks   | Capitalized development costs <sup>1) 2)</sup> | Patents & Agreements | Customer relations | Technical know-how | Intangible assets, other | Total          |
|---|---------------|--------------|--|----------------------|--------------------|--------------------|--------------------------|----------------|
| <b>Acquisition cost, Jan 1, 2024</b>                          | <b>25,579</b> | <b>1,130</b> | <b>9,131</b>                                   | <b>1,146</b>         | <b>4,493</b>       | <b>1,623</b>       | <b>5,886</b>             | <b>48,988</b>  |
| Investments   | –             | –            | 660  | –                    | –                  | –                  | 196                      | 856            |
| Acquisitions  | 3,104         | 226          | –  | –                    | 325                | 2,690              | –                        | 6,345          |
| Sales/disposals   | –             | –            | -217   | -79                  | –                  | –                  | -643                     | -939           |
| Reclassifications   | –             | –            | 0  | –                    | –                  | –                  | 0                        | 0              |
| Translation differences                                       | 2,148         | 105          | 305  | 88                   | 408                | 301                | 370                      | 3,726          |
| <b>Accumulated cost, Dec 31, 2024</b>                         | <b>30,831</b> | <b>1,461</b> | <b>9,879</b>                                   | <b>1,154</b>         | <b>5,226</b>       | <b>4,615</b>       | <b>5,809</b>             | <b>58,975</b>  |
| <b>Amortization and write-downs, Jan 1, 2024</b>              | <b>-710</b>   | <b>-627</b>  | <b>-6,176</b>                                  | <b>-1,126</b>        | <b>-3,146</b>      | <b>-1,427</b>      | <b>-5,106</b>            | <b>-18,318</b> |
| Amortization for the year                                     | 0             | -4           | -398   | -7                   | -134               | -121               | -275                     | -939           |
| Write-downs   | –             | –            | -309   | –                    | –                  | –                  | 0                        | -309           |
| Acquisitions  | –             | –            | –  | 0                    | –                  | 0                  | –                        | 0              |
| Sales/disposals   | –             | –            | 217  | 79                   | –                  | –                  | 639                      | 935            |
| Reclassifications   | –             | –            | 0  | –                    | –                  | –                  | –                        | 0              |
| Translation differences                                       | -33           | -55          | -186   | -87                  | -272               | -133               | -337                     | -1,102         |
| <b>Accumulated amortization and write-downs, Dec 31, 2024</b> | <b>-743</b>   | <b>-687</b>  | <b>-6,852</b>                                  | <b>-1,140</b>        | <b>-3,551</b>      | <b>-1,682</b>      | <b>-5,078</b>            | <b>-19,734</b> |
| <b>Closing carrying amount, Dec 31, 2024</b>                  | <b>30,088</b> | <b>774</b>   | <b>3,027</b>                                   | <b>14</b>            | <b>1,675</b>       | <b>2,932</b>       | <b>731</b>               | <b>39,242</b>  |

1) Research and Development cost, gross amounted to SEK 2,091 M (1,821) whereof SEK 660 M (629) were capitalized.

2) Write-downs of capitalized development costs amounted to SEK -309 M (-133), whereof SEK -278 M (-133) within Acute Care Therapies mainly attributable to the phase out of Surgical Perfusion, SEK -31 M (-) within Life Science and SEK - M (-0) within Surgical Workflows.

| Intangible assets, SEK M                                      | Goodwill      | Trademarks   | Capitalized development costs <sup>1) 2)</sup> | Patents & Agreements | Customer relations | Technical know-how | Intangible assets, other | Total          |
|---|---------------|--------------|--|----------------------|--------------------|--------------------|--------------------------|----------------|
| <b>Acquisition cost, Jan 1, 2023</b>                          | <b>23,232</b> | <b>848</b>   | <b>8,683</b>                                   | <b>1,182</b>         | <b>3,412</b>       | <b>1,638</b>       | <b>5,841</b>             | <b>44,836</b>  |
| Investments   | –             | –            | 629  | –                    | –                  | –                  | 166                      | 795            |
| Acquisitions  | 3,260         | 331          | –  | –                    | 1,284              | 43                 | 12                       | 4,930          |
| Sales/disposals   | –             | –            | -93  | –                    | –                  | –                  | -18                      | -111           |
| Reclassifications   | –             | –            | -2   | 0                    | –                  | –                  | 2                        | 0              |
| Translation differences                                       | -913          | -49          | -86  | -36                  | -203               | -57                | -117                     | -1,462         |
| <b>Accumulated cost, Dec 31, 2023</b>                         | <b>25,579</b> | <b>1,130</b> | <b>9,131</b>                                   | <b>1,146</b>         | <b>4,493</b>       | <b>1,623</b>       | <b>5,886</b>             | <b>48,988</b>  |
| <b>Amortization and write-downs, Jan 1, 2023</b>              | <b>-718</b>   | <b>-641</b>  | <b>-5,832</b>                                  | <b>-1,142</b>        | <b>-3,174</b>      | <b>-1,406</b>      | <b>-4,912</b>            | <b>-17,825</b> |
| Amortization for the year                                     | –             | -7           | -357   | -20                  | -77                | -75                | -306                     | -843           |
| Write-downs   | –             | –            | -133   | –                    | –                  | –                  | -5                       | -139           |
| Acquisitions  | –             | –            | –  | –                    | –                  | –                  | -9                       | -9             |
| Sales/disposals   | –             | –            | 93   | –                    | –                  | –                  | 18                       | 111            |
| Reclassifications   | –             | –            | 1  | 0                    | –                  | –                  | -1                       | –              |
| Translation differences                                       | 8             | 22           | 52   | 36                   | 105                | 54                 | 110                      | 386            |
| <b>Accumulated amortization and write-downs, Dec 31, 2023</b> | <b>-710</b>   | <b>-627</b>  | <b>-6,176</b>                                  | <b>-1,126</b>        | <b>-3,146</b>      | <b>-1,427</b>      | <b>-5,106</b>            | <b>-18,318</b> |
| <b>Closing carrying amount, Dec 31, 2023</b>                  | <b>24,869</b> | <b>503</b>   | <b>2,956</b>                                   | <b>19</b>            | <b>1,347</b>       | <b>196</b>         | <b>780</b>               | <b>30,670</b>  |

1) Research and Development cost, gross amounted to SEK 1,821 M (1,658) whereof SEK 629 M (473) were capitalized.

2) Write-downs of capitalized development costs amounted to SEK -133 M (-230), whereof SEK -133 M (-228) within Acute Care Therapies, SEK - M (-) within Life Science and SEK -0 M (-2) within Surgical Workflows.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

Note 9 Intangible assets cont.

**Impairment testing**

| <b>Goodwill, SEK M</b> | <b>2024</b>   | <b>2023</b>   |
|------------------------|---------------|---------------|
| Acute Care Therapies   | 21,882        | 17,391        |
| Surgical Workflows     | 6,161         | 5,780         |
| Life Science           | 2,046         | 1,697         |
| <b>Total</b>           | <b>30,088</b> | <b>24,869</b> |

Goodwill is distributed among the group's cash generating units (CGUs), which are identified per business area.

Goodwill and other net assets are tested for impairment annually and whenever conditions indicate that impairment may be necessary. The recoverable amount for CGUs is determined based on the calculated value in use. For impairment testing purposes, this has been done at the lowest level where separable cash flows have been identified, which for Getinge is the same as its business areas.

**Assumptions**

The value in use of goodwill and other net assets attributable to Acute Care Therapies, Surgical Workflows and Life Science was calculated based on discounted cash flows, which are based on assumptions regarding sales growth and the cost trend. Cash flows for the first three years are based on a financial plan approved by the Board. Cash flows after this three-year period have been determined using a growth rate corresponding to 2%. This growth is based on reasonable prudence and does not exceed long-term growth for the industry as a whole. A discount rate before tax for Acute Care Therapies of 9.5% (10.1) and for Surgical Workflows and Life Science of 10.2% (11.0), was applied when calculating the value in use of all business areas. Right-of-use assets are included in the net assets tested for impairment for each business area and future cash flows referring to lease contracts are taken into account when determining the value in use. With the assumptions described above, value in use exceeds the carrying amount for all CGUs.

**Sensitivity analysis**

In connection with the impairment test, sensitivity analyses have been performed regarding changes in growth rate and discount rate, which have a significant impact on the calculation of the discounted cash flows. The sensitivity analyses showed that the negative changes below would not individually generate a need for impairment in any business area:

- Growth rate after year three decreases to 1%
- Discount rate before tax increases 1 percentage point to 10.5% and 11.2%

**Intangible assets**

Except goodwill, there are within intangible assets also trademarks amounting to SEK 739 M (463) whose useful life has been assessed as indefinite. For these trademarks, no foreseeable time limit have been applied for Getinge's expected future cash flows. The useful life for other intangible assets is three to 15 years. For strategic acquisitions, the useful life exceeds five years.

Introduction

Strategy

Corporate Governance Report

Financial statements

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

Sustainability Report

Other information

NOTE 10 Tangible assets

| Tangible assets, SEK M  | Buildings and land <sup>1)</sup> | Plant and machinery | Equipment, tools, fixtures, fittings | Rental equipment | Construction in progress | Total         |
|---|----------------------------------|---------------------|--------------------------------------|------------------|--------------------------|---------------|
| <b>Acquisition cost, Jan 1, 2024</b>                          | <b>3,689</b>                     | <b>2,095</b>        | <b>3,212</b>                         | <b>560</b>       | <b>654</b>               | <b>10,210</b> |
| Investments   | 113                              | 56                  | 84                                   | 3                | 196                      | 453           |
| Acquisitions  | 1                                | 17                  | 19                                   | –                | –                        | 38            |
| Sales/disposals   | -22                              | -61                 | -254                                 | -65              | -10                      | -411          |
| Reclassifications   | 139                              | 161                 | 139                                  | 101              | -391                     | 150           |
| Translation differences                                       | 221                              | 119                 | 129                                  | 24               | 38                       | 532           |
| <b>Accumulated cost, Dec 31, 2024</b>                         | <b>4,141</b>                     | <b>2,388</b>        | <b>3,330</b>                         | <b>624</b>       | <b>488</b>               | <b>10,971</b> |
| <b>Depreciation and write-downs, Jan 1, 2024</b>              | <b>-2,033</b>                    | <b>-1,700</b>       | <b>-2,381</b>                        | <b>-372</b>      | <b>–</b>                 | <b>-6,488</b> |
| Depreciation for the year                                     | -174                             | -97                 | -263                                 | -58              | –                        | -591          |
| Write-downs   | 0                                | –                   | -48                                  | –                | –                        | -48           |
| Acquisitions  | 0                                | -3                  | -12                                  | –                | –                        | -15           |
| Sales/disposals   | 18                               | 59                  | 244                                  | 55               | –                        | 376           |
| Reclassifications   | 0                                | 0                   | 54                                   | -52              | –                        | 2             |
| Translation differences                                       | -105                             | -91                 | -92                                  | -17              | –                        | -305          |
| <b>Accumulated depreciation and write-downs, Dec 31, 2024</b> | <b>-2,295</b>                    | <b>-1,832</b>       | <b>-2,498</b>                        | <b>-444</b>      | <b>–</b>                 | <b>-7,069</b> |
| <b>Closing carrying amount, Dec 31, 2024</b>                  | <b>1,846</b>                     | <b>556</b>          | <b>832</b>                           | <b>180</b>       | <b>488</b>               | <b>3,902</b>  |

1) Closing carrying amount for land amounted to SEK 180 M (170).

| Tangible assets, SEK M  | Buildings and land <sup>1)</sup> | Plant and machinery | Equipment, tools, fixtures, fittings | Rental equipment | Construction in progress | Total         |
|---|----------------------------------|---------------------|--------------------------------------|------------------|--------------------------|---------------|
| <b>Acquisition cost, Jan 1, 2023</b>                          | <b>3,445</b>                     | <b>2,011</b>        | <b>2,951</b>                         | <b>815</b>       | <b>502</b>               | <b>9,724</b>  |
| Investments   | 40                               | 37                  | 149                                  | 1                | 331                      | 558           |
| Acquisitions  | 256                              | 50                  | 89                                   | 3                | 15                       | 414           |
| Sales/disposals   | -13                              | -20                 | -200                                 | -146             | -12                      | -392          |
| Reclassifications   | 48                               | 53                  | 299                                  | -118             | -162                     | 119           |
| Translation differences                                       | -86                              | -36                 | -74                                  | 4                | -19                      | -212          |
| <b>Accumulated cost, Dec 31, 2023</b>                         | <b>3,689</b>                     | <b>2,095</b>        | <b>3,212</b>                         | <b>560</b>       | <b>654</b>               | <b>10,210</b> |
| <b>Depreciation and write-downs, Jan 1, 2023</b>              | <b>-1,883</b>                    | <b>-1,615</b>       | <b>-2,203</b>                        | <b>-492</b>      | <b>–</b>                 | <b>-6,192</b> |
| Depreciation for the year                                     | -133                             | -91                 | -269                                 | -64              | –                        | -557          |
| Write-downs   | -26                              | -16                 | 0                                    | -1               | –                        | -43           |
| Acquisitions  | -36                              | -19                 | -51                                  | –                | –                        | -105          |
| Sales/disposals   | 10                               | 19                  | 187                                  | 79               | –                        | 295           |
| Reclassifications   | –                                | -8                  | -100                                 | 107              | –                        | -1            |
| Translation differences                                       | 35                               | 28                  | 54                                   | -1               | –                        | 116           |
| <b>Accumulated depreciation and write-downs, Dec 31, 2023</b> | <b>-2,033</b>                    | <b>-1,700</b>       | <b>-2,381</b>                        | <b>-372</b>      | <b>–</b>                 | <b>-6,488</b> |
| <b>Closing carrying amount, Dec 31, 2023</b>                  | <b>1,655</b>                     | <b>394</b>          | <b>831</b>                           | <b>188</b>       | <b>654</b>               | <b>3,723</b>  |

1) Closing carrying amount for land amounted to SEK 170 M (174).

Accounting policies

Properties, machinery, equipment and other tangible assets are recognized at acquisition cost, with deductions for accumulated depreciation and any impairment losses. The acquisition cost includes the purchase price and expenses directly attributable to the asset to bring the asset to the site and in the working condition for its intended use. Examples of directly attributable expenses included in the acquisition cost are delivery and handling costs, installation, legal services and consultancy services. Assets provided to the company in conjunction with the acquisition of new subsidiaries are recognized at market value on the acquisition date. Depreciation is conducted straight line. The value in the balance sheet represents acquisition costs with deduction for accumulated depreciation and any impairment losses. Land is not depreciated since it is deemed to have an infinite economic life, however, the depreciation of other assets is based on the following anticipated useful lives:

| Class of assets    | Depreciation, number of years |
|--------------------|-------------------------------|
| Land improvements  | 40–50                         |
| Buildings          | 10–50                         |
| Machinery          | 5–25                          |
| Equipment          | 10                            |
| Production tools   | 5                             |
| Rental equipment   | 5                             |
| Cars               | 4                             |
| Computer equipment | 3                             |

Tangible assets comprising parts with different useful lives are treated as separate components of tangible assets. Standard maintenance and repair costs are expensed during the periods in which they arise. More extensive repair and upgrading costs are capitalized and depreciated over the item's remaining anticipated useful life. Capital gains/losses are recognized under other operating income/expenses.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 11**

Leases

**Accounting policies**

*Getinge as a lessee*

The group's leases mainly comprise right-of-use assets for premises and vehicles. The leases are recognized as a right-of-use asset with a corresponding lease liability when the leased asset is available for use by the group. Short-term leases and leases for which the underlying asset is of low value are exempted. Each lease payment should be divided between amortization of the lease liability and a financial cost. The financial cost should be allocated over the lease term, so that each reporting period is charged with an amount corresponding to a fixed interest rate for the liability recognized under each period.

The groups lease liabilities are recognized at the present value of the group's fixed lease payments. Purchase options are included if it is reasonably certain that Getinge will exercise the option to acquire the underlying asset. Penalties for terminating the lease are included if the lease term reflects that the lessee will exercise an option to cancel the lease.

The group's right-of-use assets are recognized at acquisition cost, and include initial present value of the lease liability, adjusted for lease payments made at or before the commencement date and any initial direct expenses. Restoration costs are included in the asset if a corresponding provision for restoration costs exists. The right-of-use asset is depreciated on a straight-line basis over the assets useful life and the lease term, whichever is the shortest.

For leases of premises and vehicles, service components are normally a considerable portion of the contracts and are therefore separated. The service components, if these are distinguishable, are recognized as operating expenses and not included in the right of use asset and the lease liability. If a lease contract includes variable lease payments not dependent on an index or rate, or include a low value asset or has a lease term that is twelve months or less, the lease payments are recognized as operating expenses as they occur.

*Getinge as a lessor*

Leases in which Getinge is the lessor are defined in two categories, operating and finance, depending on the financial significance of the agreement. Operating leases are recognized as tangible assets in the category rental equipment. Revenue from operating leases is recognized evenly over the lease term.

Straight-line depreciation is applied to these assets in accordance with the undertakings and the depreciation amount is adjusted to correspond with the estimated realizable value when the undertaking expires. The estimated impairment requirement is immediately charged to profit or loss. The products' estimated realizable value at the expiration of the undertaking is continuously followed up on an individual basis. Finance leases are recognized as long-term or current receivables. Payments received from finance leases are divided between interest income and depreciation of receivables.

**Significant estimates and assessments**

*Getinge as a lessee*

*Measurement of lease liabilities and right-of-use assets*

When entering a lease contract, judgments related to contract scope, lease term and interest rate to be used when discounting future lease payments are made which affect the measurement of the lease liability and the right-of-use asset. Assessment of contract scope includes judgments whether a leased asset is identified in the contract. When determining the lease term of a contract, judgments are also required. Getinge evaluates all agreements with the exception of vehicles, which are evaluated as a portfolio. The lease term includes the non-cancellable period. If Getinge is reasonably certain to use an option to extend the lease, or not to use an option to terminate the lease in advance, this is also considered. The contracts contain a range of different conditions. Extension and termination options are mainly related to real estate leases. Thus, all relevant facts and circumstances that create an economic incentive to include optional periods are evaluated.

The importance of the underlying asset in the operations and its location, significant leasehold improvements and level of rentals in optional periods compared to market rates are examples of factors included in the assessment. Lease terms are negotiated on an individual basis and are reassessed if an option is exercised. Judgments are also required to determine the interest rate when discounting future lease payments and whether the interest rate implicit in the lease can be readily determined and thereby used, or if Getinge's incremental borrowing rate should be used.

*Getinge as a lessor*

*Measurement of lease liabilities and right-of-use assets*

Income from equipment for rental primarily refers to capital goods utilized within the healthcare sector. The typical contract duration ranges from six months to five years. In the period, there have been no material gains or losses recognized from the sale of assets related to the rental operations. The estimated resale value of the rented products at the conclusion of the commitments is continuously monitored on an individual basis. No significant impairments have been recorded against the reported net value of rented products during the year. For further details regarding rental equipment, please refer to Note 10 Tangible assets. Interest income related to lease agreements classified as financial leases is reported within financial items .

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

Note 11 Leases cont.

| Right-of-use assets, SEK M                                    | Building     | Cars & other vehicles | Machinery & equipment | Total         |
|---|--------------|-----------------------|-----------------------|---------------|
| <b>Acquisition cost, Jan 1, 2024</b>                          | <b>1,930</b> | <b>710</b>            | <b>23</b>             | <b>2,663</b>  |
| Entered into new leasing contracts                            | 369          | 359                   | 3                     | 731           |
| End of lease contracts  | -213         | -206                  | -4                    | -423          |
| Reassessment/modifications                                    | 77           | -                     | 1                     | 78            |
| Translation differences                                       | 91           | 40                    | 1                     | 131           |
| <b>Accumulated cost, Dec 31, 2024</b>                         | <b>2,253</b> | <b>903</b>            | <b>24</b>             | <b>3,181</b>  |
| <b>Depreciation and write-downs, Jan 1, 2024</b>              | <b>-816</b>  | <b>-347</b>           | <b>-15</b>            | <b>-1,177</b> |
| Depreciation for the year                                     | -303         | -227                  | -4                    | -534          |
| End of lease contracts  | 165          | 206                   | 4                     | 375           |
| Translation differences                                       | -30          | -19                   | -0                    | -49           |
| <b>Accumulated depreciation and write-downs, Dec 31, 2024</b> | <b>-984</b>  | <b>-386</b>           | <b>-15</b>            | <b>-1,385</b> |
| <b>Closing carrying amount, Dec 31, 2024</b>                  | <b>1,270</b> | <b>517</b>            | <b>9</b>              | <b>1,795</b>  |

| Right-of-use assets, SEK M                                    | Building     | Cars & other vehicles | Machinery & equipment | Total         |
|---|--------------|-----------------------|-----------------------|---------------|
| <b>Acquisition cost, Jan 1, 2023</b>                          | <b>1,677</b> | <b>653</b>            | <b>25</b>             | <b>2,355</b>  |
| Entered into new leasing contracts                            | 449          | 246                   | 2                     | 697           |
| End of lease contracts  | -182         | -168                  | -4                    | -354          |
| Reassessment/modifications                                    | 41           | -                     | 1                     | 41            |
| Translation differences                                       | -54          | -21                   | 0                     | -75           |
| <b>Accumulated cost, Dec 31, 2023</b>                         | <b>1,930</b> | <b>710</b>            | <b>23</b>             | <b>2,663</b>  |
| <b>Depreciation and write-downs, Jan 1, 2023</b>              | <b>-670</b>  | <b>-335</b>           | <b>-14</b>            | <b>-1,019</b> |
| Depreciation for the year                                     | -316         | -190                  | -5                    | -512          |
| End of lease contracts  | 148          | 168                   | 4                     | 320           |
| Translation differences                                       | 23           | 11                    | -0                    | 33            |
| <b>Accumulated depreciation and write-downs, Dec 31, 2023</b> | <b>-816</b>  | <b>-347</b>           | <b>-15</b>            | <b>-1,177</b> |
| <b>Closing carrying amount, Dec 31, 2023</b>                  | <b>1,114</b> | <b>363</b>            | <b>9</b>              | <b>1,486</b>  |

The leasing period for buildings usually amounts to between 3 to 5 years, while for cars and other vehicles it is between 3 to 4 years. Leasing payments are discounted with the group's marginal borrowing rate. The group's weighted average marginal borrowing rate was 3.9% (4.1).

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

Note 11 Leases cont.

| <b>Recognized cost for lease contracts, SEK M</b> | <b>2024</b> | <b>2023</b> |
|---|-------------|-------------|
| Depreciation on right-of-use assets               | -534        | -512        |
| Interest expenses on lease liabilities            | -66         | -45         |
| Cost related to short-term leases                 | -2          | -1          |
| Cost related to low-value leases                  | -19         | -17         |
| <b>Total</b>                                      | <b>-621</b> | <b>-575</b> |

Payments for short-term leasing agreements regarding equipment and vehicles and all leasing agreements of low-value are expensed in the income statement.

Short-term leasing agreements are agreements with a leasing period of less than 12 months. Low-value contracts include IT equipment and office equipment.

| <b>Leasing liabilities, SEK M</b> | <b>2024</b>  | <b>2023</b>  |
|-----------------------------------|--------------|--------------|
| Short-term                        | 491          | 422          |
| Long-term                         | 1,309        | 1,057        |
| <b>Total</b>                      | <b>1,800</b> | <b>1,479</b> |

The total cash-outflow for leasing contracts amounted to SEK -607 M (-573).

Information about Getinge's leasing liabilities undiscounted cash out-flows, see Note 19 Financial instruments.

**Getinge as a lessor**

| <b>Operating leases, SEK M</b>            | <b>2024</b> | <b>2023</b> |
|---|-------------|-------------|
| Leasing income recognized during the year | 64          | 62          |
| Due within 1 year                         | 49          | 41          |
| Due within 2 to 5 years                   | 68          | 57          |
| Due in more than 5 years                  | 31          | 22          |
| <b>Total</b>                              | <b>212</b>  | <b>183</b>  |

| <b>Financial leases, SEK M</b>            | <b>2024</b> | <b>2023</b> |
|---|-------------|-------------|
| Leasing income recognized during the year | 9           | 9           |
| Due within 1 year                         | 8           | 10          |
| Due within 2 to 5 years                   | 21          | 33          |
| Due in more than 5 years                  | 9           | 19          |
| <b>Total</b>                              | <b>48</b>   | <b>71</b>   |

**NOTE 12** Inventories

**Accounting policies**

Inventories are measured at the lower of cost and production value, according to the first in/first out (FIFO) principle, and net realizable value. The carrying amount of finished products includes raw materials, direct labor, other direct costs and production-related expenses including depreciation.

**Significant estimates and assessments**

Assessment of obsolescence in inventories is conducted on an ongoing basis during the year. The value of inventories is adjusted for the estimated decrease in value for products no longer sold, surplus inventories, items under shipping restrictions, physical damage, lead times for inventories, and handling and sales overheads.

| <b>Inventories, SEK M</b> | <b>2024</b>  | <b>2023</b>  |
|---------------------------|--------------|--------------|
| Raw materials             | 2,585        | 2,626        |
| Work in progress          | 879          | 981          |
| Finished products         | 3,126        | 2,809        |
| <b>Total</b>              | <b>6,590</b> | <b>6,416</b> |

Of the group's inventories, SEK 6,382 M (6,243) is measured at cost and SEK 208 M (174) at net realizable value. The write-down during the year amounted to SEK 913 M (428) and reversed amounts from prior years amounted to SEK 221 M (198) for the group. The amounts are included in cost of goods sold in the income statement, with the exception of a write-down amounting to SEK 150 M, which is included in restructuring cost.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 13** Accounts receivable

**Accounting policies**

Accounts receivable belong to the category of financial assets that are measured at amortized cost since the purpose of the holding is to collect contractual cash flows. They are included in current assets with the exception of items that fall due more than 12 months after the end of the reporting period, which are classified as non-current assets. After the acquisition date, they are recognized at amortized cost using the effective interest method. The Group assesses the future expected credit losses related to assets measured at amortized cost and recognizes a reserve for such credit losses ("loss allowance") on each reporting date. For accounts receivable, the Group applies the simplified approach for loss allowance, meaning that the reserve will correspond to the expected loss for the full lifetime of the receivable. Expected credit losses on accounts receivable are recognized under the item selling expenses in profit or loss. More information on the measurement of accounts receivable and credit losses can be found in Note 19 Financial instruments.

| SEK M                                 | 2024         | 2023         |
|---------------------------------------|--------------|--------------|
| Accounts receivable before provisions | 6,556        | 5,957        |
| Provision for doubtful receivables    | -209         | -218         |
| <b>Total</b>                          | <b>6,348</b> | <b>5,739</b> |

Accounts receivable net, after provision for doubtful receivables, theoretically constitutes maximum exposure for the calculated risk of losses. Accordingly, the carrying amount of accounts receivable represents the fair value. It is the group's opinion that there is no significant concentration of accounts receivable to any single client. Letters of credit or the equivalent normally cover sales to countries outside the OECD. Confirmed credit losses in relation to net sales amounted to 0.1% (0.0) for the fiscal year 2024.

The provision for doubtful receivables is based on historical credit losses and taking into consideration current and forward-looking information about customers' payment capacity.

| Maturity analysis of accounts receivable before provision for doubtful receivables, SEK M | 2024         | 2023         |
|---|--------------|--------------|
| Not fallen due  | 4,961        | 4,446        |
| Fallen due 1–5 days   | 232          | 263          |
| Fallen due 6–30 days  | 415          | 413          |
| Fallen due 31–60 days   | 346          | 281          |
| Fallen due 61–90 days   | 119          | 128          |
| Fallen due, more than 90 days   | 483          | 427          |
| <b>Total</b>  | <b>6,556</b> | <b>5,957</b> |

At December 31, 2024, the group's provisions for doubtful receivables totaled SEK 209 M (218).

| Maturity analysis of provision for doubtful receivables, SEK M | 2024        | 2023        |
|--|-------------|-------------|
| Not fallen due   | -31         | -24         |
| Fallen due 1–5 days  | -1          | -1          |
| Fallen due 6–30 days   | -1          | -2          |
| Fallen due 31–60 days  | -1          | -12         |
| Fallen due 61–90 days  | -2          | -9          |
| Fallen due, more than 90 days                                  | -172        | -171        |
| <b>Total</b>   | <b>-209</b> | <b>-218</b> |

**Recognized amounts, by currency, for the group's accounts receivables, SEK M**

|                  | 2024         | 2023         |
|------------------|--------------|--------------|
| USD              | 2,523        | 2,178        |
| EUR              | 1,845        | 1,753        |
| JPY              | 384          | 357          |
| GBP              | 227          | 199          |
| CNY              | 147          | 192          |
| INR              | 136          | 127          |
| CAD              | 133          | 122          |
| SEK              | 125          | 111          |
| AUD              | 97           | 93           |
| HKD              | 85           | 89           |
| Other currencies | 854          | 736          |
| <b>Total</b>     | <b>6,556</b> | <b>5,957</b> |

**Changes in provision for doubtful receivables, SEK M**

|  | 2024        | 2023        |
|--|-------------|-------------|
| <b>Opening balance</b>   | <b>-218</b> | <b>-256</b> |
| Acquisitions   | -2          | -5          |
| Provision for expected losses                                    | -33         | -9          |
| Receivables written off during the year that cannot be recovered | 24          | 15          |
| Recovered doubtful receivables                                   | 29          | 30          |
| Translation differences  | -9          | 7           |
| <b>Closing balance</b>   | <b>-209</b> | <b>-218</b> |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 14** Contract assets and liabilities

**Contract assets**

A contract asset represents accrued income in projects where performance conditions are met over time. Performance conditions fulfilled over time may occur in the case of sale of service and installation as well as longer projects. Contract assets are reclassified as accounts receivable when invoicing. If, in a specific project, advance payments have been received from the customer, the payment reduces the value of the contract asset in accordance with IFRS 15. A contractual asset can also represent the right to compensation for goods and services supplied that have not yet been invoiced.

**Contract liabilities**

A contractual liability is recognized where the group has received compensation from the customer but has not fulfilled its contractual obligations regarding the delivery of goods and services. At Getinge, contractual liabilities typically refer to prepaid revenues for service contracts and advances related to projects. If advances have been obtained for a specific project, this has reduced the value of the contract liability in accordance with IFRS15. Contract liabilities in the form of deferred income and advances from customers in the beginning of the year are essentially recognized in income during the financial year.

| <b>Contract assets, SEK M</b> | <b>2024</b> | <b>2023</b> |
|-------------------------------|-------------|-------------|
| Service                       | 138         | 112         |
| Projects                      | 741         | 442         |
| Other                         | 48          | 72          |
| <b>Total</b>                  | <b>926</b>  | <b>625</b>  |

| <b>Contract liabilities, SEK M</b> | <b>2024</b>  | <b>2023</b>  |
|------------------------------------|--------------|--------------|
| Advances from customers            | 1,243        | 1,380        |
| Service                            | 810          | 810          |
| Other                              | 410          | 262          |
| <b>Total</b>                       | <b>2,464</b> | <b>2,453</b> |

**NOTE 15** Other provisions

**Accounting policies**

Provisions are recognized when the group has a legal or informal obligation as a result of past events and it is probable that payment will be required to fulfill the commitment and if a reliable estimation can be made of the amount to be paid. Restructuring measures, guarantee commitments and similar items are recognized as provisions in the balance sheet. Provisions are reviewed at the end of each accounting period.

**Significant estimates and assessments**

*Disputes and claims for damages*

Provisions for disputes and claims for damages represent management's best estimate of the future cash flow required to settle the obligations. The disputes primarily relate to contractual commitments in contracts with customers and suppliers and damages related to product liability. Management's assessment is that the need for a provision or contingent liability depends on the legal processes in the country in question and the course of the proceedings. Comments from external and internal advisors are taken into consideration, as is experience from similar cases. The results of complicated disputes and claims for damages may nevertheless be difficult to predict and disputes could be both time-consuming and costly (see Note 25 Pledge assets and contingent liabilities). Provision for disputes and claims for damages are included under the item other.

Provision under the item other in 2024 refer to ongoing government investigations regarding anti-competitive practices relating to the sale of medical devices between 2004 and 2017, mainly to public hospitals, Getinge has previously entered into Settlement Agreements with the Brazilian Federal Prosecutor's Office (Ministério Público Federal) and the competition authority, the Administrative Council for Economic Defense (CADE). The negotiations with the federal agency for internal control, public transparency and counter-corruption, Comptroller General of the Union (CGU), are still pending and in Q3 2024, Getinge made a provision of SEK 482 M related to these negotiations.

In addition to the investigations with CGU, Getinge has previously communicated that settlement agreements have been reached with the Brazilian Federal Prosecutor's Office (Ministério Público Federal) in 2018 and the competition authority, Administrative Council for Economic Defense (CADE) in 2019, both related to anti-competitive practices relating to the sale of medical devices. It cannot be ruled out that any further agreements with authorities may have a material impact on the company's financial earnings and position, but it is not currently possible to estimate the amount or date. Getinge has a zero tolerance policy when it comes to contraventions of these regulations.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

Note 15 Other provisions cont.

| 2024, SEK M               | Other provision   |            |              | Total Other provisions | Restructuring reserves |
|---------------------------|-------------------|------------|--------------|------------------------|------------------------|
|                           | Guarantee reserve | Personnel  | Other        |                        |                        |
| <b>Opening balance</b>    | <b>368</b>        | <b>204</b> | <b>769</b>   | <b>1,341</b>           | <b>103</b>             |
| Provisions                | 536 <sup>1</sup>  | 50         | 569          | 1,155                  | 300                    |
| Used amount               | -211              | -55        | -132         | -399                   | -186                   |
| Unutilized funds restored | -32               | -5         | -36          | -73                    | -29                    |
| Translation differences   | 25                | 7          | -9           | 23                     | 8                      |
| <b>Closing balance</b>    | <b>686</b>        | <b>201</b> | <b>1,161</b> | <b>2,048</b>           | <b>196</b>             |
| <i>Of which:</i>          |                   |            |              |                        |                        |
| Short-term                |                   |            |              | 1,537                  | 177                    |
| Long-term                 |                   |            |              | 510                    | 19                     |
| <b>Closing balance</b>    |                   |            |              | <b>2,048</b>           | <b>196</b>             |

1) Includes provision for field actions for Cardiosave amounting to SEK 297 M, for more information see page 50, risk section.

**Expected timing of outflow 2024, SEK M**

|                        |              |            |
|------------------------|--------------|------------|
| Within 1 year          | 1,537        | 177        |
| Within 3 years         | 465          | 19         |
| Within 5 years         | 14           | -          |
| > 5 years              | 31           | -          |
| <b>Closing balance</b> | <b>2,048</b> | <b>196</b> |

| 2023, SEK M               | Other provision   |            |              | Total Other provisions | Restructuring reserves |
|---------------------------|-------------------|------------|--------------|------------------------|------------------------|
|                           | Guarantee reserve | Personnel  | Other        |                        |                        |
| <b>Opening balance</b>    | <b>395</b>        | <b>184</b> | <b>2,436</b> | <b>3,016</b>           | <b>229</b>             |
| Acquisitions              | -                 | -          | 0            | 0                      | -                      |
| Provisions                | 179               | 87         | 251          | 517                    | 37                     |
| Used amount               | -179              | -65        | -1,894       | -2,138                 | -137                   |
| Unutilized funds restored | -19               | -4         | -32          | -55                    | -28                    |
| Reclassification          | -                 | 5          | -5           | -                      | -                      |
| Translation differences   | -8                | -3         | 13           | 2                      | 1                      |
| <b>Closing balance</b>    | <b>368</b>        | <b>204</b> | <b>769</b>   | <b>1,341</b>           | <b>103</b>             |
| <i>Of which:</i>          |                   |            |              |                        |                        |
| Short-term                |                   |            |              | 960                    | 96                     |
| Long-term                 |                   |            |              | 381                    | 6                      |
| <b>Closing balance</b>    |                   |            |              | <b>1,341</b>           | <b>103</b>             |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 16** Prepaid and accrued items

| <b>Prepaid expenses and accrued income, SEK M</b> | <b>2024</b> | <b>2023</b> |
|---|-------------|-------------|
| Insurance expenses                                | 50          | 59          |
| Commissions                                       | 43          | 57          |
| IT expenses                                       | 191         | 148         |
| Other   | 171         | 121         |
| <b>Total</b>                                      | <b>455</b>  | <b>386</b>  |

| <b>Accrued expenses and deferred income, SEK M</b> | <b>2024</b>  | <b>2023</b>  |
|--|--------------|--------------|
| Salaries   | 1,965        | 1,594        |
| Social security expenses                           | 476          | 418          |
| Commissions  | 180          | 142          |
| Interest expenses                                  | 49           | 70           |
| Consultancy fees                                   | 69           | 69           |
| Office related expenses                            | 15           | 13           |
| Logistics, warehousing and freight expenses        | 72           | 71           |
| Other  | 696          | 542          |
| <b>Total</b>                                       | <b>3,522</b> | <b>2,919</b> |

**NOTE 17** Supplementary disclosure to equity

**Accounting policies**

*Dividend*

Decision on dividends are made at the Annual General Meeting, or, when applicable, during an Extraordinary General Meeting. After the decision is made, equity is reduced and the dividend is reported as a liability to shareholders in the balance sheet until payment.

**Share capital**

| <b>Class of shares</b>               | <b>A</b>    | <b>B</b>    | <b>Total</b>       |
|--------------------------------------|-------------|-------------|--------------------|
| Quotient value per share, SEK        | 0.50        | 0.50        |                    |
| <i>Number of shares outstanding:</i> |             |             |                    |
| December 31, 2023                    | 18,217,200  | 254,152,373 | <b>272,369,573</b> |
| December 31, 2024                    | 18,217,200  | 254,152,373 | <b>272,369,573</b> |
| <b>Shares' voting rights in %</b>    | <b>41.8</b> | <b>58.2</b> | <b>100.0</b>       |

In accordance with the Articles of Association, the company's share capital amounts to not less than SEK 75 M and not more than SEK 300 M. Within these limits, the share capital can be raised or lowered without requiring an amendment to the Articles of Association. The maximum number of shares is 600 million. One Class A share carries ten votes and one Class B share carries one vote. Both classes of shares have the same quotient value, which is SEK 0.50. At December 31, 2024, the company's share capital totaled SEK 136 M (136).

**Dividend**

On April 29, 2024, shareholders were paid a dividend of SEK 4.40 per share (SEK 1,198 M in total) relating to 2023.

The Board and the CEO propose to the Annual General Meeting that a dividend of SEK 4.60 per share, relating to 2024 (SEK 1,243 M in total), to be paid to shareholders. The proposed record date is April 24, 2025. Euroclear is expected to distribute the dividend to shareholders on April 29, 2025.

Getinge's dividend policy is to pay dividends of 30–50% of net profit to shareholders. The Board's dividend proposal for 2024 is a deviation from the policy of paying dividends of 30–50% of net profit. The proposal is based on the favorable cash flow generated by the operations.

**Earnings per share**

Earnings per share, before and after dilution, amounted to SEK 6.01 (8.86). The calculation of earnings per share relating to the Parent Company's shareholders is based on the following information:

| <b>Earnings (numerator), SEK M</b>   | <b>2024</b> | <b>2023</b> |
|--|-------------|-------------|
| Earnings relating to the Parent Company's shareholders, which form the basis for calculation of earnings per share | 1,638       | 2,412       |

| <b>Number of shares (denominator)</b>  | <b>2024</b> | <b>2023</b> |
|--|-------------|-------------|
| Weighted average number of outstanding ordinary shares for calculation of earnings per share | 272,369,573 | 272,369,573 |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 18** Financial risk management

**Financial risks**

Through its global operations, Getinge is exposed to a number of financial risks in the form of currency risks, interest-rate risks, financing risks, and credit and counterparty risks. Risk management is regulated by the finance policy adopted by the Board with an associated Treasury directive decided by the Getinge Executive Team and revised yearly. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with the Getinge Executive Team and the finance function. Getinge's financial activities are centralized to benefit from economies of scale, to ensure good internal control and to facilitate monitoring of risk.

**Currency risks**

Currency risks comprise exchange-rate fluctuations, which have an impact on the Group's earnings and equity. Currency exposure occurs in connection with payments in foreign currency (transaction exposure) and when translating foreign subsidiaries' balance sheets and income statements to the presentation currency Swedish kronor (translation exposure).


**Transaction exposure**

*Policy*

The Group's policy states that in the first instance currency exposure is to be reduced by matching inflows and outflows in foreign currency to endeavor to achieve a "natural hedge" as far as possible. In addition, Getinge's Treasury Directive stipulates that the President and CEO has the mandate to decide to hedge all of the annual forecasted net flow in a foreign currency and half of the flow for the next 13–24 months. Hedging may take place using currency forwards, currency swaps and currency options.

The Group's payment flows in foreign currencies are mainly generated by export sales, with the largest flows in USD, EUR, CNY and JPY. The market value of financial currency derivative instruments that meet the cash flow hedging requirements amounted to SEK 0 M (3) on December 31, 2024.

**Transaction exposure in selected foreign currencies, 2024<sup>1)</sup>**



<sup>1)</sup> In values: 1,236 SEK M in currency CNY; -4,067 SEK M in currency EUR; 537 SEK M in currency JPY; 2,754 SEK M in currency USD

**Translation exposure**

*Policy*

When translating net assets of foreign subsidiaries into Swedish kronor, a translation difference occurs, which can affect consolidated other comprehensive income.

When translating the results of foreign subsidiaries into Swedish kronor, a translation difference also arises, which affects the Group's earnings when exchange rates fluctuate. Getinge's policy is not to hedge this risk.

Although Getinge does not have the specifically stated goal of hedging translation exposure, the Group's borrowing in foreign currency takes place in currencies that limit translation exposure through what is known as "natural hedging".

**Sensitivity analysis of currency exposure**

At a 5% rate movement in all exposure currencies, the impact of revaluation effects on equity is approximately SEK 1,513 M (1,355). The extent to which operating profit is impacted by exchange-rate fluctuations is detailed in the following table, based on the exchange rates specified. The effect of exchange-rate movements on operating profit below is calculated using volumes and operating profit in foreign currency for 2024.

| Currency:  | Net volume in 2024, millions (local currency) | Impact in SEK M of 5% rate movement |
|------------|---|-------------------------------------|
| CNY: 1.50  | 1,042   | +/-78                               |
| EUR: 11.47 | -222  | +/-127                              |
| JPY: 0.07  | 9,166   | +/-32                               |
| USD: 11.00 | 272   | +/-149                              |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes


Auditor's report

**Sustainability Report**

**Other information**


Note 18 Financial risk management cont.

**Transaction exposure in selected foreign currencies<sup>1)</sup>**



1) In values: 1,260 SEK M (1,074) in currency CNY; 9,012 SEK M (9,058) in currency EUR; 709 SEK M (599) in currency GBP; -7,621 SEK M (-6,953) in currency SEK; 26,781 SEK M (23,414) in currency USD; 3,069 SEK M (3,210) in other currencies.

**Interest-bearing debt per currency<sup>1,2)</sup>**



1) Excludes pension provisions and lease liabilities.

2) In values: -143 SEK M (-277) in currency EUR; -5,253 SEK M (-4,462) in currency SEK; -3,483 SEK M (-1,757) in currency USD; -48 SEK M (-101) in other currencies.

**Interest-rate risk**

Interest-rate risks are the changes in market interest rates that affect the Group's net interest.

*Policy*

How quickly interest-rate changes impact net interest depends primarily on the fixed-interest term of the debt portfolio. To mitigate the effect of potential increases in market rates, the Group's finance policy stipulates defined frameworks for decisions on the distribution of debt at fixed and variable interest rates.


Of the total loan portfolio of SEK 8,927 M, SEK 3,133 M was raised with fixed interest or hedged using interest-rate derivative instruments, and all other loans with variable interest. The market value of financial interest-rate derivative instruments that meet the cash flow hedging requirements amounted to SEK 15 M (0) on December 31, 2024. The average interest expense for the Group's liabilities to credit institutions amounted to approximately 5.4% (5.2). If the average interest rate for currencies represented in the Group's loan portfolio at the end of the year changed by 1 percentage point, this would affect profits by SEK +/-58 M on an annual basis.

**Capital structure**

*Policy*

Getinge monitors its leverage ratio (net debt in relation to adjusted EBITDA). The finance policy stipulates that the leverage ratio is to be kept within a multiple of 2.5x. However, Getinge's leverage ratio may temporarily exceed this level from time to time in order to finance acquisitions or on the basis of short-term effects. Getinge's ambition is to meet credit ratios equivalent to an "investment grade rating".

**Net debt/adjusted EBITDA<sup>1)</sup>**



1) In values: Year 2020, 1.0; Year 2021, 0.5; Year 2022, 0.4; Year 2023, 1.4; Year 2024, 1.6

The financial position remains solid, although the share of net interest-bearing debt in relation to EBITDA has increased after the acquisition of Paragonix Technologies, Inc. The Group's leverage ratio (net debt in relation to adjusted EBITDA) was 1.6 (1.4) on December 31, 2024.

According to the terms of the Group's main credit facilities, the net debt/equity ratio (net debt in relation to equity) must be below a certain level. The terms also state that the net debt/equity ratio is to be reported to the counterparty every quarter. At year-end, the net debt/equity ratio was well below this level.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

Note 18 Financial risk management cont.

**Financing and liquidity risk**


Financing and liquidity risk is defined as the risk of the cost being higher and financing opportunities limited as the loan is renegotiated. This also includes not being able to fulfill payment commitments as a result of insufficient liquidity or difficulties in securing funding. Financing risk can arise through disruptions in the financial markets, for example, decisions on new regulations or the implementation of recently enacted laws.

**Policy**

To reduce financing risks, the Group strives to diversify its sources of financing and maturities according to the Group's finance policy.

Group Treasury is responsible for proactively managing and controlling the liquidity risk and for ensuring sufficient liquidity reserves and that committed back-up facilities are available.

**Maturity profile, interest-bearing debt, SEK M<sup>1,2</sup>**



1) Excludes pension provisions and lease liabilities.  
 2) In values: Year 2025, -1,956 SEK M; Year 2026, -1,619 SEK M; Year 2027, -2,415 SEK M; Year 2028, -1,621 SEK M; Year 2029, -1,316 SEK M

The Group's sources of financing primarily comprise equity, cash flow from operating activities and borrowing. Getinge has several borrowing programs, including both confirmed bank overdraft facilities and capital market financing programs. These provide a high level of contingency for temporary fluctuations in the Group's short-term liquidity requirements, at the same time as they ensure long-term financing. In addition to the capital market programs, Getinge also has a back-up revolving credit facility of EUR 470 M with a syndicate of seven banks. This loan agreement falls due in 2029 with an extension option of one year. In 2024, the Group renewed the existing MTN program from 2012 to issue bonds in the Swedish capital market. At year-end 2024, SEK 4,974 M was outstanding under this program. For short-term financing requirements, a Swedish program for commercial paper is available. In addition to these credit facilities, the Group has short-term uncommitted credit lines.

At December 31, 2024, the total granted, unutilized overdraft facilities were SEK 468 M (422). In addition, there were unutilized short-term credit facilities of SEK 441 M (476) and committed, unutilized facilities for medium and long-term credit of SEK 5,389 M (5,215), which may be utilized without qualification.

The Group's existing credit facilities are currently deemed to be sufficient. As of December 31, 2024, the Group's borrowings were in line with the requirements under the finance policy pertaining to diversification of lenders.

**Credit and counterparty risks**

The Group's financial transactions cause credit risks with regard to financial counterparties. Financial credit risks or counterparty risks constitute the risk of losses if the counterparties do not fully meet their commitments.

**Policy**

The management of the Group's financial credit risk is regulated in the finance policy through accepting only credit-worthy counterparties and fixed limits, which are monitored continuously.

As of December 31, 2024, the total counterparty exposure in derivative instruments was SEK 15 M (8). The Group has signed standard netting agreements (ISDA) with counterparties for currency transactions and interest-rate swaps. These agreements permit relevant financial assets and liabilities to be offset. Transactions take place within established limits and exposures are continuously monitored.

Commercial credit risks are limited by a diversified customer base with a high credit rating. The Group's customers are found primarily in the public sector, which means that its credit risk is generally very low. The credit risk for Getinge's customers in the private sector is also deemed to be low. When deemed necessary, credit risk is managed using letters of credit or export credit-related guarantees. The provision for doubtful receivables at year-end totaled SEK 209 M (218).

The Group's accounts receivable are presented in Note 13, which shows that the share of past due accounts receivable on December 31, 2024 amounted to SEK 1,595 M in relation to the total volume of accounts receivable, which amounted to SEK 6,556 M. For 41% of past due accounts receivable, payment is past due by a maximum of one month.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**Accounting policies**

*Financial instruments – initial recognition*

Financial assets and financial liabilities are recognized when the Group becomes party to the contractual terms of the instrument. Purchases and sales of financial assets are recognized on the transaction date, which is the date on which the Group undertakes to buy or sell the asset. A financial asset is derecognized from the balance sheet when the contractual rights to the asset are realized, extinguished or the company loses control over them. A financial liability is derecognized from the balance sheet when the contractual obligation has been fulfilled or in some other manner extinguished. Financial instruments are initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issue of a financial asset or financial liability. The Group classified its financial assets and liabilities depending on the purpose for which the financial asset or liability was acquired.

*Financial assets measured at amortized cost*

Assets held for the purpose of collecting the contractual cash flows that are solely payments of principal and interest on the principal amount are measured at amortized cost. Assets in this category are initially measured at fair value including transaction costs. After the acquisition date, they are recognized at amortized cost using the effective interest method. The carrying amount of the assets is adjusted for any impairment for expected credit losses. Interest income from these financial assets is recognized using the effective interest method and is included in financial income. Assets in this category comprise long-term financial receivables, accounts receivable and other current receivables. They are included in current assets with the exception of items that fall due more than 12 months after the end of the reporting period, which are classified as non-current assets.

*Impairment of financial assets measured at amortized cost*

The Group assesses the future expected credit losses related to assets measured at amortized cost and recognizes a reserve

for such credit losses ("loss allowance") on each reporting date. For accounts receivable, the Group applies the simplified approach for loss allowance, meaning that the reserve will correspond to the expected loss for the full lifetime of the receivable. Expected credit losses on accounts receivable are recognized under the item selling expenses in profit or loss.

*Financial liabilities measured at amortized cost*

The Group's other financial liabilities are initially measured at fair value, net after transaction costs. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Long-term liabilities have an expected term longer than one year while current liabilities have a term of less than 12 months. This category includes liabilities to credit institutions, issued bonds, accounts payable and other current liabilities.

*Cash and cash equivalents*

The major portion of cash and cash equivalents comprises cash funds held at financial institutions, and only a minor portion comprises current liquid investments with a term from the acquisition date of less than three months, which are exposed to only an insignificant risk of value fluctuations. Cash and cash equivalents are recognized at nominal amounts, which are equivalent to fair value.

*Financial assets measured at fair value*

Financial assets in this category comprise derivatives. They are included in current assets if they are expected to be settled within 12 months of the end of the reporting period, otherwise, they are classified as non-current assets. All derivatives are measured at fair value in the balance sheet. Changes in fair value are recognized as a component of other comprehensive income insofar as they are part of a hedging relationship that qualifies as hedge accounting. They are reversed to profit or loss when the hedged transaction occurs. Derivatives that do not meet the requirements for hedge accounting are measured at fair value through profit or loss.

*Hedge accounting*

For derivative instruments or other financial instruments that meet hedge accounting requirements under the cash flow hedging method or hedging of net investments in foreign operations method, the effective component of the value change is recognized in other comprehensive income. Accumulated value changes from cash flow hedges are reversed from equity to profit or loss at the same time as the hedged item impacts profit or loss. Interest-bearing liabilities in foreign currencies are defined as hedges to handle translation exposure related to net investments in foreign operations. Accumulated value changes from the hedging of net investments in foreign operations are reversed from equity to profit or loss when the foreign operation is divested in full or in part.

*Fair value*

*Derivative instruments*

The fair value of derivative instruments was calculated using the most reliable market prices available. This requires all instruments that are traded in an effective market, such as currency forward contracts, to be measured at market-to-market at current prices. In terms of instruments for which no reliable prices were available, such as interest-rate swaps, cash flows were discounted using deposit and interest-rate swaps for the currency in question. Translation to Swedish kronor is conducted at the closing day rate.

*Borrowing and other financial instruments*

Loans raised are measured at amortized cost using the effective interest method. Contingent considerations are measured at fair value at Level 3 of the fair value hierarchy. For other financial assets and liabilities, fair value is assessed as corresponding to the carrying amount due to the short expected maturity in time.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

Note 19 Financial instruments cont.

**Financial derivatives**

Getinge uses financial derivatives to manage interest and currency exposure arising in its business. The effectiveness of a hedge is assessed when the hedging relationship is entered into. The hedged item and the hedging instrument are continuously assessed to ensure that the relationship meets the hedge accounting requirements. When the Group hedges purchases and sales in foreign currency, a hedging relationship is entered into whereby the critical terms of the hedging instrument match the terms of the hedged item. In this way, a qualitative assessment of the effectiveness of the hedging relationship is performed and the relationship is expected to be effective for the period for which it is valid.

The Group also enters into interest-rate swap agreements that have the same critical terms as the hedged item. Critical terms may be benchmark interest rates, reset dates, currency, maturities and nominal amount. The Group does not hedge 100% of the principal and thus identifies only a portion of the principal outstanding that corresponds to the nominal amount of the swap. The Group applies hedge accounting.

All derivatives are classified under level 2 of the value hierarchy. Fair value measurements for currency forwards are based on published forward rates in an active market. The measurement of interest-rate swaps is based on forward rates as expressed in market yield curves.

**Contingent considerations**

Getinge signed agreements on contingent considerations in connection with acquisitions of business and subsidiaries. The liabilities for these additional purchase prices are measured at fair value through profit or loss. In most cases, the additional purchase prices are contingent on securing government approval for the acquired product development projects and contingent on the earnings performance of the acquired businesses.

The future cash flows are discounted if the planned disbursement date exceeds 12 months. Assessments about future cash flows linked to the contingent considerations are regularly reviewed by company management and are reported at fair value. The discount effect is recognized on an ongoing basis in profit or loss under financial items.

| <b>Contingent consideration, SEK M</b>              | <b>2024</b>  | <b>2023</b> |
|---|--------------|-------------|
| <b>Opening balance</b>                              | <b>498</b>   | <b>571</b>  |
| Business combinations                               | 3,112        | 14          |
| Dissolution of provision                            | -13          | -49         |
| Fair value adjustments recognized in profit or loss | 11           | -           |
| Payments  | -512         | -40         |
| Discount effect                                     | 32           | 18          |
| Translation differences                             | 152          | -17         |
| <b>Closing balance</b>                              | <b>3,280</b> | <b>498</b>  |
| <i>Of which:</i>                                    |              |             |
| Short-term  | 1,523        | 445         |
| Long-term   | 1,756        | 53          |
| <b>Closing balance</b>                              | <b>3,280</b> | <b>498</b>  |

Contingent considerations are included in other liabilities in the balance sheet.

Regarding the acquisition of Aseptic Solutions LLC, a maximum of approximately SEK 1,507 M (USD 137 M) may be paid in 2025–2030 if contracted results-based milestones are achieved in 2025–2029, and in relation to this, a liability of SEK 396 M (USD 36 M) was recognized in the balance sheet.

Regarding the acquisition of Paragonix Technologies, Inc, approximately SEK 118 M (USD 11 M) may be paid in 2025–2026 if certain regulatory clearance is obtained in 2025. A liability of SEK 100 M (USD 9 M) was recognized in relation to this. In addition, certain results-based milestones have been agreed for which payments may be made in 2025–2026, and for which a liability of SEK 2,571 M (USD 234 M) was recognized.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

Note 19 Financial instruments cont.

**Cash flow for financial liabilities**

The table below shows the Group's financial liabilities and derivative instruments that comprise financial liabilities, subdivided into the periods remaining on the closing date until the agreed date of maturity. The amounts stated in the table comprise contractual, undiscounted cash flows.

| At December 31, 2024, SEK M                    | < 1 year      | 1–2 Years     | 2–5 Years     | > 5 years   |
|--|---------------|---------------|---------------|-------------|
| Bank loans and bond loans (including interest) | -2,321        | -1,941        | -5,709        | –           |
| Leasing liabilities                            | -546          | -433          | -597          | -476        |
| Accounts payable                               | -2,398        | –             | –             | –           |
| <b>Total</b>                                   | <b>-5,265</b> | <b>-2,374</b> | <b>-6,306</b> | <b>-476</b> |

**Outstanding derivative instruments**

| SEK M                     | 2024           |            | 2023           |            |
|---------------------------|----------------|------------|----------------|------------|
|                           | Nominal amount | Fair value | Nominal amount | Fair value |
| Interest-rate derivatives | 750            | 15         | –              | –          |
| Currency derivatives      | 2,408          | -11        | 2,647          | -24        |
| <b>Total</b>              | <b>3,158</b>   | <b>4</b>   | <b>2,647</b>   | <b>-24</b> |

| SEK M                     | 2024      |           | 2023      |           |
|---------------------------|-----------|-----------|-----------|-----------|
|                           | Asset     | Liability | Asset     | Liability |
| Interest-rate derivatives | 15        | –         | –         | –         |
| Currency derivatives      | 3         | 13        | 36        | 60        |
| <b>Total</b>              | <b>17</b> | <b>13</b> | <b>36</b> | <b>60</b> |

Of which:

|            |    |    |    |    |
|------------|----|----|----|----|
| Short-term | 3  | 13 | 36 | 60 |
| Long-term  | 15 | –  | –  | –  |

Paid and accrued interest on interest-rate derivatives is continuously recognized in profit or loss. The fair value of derivative instruments is established using valuation techniques based on observable market information.

**Financial instruments by category**

| Financial assets, SEK M  | Assets at amortized cost |              | Assets at fair value through profit or loss |           | Derivatives used for hedging purposes |          | Total         |              |
|--|--------------------------|--------------|---|-----------|---------------------------------------|----------|---------------|--------------|
|  | 2024                     | 2023         | 2024  | 2023      | 2024                                  | 2023     | 2024          | 2023         |
| Derivative instruments   | –                        | –            | 3   | 33        | 15                                    | 3        | 17            | 36           |
| Accounts receivable, financial receivables and other receivables | 7,186                    | 6,381        | –   | –         | –                                     | –        | 7,186         | 6,381        |
| Cash and cash equivalents  | 2,961                    | 2,728        | –   | –         | –                                     | –        | 2,961         | 2,728        |
| <b>Total</b>   | <b>10,147</b>            | <b>9,109</b> | <b>3</b>                                    | <b>33</b> | <b>15</b>                             | <b>3</b> | <b>10,165</b> | <b>9,145</b> |

| Financial liabilities, SEK M                     | Liabilities at amortized cost |               | Liabilities at fair value through profit or loss |            | Derivatives used for hedging purposes |          | Total         |               |
|--|-------------------------------|---------------|--|------------|---------------------------------------|----------|---------------|---------------|
|  | 2024                          | 2023          | 2024   | 2023       | 2024                                  | 2023     | 2024          | 2023          |
| Borrowing  | 8,927                         | 6,597         | –  | –          | –                                     | –        | 8,927         | 6,597         |
| Derivative instruments                           | –                             | –             | 13   | 60         | –                                     | –        | 13            | 60            |
| Leasing liabilities                              | 1,800                         | 1,479         | –  | –          | –                                     | –        | 1,800         | 1,479         |
| Contingent considerations                        | –                             | –             | 3,280  | 498        | –                                     | –        | 3,280         | 498           |
| Accounts payable and other financial liabilities | 3,055                         | 2,882         | –  | –          | –                                     | –        | 3,055         | 2,882         |
| <b>Total</b>                                     | <b>13,783</b>                 | <b>10,958</b> | <b>3,293</b>                                     | <b>558</b> | <b>–</b>                              | <b>–</b> | <b>17,076</b> | <b>11,516</b> |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

Note 19 Financial instruments cont.

**Distribution of currency for outstanding derivative instruments in nominal amounts, SEK M**

The table below shows the Group's financial liabilities distributed over the remaining maturity. The amounts shown in the table are the contractual, undiscounted cash flows.

|              | 2024         | 2023         |
|--------------|--------------|--------------|
| AUD          | –            | 17           |
| CHF          | –            | 3            |
| CNY          | 301          | 603          |
| CZK          | –            | 15           |
| DKK          | 58           | 2            |
| EUR          | 1,190        | 1,181        |
| GBP          | 69           | 32           |
| HKD          | –            | 230          |
| JPY          | 0            | 57           |
| NOK          | 20           | 10           |
| PLN          | –            | 56           |
| SEK          | 750          | –            |
| SGD          | 41           | –            |
| TRY          | 0            | –            |
| USD          | 728          | 427          |
| ZAR          | –            | 14           |
| <b>Total</b> | <b>3,158</b> | <b>2,647</b> |

**Maturity structure for outstanding derivative instruments in 2024, SEK M**

|                           | 2025         | 2026     | 2027     | 2028     | 2029       | Total        |
|---------------------------|--------------|----------|----------|----------|------------|--------------|
| Interest-rate derivatives | –            | –        | –        | –        | 750        | 750          |
| Currency derivatives      | 2,408        | –        | –        | –        | –          | 2,408        |
| <b>Total</b>              | <b>2,408</b> | <b>–</b> | <b>–</b> | <b>–</b> | <b>750</b> | <b>3,158</b> |

**Maturity structure for outstanding derivative instruments in 2023, SEK M**

|                           | 2024         | 2025     | 2026     | 2027     | 2028     | Total        |
|---------------------------|--------------|----------|----------|----------|----------|--------------|
| Interest-rate derivatives | –            | –        | –        | –        | –        | –            |
| Currency derivatives      | 2,647        | –        | –        | –        | –        | 2,647        |
| <b>Total</b>              | <b>2,647</b> | <b>–</b> | <b>–</b> | <b>–</b> | <b>–</b> | <b>2,647</b> |

**Reserve of cash flow hedges**

The table below shows the composition of the Group's reserve of cash flow hedges and the change in each component during the year.

|  | Currency derivatives | Interest-rate derivatives | Total      |
|--|----------------------|---------------------------|------------|
| <b>Opening balance 2023</b>  | <b>-21</b>           | <b>–</b>                  | <b>-21</b> |
| Change in fair value of hedging instruments recognized in other comprehensive income | 3                    | –                         | <b>3</b>   |
| Reclassification to profit or loss   | 27                   | –                         | <b>27</b>  |
| Deferred tax   | -6                   | –                         | <b>-6</b>  |
| <b>Closing balance 2023</b>  | <b>3</b>             | <b>–</b>                  | <b>3</b>   |
| <b>Opening balance 2024</b>  | <b>3</b>             | <b>–</b>                  | <b>3</b>   |
| Change in fair value of hedging instruments recognized in other comprehensive income | –                    | 15                        | <b>15</b>  |
| Reclassification to profit or loss   | -3                   | 0                         | <b>-3</b>  |
| Deferred tax   | 1                    | -3                        | <b>-2</b>  |
| <b>Closing balance 2024</b>  | <b>0</b>             | <b>12</b>                 | <b>12</b>  |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

Note 19 Financial instruments cont.

**Derivative instruments – currency derivatives**

Currency derivatives, in the three largest currency pairs, impact the Group's financial position and earnings as follows:

| <b>Derivative instruments<br/>– currency derivatives CNY/SEK, SEK M</b>                | <b>2024</b>       | <b>2023</b>       |
|--|-------------------|-------------------|
| Recognized amount (asset/liability(-))   | 1                 | -15               |
| Nominal amount CNY M   | 200               | 427               |
| Maturity   | Jan 2025          | Jan 2024–Mar 2024 |
| Hedge ratio  | 1:1               | 1:1               |
| Change in discounted forward rates for outstanding hedging instruments since January 1 | 1                 | -15               |
| Change in value of hedged item to determine effectiveness                              | -1                | 15                |
| Weighted average of forward rates at year-end (including forward points)               | 1.50              | 1.45              |
| <b>Derivative instruments<br/>– currency derivatives EUR/SEK, SEK M</b>                | <b>2024</b>       | <b>2023</b>       |
| Recognized amount (asset/liability(-))   | -1                | -15               |
| Nominal amount EUR M   | 104               | 106               |
| Maturity   | Jan 2025–Apr 2025 | Jan 2024–Jun 2024 |
| Hedge ratio  | 1:1               | 1:1               |
| Change in discounted forward rates for outstanding hedging instruments since January 1 | -1                | -12               |
| Change in value of hedged item to determine effectiveness                              | 1                 | 12                |
| Weighted average of forward rates at year-end (including forward points)               | 11.48             | 11.23             |
| <b>Derivative instruments<br/>– currency derivatives USD/SEK, SEK M</b>                | <b>2024</b>       | <b>2022</b>       |
| Recognized amount (asset/liability(-))   | -9                | 10                |
| Nominal amount USD M   | 66                | 43                |
| Maturity   | Jan 2025–Apr 2025 | Jan 2024–Jun 2024 |
| Hedge ratio  | 1:1               | 1:1               |
| Change in discounted forward rates for outstanding hedging instruments since January 1 | -9                | 9                 |
| Change in value of hedged item to determine effectiveness                              | 9                 | -9                |
| Weighted average of forward rates at year-end (including forward points)               | 10.81             | 10.24             |

**Derivative instruments – interest-rate derivatives**

Interest-rate derivatives impact the Group's financial position and earnings as follows:

| <b>SEK M</b>   | <b>2024</b> | <b>2023</b> |
|--|-------------|-------------|
| Recognized amount (asset/liability(-))                                   | 15          | -           |
| Nominal amount   | 750         | -           |
| Maturity   | Sep 2029    | -           |
| Hedge ratio  | 1:1         | -           |
| Change in value of outstanding derivative instruments since January 1    | 15          | -           |
| Change in value of hedged item to determine effectiveness                | -15         | -           |
| Weighted average of forward rates at year-end (including forward points) | 2.00%       | -           |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 20** Net interest-bearing debt

| SEK M   | 2024          | Change       | 2023         |
|---|---------------|--------------|--------------|
| Interest-bearing current liabilities                            | 1,956         | -738         | 2,694        |
| Interest-bearing long-term liabilities                          | 6,971         | 3,068        | 3,903        |
| Provision for pension and similar obligations, interest-bearing | 2,700         | 36           | 2,664        |
| Leasing liabilities   | 1,800         | 321          | 1,479        |
| Less cash and cash equivalents                                  | -2,961        | -233         | -2,728       |
| <b>Total</b>  | <b>10,467</b> | <b>2,455</b> | <b>8,012</b> |

| Net interest-bearing debt 2024, SEK M  | Cash and cash equivalents | Leasing liabilities | Interest-bearing liabilities | Pension provision, interest-bearing | Total         |
|--|---------------------------|---------------------|------------------------------|-------------------------------------|---------------|
| <b>Opening balance</b>                 | <b>-2,728</b>             | <b>1,479</b>        | <b>6,597</b>                 | <b>2,664</b>                        | <b>8,012</b>  |
| <b>Cash flow affecting net debt</b>    |                           |                     |                              |                                     |               |
| - Raising of loans                     | -                         | -                   | 7,736                        | -                                   | 7,736         |
| - Amortization                         | -                         | -506                | -5,513                       | -16                                 | -6,035        |
| - Changes in cash                      | -532                      | -                   | -                            | -                                   | -532          |
| <b>Non cash flow changes</b>           |                           |                     |                              |                                     |               |
| - Changes in lease agreements          | -                         | 745                 | -                            | -                                   | 745           |
| - Actuarial gains/losses pension plans | -                         | -                   | -                            | -31                                 | -31           |
| - Translation differences              | 299                       | 83                  | 107                          | 83                                  | 572           |
| <b>Closing balance</b>                 | <b>-2,961</b>             | <b>1,800</b>        | <b>8,927</b>                 | <b>2,700</b>                        | <b>10,467</b> |

| Net interest-bearing debt 2023, SEK M  | Cash and cash equivalents | Leasing liabilities | Interest-bearing liabilities | Pension provision, interest-bearing | Total        |
|--|---------------------------|---------------------|------------------------------|-------------------------------------|--------------|
| <b>Opening balance</b>                 | <b>-5,676</b>             | <b>1,314</b>        | <b>4,510</b>                 | <b>2,454</b>                        | <b>2,602</b> |
| <b>Cash flow affecting net debt</b>    |                           |                     |                              |                                     |              |
| - Raising of loans                     | -                         | -                   | 3,133                        | -                                   | 3,133        |
| - Amortization                         | -                         | -476                | -909                         | -28                                 | -1,413       |
| - Changes in cash                      | 2,919                     | -                   | -                            | -                                   | 2,919        |
| <b>Non cash flow changes</b>           |                           |                     |                              |                                     |              |
| - Changes in lease agreements          | -                         | 682                 | -                            | -                                   | 682          |
| - Actuarial gains/losses pension plans | -                         | -                   | -                            | 258                                 | 258          |
| - Translation differences              | 28                        | -41                 | -138                         | -19                                 | -170         |
| <b>Closing balance</b>                 | <b>-2,728</b>             | <b>1,479</b>        | <b>6,597</b>                 | <b>2,664</b>                        | <b>8,012</b> |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 21** Provisions for pensions and similar obligations

**Accounting policies**

Getinge has both defined-contribution and defined-benefit pension plans, of which some have assets in special funds or similar securities. The plans are usually financed by payments from the respective group companies and the employees. The Group's Swedish companies are generally covered by the ITP plan, which does not require any payments from employees.

**Defined-contribution plans**

Defined-contribution plans are plans in which Getinge pays fixed fees to an independent legal entity and does not have any legal or informal obligation to pay additional fees. The Group's payments for defined-contribution plans are recognized as expenses during the period in which the employees perform the services that the fee covers.

**Defined-benefit plans**

Some post-employment benefits are fulfilled through so-called define-benefit plans where the obligations remain within Getinge and are primarily secured by own foundations or similar. Getinge's largest defined benefit plans are found in subsidiaries in Sweden, Germany, and the US. Pension expenses for defined-benefit plans is calculated annually by independent actuaries using the so-called Projected Unit Credit Method, which allocates the expenses over the employees working life. These commitments are measured at the present value of expected future payments, with consideration given to calculated future salary increases, and utilizing a discount rate corresponding to the interest rate of first-class company or government bonds with a remaining term that is almost equivalent to the actual commitments. For the significant pension plans, an assessment is also made quarterly, and if significant assumptions have changed, a revaluation is carried out. The Group's net liabilities for each defined-benefit plan are recognized in the balance sheet and comprises the present value

of the obligation less the fair value of the plan assets. If the value of the plan assets exceeds the value of the obligation, a surplus arises, which is recognized as an asset. The recognized asset value is limited to the present value of future repayments from the plan, or reductions in future contributions to the plan. Actuarial gains and losses are recognized in other comprehensive income for the period in which they are incurred.

Costs for defined-benefit pension plans in profit or loss comprise the total costs for service during the current and earlier years and interest on commitments. Costs for service during the current period and previous periods are recognized as employee costs. The interest component of pension expenses is recognized under financial expenses.

**Significant estimates and assessments**

**Pension commitments**

Recognition of the costs of defined-benefit pensions and other applicable retirement benefits is based on actuarial valuations, relying on key assumptions for discount rates, future salary increases and expected inflation. The actuarial assumptions constitute the company's best assessment of the different variables that determine the costs of providing the benefits. Special assumptions and actuarial calculations are made for each defined-benefit plan. In turn, the discount rate assumptions are based on rates for high-quality fixed-interest investments with durations similar to the pension plans. In Sweden the pension commitments were calculated at a discount rate based on the return on the market rate of Swedish mortgage bonds. These bonds are deemed to be of high quality since they are guaranteed by assets and the mortgage bond market in Sweden is considered to be deep and liquid. In Germany and the US the discount rate is based on high-quality corporate bonds with a term corresponding to the average remaining term of the commitment.

**Defined-contribution plans**

In several countries, the group's employees are covered by defined-contribution pension plans. The pension plans are primarily retirement pensions. The premiums are paid continuously throughout the year by each group company to independent legal entities, such as insurance companies. The size of the premium paid by the employees and group companies is normally based on a set proportion of the employee's salary and in certain cases the employees pay for a portion of the premiums themselves. The expense for defined-contribution plans amounted to SEK 455 M (425) during 2024.

**Defined-benefit plans**

Getinge has large defined-benefit pension plans mainly in Sweden, Germany and the US. The pension plans primarily comprise retirement pensions. Each employer normally has an obligation to pay a lifelong pension. The pension is earned according to the number of employment years and the employee must be affiliated with the plan for a certain number of years to achieve full retirement pension entitlement.

**Sweden**

Most of the Group's defined-benefit pension commitments in Sweden are so called PRI liabilities. These plans are closed for new employees but remain open for the employees encompassed by the plans. The commitments pertain to lifelong retirement pensions and the benefits are primarily based on the employees' final salary. The term of the commitments is 20 years.

At year-end, the amount of the group's defined-benefit pension commitments in Sweden totaled SEK 511 M (555). The Swedish pension commitments decreased year-on-year mainly due to a higher discount rate. Plan assets exist only to a minor extent and are attributable to a small plan that is not credit insured.

The commitment for retirement pensions and family pensions for salaried employees in Sweden is safeguarded through insurance with Alecta. According to a statement from the Swedish Corporate Reporting Board, UFR 10, this is a multi-employer defined-benefit plan. For the 2024 fiscal year, the company did not have access to such information that makes it possible to recognize this plan as a defined-benefit plan. The pension scheme

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

Note 21 Provisions for pensions and similar obligations cont.

in accordance with ITP, which is safeguarded through insurance with Alecta, is thus recognized as a defined-contribution scheme. During the year, fees for pension insurance covered by Alecta amounted to SEK 39 M (37). Alecta's surplus can be distributed to the insurers and/or the insured. At year-end 2024, Alecta's surplus in the form of the collective consolidation level was approximately 162% (158). The collective consolidation level comprises the market value of Alecta's assets as a percentage of the insurance commitment calculated in accordance with Alecta's actuarial calculation assumption, which does not correspond with IAS 19.

**Germany**

Some employees in Germany are part of defined-benefit pension plans. These plans are closed for new employees but remain open for the employees encompassed by the plan. The benefits are based on the employees' final salary and the remaining weighted average term of the total commitment is 13 years. The pension plans are insured in accordance with statutory requirements.

Total defined-benefit pension commitments increased to SEK 2,011 M (1,925) during the year. The increase was mainly due to lower discount rate assumptions.

**USA**

The Group's defined-benefit pension commitment in the US is closed for new employees and also to the employees encompassed by the plan, meaning that no new pension rights are vested. The commitment's remaining average term is 10 years.

The total defined-benefit commitment increased to SEK 1,081 M (1,053), mainly due to currency rate fluctuation.

The value of the plan assets increased from SEK 833 M to SEK 915 M, mainly due to currency rate change.

| Pension and similar commitments, SEK M                           | 2024                         |                           |                                    | 2023                         |                           |                                    |
|--|------------------------------|---------------------------|------------------------------------|------------------------------|---------------------------|------------------------------------|
|  | Present value of commitments | Fair value of plan assets | Net provision in the balance sheet | Present value of commitments | Fair value of plan assets | Net provision in the balance sheet |
| <b>Opening balance</b>   | <b>-3,663</b>                | <b>879</b>                | <b>-2,784</b>                      | <b>-3,451</b>                | <b>854</b>                | <b>-2,597</b>                      |
| Costs for service in the current year <sup>1)</sup>              | -37                          | -                         | -37                                | -30                          | -                         | -30                                |
| (Interest expenses)/interest income <sup>2)</sup>                | -142                         | 43                        | -98                                | -148                         | 42                        | -107                               |
| Past service cost <sup>1)</sup>                                  | -3                           | -                         | -3                                 | 0                            | -                         | 0                                  |
| Remeasurements <sup>3)</sup> :                                   |                              |                           |                                    |                              |                           |                                    |
| – Return on plan assets  | -                            | -29                       | -29                                | -                            | 31                        | 31                                 |
| – Gains/(losses) attributable to changed demographic assumptions | 0                            | -                         | 0                                  | -4                           | -                         | -4                                 |
| – Gains/(losses) attributable to changed financial assumptions   | 89                           | -                         | 89                                 | -221                         | -                         | -221                               |
| – Experience-based gains/(losses)                                | -42                          | -                         | -42                                | -53                          | -                         | -53                                |
| – Special employer's contribution on actuarial assumptions       | 15                           | -                         | 15                                 | -12                          | -                         | -12                                |
| – Restriction in plan surpluses with regard to asset ceilings    | -                            | -1                        | -1                                 | -                            | 1                         | 1                                  |
| Translation differences  | -162                         | 80                        | -81                                | 52                           | -34                       | 18                                 |
| Contributions paid by employer                                   | -1                           | 60                        | 59                                 | -                            | 58                        | 58                                 |
| Paid benefits  | 204                          | -70                       | 134                                | 204                          | -72                       | 132                                |
| Other changes  | -7                           | -                         | -7                                 | -                            | -                         | -                                  |
| <b>Closing balance</b>   | <b>-3,749</b>                | <b>962</b>                | <b>-2,787</b>                      | <b>-3,663</b>                | <b>879</b>                | <b>-2,784</b>                      |
| <i>Of which:</i>   |                              |                           |                                    |                              |                           |                                    |
| Interest-bearing pension commitments                             | -3,663                       | 962                       | -2,700                             | -3,543                       | 879                       | -2,664                             |
| Non-interest-bearing pension commitments                         | -86                          | -                         | -86                                | -120                         | -                         | -120                               |
| <i>Of which:</i>   |                              |                           |                                    |                              |                           |                                    |
| Funded pension plans   | -1,089                       | 962                       | -127                               | -1,068                       | 879                       | -189                               |
| Unfunded pension plans   | -2,660                       | -                         | -2,660                             | -2,596                       | -                         | -2,596                             |

1) Costs for service during the current period and previous periods are recognized as employee costs. 2) The interest component of pension expenses is recognized under financial expenses. 3) Actuarial gains and losses are recognized in other comprehensive income for the period in which they are incurred.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

Note 21 Provisions for pensions and similar obligations cont.

| The defined-benefit pension commitment and composition of plan assets 2024, SEK M | Present value of commitments | Fair value of plan assets | Net provision in the balance sheet |
|---|------------------------------|---------------------------|------------------------------------|
| Sweden  | -511                         | 26                        | -485                               |
| Germany   | -2,011                       | 15                        | -1,996                             |
| USA   | -1,081                       | 915                       | -166                               |
| Other countries   | -146                         | 6                         | -140                               |
| <b>Total</b>  | <b>-3,749</b>                | <b>962</b>                | <b>-2,787</b>                      |

| The defined-benefit pension commitment and composition of plan assets 2023, SEK M | Present value of commitments | Fair value of plan assets | Net provision in the balance sheet |
|---|------------------------------|---------------------------|------------------------------------|
| Sweden  | -555                         | 26                        | -529                               |
| Germany   | -1,925                       | 12                        | -1,913                             |
| USA   | -1,053                       | 833                       | -221                               |
| Other countries   | -130                         | 9                         | -121                               |
| <b>Total</b>  | <b>-3,663</b>                | <b>879</b>                | <b>-2,784</b>                      |

| Significant actuarial assumptions 2024, % | Sweden | Germany | USA |
|---|--------|---------|-----|
| <i>Weighted average, %</i>                |        |         |     |
| Discount rate                             | 3.8    | 3.5     | 5.4 |
| Expected salary increase rate             | 2.0    | 2.5     | –   |
| Expected inflation                        | 2.0    | 2.2     | –   |

| Significant actuarial assumptions 2023, % | Sweden | Germany | USA |
|---|--------|---------|-----|
| <i>Weighted average, %</i>                |        |         |     |
| Discount rate                             | 3.3    | 3.6     | 4.8 |
| Expected salary increase rate             | 2.0    | 2.5     | –   |
| Expected inflation                        | 2.0    | 2.2     | –   |

| Sensitivity of defined-benefit commitments to changes in the significant assumptions 2024, SEK M | Change in assumption | Effect on commitment |
|--|----------------------|----------------------|
| Discount rate  | +1 percentage point  | 399                  |
|  | -1 percentage point  | -490                 |
| Inflation  | +1 percentage point  | -322                 |
|  | -1 percentage point  | 267                  |
| Salary increases   | +1 percentage point  | -39                  |
|  | -1 percentage point  | 32                   |

The sensitivity analyses above covers the significant pension plans in Sweden, Germany, and the US and are based on a change in an assumption, while all other assumptions remain constant. It is unlikely that this will happen in practice, and changes in some of the assumptions may correlate. The calculation of sensitivity in the defined-benefit commitments for material actuarial assumptions uses the same method as that used in the calculation of pension liabilities.

| Composition of plan assets, SEK M            | 2024       | 2023       |
|--|------------|------------|
| Equities                                     | 157        | 137        |
| Debt instruments                             | 734        | 652        |
| Properties                                   | 13         | 22         |
| Cash and cash equivalents and similar assets | 14         | 16         |
| Other  | 44         | 53         |
| <b>Total</b>                                 | <b>962</b> | <b>879</b> |

The weighted average term of the significant plans' pension commitments amounts to 13 years (13). For the 2025 fiscal year, the expenses for defined-benefit plans are expected to amount to SEK 133 M.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 22** Employee costs

| SEK M                     | 2024                        |                |                | 2023                        |                |                |
|---------------------------|-----------------------------|----------------|----------------|-----------------------------|----------------|----------------|
|                           | Board and CEO <sup>1)</sup> | Other          | Total          | Board and CEO <sup>1)</sup> | Other          | Total          |
| Salaries and remuneration | -253                        | -10,861        | -11,113        | -228                        | -9,603         | -9,831         |
| Social security expenses  | -40                         | -1,582         | -1,622         | -39                         | -1,472         | -1,511         |
| Pension expenses          | -20                         | -474           | -495           | -19                         | -436           | -455           |
| <b>Total</b>              | <b>-313</b>                 | <b>-12,917</b> | <b>-13,230</b> | <b>-286</b>                 | <b>-11,511</b> | <b>-11,797</b> |

1) Refers to the entire Getinge Group.

**Remuneration and other benefits to Senior Executives in 2024**

| SEK 000s                           | Board fee <sup>1)</sup> | Fixed remuneration |                | Variable remuneration            |                                 | Pension expenses | Total           |
|------------------------------------|-------------------------|--------------------|----------------|----------------------------------|---------------------------------|------------------|-----------------|
|                                    |                         | Fixed salary       | Other benefits | Short-term variable remuneration | Long-term variable remuneration |                  |                 |
| Chairman of the Board              | -1,806                  | –                  | –              | –                                | –                               | –                | -1,806          |
| Board members                      | -5,604                  | –                  | –              | –                                | –                               | –                | -5,604          |
| Mattias Perjos, President & CEO    | –                       | -27,141            | -790           | -21,088                          | –                               | -10,826          | -59,845         |
| Other Senior Executives (9 people) | –                       | -38,328            | -3,026         | -36,902                          | –                               | -5,655           | -83,911         |
| <b>Total</b>                       | <b>-7,410</b>           | <b>-65,469</b>     | <b>-3,816</b>  | <b>-57,990</b>                   | <b>–</b>                        | <b>-16,481</b>   | <b>-151,166</b> |

1) Also includes fees for work on Board Committees.

**Remuneration and other benefits to Senior Executives in 2023**

| SEK 000s                            | Board fee <sup>1)</sup> | Fixed remuneration |                | Variable remuneration            |                                 | Pension expenses | Total           |
|-------------------------------------|-------------------------|--------------------|----------------|----------------------------------|---------------------------------|------------------|-----------------|
|                                     |                         | Fixed salary       | Other benefits | Short-term variable remuneration | Long-term variable remuneration |                  |                 |
| Chairman of the Board               | -1,728                  | –                  | –              | –                                | –                               | –                | -1,728          |
| Board members                       | -6,035                  | –                  | –              | –                                | –                               | –                | -6,035          |
| Mattias Perjos, President & CEO     | –                       | -25,915            | -498           | -5,944                           | -3,847                          | -10,184          | -46,388         |
| Other Senior Executives (10 people) | –                       | -38,283            | -2,655         | -8,431                           | -3,377                          | -6,968           | -59,714         |
| <b>Total</b>                        | <b>-7,763</b>           | <b>-64,198</b>     | <b>-3,153</b>  | <b>-14,375</b>                   | <b>-7,224</b>                   | <b>-17,152</b>   | <b>-113,865</b> |

1) Also includes fees for work on Board Committees.

**Comments on the table remuneration and other benefits**

- Other Senior Executives refers to members in the Getinge Executive Team, other than the CEO. Excluding the CEO, the Getinge Executive Team comprised 9 individuals at year-end. Only remuneration that has been received as a member of the Getinge Executive Team is included in the amounts recognized, which includes individuals that joined and left the Getinge Executive Team during the year.
- For information on Board fees for each member, refer to pages 39–41.
- Fixed salary pertains base salary including vacation payment.
- Other benefits refer to benefits such as company car, medical insurance (sw: sjukvårdsförsäkring), etc.
- Short-term variable remuneration refers to bonuses for the 2024 fiscal year, which will be paid in 2025.
- Short-term variable remuneration also includes other extraordinary variable remuneration, decided with the support of the guidelines for remunerations to senior executives, which were recognized and paid during 2024.
- Long-term variable remuneration refers to amounts earned in a long-term bonus program for 2022–2024, which will be paid in 2025.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

Note 22 Employee costs cont.

**Annual General Meeting's guidelines for remuneration to Senior Executives**

The 2024 Annual General Meeting resolved on guidelines for remuneration to Senior Executives, which are described in pages 61–63. Getinge applied the guidelines adopted by the AGM as follows:

**Principles:** The Annual General Meeting decides on remuneration to the Chairman of the Board and Board members. Employee representatives do not receive Board remuneration. Remuneration to the CEO and other Senior Executives comprises base salary, variable remuneration, other benefits as well as pensions. Other Senior Executives comprise the individuals, who together with the CEO, comprise the Getinge Executive Team. For the Getinge Executive Team structure, see pages 43–44. The allocation between base salary and variable remuneration should be proportionate to the Senior Executive's responsibility and authority. The CEO's variable remuneration is maximized to 80% of base salary. For other Senior Executives, the variable remuneration is maximized to between 60 and 90% of the base salary.

**Annual variable remuneration:** The variable remuneration for Senior Executives is based on performance targets set by the Board and in order to promote the company's development, all members of the Getinge Executive Team have identical targets. For the 2024 fiscal year, the goals were related to earnings, organic sales growth, working capital, cash flow and sustainability.

**Variable long-term remuneration:** In addition to base salary and the above annual variable remuneration, Senior Executives may also receive a variable long-term bonus that rewards and promotes the company's long term value creation. The earning period for this bonus must be at least three fiscal years and the bonus may amount to a maximum of 100% of base salary. In addition, a limitation rule applies to the CEO regarding the payment of variable long-term

remuneration that payment of the annual variable remuneration and variable long-term remuneration together may not exceed 100% of basic salary. The part of long-term variable remuneration that cannot be paid due to the limitation rule will be payable in coming years or later to the extent that the limitation rule is not exceeded for the current year.

**Pensions:** The CEO is entitled to a pension from the age of 62. The pension is premium based and pension expenses amount to 40% of base salary. Variable cash remunerations do not qualify for pension benefits. For other Senior Executives, the retirement age is 65 years, except for one Senior Executive whose retirement age is 62 years in accordance with local regulations in the country of residence. All pension benefits are transferable, i.e. not conditional on future employment.

**Severance pay:** The period of notice for the CEO is a minimum of six months. If termination of employment is initiated by the company then termination pay of 12 months' pay will be awarded. Termination pay is not offset against any other income. After the end of the period of notice, severance pay corresponding to one annual salary is paid. The company is entitled to deduct any income the CEO may receive from other employment or business activities from the severance pay. Upon termination of employment of any other Senior Executives, they have the right to termination pay of six months and a maximum of one year.

**Getinge's total cost for remunerations to the Getinge Executive Team:** The total cost for remunerations to the Getinge Executive Team amounted to SEK 165 M (170) and pertain base salaries, variable short-term and long-term remuneration, other benefits and pensions. It also includes social security expenses on salaries and benefits and special payroll tax on pensions.

**Drafting and decision-making process:** During the year, the Remuneration Committee gave the Board its recommendations concerning policies for the remuneration to Senior Executives. The Board discussed the Remuneration Committee's proposals and decided in line with the Remuneration Committee's recommendations. Remuneration to the CEO for the 2024 fiscal year was decided by the Board taking into account the Remuneration Committee's recommendations. Remuneration to other Senior Executives was decided by the Remuneration Committee following a recommendation by the CEO and in consultation with the Chairman of the Board.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 23** Average number of employees

| By region               | 2024         |              |                   |               | 2023         |              |          |               |
|-------------------------|--------------|--------------|-------------------|---------------|--------------|--------------|----------|---------------|
|                         | Men          | Women        | Unknown           | Total         | Men          | Women        | Unknown  | Total         |
| EMEA                    | 4,213        | 2,669        | 7                 | 6,889         | 4,182        | 2,540        | 6        | 6,728         |
| <i>of which, Sweden</i> | 900          | 388          | 2                 | 1,290         | 893          | 360          | 2        | 1,255         |
| Americas                | 1,859        | 1,225        | 215               | 3,299         | 1,739        | 1,140        | 2        | 2,881         |
| <i>of which, USA</i>    | 1,679        | 1,120        | 214 <sup>1)</sup> | 3,013         | 1,559        | 1,030        | 1        | 2,589         |
| APAC                    | 1,098        | 498          | 1                 | 1,597         | 1,106        | 510          | 1        | 1,617         |
| <b>Total</b>            | <b>7,170</b> | <b>4,392</b> | <b>223</b>        | <b>11,785</b> | <b>7,027</b> | <b>4,190</b> | <b>9</b> | <b>11,226</b> |

1) The large increase in the Other category relates mainly to acquisitions, where all employees have not yet been fully registered. For more information, please refer to pages 155–156 Employee metrics.

| Distribution of Senior Executives and Board members at the closing date, % | 2024 | 2023 |
|--|------|------|
| <b>Women:</b>  |      |      |
| Board members <sup>2)</sup> of the Parent Company                          | 20%  | 27%  |
| Other members of the company's management, incl. CEO                       | 50%  | 45%  |
| <b>Men:</b>  |      |      |
| Board members <sup>2)</sup> of the Parent Company                          | 80%  | 73%  |
| Other members of the company's management, incl. CEO                       | 50%  | 55%  |

2) Includes board members elected by the Annual General Meeting and members appointed by employee organizations.

**Introduction**
**Strategy**
**Corporate Governance Report**
**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**
**Other information**
**NOTE 24** Government grants

**Accounting policies**

Government grants are measured at fair value when it is probable that the terms associated with the grants will be met and that the grants will be received. Government grants that apply to costs are recognized in profit or loss as a reduction in costs in the same period as the costs that the grants are intended to cover. If the grants received do not pertain to a specific cost, the grants are recognized as revenue under the item other operating income. Government grants relating to the acquisition of assets reduce the assets' carrying amounts. Such grants affect recognized earnings over the asset's useful life by reducing depreciation.

| Government grants received, SEK M | 2024      | 2023      |
|-----------------------------------|-----------|-----------|
| Received                          | 60        | 66        |
| Repaid                            | –         | –         |
| <b>Total</b>                      | <b>60</b> | <b>66</b> |

| Government grants reported in the income statement, SEK M | 2024      | 2023      |
|---|-----------|-----------|
| Other operating income                                    | 24        | 27        |
| Other operating expenses                                  | –         | –         |
| Reduction of costs related to the grant                   | 17        | 17        |
| <b>Total</b>  | <b>41</b> | <b>44</b> |

Grants received, which have reduced the carrying amount of the assets to which the grants were related amounted to SEK 19 M (22).

**NOTE 25** Pledged assets and contingent liabilities

**Accounting policies**

Contingent liabilities are commitments and other claims for damages not recognized as liabilities/provisions either because it is not certain that an outflow of resources will be required to settle the commitment or because it is not possible to make a reliable estimate of the amount.

**Significant estimates and assessments**

For significant estimates and assessments regarding disputes and claims for damages, see Note 15 Other provisions.

**Pledged assets, SEK M**

The group had no pledged assets

| Contingent liabilities, SEK M | 2024       | 2023       |
|-------------------------------|------------|------------|
| Guarantees                    | 612        | 428        |
| Other                         | 90         | 96         |
| <b>Total</b>                  | <b>702</b> | <b>524</b> |

**NOTE 26** Supplementary disclosure to cash flow statement

**Accounting policies**

The cash flow statement is prepared in accordance with IAS 7, the indirect method. The cash flows of foreign group companies are translated at average rates. Changes in group structure, acquisitions and divestments are recognized net excluding cash and cash equivalents and are included in cash flow from investing activities, in the items acquisition of operations and divestment of operations.

| Cash and cash equivalents, SEK M | 2024         | 2023         |
|----------------------------------|--------------|--------------|
| Investments                      | 26           | 60           |
| Cash and bank balances           | 2,935        | 2,669        |
| <b>Total</b>                     | <b>2,961</b> | <b>2,728</b> |

| Adjustments for items not included in cash flow, SEK M         | 2024       | 2023      |
|--|------------|-----------|
| Gain(-)/loss(+) from divestment/disposal of non-current assets | 21         | 19        |
| Change in provisions, reversed (-)/added (+)                   | 782        | –         |
| Other  | 5          | 16        |
| <b>Total</b>   | <b>808</b> | <b>35</b> |

| Interest paid and received, SEK M | 2024        | 2023        |
|-----------------------------------|-------------|-------------|
| Interest received                 | 68          | 125         |
| Interest paid                     | -627        | -425        |
| <b>Total</b>                      | <b>-560</b> | <b>-300</b> |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 27** Acquisition of operations

**Accounting policies**

Acquired companies are included in the consolidated accounts from the date of acquisition, which is when Getinge Group can exercise control over the operations in the subsidiary. Acquired companies are consolidated in the financial statements in accordance with the purchase method, which means that the cost of the shares in subsidiaries is eliminated against their equity at the acquisition date. Accordingly, only the portion of the subsidiary's equity that has arisen after the acquisition is included in consolidated equity. Equity in the subsidiaries is thus determined on a market-based value of identifiable assets, liabilities, provisions, and contingent liabilities on the date of the acquisition. If the cost of the shares in the subsidiaries exceeds the value of the acquired net assets, the difference is assigned to goodwill. If the acquisition cost falls below the fair value of the acquired subsidiary's net assets (a bargain purchase), the difference is recognized directly in profit or loss as other operating income. Deferred tax is calculated on the difference between the calculated market values of assets and liabilities and the fiscal residual values. If assets are included in the subsidiary at the time of acquisition – for example, property, participations, or other operations – that will not be retained but sold in the near future, these assets are recognized in the acquisition analysis at the amount expected to be received. Transaction costs in connection with business combinations are expensed in profit or loss when they arise.

**Significant estimates and assessments**

In conjunction with acquisitions, all identifiable assets and liabilities in the acquired company are measured at fair value, including the value of assets and liabilities previously owned as well as the shares attributable to non-controlling interests.

**Contingent considerations**

Getinge signed agreements on contingent considerations in connection with acquisitions of business and subsidiaries. The liabilities for these additional purchase prices are measured at fair value through profit or loss. In most cases, the additional purchase prices are contingent on securing government approval for the acquired product development projects and the earnings performance of the acquired businesses. The future cash flows are discounted if the planned disbursement date exceeds 12 months. Assessments about future cash flows linked to the contingent considerations are regularly reviewed by company management and are reported at fair value. The discount effect is recognized on an ongoing basis in profit or loss under financial items. Contingent considerations are included in other non-interest bearing liabilities in the balance sheet, of which SEK 1,756 M is classified as non-current and SEK 1,523 M is classified as current.

**Acquisition of assets in Getinge Aseptic Solutions LLC**

In July 2024, Getinge's subsidiary Aseptic Solutions LLC acquired technology and intellectual property rights from Intact Solutions LLC, a company in Connecticut, USA. This technology makes aseptic processing simpler, safer and more efficient, and addresses the entire bioprocessing value chain. The acquisition was consolidated into the Getinge Group on the acquisition date and is included in the business area Life Science.

Getinge paid approximately SEK 128 M (USD 12 M) upon completion of the acquisition. Furthermore, additional earn-out payments may be made between 2027 and 2030 if agreed upon regulatory and financial performance milestones are achieved, and a non-interest-bearing liability of SEK 383 M was recognized in relation to these payments. For more information regarding contingent considerations, see Note 19 Financial instruments. Acquired goodwill amounted to SEK 260 M, which is mainly attributable to growth opportunities and synergies within Life Science. The costs of the acquisition amounted to SEK 14 M and were charged to earnings. The acquisition did not have any material impact on Getinge's sales or earnings in the period. The acquisition analysis was not yet completed during the period.

**Paragonix Technologies, Inc**

In September 2024, Getinge carried out the acquisition of 100% of the shares in Paragonix Technologies, Inc., a leading US company in organ transport products and services. The company, which was founded in 2010, employs approximately 100 people and is headquartered in Waltham, Massachusetts, USA. The acquisition was consolidated into the Getinge Group on the acquisition date and is included in the business area Acute Care Therapies.

Getinge paid approximately SEK 2,619 M (USD 253 M) in cash upon completion of the acquisition. Furthermore, additional earn-out payments may be made until 2026 if agreed upon regulatory and financial performance milestones are achieved. Linked to these, an additional purchase price of SEK 2,660 M was, at acquisition, recognized as a liability and is included in other non-interest-bearing liabilities in the balance sheet. For more information regarding contingent considerations, see Note 19 Financial instruments.

**Introduction**
**Strategy**
**Corporate Governance Report**
**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**
**Other information**

## Note 27 Acquisition of operations cont.

The goodwill that arose on acquisition amounted to SEK 2,843 M and was primarily attributable to the value of new technology and a new future customer base. Since the acquisition, the company has contributed SEK 293 M to the Group's net sales and net earnings of SEK -44 M. If the acquisition had been carried out on January 1, 2024, the contribution to the Group's net sales would have been SEK 826 M and to net earnings SEK -115 M. The costs of the acquisition amounted to SEK 43 M and were charged to earnings. The acquisition analysis was not yet completed during the period.

During the fourth quarter of 2024, Paragonix achieved one performance-related target, whereby a payout of SEK 166 M (USD 15 M) took place in December.

**Other acquisitions**

In 2024, additional earn-out payments of SEK 325 M were made relating to Talis Clinical LLC. The acquisition analyses for Healthmark Industries and High Purity New England were completed during the year, whereby Getinge received SEK 34 M in reduced purchase price for these acquisitions. Shares were also acquired from non-controlling interests in the subsidiary Pulsion Medical Systems SE for SEK 31 M.

|  | Aseptic Solutions | Paragonix Technologies | Other acquisitions | 2024         | 2023         |
|--|-------------------|------------------------|--------------------|--------------|--------------|
| <b>Net assets acquired, SEK M</b>                      |                   |                        |                    |              |              |
| Intangible assets                                      | 251               | 2,990                  | –                  | 3,241        | 1,661        |
| Tangible assets  | –                 | 23                     | –                  | 23           | 309          |
| Deferred tax assets                                    | –                 | 25                     | –                  | 25           | –            |
| Financial assets                                       | –                 | –                      | –                  | –            | 2            |
| Inventories  | –                 | 93                     | –                  | 93           | 247          |
| Accounts receivables                                   | –                 | 142                    | –                  | 142          | 178          |
| Other current receivables                              | –                 | 8                      | –                  | 8            | 15           |
| Cash and cash equivalents                              | –                 | 115                    | –                  | 115          | 98           |
| Deferred tax liabilities                               | –                 | -755                   | –                  | -755         | -464         |
| Accounts payables                                      | –                 | -32                    | –                  | -32          | -102         |
| Other short-term liabilities                           | –                 | -57                    | –                  | -57          | -94          |
| <b>Identifiable net assets</b>                         | <b>251</b>        | <b>2,551</b>           | <b>–</b>           | <b>2,802</b> | <b>1,851</b> |
| Goodwill   | 260               | 2,843                  | –                  | 3,103        | 3,260        |
| <b>Total purchase prices</b>                           | <b>511</b>        | <b>5,394</b>           | <b>–</b>           | <b>5,905</b> | <b>5,111</b> |
| Add/Less:  |                   |                        |                    |              |              |
| Additional purchase prices and other adjustments       | –                 | –                      | 290                | 290          | 41           |
| Acquisition of shares from non-controlling interests   | –                 | –                      | 31                 | 31           | 170          |
| Unpaid purchase prices                                 | -383              | -2,472                 | –                  | -2,855       | -14          |
| Cash and cash equivalents in the acquired operations   | 0                 | -115                   | –                  | -115         | -98          |
| <b>Impact on the group's cash and cash equivalents</b> | <b>128</b>        | <b>2,807</b>           | <b>321</b>         | <b>3,256</b> | <b>5,209</b> |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

**Group notes**

Parent Company financial statements

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 28** Transactions with related parties

Transactions between Getinge AB (publ) and its subsidiaries, which are related companies to Getinge AB (publ), were eliminated in the consolidated financial statements. Business terms and conditions as well as market-regulated pricing apply for delivery of products and services between group companies. No Board member or Senior Executive has, or has had, any direct or indirect participation in any business transactions, between themselves and the company, that are or were non-transparent in nature, regarding the applicable terms or conditions. In addition to the above, there were no significant transactions with related parties. For remuneration and benefits to Senior Executives and Board members, see Note 22 Employee costs.

**NOTE 29** Events after the end of the reporting period

Except what is described below, no significant events have occurred after the end of the reporting period.

**Intention to phase-out Surgical Perfusion**

Getinge has announced its intention to phase out the Surgical Perfusion product portfolio, which is part of the product area Cardiopulmonary in Acute Care Therapies, in 2025. The intention is to reallocate resources to areas of more profitable growth, mainly in ECLS and Transplant Care. The Surgical Perfusion market has experienced low growth and Getinge has continuously lost market share to the current level of 7% outside the US, which is the largest market globally.

The products intended to be phased out are the HL40 heart-lung machine and the HCU40 heater-cooler unit, as well as consumables used in Surgical Perfusion. The assumption is that competitors will be able to meet demand. Getinge is aware of the potential impact of this intention and is committed to working closely with customers during a potential transition. The production facilities concerned are located in Hechingen and Rastatt in

Germany and in Antalya, Türkiye. The intention is to maintain all three production facilities with a continued focus on producing ECLS solutions.

The intention has been shared with relevant employee representation bodies and employees, in line with local labour regulations, and necessary steps have been initiated. The final decision on the restructuring is dependent on the outcome of negotiations with the employee representation bodies.

In 2024, Surgical Perfusion had net sales of approximately SEK 450 M. The preliminary assessment is that approximately 385 positions are in scope of the intended phase-out and the expected restructuring costs amount to a total of approximately SEK 800 M, of which SEK 522 M is recognized in the fourth quarter of 2024 as an item affecting comparability, primarily consisting of write downs of capitalized R&D and inventory. This means limited impact on cashflow. In total, the restructuring process is expected to have a marginally positive impact on adjusted EBITA in 2025 and beyond.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

**Parent Company financial statements**

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

# Parent Company's income statement

| SEK M   | Note      | 2024         | 2023         |
|---|-----------|--------------|--------------|
| Net sales                                     |           | 293          | 246          |
| Administrative expenses                       | 2, 15, 16 | -328         | -373         |
| <b>Operating result</b>                       |           | <b>-35</b>   | <b>-127</b>  |
| Result from participations in group companies | 5         | 1,743        | 2,549        |
| Interest income and other similar income      | 6         | 37           | 38           |
| Interest expenses and other similar expenses  | 6         | -218         | -260         |
| <b>Profit after financial items</b>           |           | <b>1,527</b> | <b>2,200</b> |
| Appropriations                                | 7         | 139          | 141          |
| Taxes   | 8         | -39          | -21          |
| <b>Net profit for the year</b>                |           | <b>1,627</b> | <b>2,320</b> |

# Parent Company's statement of comprehensive income

| SEK M                                    | Note | 2024         | 2023         |
|--|------|--------------|--------------|
| <b>Net profit for the year</b>           |      | <b>1,627</b> | <b>2,320</b> |
| Other comprehensive income               |      | -            | -            |
| <b>Comprehensive income for the year</b> |      | <b>1,627</b> | <b>2,320</b> |

Introduction

Strategy

Corporate Governance Report

Financial statements

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

Sustainability Report

Other information

# Parent Company's balance sheet

| SEK M                               | Note | 2024          | 2023          | SEK M                                   | Note   | 2024          | 2023          |
|-------------------------------------|------|---------------|---------------|---|--------|---------------|---------------|
| <b>ASSETS</b>                       |      |               |               | <b>EQUITY AND LIABILITIES</b>           |        |               |               |
| <b>Non-current assets</b>           |      |               |               | <b>Equity</b>                           |        |               |               |
| Intangible assets                   | 3    | –             | 1             | Restricted equity                       | 17     |               |               |
| Tangible assets                     | 4    | 2             | 2             | Share capital                           |        | 136           | 136           |
| Participations in group companies   | 9    | 29,582        | 28,336        | Statutory reserve                       |        | 2,525         | 2,525         |
| Deferred tax assets                 |      | 99            | 97            | <i>Non-restricted equity</i>            |        |               |               |
| <b>Total non-current assets</b>     |      | <b>29,683</b> | <b>28,436</b> | Share premium reserve                   |        | 4,264         | 4,264         |
| <b>Current assets</b>               |      |               |               | Retained earnings                       |        | 17,117        | 15,994        |
| Accounts receivable                 |      | 1,244         | 1,102         | Net profit for the year                 |        | 1,627         | 2,320         |
| Current tax assets                  |      | –             | 7             | <b>Total equity</b>                     |        | <b>25,668</b> | <b>25,239</b> |
| Other receivables                   |      | 2             | 14            | <b>Long-term liabilities</b>            |        |               |               |
| Prepaid expenses and accrued income |      | 16            | 16            | Interest-bearing long-term liabilities  | 10, 11 | 3,595         | 3,470         |
| Cash and cash equivalents           | 11   | 0             | 1             | Other provisions, long-term             |        | 16            | 17            |
| <b>Total current assets</b>         |      | <b>1,262</b>  | <b>1,140</b>  | <b>Total long-term liabilities</b>      |        | <b>3,611</b>  | <b>3,487</b>  |
| <b>TOTAL ASSETS</b>                 |      | <b>30,945</b> | <b>29,576</b> | <b>Current liabilities</b>              |        |               |               |
|                                     |      |               |               | Interest-bearing short-term liabilities | 10     | 1,374         | 570           |
|                                     |      |               |               | Accounts payable                        |        | 17            | 37            |
|                                     |      |               |               | Liabilities to group companies          |        | 7             | 5             |
|                                     |      |               |               | Current tax liabilities                 |        | 15            | -             |
|                                     |      |               |               | Other liabilities                       |        | 6             | 7             |
|                                     |      |               |               | Accrued expenses and deferred income    | 12     | 247           | 231           |
|                                     |      |               |               | <b>Total current liabilities</b>        |        | <b>1,666</b>  | <b>850</b>    |
|                                     |      |               |               | <b>TOTAL EQUITY AND LIABILITIES</b>     |        | <b>30,945</b> | <b>29,576</b> |

Refer to Note 13 Pledge assets and contingent liabilities for information concerning pledged assets and contingent liabilities.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

**Parent Company financial statements**

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

# Changes in Parent Company equity

| SEK M                             | Restricted equity           |                   | Non-restricted equity |   | Total equity  |
|-----------------------------------|-----------------------------|-------------------|-----------------------|---|---------------|
|                                   | Share capital <sup>1)</sup> | Statutory reserve | Share premium reserve | Retained earnings and net profit for the year |               |
| <b>Opening balance, 2024</b>      | 136                         | 2,525             | 4,264                 | <b>18,314</b>                                 | <b>25,239</b> |
| Comprehensive income for the year | –                           | –                 | –                     | 1,627   | 1,627         |
| Dividend                          | –                           | –                 | –                     | -1,198  | -1,198        |
| <b>Closing balance, 2024</b>      | <b>136</b>                  | <b>2,525</b>      | <b>4,264</b>          | <b>18,743</b>                                 | <b>25,668</b> |
| <b>Opening balance, 2023</b>      | <b>136</b>                  | <b>2,525</b>      | <b>4,264</b>          | <b>17,152</b>                                 | <b>24,077</b> |
| Comprehensive income for the year | –                           | –                 | –                     | 2,320   | 2,320         |
| Dividend                          | –                           | –                 | –                     | -1,158  | -1,158        |
| <b>Closing balance, 2023</b>      | <b>136</b>                  | <b>2,525</b>      | <b>4,264</b>          | <b>18,314</b>                                 | <b>25,239</b> |

<sup>1)</sup> The share capital consists of 18,217,200 Class A shares and 254,152,373 Class B shares. Each share's quotient value is SEK 0.50 and all shares carry equal rights to dividends. One Class A share carries ten votes and one Class B share carries one vote.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

**Parent Company financial statements**

Parent Company notes

Auditor's report

**Sustainability Report**

**Other information**

# Parent Company's cash flow statement

| SEK M  | Note | 2024          | 2023          |
|--|------|---------------|---------------|
| <b>Operating activities</b>                            |      |               |               |
| Operating result                                       |      | -35           | -127          |
| Adjustments for items not included in cash flow        |      | -             | 4             |
| Interest received and similar items                    |      | 5             | 38            |
| Dividend received                                      |      | 1,743         | 2,622         |
| Interest paid and similar items                        |      | -191          | -239          |
| Taxes paid   |      | -22           | -22           |
| <b>Cash flow before changes in working capital</b>     |      | <b>1,500</b>  | <b>2,276</b>  |
| <b>Changes in working capital</b>                      |      |               |               |
| Current receivables                                    |      | -133          | -749          |
| Current liabilities                                    |      | 4             | -3,867        |
| <b>Cash flow from operating activities</b>             |      | <b>1,371</b>  | <b>-2,340</b> |
| <b>Investing activities</b>                            |      |               |               |
| Investments in subsidiaries                            |      | -1,246        | -             |
| Divestment of shares in subsidiaries                   |      | -             | 5             |
| Repayment of shareholders' contribution                |      | -             | -             |
| <b>Cash flow from investing activities</b>             |      | <b>-1,246</b> | <b>5</b>      |
| <b>Financing activities</b>                            |      |               |               |
| Raising of loans                                       | 11   | 2,439         | 1,500         |
| Repayment of loans                                     | 11   | -1,510        | -4            |
| Change in long-term receivables                        |      | -             | 191           |
| Dividend paid  |      | -1,198        | -1,158        |
| Group contributions received                           |      | 143           | 135           |
| <b>Cash flow from financing activities</b>             |      | <b>-126</b>   | <b>665</b>    |
| <b>Cash flow for the year</b>                          |      | <b>-1</b>     | <b>-1,670</b> |
| Cash and cash equivalents at the beginning of the year |      | 1             | 1,671         |
| Cash flow for the year                                 |      | -1            | -1,670        |
| <b>Cash and cash equivalents at year-end</b>           |      | <b>0</b>      | <b>1</b>      |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

**Parent Company notes**

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 1** Parent Company's accounting policies

The Parent Company has prepared its annual report in accordance with the Annual Accounts Act and the Council for Sustainable and Financial Reporting's recommendation RFR 2, Accounting for Legal Entities. The rules in RFR 2 stipulate that the Parent Company, in its annual report for the legal entity, shall apply all EU-approved IFRS Accounting Standards to the extent possible within the framework of the Annual Accounts Act and considering the relationship between accounting and taxation. The recommendation specifies the exceptions to be made from IFRS Accounting Standards. For further information regarding IFRS Accounting Standards, see Note 1 Accounting Principles in the group's financial reports. The Parent Company applies the accounting policies detailed for the group with the exception of the following:

**Revenue recognition**

The recognized net sales in the parent company pertain revenues from sale of services to group companies. Revenue is recognized when the control of the service has been transferred to the group company, which is when the parent company incurs the associated cost to deliver the service and the receiver can benefit from the use of the delivered services.

**Remuneration to employees**

The Parent Company complies with the Swedish Pension Obligations Vesting Act and directives from the Swedish Financial Supervisory Authority when calculating defined-benefit pension plans.

**Financial derivatives**

For derivatives, the exception in RFR 2 regarding IFRS 9 is applied, i.e., financial instruments are valued and reported based on acquisition values according to the Annual Accounts Act.

The parent company applies hedge accounting for its derivatives (interest rate swaps), which means that the derivatives are not continuously reported at fair value. Any interest difference to be received or paid due to an interest rate swap is continuously reported in the income statement.

**Shares and participations**

Subsidiaries are recognized in accordance with the acquisition method, implying that holdings are recognized at cost in the balance sheet less any impairment and with the addition of acquisition costs. Dividends from subsidiaries are recognized as dividend income.

**Group contributions**

Group contributions received and paid are recognized as appropriations according to the alternative rule in RFR 2.

**Operational leases**

All leasing agreements in the Parent Company are recognized as operational leases.

**NOTE 2** Depreciation/amortization according to plan

| SEK M                                   | 2024      | 2023      |
|---|-----------|-----------|
| Equipment, tools, fixtures and fittings | -1        | -1        |
| Intangible assets                       | -1        | -2        |
| <b>Total</b>                            | <b>-2</b> | <b>-3</b> |

**NOTE 3** Intangible assets

| Intangible assets, SEK M                    | 2024       | 2023       |
|---|------------|------------|
| Opening acquisition cost                    | 19         | 19         |
| <b>Closing accumulated acquisition cost</b> | <b>19</b>  | <b>19</b>  |
| Opening amortization                        | -18        | -16        |
| Amortization for the year                   | -1         | -2         |
| <b>Closing accumulated amortization</b>     | <b>-19</b> | <b>-18</b> |
| <b>Closing carrying amount</b>              | <b>0</b>   | <b>1</b>   |

**NOTE 4** Tangible assets

| Equipment, tools, fixtures and fittings, SEK M | 2024      | 2023      |
|--|-----------|-----------|
| Opening acquisition cost                       | 9         | 9         |
| <b>Closing accumulated acquisition cost</b>    | <b>9</b>  | <b>9</b>  |
| Opening depreciation                           | -7        | -6        |
| Depreciation for the year                      | -1        | -1        |
| Reclassifications                              | 1         | -         |
| <b>Closing accumulated depreciation</b>        | <b>-7</b> | <b>-7</b> |
| <b>Closing carrying amount</b>                 | <b>2</b>  | <b>2</b>  |

**Introduction**
**Strategy**
**Corporate Governance Report**
**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

**Parent Company notes**

Auditor's report

**Sustainability Report**
**Other information**
**NOTE 5** Result from participations in group companies

| SEK M                                | 2024         | 2023         |
|--------------------------------------|--------------|--------------|
| Dividends from Group companies       | 1,743        | 2,621        |
| Impairment of shares in subsidiaries | –            | -72          |
| <b>Total</b>                         | <b>1,743</b> | <b>2,549</b> |

**NOTE 6** Financial items

| Interest income and other similar income, SEK M | 2024      | 2023      |
|---|-----------|-----------|
| Interest income from group companies            | 37        | 10        |
| Interest income                                 | –         | 28        |
| <b>Total</b>                                    | <b>37</b> | <b>38</b> |

| Interest expenses and other similar expenses, SEK M | 2024        | 2023        |
|---|-------------|-------------|
| Interest expenses to group companies                | –           | -102        |
| Interest expenses                                   | -215        | -152        |
| Exchange rate losses                                | -1          | -5          |
| Other   | -2          | -1          |
| <b>Total</b>  | <b>-218</b> | <b>-260</b> |

**NOTE 7** Appropriations

| SEK M                        | 2024       | 2023       |
|------------------------------|------------|------------|
| Group contributions received | 139        | 141        |
| <b>Total</b>                 | <b>139</b> | <b>141</b> |

**NOTE 8** Income taxes

| Taxes, SEK M | 2024       | 2023       |
|--------------|------------|------------|
| Current tax  | -41        | -22        |
| Deferred tax | 2          | 1          |
| <b>Total</b> | <b>-39</b> | <b>-21</b> |

**The relationship between the year's tax expense and the recognized profit before tax, SEK M**

|   | 2024         | 2023         |
|---|--------------|--------------|
| <b>Recognized profit before tax</b>                 | <b>1,666</b> | <b>2,341</b> |
| Tax according to current tax rate in Sweden (20.6%) | -343         | -482         |
| Tax effect of non-deductible costs                  | -39          | -61          |
| Tax effect of non-taxable income                    | 363          | 544          |
| Foreign withholding tax                             | -20          | -22          |
| <b>Recognized tax expense</b>                       | <b>-39</b>   | <b>-21</b>   |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

**Parent Company notes**

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 9** Participations in group companies

| Parent Company's holdings            | Reg. office | Swedish Corp. Reg. No. | No. of shares | Percentage holding | Carrying amount 2024, SEK M | Carrying amount 2023, SEK M |
|--------------------------------------|-------------|------------------------|---------------|--------------------|-----------------------------|-----------------------------|
| Getinge Finance Holding AB           | Göteborg    | 556473-1700            | 23,062,334    | 100                | 9,672                       | 9,672                       |
| Getinge Sterilization AB             | Halmstad    | 556031-2687            | 50,000        | 100                | 848                         | 848                         |
| Getinge Business Support Services AB | Göteborg    | 556535-6317            | 1,000         | 100                | 1,031                       | 1,031                       |
| Getinge Disinfection AB              | Halmstad    | 556042-3393            | 25,000        | 100                | 208                         | 118                         |
| Getinge Australia Pty Ltd            | Australia   |                        | 56,975        | 100                | 72                          | 72                          |
| Getinge Danmark A/S                  | Denmark     |                        | 10,000        | 100                | 41                          | 41                          |
| Getinge IT Solutions ApS             | Denmark     |                        | 533,000       | 100                | 27                          | 27                          |
| Getinge Finland Oy                   | Finland     |                        | -             | -                  | -                           | 0                           |
| Getinge Infection Control SAS        | France      |                        | 1,666,712     | 85                 | 698                         | 698                         |
| Getinge/Castle International Ltd     | Greece      |                        | 100           | 100                | 0                           | 0                           |
| Getinge Treasury Ireland DAC         | Ireland     |                        | 2             | 100                | -                           | -                           |
| Neuromedica SA                       | Spain       |                        | 40,000        | 100                | 3                           | 3                           |
| Getinge Shared Services Sp. z o.o.   | Poland      |                        | 60,600        | 100                | 29                          | 29                          |
| Getinge Holding USA, Inc.            | US          |                        | 10,000        | 100                | 16,697                      | 15,542                      |
| Getinge Polska Sp. z o.o.            | Poland      |                        | 2,109         | 35                 | 13                          | 13                          |
| Getinge Group Japan KK               | Japan       |                        | 800           | 100                | 243                         | 243                         |
| <b>Total carrying amount</b>         |             |                        |               |                    | <b>29,582</b>               | <b>28,336</b>               |

The Parent Company's holding of shares in the subsidiaries constitutes the entire capital of the respective company, which also corresponds to 100% of the voting rights, unless otherwise stated.

**Subsidiaries of sub-groups**

Getinge Group, with operations in many countries, is organized into sub-groups in several categories, and accordingly, the legal structure cannot be reflected in a simpler manner in a tabular presentation.

Group companies directly or indirectly owned by Getinge AB (publ) are specified below. The ownership interest is 100% except in cases where the ownership interest is stated in parentheses.

**Sweden**

- Getinge Business Support Services AB, 556535-6317, Göteborg
- Getinge Disinfection AB, 556042-3393, Halmstad
- Getinge Finance Holding AB, 556473-1700, Göteborg
- Getinge Global Sales and Service AB, 559421-7928, Göteborg
- Getinge Logistics AB, 556547-8798, Halmstad
- Getinge Sterilization AB, 556031-2687, Halmstad
- Getinge Sverige AB, 556509-9511, Halmstad
- Getinge Treasury AB, 556535-6309, Göteborg
- Maquet Critical Care AB, 556604-8731, Solna
- Maquet Nordic AB, 556648-1163, Solna

**Australia**

- Getinge Australia Pty Ltd

**Austria**

- Getinge Österreich GmbH

**Belgium**

- Getinge Belgium NV

**Brazil**

- Getinge do Brasil Equipamentos Médicos Ltda

**Canada**

- Getinge Canada Ltd

**China**

- Getinge (Shanghai) Trading Co., Ltd
- Maquet (Shanghai) Medical Equipment Co., Ltd
- Maquet (Suzhou) Co., Ltd

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

**Parent Company notes**

Auditor's report

**Sustainability Report**

**Other information**

Note 9 Participations in group companies cont.

**Colombia**

- Getinge Colombia SAS

**Czech Republic**

- Getinge Czech Republic, s.r.o.

**Denmark**

- Getinge Cetrea A/S
- Getinge Danmark A/S
- Getinge IT Solutions ApS

**Finland**

- Getinge Finland Oy

**France**

- Fluoptics SAS
- Getinge France SAS
- Getinge Infection Control SAS
- Getinge Life Science France SAS

- Intervascular SAS
- LTA Medical
- Maquet SAS

**Germany**

- Getinge Deutschland GmbH
- Getinge Financial Services GmbH
- Getinge Holding B.V. & Co KG
- Getinge Holding GmbH
- Getinge IT Solutions GmbH
- Getinge Vertriebs Holding GmbH
- Irasun GmbH

- Maquet Cardiopulmonary GmbH
- Maquet GmbH
- Maquet Medical Systems AG
- MediKomp GmbH
- Pulsion Medical Systems SE (96%)

**Greece**

- Getinge/Castle International Ltd

**Hong Kong**

- Getinge Group Hong Kong Ltd

**India**

- Atrium Medical India Pvt Ltd
- Getinge India Pvt Ltd
- Getinge Medical India Pvt Ltd

**Ireland**

- Getinge Ireland Ltd.
- Getinge Treasury Ireland DAC
- Quadralene International Ltd.

**Italy**

- Getinge Italia Srl

**Japan**

- Getinge Group Japan KK

**Mexico**

- Maquet Mexicana, S. de R.L. de C.V.

**Netherlands**

- Applikon Biotechnology B.V.
- Getinge Holding Netherlands B.V.
- Getinge Netherlands B.V.
- Maquet Verwaltungs B.V.

**Norway**

- Getinge Norge AS

**Poland**

- Getinge IC Production Poland Sp. z o.o.
- Getinge Polska Sp. z o.o.
- Getinge Shared Services Sp. z o.o.

**Portugal**

- Getinge Group Portugal Unipessoal Lda

**Russia**

- Maquet LLC

**Saudi Arabia**

- Getinge Regional Headquarter

**Serbia**

- Getinge Group South East Europe d.o.o. Beograd

**Singapore**

- Maquet Singapore Pte. Ltd.
- Getinge South East Asia Pte. Ltd.

**South Africa**

- Maquet Southern Africa (Pty) Ltd

**South Korea**

- Getinge Medical Korea Co., Ltd

**Spain**

- Getinge Group Spain SL
- Neuromedica SA

**Switzerland**

- Getinge Schweiz AG

**Taiwan**

- Getinge Group Taiwan Co., Ltd.

**Thailand**

- Getinge (Thailand) Co., Ltd. (49%)

**Türkiye**

- Maquet Cardiopulmonary Medikal Teknik San.Tic.Ltd. Şti
- Getinge Medikal Sistemler San. Ve Tic. A.Ş.

**Ukraine**

- Maquet Ukraine LLC

**United Arab Emirates**

- Getinge Group Middle East FZ-LLC

**United Kingdom**

- Biocleanse Ltd
- Bioclear Ltd
- Dentisan Ltd
- Getinge Holding Ltd
- Getinge IT Solutions Ltd
- Getinge Ltd
- Quadralene Holdings Ltd
- Quadralene Ltd
- Teknon Ltd

**USA**

- Atrium Medical Corporation
- Datascope Corp.
- Getinge Aseptic Solutions, LLC
- Getinge Group Logistics Americas, LLC
- Getinge Holding USA, Inc.
- Getinge USA Sales, LLC
- Healthmark Industries Co., Inc.
- High Purity New England Inc.,
- Lunatron Incorporated
- Maquet Cardiovascular LLC
- Maquet Cardiovascular US Sales, LLC

- Paragonix Technologies, Inc.
- Steritec Products Mfg. Co., Inc.
- Talis Clinical LLC
- Transplant Advocates LLC
- Ultra Clean Systems Inc.

**Vietnam**

- Getinge Vietnam Company Ltd

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

**Parent Company notes**

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 10** Interest-bearing liabilities

| Interest-bearing long-term liabilities, SEK M | 2024         | 2023         |
|---|--------------|--------------|
| Bond loans                                    | 3,595        | 3,470        |
| <b>Total</b>                                  | <b>3,595</b> | <b>3,470</b> |

All loans fall due for payment within five years.

| Interest-bearing short-term liabilities, SEK M | 2024         | 2023       |
|--|--------------|------------|
| Bond loans                                     | 1,374        | 570        |
| <b>Total</b>                                   | <b>1,374</b> | <b>570</b> |

**NOTE 11** Net interest-bearing debt

| SEK M                                   | 2024         | Change     | 2023         |
|---|--------------|------------|--------------|
| Interest-bearing short-term liabilities | 1,374        | 804        | 570          |
| Interest-bearing long-term liabilities  | 3,595        | 125        | 3,470        |
| Less cash and cash equivalents          | 0            | 0          | -1           |
| <b>Total</b>                            | <b>4,969</b> | <b>929</b> | <b>4,039</b> |

| Net interest-bearing debt 2024, SEK M | Cash and cash equivalents | Interest-bearing liabilities | Total         |
|---------------------------------------|---------------------------|------------------------------|---------------|
| <b>Opening balance</b>                | <b>-1</b>                 | <b>4,040</b>                 | <b>-1,671</b> |
| Cash flow affecting net debt          | 0                         | 929                          | 1,670         |
| <b>Closing balance</b>                | <b>0</b>                  | <b>4,969</b>                 | <b>-1</b>     |

| Net interest-bearing debt 2023, SEK M | Currency forwards | Interest-rate swaps | Total        |
|---------------------------------------|-------------------|---------------------|--------------|
| <b>Opening balance</b>                | <b>-1,671</b>     | <b>2,544</b>        | <b>873</b>   |
| Cash flow affecting net debt          | 1,670             | 1,496               | 3,166        |
| <b>Closing balance</b>                | <b>-1</b>         | <b>4,040</b>        | <b>4,039</b> |

**NOTE 12** Accrued expenses and deferred income

| SEK M                    | 2024       | 2023       |
|--------------------------|------------|------------|
| Salaries                 | 68         | 60         |
| Social security expenses | 140        | 123        |
| Interest expenses        | 30         | 34         |
| Other                    | 9          | 14         |
| <b>Total</b>             | <b>247</b> | <b>231</b> |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

**Parent Company notes**

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 13** Pledged assets and contingent liabilities

**Pledged assets, SEK M**

The Parent Company has no pledged assets.

| <b>Contingent liabilities, SEK M</b> | <b>2024</b>  | <b>2023</b>  |
|--------------------------------------|--------------|--------------|
| Guarantees FPG/PRI                   | 418          | 391          |
| Other guarantees                     | 5,173        | 2,457        |
| <b>Total</b>                         | <b>5,591</b> | <b>2,848</b> |

**NOTE 14** Average number of employees

|              | <b>2024</b> | <b>2023</b> |
|--------------|-------------|-------------|
| Men          | 32          | 38          |
| Women        | 45          | 42          |
| <b>Total</b> | <b>77</b>   | <b>80</b>   |

**Distribution of senior executives at the closing date**

|  | <b>2024</b> | <b>2023</b> |
|--|-------------|-------------|
| <b>Women:</b>  |             |             |
| Board members of the Parent Company                  | 2           | 3           |
| Other members of the company's management, incl. CEO | 1           | 1           |
| <b>Men:</b>  |             |             |
| Board members of the Parent Company                  | 8           | 8           |
| Other members of the company's management, incl. CEO | 2           | 3           |

**NOTE 15** Employee costs

**2024, SEK M**

|                           | <b>Board and CEO</b> | <b>Other</b> | <b>Total</b> |
|---------------------------|----------------------|--------------|--------------|
| Salaries and remuneration | -56                  | -90          | -146         |
| Social security expenses  | -20                  | -46          | -66          |
| Pension expenses          | -11                  | -23          | -34          |
| <b>Total</b>              | <b>-87</b>           | <b>-159</b>  | <b>-246</b>  |

**2023, SEK M**

|                           | <b>Board and CEO</b> | <b>Other</b> | <b>Total</b> |
|---------------------------|----------------------|--------------|--------------|
| Salaries and remuneration | -44                  | -102         | -146         |
| Social security expenses  | -16                  | -41          | -57          |
| Pension expenses          | -10                  | -20          | -30          |
| <b>Total</b>              | <b>-70</b>           | <b>-163</b>  | <b>-233</b>  |

**NOTE 16** Auditing

| <b>Fee to PwC, SEK M</b>                            | <b>2024</b> | <b>2023</b> |
|---|-------------|-------------|
| Auditing assignment                                 | -12         | -9          |
| Auditing activities other than auditing assignments | -1          | -1          |
| Other services                                      | -1          | -11         |
| <b>Total</b>  | <b>-14</b>  | <b>-21</b>  |

Öhrlings PricewaterhouseCoopers AB has the auditing assignment for the Parent Company. Auditing assignments refer to auditing of the financial statements, statutory accounts and other required legal audit. Auditing activities other than auditing assignments include the review of sustainability report and review of interim reports. Other services referred to services in connection with acquisitions and other advisory services. Of other services SEK 1 M (0) was attributable to the registered auditing firm Öhrlings PricewaterhouseCoopers AB.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

**Parent Company notes**

Auditor's report

**Sustainability Report**

**Other information**

**NOTE 17** Proposed appropriation of profit

**The following non-restricted equity in the Parent Company is at the disposal of the Annual General Meeting, SEK M:**

|                         |               |
|-------------------------|---------------|
| Share premium reserve   | 4,264         |
| Retained earnings       | 17,117        |
| Net profit for the year | 1,627         |
| <b>Total</b>            | <b>23,008</b> |

|  |               |
|--|---------------|
| The Board and CEO propose that a dividend of SEK 4.60 per share shall be distributed to shareholders | 1,253         |
| to be carried forward  | 21,755        |
| <b>Total</b>   | <b>23,008</b> |

**NOTE 18** Events after the end of the reporting period

No significant events have occurred after the end of the reporting period.

**Introduction****Strategy****Corporate Governance Report****Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

**Auditor's report****Sustainability Report****Other information**

# Auditor's report

**To the general meeting of the shareholders of Getinge AB (publ), corporate identity number 556408-5032****Report on the annual accounts and consolidated accounts Opinions**

We have performed an audit of the annual accounts and consolidated accounts of Getinge AB (publ) for the year 2024. The annual accounts and consolidated accounts of the company are included on pages 55–122 in this document with the exception of the Remuneration Report on pages 64–67.

In our opinion, the annual accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of the parent company as of December 31, 2024 and its financial performance and cash flow for the year then ended in accordance with the Annual Accounts Act. The consolidated accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of the group as of December 31, 2024 and their financial performance and cash flow for the year then ended in accordance with IFRS Accounting Standards, as adopted by the EU, and the Annual Accounts Act. The statutory administration report is consistent with the other parts of the annual accounts and consolidated accounts.

We therefore recommend that the general meeting of shareholders adopts the income statement and balance sheet for the parent company and group.

Our opinions in this report on the annual accounts and consolidated accounts are consistent with the content of the additional report that has been submitted to the parent company's audit committee in accordance with the Audit Regulation (537/2014) Article 11.

**Basis for Opinions**

We conducted our audit in accordance with International Standards on Auditing (ISA) and generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent of the parent company and group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements. This includes that, based on the best of our knowledge and belief, no prohibited services referred to in the Audit Regulation (537/2014) Article 5.1 have been provided to the audited company or, where applicable, its parent company or its controlled companies within the EU.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

**Our audit approach***Focus and scope of the audit*

We designed our audit by determining materiality and assessing the risks of material misstatement in the consolidated financial statements. In particular, we considered where management made subjective judgements; for example, in respect of significant accounting estimates that involved making assumptions and considering future events that are inherently uncertain. As in all of our audits, we also addressed the risk of override of internal controls by the Managing Director or Board of Directors, including among other matters consideration of whether there was evidence of bias that represented a risk of material misstatement due to fraud.

We tailored the scope of our audit in order to perform sufficient work to enable us to provide an opinion on the consolidated financial statements as a whole, taking into account the structure of the Group, the accounting processes and controls, and the industry in which the Group operates.

*Materiality*

The scope of our audit was influenced by our application of materiality. An audit is designed to obtain reasonable assurance whether the financial statements are free from material misstatement. Misstatements may arise due to fraud or error. They are considered material if individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the consolidated financial statements.

Based on our professional judgement, we determined certain quantitative thresholds for materiality, including the overall group materiality for the consolidated financial statements as a whole. These, together with qualitative considerations, helped us to determine the scope of our audit and the nature, timing and extent of our audit procedures and to evaluate the effect of misstatements, both individually and in aggregate on the financial statements as a whole.

*Key audit matter*

Key audit matters of the audit are those matters that, in our professional judgment, were of most significance in our audit of the annual accounts and consolidated accounts of the current period. These matters were addressed in the context of our audit of, and in forming our opinion thereon, the annual accounts and consolidated accounts as a whole, but we do not provide a separate opinion on these matters.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

**Auditor's report**

**Sustainability Report**

**Other information**

**Key audit matter**

**Impairment test of intangible assets with indefinite life**

*With reference to Note 9.*

Goodwill and other intangible assets represent a significant part of the Group's balance sheet. The company performs a yearly impairment test of the assets based on a calculation of the discounted future cash flow for the cash generating units in which goodwill and other intangible assets with indefinite life are reported.

This impairment test is based on a high level of judgments and assumptions regarding future cash flows. Information is provided in Note 9 as to how the company's management has undertaken its assessments and provides information on important assumptions and sensitivity analyses. Key variables in the test are growth rate, cost trend and discount factor (cost of capital).

As noted in the disclosures, no impairment need has been identified based on assumptions made.

**How our audit considered the key audit matter**

In our audit, we have evaluated the calculation model applied by management.

We have reconciled and evaluated key variables against forecasts and strategic plans for the business areas included in the financial plan approved by the Board of Directors. We have analyzed the accuracy on how previous years assumptions have been met as well as assessed any adjustments to assumptions compared to previous year, as a result from changes in the business and external factors.

We have tested the sensitivity from changes in key variables to assess the risk for an impairment need to arise.

We have considered and evaluated the additional goodwill from acquisitions made during the financial year.

We have also assessed the disclosures included in the consolidated accounts.

**Accounting for provisions relating to legal exposures**

*With reference to Note 15 and 25.*

The assessment of provisions or contingent liabilities for legal exposures for specific significant disputes and claims from regulatory investigations is a significant area for the Group's financial statements.

The assessment of relevant provisions for legal exposures is inherently associated with a high degree of uncertainty and subjectivity. The outcome of disputes and other claims may be difficult to predict, and the final outcome may deviate from initial assessments.

During the year, negotiations with the Brazilian federal authority for internal control, transparency and anti-corruption, Comptroller General of the Union (CGU), have been ongoing linked to investigations relating to previous years. As stated in Note 15, these negotiations are still ongoing and in 2024 the Group made a provision linked to these negotiations.

In our audit, we have particularly focused our procedures on the assessment of underlying calculations for provisions and disclosures regarding ongoing negotiations with CGU.

We have reviewed management's calculations and assessments of the legal exposures and obtained a statement from external legal advisors on relevant matters. We have assessed the reasonableness of management's assessments of required provisions, taking into account the information from legal counsel.

We have obtained legal letters from external legal counsels and obtained management's assessment on other significant matters.

We have also assessed the accuracy of the disclosures presented in the annual report.

**Accounting for acquisitions and contingent considerations**

*With reference to Note 19 and 27.*

Getinge has made an acquisition through Aseptic Solutions LLC and of Paragonix Technologies Inc during 2024.

The acquisitions have resulted in additional goodwill and other intangible assets of SEK 6.3 billion.

The acquisitions involve contingent considerations linked to future performance-based criteria.

Liabilities for these additional considerations are measured at fair value through profit or loss. Assessments of future cash flows constitute an area of significant judgement.

In light of the relative size and complexity of the acquisitions and the associated valuation of assets and liabilities, the accounting for acquisitions and contingent consideration constitutes a key audit matter for the 2024 audit.

In our audit, we have particularly focused on the acquisitions that Getinge has completed during the year. Our procedures include but are not limited to the following:

We have assessed the appropriateness of the accounting for identified assets in relation to the criteria in IFRS 3, Business Combinations and IAS 38, Intangible Assets.

We have reviewed the company's purchase price analyses against underlying acquisition agreements and reconciliation of opening balances. Our procedures have also included testing and evaluation of calculations and assumptions when identifying and measuring acquired assets and liabilities in purchase price analyses.

We have assessed the measurement and accounting for contingent consideration in relation to accounting principles for financial instruments that are measured at fair value at the acquisition date and subsequent accounting at the balance sheet date.

We have involved valuation specialists in assessing the appropriateness of valuation methods and relevant assumptions for determining the fair value of the contingent consideration and for acquisition analyses.

We have also made reconciliations with accounting specialists in relation to the accounting of contingent consideration at the time of acquisition as well as in subsequent accounting.

Finally, we have assessed the accuracy of the disclosures presented in the annual report

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

**Auditor's report**

**Sustainability Report**

**Other information**

**Other information than the annual accounts**

This document also contains other information than the annual accounts and consolidated accounts and is found on pages 1–31 and 169–185, the Remuneration Report on pages 64–67 and the Sustainability Reporting on pages 127–167. The Board of Directors and the Managing Director are responsible for this other information.

Our opinion on the annual accounts does not cover this other information and we do not express any form of assurance conclusion regarding this other information.

In connection with our audit of the annual accounts and consolidated accounts, our responsibility is to read the information identified above and consider whether the information is materially inconsistent with the annual accounts and consolidated accounts. In this procedure we also take into account our knowledge otherwise obtained in the audit and assess whether the information otherwise appears to be materially misstated.

If we, based on the work performed concerning this information, conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**Responsibility of the Board of Directors and the Managing Director**

The Board of Directors and the Managing Director are responsible for the preparation of the annual accounts and consolidated accounts and that they give a fair presentation in accordance with the Annual Accounts Act and, as regards the consolidated accounts, according to IFRS Accounting Standards, as adopted by the EU, and the Annual Accounts Act. The Board of Directors and the Managing Director are also responsible for such internal control as they determine is necessary to enable the preparation of annual accounts and consolidated accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts and consolidated accounts, the Board of Directors and the Managing Director are responsible for the assessment of the company and group's ability to continue as a going concern. They disclose, as applicable, matters related to going concern and using the going concern basis of accounting. The going concern basis of accounting is however not applied if the Board of Directors and the Managing Director intends to liquidate the company, cease operations or has no realistic alternative to doing any of this.

The Audit Committee shall, without prejudice to the Board of Director's responsibilities and tasks in general, among other things oversee the company's financial reporting process.

**Auditor's responsibility**

Our objectives are to obtain reasonable assurance about whether the annual accounts and consolidated accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts and consolidated accounts.

A further description of our responsibility for the audit of the annual accounts and consolidated accounts is available on Revisorsinspektionen's website: [www.revisorsinspektionen.se/revisornsansvar](http://www.revisorsinspektionen.se/revisornsansvar). This description is part of the auditor's report.

**Report on other legal and regulatory requirements**

*The auditor's examination of the administration of the company and the proposed appropriations of the company's profit or loss*

**Opinions**

In addition to our audit of the annual accounts and consolidated accounts, we have also audited the administration of the Board of Directors and the Managing Director of Getinge AB (publ) for the year 2024 and the proposed appropriations of the company's profit or loss.

We recommend to the general meeting of shareholders that the profit be appropriated in accordance with the proposal in the statutory administration report and that the members of the Board of Directors and the Managing Director be discharged from liability for the financial year.

**Basis for Opinions**

We conducted the audit in accordance with generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities

section. We are independent in relation of the parent company and group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

**Responsibility of the Board of Directors and the Managing Director**

The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is justifiable considering the requirements which the company and group's type of operations, size and risks place on the size of the parent company's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the management of the company's affairs. This includes among other things continuous assessment of the company and group's financial situation and ensuring that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner. The Managing Director shall manage the ongoing administration according to the Board of Directors' guidelines and instructions and among other matters take measures that are necessary to fulfill the company's accounting in accordance with law and handle the management of assets in a reassuring manner.

**Auditor's responsibility**

Our objective concerning the audit of the administration, and thereby our opinion about discharge from liability, is to obtain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of Directors or the Managing Director in any material respect:

- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

**Auditor's report**

**Sustainability Report**

**Other information**

Our objective concerning the audit of the proposed appropriations of the company's profit or loss, and thereby our opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always detect actions or omissions that can give rise to liability to the company, or that the proposed appropriations of the company's profit or loss are not in accordance with the Companies Act.

A further description of our responsibility for the audit of the administration can be found on the Auditor's Inspection's website: [www.revisorsinspektionen.se/revisornsansvar](http://www.revisorsinspektionen.se/revisornsansvar). This description is part of the auditor's report.

*The auditor's examination of the ESEF report*

**Opinions**

In addition to our audit of the annual accounts and consolidated accounts, we have also examined that the Board of Directors and the Managing Director have prepared the annual accounts and consolidated accounts in a format that enables uniform electronic reporting (the ESEF report) pursuant to Chapter 16, Section 4(a) of the Swedish Securities Market Act (2007:528) for Getinge AB (publ) for the year 2024.

Our examination and our opinion relate only to the statutory requirements.

In our opinion, the ESEF report has been prepared in a format that, in all material respects, enables uniform electronic reporting.

**Basis for Opinions**

We have performed the examination in accordance with FAR's recommendation RevR 18 Examination of the ESEF report. Our responsibility under this recommendation is described in more detail in the Auditors' responsibility section. We are independent of Getinge AB (publ) in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Responsibilities of the Board of Director's and the Managing Director**

The Board of Directors and the Managing Director are responsible for the preparation of ESEF report in accordance with the Chapter 16, Section 4(a) of the Swedish Securities Market Act (2007:528), and for such internal control that the Board of Directors and the Managing Director determine is necessary to prepare the ESEF report without material misstatements, whether due to fraud or error.

**Auditor's responsibility**

Our responsibility is to obtain reasonable assurance whether the ESEF report is in all material respects prepared in a format that meets the requirements of Chapter 16, Section 4(a) of the Swedish Securities Market Act (2007:528), based on the procedures performed.

RevR 18 requires us to plan and execute procedures to achieve reasonable assurance that the ESEF report is prepared in a format that meets these requirements.

Reasonable assurance is a high level of assurance, but it is not a guarantee that an engagement carried out according to RevR 18 and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the ESEF report.

The firm applies International Standard on Quality Management 1, which requires the firm to design, implement and operate a system of quality management including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

The examination involves obtaining evidence, through various procedures, that the ESEF report has been prepared in a format that enables uniform electronic reporting of the annual accounts. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement in the report, whether due to fraud or error. In carrying out this risk assessment, and in order to design audit procedures that are appropriate in the circumstances, the auditor considers those elements of internal control that are relevant to the preparation of the ESEF report by the Board of Directors and the Managing Director, but not for the purpose of expressing an opinion on the effectiveness of those internal controls. The examination also includes an evaluation of the appropriateness and reasonableness of assumptions made by the Board of Directors and the Managing Director.

The procedures mainly include a validation that the ESEF report has been prepared in a valid XHTML format and a reconciliation of the ESEF report with the audited annual accounts and consolidated accounts.

Furthermore, the procedures also include an assessment of whether the consolidated statement of financial performance, financial position, changes in equity, cash flow and disclosures in the ESEF report have been marked with iXBRL in accordance with what follows from the ESEF regulation.

Öhrlings PricewaterhouseCoopers AB, was appointed as Getinge AB's (publ) auditor by the general meeting on April 22, 2024 and has been the company's auditor since April 17, 2008.

*This is a translation of the Swedish language original. In the event of any differences between this translation and the Swedish language original, the latter shall prevail.*

Gothenburg March 27, 2025  
Öhrlings PricewaterhouseCoopers AB

Cecilia Andrén Dorselius  
Authorized Public Accountant  
Auditor in charge

Karin Olsson  
Authorized Public Accountant

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance  
and management

Environment

Social responsibility

Governance

Reporting principles

GRI content index

Auditor's Limited Assurance Report  
on Getinge AB (publ)'s Sustainability  
Report and statement on the Statutory  
Sustainability Report

**Other information**



# Sustainability Report

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**About the Report**

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**Contents**

128 About the Report

129 Sustainability at Getinge

130 Materiality & Stakeholders

135 Sustainability Governance & Management

138 Environment

150 Social

160 Governance

162 Reporting principles

164 GRI index

168 Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**About the Report**

The 2024 Annual and Sustainability Report for Getinge AB (publ) is submitted by the Board of Directors and describes the company’s overall sustainability policies, strategic directions, actions, targets, key figures and results. Getinge’s 2024 sustainability report’s structure is inspired by the European Sustainability Reporting Standards.

The Sustainability Report has been created in accordance with the GRI Standards and Getinge’s own reporting principles (see GRI index on pages 164–167) for the period from January 1 to December 31, 2024. Getinge’s reporting cycle is annual. The report was reviewed by the company’s auditor with limited assurance and it was published on March 27, 2025.

The sustainability report covers all subsidiaries in the Getinge Group (see pages 118–119), including those subsidiaries owned directly or indirectly by Getinge AB (publ). The reporting approach across all material topics and disclosures is consistent for all subsidiaries. Acquired companies are expected to start reporting according to Getinge’s reporting manual no later than 24 months after the acquisition date, and are included in the reporting on an ongoing basis. When new acquisitions are included in the reporting, retroactive baseline values, including the baseline year, are included. Data on carbon scope 1, 2 and 3 emissions and energy consumption are not included for Quadralene. Quadralene was acquired in 2020 and reporting has been delayed due to relocation of the production facilities. Environmental data is not included in the report for Ultra Clean, Healthmark and Paragonix as they were acquired less than 24 months ago. Data on health and safety is not included for Paragonix. Data on carbon scope 1 and 2 emissions and energy consumption from High Purity New England (HPNE) are included in the 2024 report for the first time, but HPNE’s scope 3 emissions are not included.

In 2024, the following restatements of information were made: efforts to further enhance the quality of Getinge’s sustainability data have resulted in the restatement of some data regarding climate and energy for the period 2021–2024. The gas metric was

restated for three legal entities in Germany, which transitioned to more granular measurement methodologies. The metrics related to gas and electricity for one legal entity were corrected and the reporting process was improved to reduce the risk of inaccuracies going forward. Scope 1 data for leased vehicles has been restated, as the new method is more coherent over the reporting period 2021–2024. Scope 2 data for leased spaces has been restated, as a number of production sites were double counted and already included in production figures.

The Sustainability Report also covers the statutory Sustainability Report for 2024 according to the Swedish Annual Accounts Act and constitutes of the following pages: About Getinge: 3, 56, Business Strategy: 12–31, Governance: 32–54, 135–137, Business Risk Management: 47–52, Anti-corruption: 160–161, Environment: 138–145, Employees: 150–156, Human Rights: 132, Social aspects: 150–159, EU Taxonomy: 146–149, and Board diversity policy: 36.

**Limited assurance (‘review’) of the Sustainability Report**

In 2024, the company’s external auditor has been engaged to perform a limited assurance (‘review’) on the Sustainability Report. The relationship between Getinge and the appointed external auditor is described on page 36. The limited assurance has been performed in accordance with the International Standard on Assurance Engagements, ISAE 3000, see page 168 for details. The objective is to form a conclusion on whether anything has come to the auditor’s attention that causes them to believe that the information in the Sustainability Report has not, in all material respects, been prepared in accordance with suitable criteria and the company’s own reporting principles. The suitable criteria for the Sustainability Report consist of the GRI Sustainability Reporting Standards and Getinge’s own reporting principles.

**Contact for the Sustainability Report:**

Catarina Paulson, Head of Corporate Sustainability

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

**Sustainability at Getinge**

Materiality and stakeholders

Sustainability governance and management

Environment

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

# General information

The first section of Getinge's sustainability report gives an overview of the company's sustainability framework, the process of identifying material topics and engaging with stakeholders, and the governance structures and management practices that guide the sustainability efforts. The information presented in this section outlines Getinge's sustainability approach and establishes the foundation for the company's reporting, ensuring transparency in addressing critical environmental, social, and governance (ESG) issues.

## Sustainability at Getinge

Sustainability is an integral part of the company's strategy (see pages 13–15) to shape a future where healthcare is better, more efficient, and accessible. Together with partners and customers, the company strives to create a healthier and more sustainable future for patients, customers, and the planet. Getinge's sustainability efforts are anchored in three key pillars: innovation, responsibility, and engagement. Innovation means that the company works continually to develop innovative solutions including minimizing its environmental impact across the value chain. Responsibility is first and foremost about ensuring that quality is the highest priority in all steps of the products' life cycle. It also means conducting business in compliance with regulations and ethical principles. Engaged employees are critical to Getinge's success. This means that the company strives to create the best possible conditions for coworkers to thrive and reach their highest potential. Health and safety and ensuring employees feel included and equally valued are at the core of this engagement.

The following pages describe how impacts are identified through materiality assessment. Detailed information about each material topic, including policies, strategic direction, actions, targets, key figures, results, and performance data, can be found in the topical sections under the respective areas 'Environment', 'Social' and 'Governance'.

### GETINGE'S SUSTAINABILITY APPROACH



**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

**Materiality and stakeholders**

Sustainability governance and management

Environment

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

## Materiality and stakeholders

### PROCESS

The Corporate Sustainability Reporting Directive (CSRD) is incorporated in the Swedish Annual Accounts Act and will be mandatory for Getinge in 2025. In preparation the company initiated work on a preliminary double materiality assessment (DMA) based on the available draft for the European Sustainability Reporting Standards (ESRS) and by using guidance available from the European Financial Reporting Advisory group (EFRAG) in Q1 2024. The assessment covered all parts of the organization and group companies. However, it did not include acquisitions made during the reporting year, as the assessment was completed prior to these acquisitions in 2024. Moving forward, Getinge will continue to refine its approach as more guidance becomes available and best practices evolve.

The work during 2024 began by evaluating both actual and potential impacts of Getinge’s operations on the environment and society across the value chain (inside-out). The focus on impact materiality ensures compliance with the GRI reporting requirements for 2024.

During the year, Getinge conducted activities related to a first DMA including a financial impact assessment (outside-in), focusing on sustainability-related risks and opportunities that could affect its business. Where possible, these risks were quantified and supplemented with qualitative analysis. The financial assessment methodology was aligned with the company Enterprise Risk Management (ERM) methodology and is part of the base for the DMA. Given that the 2024 Sustainability report is established according to GRI, only impacts are included in this report meaning that financial risks and opportunities will be reported on starting 2025. In this initial assessment the stakeholder involvement was limited to internal subject-matter experts. To ensure accuracy and alignment, the results of the DMA were compared to previous materiality assessments, which had incorporated external stakeholder views and interests more broadly. The DMA update during 2025 is planned to incorporate external stakeholder involvement.

### Considerations in materiality assessment

*Positive/negative impacts:* Both positive and negative impacts have been assessed.

*Actual/potential impacts:* Impacts have been identified as actual or potential. For actual negative impacts, scale, scope, and remediability have been the focus of the assessment. For potential negative impacts, likelihood has also been assessed. For positive impacts, scale, scope, and likelihood have been assessed.

*Own operations/value chain:* Impacts and risks were assessed for Getinge’s own operations, and for the value chain (see page 133) where relevant and possible.

*Risks/opportunities:* An initial assessment of risks and opportunities was carried out aligned with the Enterprise Risk Management process.

*Time horizons (short, medium and long term):* Have been used as described in the ESRS standards and have been considered where possible.



**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

**Materiality and stakeholders**

Sustainability governance and management

Environment

Social responsibility

Governance

Reporting principles

GRI content index

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**The process to determine the material topics included four steps:**



**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

**Materiality and stakeholders**

Sustainability governance and management

Environment

Social responsibility

Governance

Reporting principles

GRI content index


Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

## Materiality assessment outcome

Getinge identified its actual and potential impacts on the environment and society (impact materiality assessment) and these are presented according to GRI standards in this report. Identified potential, actual, negative and positive impacts are further explained in each section pertaining to the material topic. The topics that have been identified as material are presented in the table below. Compared to 2023 year’s report, the material topics have been updated to include water consumption. Human rights are included in each of the different material topics not as a separate material topic, and employee training has been removed from material topics.

|                    | Material topics                      | Page |
|--------------------|--------------------------------------|------|
| <b>Environment</b> | Climate and Energy                   | 138  |
|                    | Water consumption                    | 142  |
|                    | Circular economy: Resource use       | 144  |
| <b>Social</b>      | Occupational Health & Safety         | 151  |
|                    | Inclusion and belonging (DEIB)       | 153  |
|                    | Sustainable and responsible sourcing | 157  |
|                    | Patient safety and quality           | 158  |
| <b>Governance</b>  | Anti-corruption                      | 160  |



**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

**Materiality and stakeholders**

Sustainability governance and management

Environment

Social responsibility

Governance

Reporting principles


GRI content index

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

## Impacts on people and the environment across the value chain

Material impacts across the company's own operations and its value chain are illustrated below. The intention of the illustration is to provide an overview of the material impacts from the company's activities and it is not exhaustive. More detailed information on each material topic and where impacts occur in the value chain as well as policies, strategic direction and actions, targets, key figures, results, and performance data, can be found in the topical sections under 'Environment', 'Social' and 'Governance'.



**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

**Materiality and stakeholders**

Sustainability governance and management

Environment

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

## Stakeholder groups and stakeholder dialogue

Maintaining an open dialogue with stakeholders is important to ensure that Getinge continues to integrate relevant sustainability aspects into its business model, strategy and daily operations. Input on stakeholder expectations and requirements is gathered through various channels such as: customer meetings and surveys, investor meetings, industry forums, supplier follow-ups and in dialogues and surveys with company employees. This engagement directly informs Getinge’s strategic priorities and materiality assessment, helping to shape focus areas and decision-making. One example is that water has been added as a material topic in 2024. During the year, the stakeholder engagement was limited to internal subject-matter experts. To ensure accuracy and alignment, Getinge reviewed and compared with previous stakeholder dialogues, which had incorporated external stakeholder views and interests. Getinge’s main stakeholders, their ESG expectations, and the way in which the company engages with them are listed in the table below.

| Employees   | Customers   | Business partners  | Investors and owners   | Governments and regulators  | Affected communities and nature   |
|---|---|--|--|---|---|
| <p>Getinge’s employees play a key role in enabling the company to successfully deliver on its business strategy.</p> <p><b>ESG expectations</b><br/>Employee surveys show that the expectations are: fair and safe treatment, meaningful work, fair wages, a sense of belonging and good development opportunities.</p> <p><b>Engagement channels</b></p> <ul style="list-style-type: none"> <li>• Daily interactions between managers and employees</li> <li>• Employee materiality survey</li> <li>• Meetings, interviews and workshops</li> <li>• Education and training</li> <li>• Employee Engagement Survey</li> <li>• GetNet (internal digital platform)</li> <li>• Speak-Up Line</li> </ul> | <p>Getinge has close relationships and a continuous dialogue with its customers. By actively listening to their feedback the company ensures the delivery of valuable products and services.</p> <p><b>ESG expectations</b><br/>Getinge has gradually experienced an increase in ESG-related questions from customers. Beyond quality and safety of products, customers place high importance on environmental considerations and value chain due diligence.</p> <p><b>Engagement channels</b></p> <ul style="list-style-type: none"> <li>• Meetings and interviews</li> <li>• Analysis of tender specifications and requirements of purchasing organizations</li> <li>• Financial and non-financial reporting including Getinge Capital Markets Day</li> <li>• Product-related information and customer trainings</li> <li>• Speak-Up Line</li> <li>• Getinge.com</li> </ul> | <p>Collaboration and dialogue with external experts are essential to enable positive contribution to society.</p> <p><b>ESG expectations</b><br/>Responsible business practices and partnership on strategic issues.</p> <p><b>Engagement channels</b></p> <ul style="list-style-type: none"> <li>• Meetings and interviews with suppliers and financial stakeholders</li> <li>• ESG rating agencies</li> <li>• Communication and training on Supplier Code of Conduct and Business Partner Code of Conduct</li> <li>• Speak-Up Line</li> <li>• Getinge.com</li> </ul> | <p>Getinge has regular dialogues with investors.</p> <p><b>ESG expectations</b><br/>Beyond the company’s financial performance (profitability) and economic efficiency as well as tangible and intangible assets, investors rank governance-related aspects highest.</p> <p><b>Engagement channels</b></p> <ul style="list-style-type: none"> <li>• Meetings and interviews</li> <li>• Financial and non-financial reporting including Getinge Capital Markets Day</li> <li>• Quarterly teleconferences and dedicated meetings with Sustainability analysts</li> </ul> | <p>Getinge is committed to complying with applicable regulations in the markets and in the geographic locations where it operates. A strong regulatory framework is vital to the company’s success.</p> <p><b>ESG expectations</b><br/>Compliance with regulations and leadership on product quality.</p> <p><b>Engagement channels</b></p> <ul style="list-style-type: none"> <li>• Memberships in UN Global Compact and local Swedish Associations</li> <li>• Industry associations Advamed and MedTech Europe</li> <li>• Ongoing dialogues with regulators on certification/ registration of products</li> </ul> | <p>Getinge acknowledges nature and communities as important silent stakeholders. By minimizing environmental impacts and supporting community well-being, the company wants to contribute to sustainable ecosystems and resilient societies.</p> <p><b>ESG expectations</b><br/>There are implicit expectations that Getinge will act responsibly across environmental, social, and governance dimensions. This includes protecting ecosystems and biodiversity, reducing environmental footprint, fostering social equity and community well-being, and maintaining ethical and transparent governance practices that prioritize long-term sustainability.</p> <p><b>Engagement channels</b></p> <ul style="list-style-type: none"> <li>• Scientific reports and tools. Examples of which are Encore, World Resource Institute Aqueduct, ILOSTAT, environment at a glance indicators (OECD), WASH, Forced Labor Observatory</li> </ul> |

## External ESG Ratings

ESG ratings are sources of information and provide insights on the expectations from different stakeholders. The most relevant ESG ratings that have been considered include Sustainalytics, ISS ESG, MSCI and EcoVadis. Getinge is in continuous dialogue with financial stakeholders and rating agencies, to follow up on emerging ESG topics and to provide transparent communication.

| Rating Agency  | Results   | Latest assessment |
|----------------|---|-------------------|
| Sustainalytics | ESG Risk Rating 2024: 22.8 Medium Risk  | Dec 2024          |
| ISS ESG        | Rating B-<br>Governance Quality Score: 9<br>SDG impact Rating: 5.9<br>Status: Prime | Jan 2025          |
| MSCI           | Rating B  | Sept 2024         |
| EcoVadis       | Score 67  | Feb 2025          |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

**Sustainability governance and management**

Environment

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

## Sustainability Governance and Management

Corporate governance at Getinge is described in the Corporate Governance Report on pages 32–54. The main governing bodies as regards to sustainability governance are presented below.


**Board of Directors**

The Board of Directors holds the ultimate responsibility for material matters within the group, including sustainability and quality. It sets Getinge’s sustainability targets, oversees the group’s goals and strategies, risk management, M&A strategy, how the customer offering should be designed and the policy implementation – with the overall sustainability and quality approach integrated into all decisions. Parts of the preparatory work has been delegated by the board to relevant board committees.

The Board of Directors approves the group’s annual materiality assessment which guides sustainability efforts, and is accountable for the group’s reporting, including the sustainability report and its assurance by the auditors. The Board’s primary role is supervisory, ensuring the governance and work of the Getinge Executive Team, monitoring, managing and overseeing impacts, risk and opportunities. This includes incorporating sustainability and quality into all decisions it makes on major acquisitions of companies and in the risk management process.

The members of the Board of Directors are considered, by the Nomination Committee, to possess competence and experience from the sustainability field, for example through one board member’s previous assignment as chairman of a Sustainability Committee but also through other Board members’ operational assignments in executive positions.

In December 2024, the Board participated in a training conducted by an external party in Responsible Business to further enhance their skills and expertise in overseeing related matters. The training focused on how the company ensures integrity in interactions with Healthcare Professionals and Healthcare Organisations. During 2024, the Board of Directors and the Ethics and Sustainability Committee addressed the material impacts outlined in this report.



**Board Committees responsible for sustainability**

The Ethics and Sustainability Committee, established in 2023 by the Board of Directors, works with ensuring a more in-depth follow up on the strategic integration of sustainability, including quality, and prepares policies, actions and targets, for decisions to be made by the Board of Directors. Additionally, as delegated by the Audit and Risk Committee, the Committee monitors reported sustainability information in both quarterly reports and the annual report and follows up on the auditor’s review of the yearly sustainability report.

In 2024, the Ethics and Sustainability Committee received training in the material area "Consumer protection", i.e. product safety and quality, conducted by an external party. In addition to

the Ethics and Sustainability Committee, the Board of Directors Remuneration Committee is responsible for the sustainability-related elements of the company’s remuneration system. The Audit and Risk Committee is ultimately responsible for preparing the sustainability reporting and internal controls over sustainability reporting.

**Executive Team**

Getinge’s CEO has the ultimate responsibility for the ongoing management and leadership of the Group, and is supported in this work by the Getinge Executive Team (GET), who holds the operational responsibility for integration of sustainability and quality

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

**Sustainability governance and management**

Environment

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

into the company's strategy, business model and operations. Within the Getinge Executive Team, the ultimate responsibility for Getinge's sustainability approach including monitoring, managing and overseeing impacts, risks and opportunities, rests with the Executive Vice President (EVP) Sustainability, Legal & Compliance.

Progress on implementation is reviewed as part of the recurring business and functional reviews. In addition, a quarterly meeting is held with the Sustainability Board, consisting of all members of the Getinge Executive Team, to enable focus on key topics.

**Sustainability function**

The Corporate Sustainability function, which is part of the overall Sustainability, Legal & Compliance team, is responsible for advancing the sustainability approach on an operational level.

To support this work a cross functional working group, the Sustainability Advisory group (SAG), has been established. A management team member from each business area and function has been appointed to SAG to ensure implementation of sustainability policies, actions and targets in all business areas and functions. SAG is chaired by the Head of Corporate Sustainability, each SAG member is responsible for ensuring that business area and functional management teams are adequately informed about the expected implementation of sustainability policies, actions and targets. Dedicated controls and procedures to follow up on the implementation are also ensured through a Sustainability Controller, integrated in the Finance function.

The Corporate Sustainability function is the subject matter expert of environmental matters as well as driver of key cross functional projects as decided by SAG.

The EVP Sustainability, Legal & Compliance oversees the work of the Corporate Sustainability function on material impacts, risks and opportunities, and follows up on its execution of the strategy. The outcome of this work is also reported by the EVP Sustainability, Legal & Compliance to the Ethics and Sustainability Committee and reported to the Board of Directors at least once a year.

Sustainability targets are prepared by the Corporate Sustainability function, as instructed by the Ethics and Sustainability Committee, and ultimately decided upon by the Board of Directors. The responsibility to follow up and monitor Getinge’s progress lies with the Ethics and Sustainability Committee.

**Ethics and Compliance function**

The governance of ethics and compliance is led by the Ethics & Compliance function, part of the Sustainability, Legal & Compliance team. This function has adopted a risk-based approach to ensure that compliance programs are designed and implemented addressing relevant risk areas such as anti-bribery & corruption, healthcare compliance, human rights and trade sanctions. While the function provides day-to-day support for implementation, ultimate responsibility for implementation of the compliance programs lies with each respective business area and function. The Chief Ethics & Compliance Officer reports to the Board's Audit & Risk Committee, Ethics & Sustainability Committee as well at the Getinge Executive Team on a periodic basis.

**Quality Compliance, Regulatory and Medical Affairs function**

Quality and patient safety is a critical material topic for the company. A function for Quality Compliance, Regulatory & Medical Affairs has been established at group level, led by the Executive Vice President (EVP) Quality Compliance, Regulatory & Medical Affairs.

The function develops relevant policies, processes, and monitoring mechanisms to ensure the effectiveness of the quality management system as well as compliance with regulatory requirements. The ultimate operational responsibility for product quality and regulatory compliance lies with business area and functional management. Quality system audits are also carried out by each certificate holder in operations to ensure that the quality system meets the applicable external requirements. The responsibility to follow up and monitor Getinge’s progress within quality related matters lies with the Ethics and Sustainability Committee.

**Business areas and functions**

Each of the business areas and functions including the global sales and service organization and corporate and group competence and support functions, are ultimately responsible for implementing policies, targets and actions. Alignment on an operational level is part of SAG and sustainability-related risks, opportunities and progress are regularly evaluated as part of this work. The business areas and functions are also responsible for integrating sustainability related considerations into their respective strategy and operational plan, which is presented to GET as well as the Board of Directors.

**Policies and steering documents**

The mandates and responsibilities of the Board of Directors and its Committees related to sustainability, including quality, as outlined in this section, are defined in the rules of procedure. Sustainability governance at Getinge is ultimately regulated by a sustainability policy adopted by the Board of Directors. The sustainability policy is part of Getinge’s global policy framework.

**Policy commitments**

The global policy framework comprises 16 global policies approved by Getinge’s Board and related global directives. Getinge’s global policies and directives are reviewed and updated at least every two years in response to the continuously evolving regulatory environment and stakeholder expectations. These documents provide additional guidance on specific areas and emphasize the company’s commitment to responsible business ethics.

Getinge’s Human Rights Policy states that all people should be treated with dignity and respect. The policy is based on the Universal Declaration of Human Rights, the United Nations Guiding Principles on Business and Human Rights, and the International Labor Organization’s (ILO) Declaration on Fundamental Principles and Rights at Work, and applies to all employees and business relationships on behalf of Getinge.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

**Sustainability governance and management**

Environment

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

Getinge’s global policies and directives are available in 12 languages and are easily accessible to all employees via the internal communication platform, GetNet. Most of the policies are publicly available for other stakeholders on Getinge’s website.

Two sustainability related policies in the framework were revised during the year: Global Anti-Trust & Fair Competition Policy and Global Intellectual Property Policy. Communication and training are provided to relevant employees to ensure that the requirements of the policy are met. Getinge’s policies define the requirements and expectations of how to conduct oneself and how this can be translated into practice through daily actions and decisions.

Getinge has also developed and maintains a Business Partner Code of Conduct, which is an extension of Getinge’s Code of Conduct and describes the ethical principles and requirements business partners are expected to comply with when doing business with Getinge.

Externally, the company is involved in several global initiatives related to responsible business ethics. Getinge is a signatory of the United Nations (UN) Global Compact and supports the ten principles on human rights, labor, environment, and anti-corruption.

Getinge also supports the 17 UN Sustainable Development Goals (SDGs) and Getinge’s 2024 Annual Report identifies and describes those SDGs that best correspond to the company’s impact on its business environment. In addition, Getinge has been a supporting member of the Swedish Anti-Corruption Institute since 2022 and actively participates in related networks.

**Embedding policy commitments**

All corporate functions and production units are responsible for complying with the Code of Conduct and achieving the sustainability targets in their line organizations. They are also responsible for evaluating sustainability-related risks in their operations, including but not limited to supplier responsibility, environment, occupational health & safety, anti-corruption, and labor & diversity. The corporate functions provide support, supervision and monitoring.

**Processes to remediate negative impacts**

Getinge is dedicated to providing open and transparent communication, internally and externally. All employees are encouraged to report any suspected or observed violations of the law or the corporate Code of Conduct. In this regard, Getinge encourages reporting to managers, HR and the global Ethics and Compliance team. Getinge also has a whistle-blower hotline – Getinge SpeakUp Line – available both internally and externally via the company’s internal communication platform GetNet and the public website getinge.com. The platform for Getinge’s Speak-Up Line has access to over 340 different languages, and Getinge currently uses around 60 different languages. Getinge has a strict non-retaliation policy and reports to senior executives the status of internal investigations on regular basis in various fora, such as the Ethics Committee, Audit & Risk Committee, during BA management meetings or regional Global Sales management meetings. By using these mechanisms, Getinge endeavors to identify, trace and take corrective action on complaints, following established routines and processes. Intended users of the Speak-Up Line are not involved in the design, review, operation or improvement of the hotline.

**Mechanisms for seeking advice and raising concerns**

Employees can seek advice from their direct managers, HR and/ or the Ethics and Compliance department. Getinge’s external whistle-blower hotline, Getinge Speak-Up Line, enables confidential reporting via a website or by telephone and is open to Getinge’s employees, suppliers, distributors and other business partners. The Chief Ethics & Compliance Officer is responsible for ensuring that all reports of suspected Code of Conduct violations or non-compliance are correctly assessed, investigated, and acted upon.

The overall governing body for the internal investigations is the Ethics Committee, which is a forum on Getinge Executive Team-level. The Ethics Committee meets at least five times a year, prior to each Audit and Risk Committee meeting, and on a needs basis. The Chief Ethics & Compliance Officer is responsible for monitoring action plans and for providing updates on these to the Ethics Committee and the Board’s Audit and Risk Committee. Relevant information is also provided to the Ethics and Sustainability Committee as deemed necessary.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

**Environment**

Social responsibility

Governance

Reporting principles

GRI content index

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**ENVIRONMENT**

# Climate and Energy

**The big picture**

The healthcare sector accounts for about 5% of global carbon emissions<sup>1</sup>. Climate change is directly linked to health, with rising temperatures and extreme weather contributing to the spread of diseases, respiratory conditions, and heat-related illnesses. This means that the healthcare sector needs to be involved in a systematic approach to deliver better health outcomes with a reduced carbon footprint.

Getinge is committed to reaching net zero emissions in line with its validated Science Based targets.

**Getinge's Targets**

**Net-zero emissions by 2050**

In 2020, Getinge committed to establish a climate target in accordance with the SBTi. The company's near and long-term targets were validated by the SBTi in 2023. The long-term target is net-zero emissions by 2050. The near-term targets are to reduce scope 1 & 2 emissions by at least 90% and scope 3 emissions by at least 25% by 2030 (base year 2021).

**Energy**

The company target is to reduce energy consumption by 20% by 2030 vs. 2021.

**Relevant Sustainability Development Goals**



<sup>1</sup>) [https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196\(20\)30121-2/fulltext](https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(20)30121-2/fulltext)

**Impacts**

Carbon emissions are prevalent at most stages of the company's value chain, with the majority of emissions arising from purchased goods and services, use of sold products and transportation of goods to and from production sites. Negative impacts in the value chain are described below.

| <b>Impacts Upstream</b><br>Scope 3 emissions   | <b>Impacts Own Operations</b><br>Scope 1 & 2 emissions   | <b>Impacts Downstream</b><br>Scope 3 emissions   |
|--|--|--|
| <p><b>Sourcing:</b><br/>Materials used in manufacturing that have high energy demands for extraction, refinement, or production (e.g., metals, electronics, plastics) increase the overall carbon footprint.</p> <p>Certain suppliers rely on carbon-intensive energy sources, contributing significantly to scope 3 emissions.</p> <p><b>Transportation:</b><br/>Transporting materials between suppliers and manufacturers results in carbon emissions, with air freight representing the majority of these emissions.</p> | <p><b>Manufacturing:</b><br/>Energy used for manufacturing and heating of production facilities and offices lead to carbon emissions in sites where fossil fuels are used.</p> <p><b>Waste generation:</b><br/>Manufacturing generates waste (e.g., production scrap), some of which requires energy-intensive disposal or end up in landfills, which often entails increased emissions.</p> | <p><b>Transportation:</b><br/>Transporting finished products from Getinge manufacturing sites to customers results in carbon emissions, particularly when air freight is used.</p> <p><b>Energy consumption during use:</b><br/>Products that require energy to operate, particularly sterilizers, contribute to increased energy demand and emissions, especially when customers rely on fossil-based electricity to generate steam.</p> <p><b>End-of-life disposal:</b><br/>Many of Getinge's products are incinerated at the end of their lifecycle due to safety regulations, leading to emissions and pollution. The absence of take-back programs or recycling systems further exacerbates these challenges.</p> |

**Assessment of impacts and management of risks**

Climate emissions are material for Getinge, as the healthcare sector contributes significantly to climate change. The long-term exposures to both physical and transition risks related to climate change exist mainly in the value chain. The main risks identified are the impact that extreme weather and rising sea levels may have on certain parts of the supply chain. An internal evaluation of exposure to physical risks is performed every year. For 2024 the evaluation concluded that the exposure to climate change in Getinge's own facilities remains relatively low.

**Mitigation actions:** To reduce the emissions from the company's value chain, net-zero targets have been established, and the carbon emission reduction targets were validated by SBTi in 2023. Actions that have reduced scope 1 and 2 emissions so far include shifting to renewable sources of energy in the company manufacturing sites and improving energy efficiency, while reducing air freight has contributed to reducing scope 3 emissions.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

**Environment**

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**ENVIRONMENT – Climate and energy**

**Policies**

Getinge’s Global Environmental Policy states the company’s commitment to reducing its environmental impact across the value chain. The reduction of greenhouse gases is a primary focus in this policy. Getinge has ISO 14001 certifications at all production units (except for a small number of recent acquisitions). ISO 14001 provides a structured framework for management and emission reduction actions to be implemented and followed up at local level. Getinge’s Standard Operating Procedure (SOP) for EcoDesign applies to hardware, accessories, spare parts, service, aftermarket, packaging and manuals. The procedure describes how the company addresses the environmental considerations in the Design Controls and Risk Management Process for Medical Devices and non-Medical Devices (local procedure), by using a standardized Life Cycle Assessment (LCA) methodology. This methodology contributes to the reduction of the environmental impact by providing information on the environmental footprint and the emission hotspots in the lifecycle of a product (including extraction of material, production, transport, product use and end-of-life treatment). Relevant employees are trained in using the LCA tool to ensure correct and consistent application.

**Strategic direction and actions**

The company is determined to measure and track carbon emissions across its full value chain, focusing on areas with greatest impact namely energy used in production, product development influencing choice of materials and energy efficiency in product use as well as choice of transport mode. Getinge will develop a transition plan for climate change.

**Continuous improvement of data and calculation methods**

Getinge has been working on emissions calculations for scope 1, 2 and 3 since 2021, constantly seeking to improve the measurements and calculations. The base year is 2021, which has been updated for the 2024 years’ report and is adjusted to the base year of SBTi. 2024 is the first year that Getinge includes parts of scope 3 in the annual report. The full scope 1, 2 & 3 emissions are reported on since 2023, in the Climate Disclosure Report available on [getinge.com](https://www.getinge.com).

**Actions Upstream**

Scope 3 emissions

**Reducing emissions from purchased goods and services**

Reducing emissions from purchased goods and services is challenging in the medtech industry due to the regulated nature of the industry. Despite this, Getinge is taking steps to reduce emissions with a focus on direct suppliers of goods that have a relatively high emission impact (metals, plastics and electronics). The aim is to obtain primary environmental data on products and alternatives, and to partner with existing suppliers to support their carbon emission reduction journeys.

The more significant impact will come from the work that has started in the three business areas to identify key EcoDesign opportunities by systematically challenging design, material and component selection as well as continuously aiming to reduce material flows. This includes replacing materials with lower-emission alternatives, e.g. biobased plastics that can replace fossil-based plastics. During 2024, Getinge reached one important milestone by developing a DPTE-BetaBag® where the beta port is made from renewable plastics replacing the previous fossil-based polycarbonate (PC).

**Actions Own Operations**

Scope 1 & 2 emissions

**Reducing emissions from production**

Scope 1 & 2 represented between 2-3% of the total carbon emissions in 2024. The emissions from energy used in manufacturing and heating of premises are the company’s priority as they are directly controllable by the company. During 2024, the focus has been on improving energy efficiency, switching to alternative sources of energy and electricity and reducing the use of fossil-fuels to the greatest extent possible.

**Electrifying the car fleet**

The electrification of the company’s vehicle fleet continued in 2024 even though challenges regarding the charging infrastructure in some parts of the world still impacts the transition.

**Actions Downstream**

Scope 3 emissions

**Decrease in emissions from goods transportation**

Goods transportation emissions have continued to decrease during 2024 as a result of shifting transport modes from air freight to sea freight on several logistics’ routes most notably between Europe and US. This modal shift has resulted in a decrease of more than 30% since the base year.

**Energy consumption during use of sold products**

For products such as sterilizers and washer-disinfectors with high carbon emissions in the use phase, Getinge continuously explores ways to improve energy efficiency. A key approach is applying Eco-Design principles in product development.

Reducing emissions during use also depends on the rate at which customers transition from fossil-based to renewable sources of electricity. Getinge provides improved usage instructions and engages in active dialogue with customers, to support emission reduction.

Energy efficiency remains a priority in product development. For example, the GEW 888 neo washer/dryer, launched in 2024, features a compact design and resource-efficient technology, reducing energy consumption by up to 25% compared to its predecessor, depending on configuration.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

**Environment**

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**ENVIRONMENT – Climate and energy**

**Scope 3 emissions**

Scope 3 emissions, representing the majority of the total emissions, are mostly outside of the company’s direct control. This means that actions to reduce emissions both up and downstream require more time and effort. The categories that will make the greatest difference in reducing emissions and achieving the company’s near and long-term targets are: purchased goods and services, upstream and downstream goods transportation and emissions from the use of the sold products .

The above-mentioned categories of scope 3 emissions represented the majority of the total emissions during 2024 and will therefore be reported on in this annual report. For information about other scope 3 emissions categories please see the Getinge Climate Disclosure report.

**Targets, key figures & results**

**Net-zero emissions by 2050**

The long-term target is net-zero emissions by 2050. The near-term targets are to reduce scope 1 & 2 emissions by at least 90% and scope 3 emissions by at least 25% by 2030 (base year 2021). Scope 1 and 2 emissions in own production decreased with 20% during 2024 compared to last year, with the main contribution being the transfer to renewable electricity. For total scope 1 and 2 emissions, the transition from fossil fuel company vehicles to electric and hybrid vehicles accounts for the majority of the reduction. Regarding emissions from the value chain (scope 3), it is primarily in outbound transportation that the company can draw conclusions from changes in emissions. Here, the focus on replacing air transport with sea freight between the EU and the US, as well as reduced air transport in general, has resulted in a reduction of over 30% since the base year 2021. For emissions from purchased goods and the use of sold products, Getinge continues to work on improving data quality to be able to make better decisions on emission-reducing measures.

**Energy**

During 2024 Getinge has continued to reduce it’s energy consumption in line with the target of reducing 20% of energy consumption compared with the base year 2021. For 2024, the energy consumption for productions sites amounted to 77 117 MWh, a -19% reduction compared with base year 2021. The reduction compared to 2023 is mainly due to reduction of gas usage in production. One site has, for example, invested in upgrading the heating loop and optimizing controls. The share of renewable energy amounts to 70% for 2024 (65% in 2023).

**Emissions, ton CO<sub>2</sub>eq\***

|  | 2024           | 2023           | 2022          | 2021          |
|--|----------------|----------------|---------------|---------------|
| <b>Emissions from own production</b>   |                |                |               |               |
| Emissions from oil   | 81             | 93             | 88            | 94            |
| Emissions from gas   | 3,720          | 3,990          | 3,602         | 5,187         |
| <b>Total Scope 1</b>   | <b>3,800</b>   | <b>4,083</b>   | <b>3,691</b>  | <b>5,280</b>  |
| Emissions from electricity   | 363            | 1,096          | 4,924         | 9,805         |
| Emissions from district heating  | 0              | 0              | 97            | 210           |
| <b>Total Scope 2</b>   | <b>363</b>     | <b>1,096</b>   | <b>5,021</b>  | <b>10,015</b> |
| <b>Total Scope 1 and 2 from own production</b>   | <b>4,163</b>   | <b>5,179</b>   | <b>8,712</b>  | <b>15,295</b> |
| <b>Reduction from base year, ton CO<sub>2</sub>eq</b>                                  | <b>-11,132</b> | <b>-10,117</b> | <b>-6,584</b> |               |
| <b>Reduction from base year (%)</b>  | <b>-73%</b>    | <b>-66%</b>    | <b>-43%</b>   |               |
| <b>Reduction from previous year, ton CO<sub>2</sub>eq</b>                              | <b>-1,015</b>  | <b>-3,533</b>  | <b>-6,584</b> |               |
| <b>Reduction from previous year (%)</b>  | <b>-20%</b>    | <b>-41%</b>    | <b>-43%</b>   |               |
| <b>Total direct GHG emissions (Scope 1)</b>  | <b>2024</b>    | <b>2023</b>    | <b>2022</b>   | <b>2021</b>   |
| Emissions from own production  | 3,800          | 4,083          | 3,691         | 5,280         |
| Emissions from leased vehicles   | 8,910          | 11,449         | 11,149        | 12,838        |
| <b>Total Direct GHG emissions (Scope 1)</b>  | <b>12,710</b>  | <b>15,532</b>  | <b>14,840</b> | <b>18,118</b> |
| <b>Total Indirect GHG emissions (Scope 2)</b>  |                |                |               |               |
| Emissions from own production  | 363            | 1,096          | 5,021         | 10,015        |
| Emissions from leased spaces   | 2,706          | 2,805          | 3,420         | 3,900         |
| <b>Total Indirect GHG emissions (Scope 2)</b>  | <b>3,069</b>   | <b>3,901</b>   | <b>8,441</b>  | <b>14,766</b> |
| <b>GHG emissions intensity</b>   | <b>2024</b>    | <b>2023</b>    | <b>2022</b>   | <b>2021</b>   |
| CO <sub>2</sub> eq emissions from own production in relation to internal sales (MSEK): | 0.256          | 0.327          | 0.543         | 0.871         |

\*Efforts to further enhance the quality of Getinge’s sustainability data have resulted in the restatement of some data regarding climate and energy for the period 2021–2023. The gas metric was restated for three legal entities in Germany, which transitioned to more granular measurement methodologies. The metrics related to gas and electricity for one legal entity were corrected and the reporting process was improved to reduce the risk of inaccuracies going forward. Scope 1 data for leased vehicles has been restated, as the new method is more coherent over the reporting period 2021–2023. scope 2 data for leased spaces has been restated, as a number of production sites were double counted and already included in production figures. One legal entity, High Purity New England, has been added through acquisition and data is updated for the period 2021–2024. All data is location based. Emission data is not included in the report for the following companies: Ultra Clean, Healthmark and Paragonix, as they were acquired less than 24 months ago.

**Scope 3 emissions, ton CO<sub>2</sub>eq\*\***

|  | 2024    | 2023    | 2022    | 2021    |
|--|---------|---------|---------|---------|
| <b>Scope 3</b>                               |         |         |         |         |
| 3.1 Purchased goods and services             | 166,387 | 160,287 | 162,224 | 163,616 |
| 3.4 Upstream transportation and distribution | 39,675  | 42,956  | 52,436  | 58,772  |
| – inbound transportation                     | 7,803   | 7,669   | 8,952   | 10,764  |
| – outbound transportation                    | 31,871  | 35,287  | 43,485  | 48,008  |
| 3.11 Use of sold products                    | 336,489 | 367,639 | 360,251 | 350,558 |

\*\*Scope 3 emissions does not include acquisitions made after January 2022

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

**Environment**

Social responsibility

Governance

Reporting principles

GRI content index

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**ENVIRONMENT – Climate and energy**

**Energy consumption within the organization\***

| Energy consumption in production, MWh                                   | 2024           | 2023           | 2022           | 2021          |
|---|----------------|----------------|----------------|---------------|
| Oil   | 297            | 342            | 326            | 345           |
| Gas   | 29,319         | 31,072         | 29,113         | 37,103        |
| Electricity   | 45,252         | 45,278         | 47,289         | 53,268        |
| District heating  | 2,250          | 2,311          | 3,455          | 4,315         |
| <b>Total energy consumption from production</b>                         | <b>77,117</b>  | <b>79,004</b>  | <b>80,183</b>  | <b>95,031</b> |
| <b>Reduction from base year 2021 (MWh)</b>                              | <b>-17,914</b> | <b>-16,027</b> | <b>-14,848</b> |               |
| <b>Reduction from base year 2021 (%)</b>                                | <b>-19%</b>    | <b>-17%</b>    | <b>-16%</b>    |               |
| <b>Reduction from previous year (MWh)</b>                               | <b>-1,887</b>  | <b>-1,179</b>  | <b>-14,848</b> |               |
| <b>Reduction from previous year (%)</b>                                 | <b>-2%</b>     | <b>-1%</b>     | <b>-16%</b>    |               |
| <b>Energy intensity:</b>  |                |                |                |               |
| Energy consumption from production (MWh/internal sales)                 | 4,7            | 5,0            | 5,0            | 5,4           |
| <b>Renewable energy sources in production, MWh</b>                      | <b>2024</b>    | <b>2023</b>    | <b>2022</b>    | <b>2021</b>   |
| <b>Total energy consumption</b>   | <b>77,117</b>  | <b>79,004</b>  | <b>80,183</b>  | <b>95,031</b> |
| Energy consumption from renewable sources                               | 53,938         | 51,383         | 44,281         | 37,523        |
| Percentage renewable energy sources                                     | 70%            | 65%            | 55%            | 39%           |
| <b>Total electricity consumption</b>                                    | <b>45,252</b>  | <b>45,278</b>  | <b>47,289</b>  | <b>53,268</b> |
| Electricity consumption from renewable sources                          | 42,705         | 41,290         | 33,608         | 28,254        |
| Percentage renewable electricity  | 94%            | 91%            | 71%            | 53%           |
| <b>Total gas consumption</b>  | <b>29,319</b>  | <b>31,072</b>  | <b>29,113</b>  | <b>37,103</b> |
| Gas consumption from renewable sources                                  | 8,984          | 7,791          | 8,094          | 6,837         |
| Percentage renewable gas  | 31%            | 25%            | 28%            | 18%           |
| <b>Total district heating consumption</b>                               | <b>2,250</b>   | <b>2,311</b>   | <b>3,455</b>   | <b>4,315</b>  |
| District heating consumption from renewable sources                     | 2,250          | 2,302          | 2,580          | 2,432         |
| Percentage renewable district heating                                   | 100%           | 100%           | 75%            | 56%           |
| <b>Gas and oil consumption, Nm<sup>3</sup></b>                          | <b>2024</b>    | <b>2023</b>    | <b>2022</b>    | <b>2021</b>   |
| Gas consumption Nm <sup>3</sup> (Heat value 0,011 MWh/Nm <sup>3</sup> ) | 2,665,946      | 2,832,463      | 2,653,908      | 3,382,216     |
| Oil consumption Nm <sup>3</sup> (Heat value 9,95 MWh/Nm <sup>3</sup> )  | 30             | 34             | 33             | 35            |

\*Efforts to further enhance the quality of Getinge's sustainability data have resulted in the restatement of some data regarding climate and energy for the period 2021–2023. The gas metric was restated for three legal entities in Germany, which transitioned to more granular measurement methodologies. The metrics related to gas and electricity for one legal entity were corrected and the reporting process was improved to reduce the risk of inaccuracies going forward. One legal entity, High Purity New England, has been added through acquisition and data is updated for the period 2021–2024. All data is location based. Energy data is not included in the report for the following companies: Ultra Clean, Healthmark and Paragonix, as they were acquired less than 24 months ago.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

**Environment**

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**ENVIRONMENT**

**Water**

**The big picture**

Globally, nearly four billion people experience severe water scarcity for at least one month each year<sup>1</sup>. Addressing water scarcity is not only crucial to secure access to water, but also essential for improving public health worldwide. The value of water in hospitals and the life science industry cannot be underestimated, as it directly impacts health outcomes and scientific progress. Water is an indispensable resource, serving as the backbone for patient care, medical processes, and scientific research. In hospitals, it ensures hygiene, for example, by supporting instrument reprocessing, and maintaining a safe environment for patients and staff.

Furthermore, in the life science industry, access to high-quality water is crucial for laboratory accuracy, pharmaceutical production, biotechnology processes, and research and development, ensuring the integrity and reliability of scientific work. Water is also necessary in the production and testing of Getinge equipment and in the upstream supply chain.

**Getinge's Target**

The target is to reduce water consumption in sites located in water scarce areas by 20% by 2030 (base year 2021). The sites in scope for the target are those located in areas of high water stress defined as “extremely high” and “high” according to Aqeduct.<sup>2</sup>

**Relevant Sustainability Development Goals**



**Impacts**

The materiality assessment resulted in water consumption being added as a material topic for 2024.

Negative impacts in the valuechain are described in the boxes below.

| Impacts Upstream   | Impacts Own Operations  | Impacts Downstream   |
|--|---|--|
| Water is necessary in producing several materials purchased by Getinge, such as electronics, metals and plastics. Increased consumption of these materials results in increased consumption of water, potentially in areas with high water stress. | Getinge consumes water in larger amounts in the sites that manufacture sterilizers and washers. Withdrawal and consumption of water in areas classified as high water-stressed can put pressure on ecosystems and community access to water. Eight of the company's manufacturing sites are located in high water-stressed areas. | Water is needed to use some of the products Getinge puts on the market such as sterilizers and washers. If these products are used in customer sites located in high water-stressed areas the impact could be significant. |

**Policies**

The company actively promotes resource efficiency in its entire value chain. The management of water follows the principles set out in both the sustainability and environmental policies and local environmental management systems. The sustainability policy describes sustainable innovations for better health which includes making products with reduced environmental impact.

Getinge’s Global Environmental Policy includes the company’s commitment to ensuring resource efficiency. The policy outlines the importance to continuously work to make manufacturing processes resource and water efficient, minimizing risk of pollution with the goal to optimize resource use throughout the company operations.

Getinge’s process for EcoDesign includes requirements and criteria that shall be considered in the design phase such as selection of materials to be used and their environmental impact.

Getinge has ISO 14001 certifications at all production units (except for a small number of recently acquired units) to comply with all local regulation including safeguarding the use of water where relevant.

**Strategic direction and actions**

In 2024, the company used the World Resources Insitute tool Acqueduct to understand which sites are located in water stressed areas. New targets to reduce water consumption in those sites were established.

With regards to the impact from use of products continuous work is done in the product development of sterilizers and washers to find solutions to reduce water consumption when these products are used. One example of this work is the GEW 888 neo washer/dryer launched in 2024. Depending on the customized configuration the new washer reduces the water consumption by up to 32% compared to the product it replaces.

1) Water scarcity | UNICEF 2) WRI Water Risk Atlas tool Aqeduct

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

**Environment**

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**


**ENVIRONMENT – Water**

**Targets, key figures & results**

The target is to reduce water consumption in sites located in water scarce areas<sup>1</sup> by 20% by 2030 (base year 2021). The sites in scope for the target are those located in areas of high water stress defined as “extremely high” and “high” according to Aqueduct. Data is compiled monthly via a data management system and data is sourced from direct measurements, either via supplier invoices or via local measuring equipment or meters. Water is not recycled or reused. For water in high stress areas, the 2024 result shows a 3% increase compared to last year, mainly explained by increased production and testing in one site and one site where the property owner has amended the cost allocation of water between the tenants.

| <b>Water consumption in own production, m<sup>3</sup></b>                          | <b>2024</b>    | <b>2023</b>    | <b>2022</b>    | <b>2021</b>    |
|--|----------------|----------------|----------------|----------------|
| <b>Total water consumption</b>   | <b>188,481</b> | <b>175,826</b> | <b>162,499</b> | <b>202,835</b> |
| Total water consumption in areas of:   |                |                |                |                |
| – water risk (high according to Aqueduct)  | 40,565         | 43,016         | 40,272         | 58,849         |
| – high water stress (extremely high and high according to Aqueduct)                | 97,710         | 95,188         | 88,413         | 109,370        |
| <b>Water intensity</b>   | <b>2024</b>    | <b>2023</b>    | <b>2022</b>    | <b>2021</b>    |
| Total water consumption in m <sup>3</sup> per net revenue (MSEK) in own operations | 11.6           | 11.1           | 10.1           | 11.5           |

1) Source: WRI Water Risk Atlas tool Aqueduct.



**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

**Environment**

Social responsibility

Governance

Reporting principles

GRI content index

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**ENVIRONMENT**

# Circularity

**The big picture**

Currently, the secondary material consumed by the global economy is only 7.2% of all material used – a decrease from 9.1% over the past five years, due primarily to increasing virgin material extraction<sup>1</sup>. Changing the way products are made and how materials are used will have an important role in reusing and recycling, as well as reducing carbon emissions. One example is that by eliminating waste and pollution, greenhouse gas emissions can be reduced across the value chain<sup>2</sup>.

According to the World Health Organization high income hospitals generate around 0,5kg of hazardous waste per bed per day and in high income countries the majority of waste (not including food waste) is plastic-based<sup>3</sup>. Working to reduce waste streams and improve material efficiency is therefore a priority for Getinge.

**Getinge's Target**

**No waste to landfill by 2030**

The target for the company towards 2030 is zero waste to landfill, excluding material required by local regulations to be landfilled.

**Relevant Sustainability Development Goals**



**Impacts**

Getinge contributes to the generation of hospital waste as some of the products put on the market are disposable products. Many of the disposables come in contact with bodily fluids and are therefore classified as hazardous waste after being used. Packaging that is needed to transport products and to maintain the necessary sterility in many of products prior to their use, becomes waste after the product is used. Waste is also generated in manufacturing of Getinge products. Negative impacts in the valuechain are described in the boxes below.

| Impacts Upstream  | Impacts Own operations   | Impacts Downstream   |
|---|--|--|
| Production of single-use plastic consumables increases the demand for high-volume raw materials that strain ecosystems and contribute to waste after disposal. Being a manufacturer of both capital goods and consumables, requires energy and resource inputs, which contribute to emissions and resource depletion. | Getinge's production sites produce waste which is partly recycled, partly incinerated and when legally obliging sent to landfill. Waste handling requires energy and contributes to emissions and pollution. | Single-use plastic consumables generate significant waste, often ending up in incineration due to their contamination in use in hospitals, contributing to pollution and emissions.<br><br>Packaging requires resources to be made such as wood, paper and plastics and the majority of the packaging becomes waste after being used for transporting goods. |

**Policies**

Getinge's Global Environmental Policy states the company's commitment to ensuring resource efficiency. The policy outlines the importance to continuously work to make manufacturing processes resource and energy efficient, minimizing risk of pollution, emissions and waste with the goal to optimize resource use throughout the company operations. The environmental policy also includes Getinge's ambition to work with circularity. The company is dedicated to the principles of circularity and actively promotes resource efficiency, avoiding hazardous substances and waste in its entire value chain. The management of waste follows the principles set out in local environmental management systems. Getinge's process for EcoDesign includes requirements and criteria that shall be considered in the design phase such as: selection of materials to

be used, reduction of material usage and the use of packaging materials as well as preparation of products for end of life and enabling reuse or recycling of material.

Getinge has ISO 14001 certifications at all production units (except for a small number of recently acquired units) to comply with all local regulation connected to waste handling.

**Strategic direction and actions**

**Waste from own operations**

Getinge is involved in waste management from its own operations, while also influencing the amount of waste generated by customers downstream through packaging and sale of single-use items, which are mainly made of plastic. The ambition is to follow the waste hierarchy aiming for prevention of waste. When this is not possible,

1) <https://www.circularity-gap.world/2024> 2) Ellen McArthur foundation  
3) <https://www.who.int/news-room/fact-sheets/detail/health-care-waste>

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

**Environment**

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**ENVIRONMENT – Circularity**

re-use and recycling are seen as the preferred alternatives and the last alternative is incineration. In some cases legislation rules that certain waste is to be landfilled. The company works together with waste handling companies treating the waste from operations to continuously find the best alternatives.

**Waste from packaging**

Product safety and clinical performance can never be compromised. This means that changing materials in the primary packaging is not an option unless the same level of safety and sterility can be maintained.

**Product resource efficiency**

Getinge has implemented Life Cycle Assessments (LCA) for products and conducted more than 10 full studies up to date. In addition, the EcoDesign SOP mandates that all new products are to be assessed according to this LCA methodology. The result from the studies aids in communicating the product’s environmental impact, identifies the focus areas, optimizes resource use, provides a data-driven basis for informed decision making in product development and supports the EcoDesign process.

**Targets, key figures & results**

**No waste to landfill by 2030**

Responsible resource use and waste management are priorities across the company. By monitoring waste handling the company ensures the best options are chosen to ensure material efficiency. By 2030, the company aims to achieve zero waste to landfill, except for materials required by local regulations to be landfilled. Waste to landfill is estimated to 121 tons for 2024 (estimation for 2023 was 120 tons). Efforts to further enhance the quality of waste data are ongoing. The total amount of generated waste for 2024 increased slightly compared to 2023 and summed up to 2 988 tons. The increase mainly relates to one site with extraordinary handling for 2024, including repair of a road surface and cleaning activities on site.

| <b>Share of recycled waste from production</b> | <b>2024</b> | <b>2023</b> | <b>2022</b> | <b>2021</b> |
|--|-------------|-------------|-------------|-------------|
| Recycling quote waste                          | 50%         | 44%         | 47%         | 51%         |
| Recycling quote waste (incl energy recovery)   | 90%         | 89%         | 91%         | 94%         |

| <b>Total waste (ton) from production</b> | <b>2024</b>  | <b>2023</b>  | <b>2022</b>  | <b>2021</b>  |
|--|--------------|--------------|--------------|--------------|
| Waste to recycling                       | 1,487        | 1,273        | 1,318        | 1,459        |
| Waste not recycled                       | 307          | 328          | 239          | 173          |
| Waste energy recovery                    | 1,195        | 1,283        | 1,239        | 1,209        |
| <b>Total generated waste</b>             | <b>2,988</b> | <b>2,884</b> | <b>2,797</b> | <b>2,841</b> |

| <b>Non-hazardous waste (ton) from production</b> | <b>2024</b>  | <b>2023</b>  | <b>2022</b>  | <b>2021</b>  |
|--|--------------|--------------|--------------|--------------|
| Non hazardous waste to recycling                 | 1,425        | 1,219        | 1,275        | 1,397        |
| Waste not recycled                               | 254          | 274          | 201          | 115          |
| Waste energy recovery                            | 1,065        | 1,177        | 1,121        | 1,085        |
| <b>Total generated waste</b>                     | <b>2,744</b> | <b>2,670</b> | <b>2,597</b> | <b>2,597</b> |

| <b>Hazardous waste (ton) from production</b> | <b>2024</b> | <b>2023</b> | <b>2022</b> | <b>2021</b> |
|--|-------------|-------------|-------------|-------------|
| Hazardous waste to recycling                 | 62          | 54          | 43          | 62          |
| Waste not recycled                           | 53          | 54          | 38          | 58          |
| Waste energy recovery                        | 129         | 106         | 119         | 124         |
| <b>Total generated waste</b>                 | <b>244</b>  | <b>214</b>  | <b>200</b>  | <b>244</b>  |

| <b>Waste (ton) to landfill from production</b> | <b>2024</b> | <b>2023</b> | <b>2022</b> | <b>2021</b> |
|--|-------------|-------------|-------------|-------------|
| Waste to landfill                              | 121         | 120         | n.a         | n.a         |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

**Environment**

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**ENVIRONMENT**

# EU Taxonomy

To identify Taxonomy-eligible activities an internal working group, supported by external expertise, has assessed the company’s economic activities and investments against the Taxonomy Regulation and its delegated acts.

In addition to the two environmental objectives of Reduced Climate Impact and Adaptation to Climate Change, four new environmental objectives were added in 2023: 1) Sustainable use and protection of water and marine resources, 2) Transition to a circular economy, 3) Prevention and mitigation of environmental pollution and 4) Protection and restoration of biodiversity and ecosystems.

In accordance with the current EU guidance, issued in November 2024, Getinge has assessed the company’s impact for the objective “Transition to a circular economy”. The current assessment is that a number of products and product groups are covered by the environmental objective according to the criteria in the economic activity 1.2: “Manufacture of electrical and electronic equipment”, which is presented in the table “Proportion of turnover” on page 147. The comparative figure for 2023 is set to zero, as the reporting for 2023 was based on a different interpretation of the principle. The capital expenditure (CapEx) and operating expenditure (OpEx) related to this activity have not yet been fully assessed.

Compliance with minimum safeguards must also be met and Getinge’s position is that the group essentially meets these requirements. During 2024, work has been undertaken to formalise a human rights compliance program, including concluding the ongoing impact assessment throughout the value chain. As this assessment is not yet concluded Getinge will not claim meeting the minimum safeguards.

Getinge aims to, by 2030, reach net zero Scope 1 and Scope 2 emissions and reduce Scope 3 by 25% compared with the base year of 2021. Getinge has also set the target of having net-zero emissions throughout the entire value chain by 2050. As part of the actions to reduce scope 1 & 2 emissions investments mainly in energy efficiency equipment and electric cars have been made.

Current amounts for the activities in question and the applied reporting policies are presented below.

Reporting data for turnover, CapEx and OpEx are based on separate account structures, therefore the risk for double counting is deemed low. Getinge is applying the International Financial Reporting Standards (IFRS), issued by the International Accounting Standards Board, as adopted by the EU.

Getinge has not yet developed a CapEx plan under the Taxonomy Regulation. As the “Draft Commission Notice on the interpretation and implementation of the EU Taxonomy Environmental Delegated act” was presented in late November 2024, Getinge will take this document in consideration and further validate during 2025 concerning the CapEx plan.

**Annex II**

Additional templates for economic activities that contribute to multiple objectives

|     | Proportion of CapEx/Total CapEX |                                 |
|-----|---------------------------------|---------------------------------|
|     | Taxonomy-aligned per objective  | Taxonomy-eligible per objective |
| CCM | 0%                              | 12%                             |
| CCA | %                               | %                               |
| WTR | %                               | %                               |
| CE  | %                               | 0%                              |
| PPC | %                               | %                               |
| WTR | %                               | %                               |

**Nuclear and fossil gas related activities**

| Row                           | Nuclear energy related activities  |    |
|-------------------------------|--|----|
| 1.                            | The undertaking carries out, funds or has exposures to research, development, demonstration and deployment of innovative electricity generation facilities that produce energy from nuclear processes with minimal waste from the fuel cycle.  | NO |
| 2.                            | The undertaking carries out, funds or has exposures to construction and safe operation of new nuclear installations to produce electricity or process heat, including for the purposes of district heating or industrial processes such as hydrogen production, as well as their safety upgrades, using best available technologies. | NO |
| 3.                            | The undertaking carries out, funds or has exposures to safe operation of existing nuclear installations that produce electricity or process heat, including for the purposes of district heating or industrial processes such as hydrogen production from nuclear energy, as well as their safety upgrades.                          | NO |
| Fossil gas related activities |  |    |
| 4.                            | The undertaking carries out, funds or has exposures to construction or operation of electricity generation facilities that produce electricity using fossil gaseous fuels.   | NO |
| 5.                            | The undertaking carries out, funds or has exposures to construction, refurbishment, and operation of combined heat/cool and power generation facilities using fossil gaseous fuels.  | NO |
| 6.                            | The undertaking carries out, funds or has exposures to construction, refurbishment and operation of heat generation facilities that produce heat/cool using fossil gaseous fuels.  | NO |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

**Environment**

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**ENVIRONMENT – EU Taxonomy**

**Proportion of turnover from products or services associated with Taxonomy-aligned economic activities – disclosure covering year 2024**

| Financial year 2024  | 2024          |               | Substantial contribution criteria |                           |                           |            |            |                  |              | DNSH criteria (“Does Not Significantly Harm”) |                           |       |           |                  |              |                    | Proportion of Taxonomy aligned (A.1.) or eligible (A.2.) turnover, year 2024 | Category enabling activity | Category transitional activity |
|--|---------------|---------------|-----------------------------------|---------------------------|---------------------------|------------|------------|------------------|--------------|---|---------------------------|-------|-----------|------------------|--------------|--------------------|--|----------------------------|--------------------------------|
|  | Code(s)       | Turnover      | Proportion of turnover 2024       | Climate change mitigation | Climate change adaptation | Water      | Pollution  | Circular economy | Biodiversity | Climate change mitigation                     | Climate change adaptation | Water | Pollution | Circular economy | Biodiversity | Minimum safeguards |  |                            |                                |
| Economic activities  |               | SEK M         | %                                 | Y; N; N/EL                | Y; N; N/EL                | Y; N; N/EL | Y; N; N/EL | Y; N; N/EL       | Y; N; N/EL   | Y/N   | Y/N                       | Y/N   | Y/N       | Y/N              | Y/N          | Y/N                | %  | E                          | T                              |
| <b>A. TAXONOMY-ELIGIBLE ACTIVITIES</b>   |               |               |                                   |                           |                           |            |            |                  |              |   |                           |       |           |                  |              |                    |  |                            |                                |
| <b>A.1. Environmentally sustainable activities (Taxonomy-aligned)</b>  |               |               |                                   |                           |                           |            |            |                  |              |   |                           |       |           |                  |              |                    |  |                            |                                |
| Turnover of environmentally sustainable activities (Taxonomy-aligned) (A.1)  |               |               | 0%                                |                           |                           |            |            |                  |              |   |                           |       |           |                  |              |                    | 0%   |                            |                                |
| Of which Enabling  |               |               | 0%                                |                           |                           |            |            |                  |              |   |                           |       |           |                  |              |                    | 0%   |                            |                                |
| Of which Transitional  |               |               | 0%                                |                           |                           |            |            |                  |              |   |                           |       |           |                  |              |                    | 0%   |                            |                                |
| <b>A.2 Taxonomy-Eligible but not environmentally sustainable activities (not Taxonomy-aligned activities)</b>        |               |               |                                   |                           |                           |            |            |                  |              |   |                           |       |           |                  |              |                    |  |                            |                                |
| 1.2 Manufacture of electrical and electronic equipment   | <b>CE 1.2</b> | 7,852         | 23%                               | N/EL                      | N/EL                      | N/EL       | N/EL       | EL               | N/EL         |   |                           |       |           |                  |              |                    |  |                            |                                |
| Turnover of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2) |               | 7,852         | 23%                               | 0%                        | 0%                        | 0%         | 0%         | 23%              | 0%           |   |                           |       |           |                  |              |                    | 0%   |                            |                                |
| <b>A. Turnover of Taxonomy eligible activities (A.1+A.2)</b>   |               | <b>7,852</b>  | <b>23%</b>                        | <b>0%</b>                 | <b>0%</b>                 | <b>0%</b>  | <b>0%</b>  | <b>23%</b>       | <b>0%</b>    |   |                           |       |           |                  |              |                    | <b>0%</b>  |                            |                                |
| <b>B. TAXONOMY-NON-ELIGIBLE ACTIVITIES</b>   |               |               |                                   |                           |                           |            |            |                  |              |   |                           |       |           |                  |              |                    |  |                            |                                |
| Turnover of Taxonomy-non-eligible activities <sup>1</sup>  |               | 26,907        | 77%                               |                           |                           |            |            |                  |              |   |                           |       |           |                  |              |                    |  |                            |                                |
| <b>Total</b>   |               | <b>34,759</b> | <b>100%</b>                       |                           |                           |            |            |                  |              |   |                           |       |           |                  |              |                    |  |                            |                                |

1) Refers to the group’s net sales (turnover) for the 2024 financial year, which corresponds to the revenue arising in the normal operations recognized in accordance with IFRS 15. Refer also to Note 2 Net sales per revenue classification, in the financial reporting.  
 2) Getinge did not identify any revenue from Taxonomy-eligible economic activities in its operations for the 2023 fiscal year. The current guidance from EU was issued in November 2024, and the figures for 2023 was built on other interpretation of the principal..

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

**Environment**

Social responsibility

Governance

Reporting principles

GRI content index

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**ENVIRONMENT – EU Taxonomy**

**Proportion of CapEx from products or services associated with Taxonomy-aligned economic activities – disclosure covering year 2024**

| Financial year 2024   | 2024           |              | Substantial contribution criteria |                           |                           |            |            |                  |              | DNSH criteria ("Does Not Significantly Harm") |                           |            |            |                  |              |                    | Proportion of Taxonomy aligned (A.1.) or eligible (A.2.) CapEx, year 2023 | Category enabling activity | Category transitional activity |
|---|----------------|--------------|-----------------------------------|---------------------------|---------------------------|------------|------------|------------------|--------------|---|---------------------------|------------|------------|------------------|--------------|--------------------|---|----------------------------|--------------------------------|
|   | Code(s)        | CapEx SEK M  | Proportion of CapEx 2024 %        | Climate change mitigation | Climate change adaptation | Water      | Pollution  | Circular economy | Biodiversity | Climate change mitigation                     | Climate change adaptation | Water      | Pollution  | Circular economy | Biodiversity | Minimum safeguards |   |                            |                                |
| Economic activities   |                |              |                                   | Y; N; N/EL                | Y; N; N/EL                | Y; N; N/EL | Y; N; N/EL | Y; N; N/EL       | Y; N; N/EL   | Y; N; N/EL                                    | Y; N; N/EL                | Y; N; N/EL | Y; N; N/EL | Y; N; N/EL       | Y; N; N/EL   | Y; N; N/EL         | %   | E                          | T                              |
| <b>A. TAXONOMY-ELIGIBLE ACTIVITIES</b>  |                |              |                                   |                           |                           |            |            |                  |              |   |                           |            |            |                  |              |                    |   |                            |                                |
| <b>A.1. Environmentally sustainable activities (Taxonomy-aligned)</b>   |                |              |                                   |                           |                           |            |            |                  |              |   |                           |            |            |                  |              |                    |   |                            |                                |
| CapEx of environmentally sustainable activities (Taxonomy-aligned) (A.1)  |                |              | 0%                                | %                         | %                         | %          | %          | %                | %            |   |                           |            |            |                  |              |                    | 0%  |                            |                                |
| Of which Enabling   |                |              | %                                 | %                         | %                         | %          | %          | %                | %            |   |                           |            |            |                  |              |                    | %   |                            |                                |
| Of which Transitional   |                |              | %                                 | %                         |                           |            |            |                  |              |   |                           |            |            |                  |              |                    | %   |                            |                                |
| <b>A.2 Taxonomy-Eligible but not environmentally sustainable activities (not Taxonomy-aligned activities)</b>                             |                |              |                                   |                           |                           |            |            |                  |              |   |                           |            |            |                  |              |                    |   |                            |                                |
| Transport by motorbikes, passenger cars and light commercial vehicles   | CCM 6.5        | 275          | 5%                                | EL                        | N/EL                      | N/EL       | N/EL       | N/EL             | N/EL         |   |                           |            |            |                  |              |                    | 6%  |                            |                                |
| Renovation of existing buildings  | CCM 7.2/CE 3.2 | 3            | 0%                                | EL                        | N/EL                      | N/EL       | N/EL       | EL               | N/EL         |   |                           |            |            |                  |              |                    | 0%  |                            |                                |
| Installation, maintenance and repair of energy efficiency equipment   | CCM 7.3        | 12           | 0%                                | EL                        | N/EL                      | N/EL       | N/EL       | N/EL             | N/EL         |   |                           |            |            |                  |              |                    | 1%  |                            |                                |
| Installation, maintenance and repair of charging stations for electric vehicles in buildings (and parking spaces attached to buildings)   | CCM 7.4        | 0            | 0%                                | EL                        | N/EL                      | N/EL       | N/EL       | N/EL             | N/EL         |   |                           |            |            |                  |              |                    | 0%  |                            |                                |
| Installation, maintenance and repair of instruments and devices for measuring, regulation and controlling energy performance of buildings | CCM 7.5        | 4            | 0%                                | EL                        | N/EL                      | N/EL       | N/EL       | N/EL             | N/EL         |   |                           |            |            |                  |              |                    | 0%  |                            |                                |
| Installation, maintenance and repair of renewable energy technologies   | CCM 7.6        | 14           | 0%                                | EL                        | N/EL                      | N/EL       | N/EL       | N/EL             | N/EL         |   |                           |            |            |                  |              |                    | 0%  |                            |                                |
| Acquisition and ownership of buildings  | CCM 7.7        | 333          | 6%                                | EL                        | N/EL                      | N/EL       | N/EL       | N/EL             | N/EL         |   |                           |            |            |                  |              |                    | 11%   |                            |                                |
| CapEx of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2)                         |                | 641          | 12%                               | 12%                       | %                         | %          | %          | %                | %            |   |                           |            |            |                  |              |                    | 18%   |                            |                                |
| <b>A. CapEx of Taxonomy eligible activities (A.1+A.2)<sup>2</sup></b>   |                | <b>641</b>   | <b>12%</b>                        | <b>12%</b>                | <b>%</b>                  | <b>%</b>   | <b>%</b>   | <b>%</b>         | <b>%</b>     |   |                           |            |            |                  |              |                    | <b>18%</b>  |                            |                                |
| <b>B. TAXONOMY-NON-ELIGIBLE ACTIVITIES</b>  |                |              |                                   |                           |                           |            |            |                  |              |   |                           |            |            |                  |              |                    |   |                            |                                |
| CapEx of Taxonomy-non-eligible activities   |                | 4,680        | 88%                               |                           |                           |            |            |                  |              |   |                           |            |            |                  |              |                    |   |                            |                                |
| <b>Total<sup>1</sup></b>  |                | <b>5,321</b> | <b>100%</b>                       |                           |                           |            |            |                  |              |   |                           |            |            |                  |              |                    |   |                            |                                |

1) Refers to capital expenditure (CapEx) related to investments in tangible assets, intangible assets and right-of-use assets under IFRS 16 (refer to Note 9 Intangible assets, Note 10 Tangible fixed assets and Note 11 Leases of the Annual Report). Assets arising through business acquisitions are included, except for goodwill which is not an identifiable intangible asset according to the definition in IAS 38.  
 2) Investments in energy-saving equipment have been judged to be Taxonomy-eligible according to activities 7.3, 7.4 and 7.5 in Annex 1 of the Taxonomy Regulation and investments in charging stations and right-of-use assets regarding electric cars are Taxonomy-eligible according to activity 7.3 and activity 6.5 in Annex 1. Investments in solar panels and right-of-use assets regarding premises and other investments in buildings are Taxonomy-eligible according to activities 7.6 and 7.7 in Annex 1.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

**Environment**

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**ENVIRONMENT – EU Taxonomy**

**Proportion of OpEx from products or services associated with Taxonomy-aligned economic activities – disclosure covering year 2024**

| Financial year 2024  | 2024    |              | Substantial contribution criteria |                                      |                                      |                  |                      |                             | DNSH criteria (“Does Not Significantly Harm”) |                               |                               |           |               |                      |                  | Proportion of Taxonomy aligned (A.1.) or eligible (A.2.) OpEx, year 2023 | Category enabling activity | Category transitional activity |
|--|---------|--------------|-----------------------------------|--------------------------------------|--------------------------------------|------------------|----------------------|-----------------------------|---|-------------------------------|-------------------------------|-----------|---------------|----------------------|------------------|--|----------------------------|--------------------------------|
|  | Code(s) | OpEx SEK M   | Proportion of OpEx 2024 %         | Climate change mitigation Y; N; N/EL | Climate change adaptation Y; N; N/EL | Water Y; N; N/EL | Pollution Y; N; N/EL | Circular economy Y; N; N/EL | Biodiversity Y; N; N/EL                       | Climate change mitigation Y/N | Climate change adaptation Y/N | Water Y/N | Pollution Y/N | Circular economy Y/N | Biodiversity Y/N |  |                            |                                |
| <b>A. TAXONOMY-ELIGIBLE ACTIVITIES</b>   |         |              |                                   |                                      |                                      |                  |                      |                             |   |                               |                               |           |               |                      |                  |  |                            |                                |
| <b>A.1. Environmentally sustainable activities (Taxonomy-aligned)</b>  |         |              |                                   |                                      |                                      |                  |                      |                             |   |                               |                               |           |               |                      |                  |  |                            |                                |
| OpEx of environmentally sustainable activities (Taxonomy-aligned) (A.1)  |         |              | %                                 | %                                    | %                                    | %                | %                    | %                           | %   |                               |                               |           |               |                      |                  |  | 0%                         |                                |
| Of which Enabling  |         |              | %                                 | %                                    | %                                    | %                | %                    | %                           | %   |                               |                               |           |               |                      |                  |  | %                          |                                |
| Of which Transitional  |         |              | %                                 | %                                    |                                      |                  |                      |                             |   |                               |                               |           |               |                      |                  |  | %                          |                                |
| <b>A.2 Taxonomy-Eligible but not environmentally sustainable activities (not Taxonomy-aligned activities)</b>    |         |              |                                   |                                      |                                      |                  |                      |                             |   |                               |                               |           |               |                      |                  |  |                            |                                |
| OpEx of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2) |         |              | 0%                                | %                                    | %                                    | %                | %                    | %                           | %   |                               |                               |           |               |                      |                  |  | 0%                         |                                |
| <b>A. OpEx of Taxonomy eligible activities (A.1+A.2)</b>   |         |              | <b>0%</b>                         | <b>%</b>                             | <b>%</b>                             | <b>%</b>         | <b>%</b>             | <b>%</b>                    | <b>%</b>                                      |                               |                               |           |               |                      |                  |  | <b>0%</b>                  |                                |
| <b>B. TAXONOMY-NON-ELIGIBLE ACTIVITIES</b>   |         |              |                                   |                                      |                                      |                  |                      |                             |   |                               |                               |           |               |                      |                  |  |                            |                                |
| OpEx of Taxonomy-non-eligible activities   |         | 1,547        | 100%                              |                                      |                                      |                  |                      |                             |   |                               |                               |           |               |                      |                  |  |                            |                                |
| <b>Total<sup>1,2</sup></b>   |         | <b>1,547</b> | <b>100%</b>                       |                                      |                                      |                  |                      |                             |   |                               |                               |           |               |                      |                  |  |                            |                                |

1) Refers to operating expenditure (OpEx) attributable to costs for research and development, renovating buildings, short-term leases, maintenance and repairs and expense for tools.

2) Identified OpEx that are Taxonomy-eligible in 2024 amount to SEK 0 M.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

**Social responsibility**

Governance

Reporting principles

GRI content index

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**SOCIAL**

# Own employees

## Employee engagement

**The big picture**

Employee engagement is essential to Getinge's success as it directly influences employee retention, business performance, and the company's ability to innovate. Engaged employees are more motivated, productive, and committed to the company's objectives.

**Getinge's Target**

The target for employee engagement is to reach an employee index score >70% measured through employee surveys.

**Relevant Sustainability Development Goals**



**Impact**

Although employee engagement is not included in the material topics, the company reports progress on engagement as it is interlinked with other material topics such as quality, inclusion and belonging, and health and safety. Training and development are important in this context to ensure employees are equipped with the necessary skills and knowledge for them to contribute effectively and grow within the organization.

**Policies**

Getinge's Global People Policy states that Getinge is committed to providing a fair and sustainable working environment for all employees. The objective of this policy is to define the company's position in relation to its people; reflecting human rights values both internally (making sure Getinge is a great place to work) and externally (when representing Getinge in business and other relations). The policy is valid for all Getinge companies, its subsidiaries and joint operations and applies to all employees and directors, as well as consultants and agency personnel who work at Getinge premises or under the direction of Getinge.

**Strategic direction and actions**

The company promotes employee engagement through regular feedback mechanisms, such as the global biannual employee survey. These surveys serve as a critical control mechanism, enabling the company to identify relevant focus areas and take timely actions based on employee feedback.

During 2024 Getinge has continued to support employee development through its comprehensive training programs, which are aligned with both employee needs and the company's strategic goals. Performance and career development are discussed annually between employees and their managers, with decisions guided by local regulations and internal governance documents. In addition, Getinge has established a comprehensive framework

for employee development, governed by key policies and procedures, including the Onboarding and Qualification SOP, the Competence, Awareness and Training directive and Product Training Certification Programs SOP. Training and development programs are delivered through both global and local initiatives, offered via face-to-face sessions or the company's e-learning platform.

The company ensures continuous monitoring and improvement of its training and development offerings. Getinge conducted 71,132 (66,270) hours of training globally in 2024, focusing on key areas such as Leadership and People Performance, Ethics and Compliance, Health and Safety, IT, Operations, and Continuous Improvement.

**Targets, key figures & results**

**The target for employee engagement is to reach an employee index score >70% measured through employee surveys.**

In 2024 the response rate was 78% (79%) and the engagement score was 71% (71%), meeting this target. The company remains committed to maintaining or exceeding this level of engagement in future surveys.

**Reduced absence from work due to sick leave**

The rate of sick leave in 2024 was: 2.6% (2023: 3.2%)



**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

**Social responsibility**

Governance

Reporting principles

GRI content index

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

## Occupational health and safety

**The big picture**

Safety at work is a basic human right. Ensuring a safe working environment protects employees from workplace hazards, enables improved productivity and reduces absenteeism. Working with Health & Safety also fosters a culture of trust and engagement. A culture of trust leads to increased employee satisfaction and engagement and can, in turn, foster innovation.

**Getinge's target**

Getinge's target is to reduce work-related accidents in relation to working hours (Work Related Accident Rate, WRAR) to less than 1 by 2025.

**Relevant Sustainability Development Goals**



**Impacts**

Getinge prioritizes health and safety measures which can positively impact the well-being of its employees. Safe working conditions can contribute to improved job satisfaction. Employees who feel cared for are more likely to be engaged, productive, and committed. Despite continuous work to reduce risks, safety-related incidents do occur in the company mostly related to ergonomics. If the company or managers thereof would neglect health and safety measures the potential negative impact of workplace accidents, injuries, and occupational illnesses could increase.

Key potential negative impacts in the company's production sites include work-related accidents and ill health, with musculo-skeletal disorders and psychosocial conditions being the most common in 2024. About 30% of the injuries in 2024 were directly linked to ergonomics.

**Policies**

Getinge's Code of Conduct mandates that all employees take responsibility for their safety and the safety of others. All employees, temporary workers and consultants must also comply with the mandatory requirements of Getinge's Global Policies, as well as adhering to local occupational health and safety standards. Getinge's global HR Policy and Code of Conduct encourage every employee to report, give feedback and avoid any hazardous situation. Getinge's Business Partner Code of conduct applies to suppliers and includes providing and maintaining a safe working environment. Health and safety are managed globally under Getinge's Health and Safety directive, with each workplace expected to follow the standards outlined by the directive. Each production site prepares and documents its own Occupational Health and Safety Policy in accordance with Getinge's directive. Employee consultation forums, such as safety committees, are set up in compliance with local laws. Getinge's management system was implemented in 2021 when the Global directive came into effect. The management system is not certified according to ISO or other standards.

The risk assessment process, guided by the Global Occupational Health and Safety Risk Assessment procedure, involves identifying

hazards and assessing risks. It provides guidance for employees to identify potential risks and method to evaluate the level of criticality. The assessment is reviewed annually or whenever there are organizational changes. Getinge's incident management process requires that a thorough investigation of incidents, corrective and preventive actions be carried out and that insights are shared across the organization. Local occupational health services carry out risk analyses regularly. After any incident, risk analyses are reviewed to ensure proactive risk management. Work-related hazards that pose a risk of high-consequence injury are monitored through risk analysis and tracked in local management systems. The main risks during 2024 were ergonomics/ manual handling and material handling.

To ensure up-to-date competence and a thorough understanding of health and safety risks, Getinge's global curricula for training and development covers health and safety awareness training.

A dedicated Speak-Up Line allows employees to report health and safety risks confidentially.

**Strategic direction and actions**

Getinge focuses on providing an incident-free workplace and fostering a safe culture with full worker engagement. In 2024, the company continued to work on improving the reporting system to support the company's goal of maintaining a structured, preventive approach to occupational health and safety. An important part of the approach is to have a safety-focused culture, as this enables employees to take ownership of their own and other employees' safety. Throughout the year, Getinge continued to roll out initiatives to reduce ergonomic-related injuries, such as introducing job rotation and implementing more frequent breaks.



**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

**Social responsibility**

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**SOCIAL – Own employees**

**Targets, key figures & results**


Getinge’s target is to reduce the work-related accident rate (WRAR) to less than 1 by 2025. In 2024, the WRAR was 0,92 (0,89), stable compared with last year and below Getinge’s target. For contractors, the work-related accident rate decreased to 0,84 (1,11). Contractor cases are mainly attributed to falls/trip, material handling cases and ergonomics.

**Work-related injuries for employees<sup>1</sup>**

| Employees   | 2024   | 2023   |
|---|--------|--------|
| Number of employees                                 | 11,791 | 11,386 |
| Number of work-related fatalities                   | 0      | 0      |
| Number of fatalities due to work-related ill health | 0      | 0      |
| Number of high consequence work-related accidents   | 0      | 2      |
| Number of work-related accidents                    | 115    | 97     |
| Number of work-related ill health                   | 11     | 21     |
| Number of lost workdays for work-related accident   | 1,100  | 1,282  |
| Number of lost workdays for work-related ill health | 577    | 786    |
| Total work related high-consequences accident rate  | 0      | 0,02   |
| Total work-related accident rate                    | 0.92   | 0.89   |
| Total work-related ill health rate                  | 0.09   | 0.19   |


<sup>1</sup>) Health and safety data is not included for Paragonix, as it was acquired less than 24 months ago

**Types of work-related injuries, employees**



**Work-related injuries for contractors**

| Contractors                                       | 2024 | 2023 |
|---|------|------|
| Number of temporary agency workers                | 631  | 691  |
| Number of contractor workers                      | 230  | 280  |
| Number of work-related fatalities                 | 0    | 0    |
| Number of high consequence work-related accidents | 0    | 0    |
| Number of work-related accidents                  | 10   | 12   |
| Number of lost workdays for work-related accident | 105  | 87   |
| Total high consequence work-related accident rate | 0    | 0    |
| Total work-related accident rate                  | 0.84 | 1.11 |



**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

**Social responsibility**

Governance

Reporting principles

GRI content index

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

## Diversity, equity, inclusion & belonging (DEIB)

### The big picture

Diversity, equity, inclusion, and belonging (DEIB) are essential for fostering innovation, creativity, and a positive workplace culture. A diverse and inclusive environment ensures that different perspectives are considered in decision-making, allowing the company to better serve its customers and remain competitive. Furthermore, a lack of diversity can lead to discriminatory practices, reduce employee well-being and hinder the advancement of underrepresented groups. Diversity does not mean only differences in gender, gender identity, but also differences in, for example, race, ethnicity, religion, age, marital or parental status, disability, sexual orientation, nationality, or other protected characteristics, backgrounds, experiences, perspectives, thoughts, interests, and ideas.

### Getinge's Target

Getinge's primary target is to ensure equal employment opportunity and non-discrimination across all levels of the organization

### Relevant Sustainability Development Goals



### Impacts

Getinge's culture promotes inclusive behavior with the ambition that all people can thrive in the workplace. Diversity in the company fosters innovative thinking and enhanced problem-solving by leveraging diverse skills and experiences. Training programs, development initiatives and regular individual development meetings between employees and managers helps ensure that career progression aligns with individual ambitions and demonstrated competence. Strong DEIB policies improve accountability to promote diversity and inclusion, which has a positive impact on employees.

The negative impacts are the potential for unconscious bias in recruitment, promotion, or performance reviews. In addition, lack of diversity in certain working groups and underrepresentation of certain demographic groups can lead to an inflexible culture that is unable to account for the interests of all stakeholders. Finally, if existing policies are not enforced, discrimination or harassment could occur.

### Policies

Getinge's commitment to equal employment opportunities and an inclusive workplace is underscored by the company's Code of Conduct and Human Rights Policy, which affirm principles of diversity, inclusion, freedom of association, and workplace safety. These foundational policies provide a clear framework for the company's zero-tolerance stance on discrimination and harassment.

Building on the above mentioned framework, the People Policy and Diversity Directive outline specific expectations and practices to ensure fairness, respect, and dignity for all employees, regardless of gender, gender identity, race, ethnicity, religion, age, marital or parental status, disability, sexual orientation, nationality, or other protected characteristics.

Additionally, employees have access to a Diversity Behaviors instruction, offering guidance on fostering conscious inclusion, reducing discrimination risk, and intervening as bystanders when necessary. Processes for unbiased recruitment are in place to secure equal opportunities and non-discrimination in recruitment. The Getinge Speak-Up Line allows employees, as well as suppliers

and partners, to report behavior that deviates from these guidelines ensuring that any issues are addressed transparently.

### Strategic direction and actions

#### Diversity

Recognizing the importance of diverse perspectives in leadership, the company has implemented initiatives to develop a broader pool of diverse talent. By focusing on mentorship, leadership development, and individual development plans between managers and employees, the company ensures that a wide range of thoughts and ideas shape its future leadership.

#### Equity

Global paid family leave is a cornerstone of Getinge's commitment to equity. Introduced in 2022, the company offers at least 16 weeks of paid parental leave and 4 weeks of paid caregiver leave to all employees with over one year of service, regardless of gender. Local regulations may provide more generous terms.

Eliminating pay disparities based on gender promotes an inclusive workplace where all employees are valued equally for their contributions, regardless of their gender. Gender pay equity analysis' was conducted in several countries, including the UK, US, Australia, France, Sweden, and Germany, ensuring compliance with local legislation and corporate guidelines.

#### Inclusion and belonging

In 2024, Getinge placed a strong emphasis on competence development to advance its commitment to inclusion. Inclusive leadership plays a pivotal role in creating an environment where every employee feels valued and heard, regardless of their background or identity.



**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

**Social responsibility**

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**SOCIAL – Own employees**

By embedding diversity, inclusion, and belonging into leadership development, Getinge ensures that its leaders are not only capable of managing diverse teams effectively but also embody the values of inclusivity in their day-to-day leadership. This focus on competence development underscores the company’s commitment to building a workplace that celebrates differences and fosters innovation through a wide range of perspectives.

A significant step was taken by integrating diversity and inclusive leadership into the company’s Leading Leaders and Leading People training programs, with approximately 130 leaders taking part throughout the year. Diversity and inclusion have also been included into the Aspiring Leaders program attended by employees who are expected to take managerial roles in the near future. More than 170 employees attended this training during 2024.

Getinge has developed an e-learning course on unconscious bias, available to all employees, with a specific focus on managers. This course aims to raise awareness of the biases that can influence decision-making and interpersonal interactions, often unconsciously. By helping managers recognize how these biases can affect team dynamics, recruitment, and leadership decisions, the training promotes greater accountability and awareness. This initiative is a vital part of the company’s broader efforts to create a more inclusive and equitable culture where every voice is heard and everyone can thrive.


Diversity and inclusion have also been embedded into the company culture approach “This is who we are” to cultivate a more inclusive and engaged workforce, which is essential to the long-term success of the company.

In addition, Getinge measured employee sentiment around DEIB through its employee surveys, which serves as a control mechanism to assess and address gaps in inclusion.

**Targets, key figures & results**

Getinge’s primary target is to ensure equal employment opportunity and non-discrimination across all levels of the organization.

**Gender representation**



While progress has been slow, the company reported a consistent upward trend in female representation in 2024. Although the proportion of all female employees increased only marginally, the proportion of female managers increased 1% and the female representation in the executive team increased 5% compared to the previous year.

Additionally, Getinge continues to aim for improvements in regards to employee rating of the level of inclusion and belonging in the company. This is tracked through questions in the biannual employee engagement survey. For 2024 the inclusion score was 75 (74) and the belonging score was 69 (71).

| Age intervals          | Female     | Male       | Other     | Total       |
|------------------------|------------|------------|-----------|-------------|
| <b>All employees</b>   |            |            |           |             |
| 15-30                  | 7%         | 7%         | 0%        | 14%         |
| 31-50                  | 21%        | 34%        | 1%        | 55%         |
| 51-70                  | 10%        | 20%        | 0%        | 30%         |
| Invalid data           | 0%         | 0%         | 0%        | 0%          |
| <b>Total FTEs 2024</b> | <b>38%</b> | <b>61%</b> | <b>1%</b> | <b>100%</b> |
| Total FTE 2023         | 38%        | 62%        | 0%        | 100%        |
| <b>Managers only</b>   |            |            |           |             |
| 15-30                  | 2%         | 1%         | 0%        | 3%          |
| 31-50                  | 24%        | 39%        | 1%        | 64%         |
| 51-70                  | 9%         | 23%        | 0%        | 33%         |
| Invalid data           | 0%         | 0%         | 0%        | 0%          |
| <b>Total FTEs 2024</b> | <b>35%</b> | <b>64%</b> | <b>2%</b> | <b>100%</b> |
| Total FTE 2023         | 34%        | 66%        | 0%        | 100%        |

The tables above present the gender and age distribution for all employees (Age intervals, All Employees) as well as for managers (Age intervals, Managers). All figures have been rounded to the nearest whole number full-time equivalents (FTE).

**Confirmed incidents of discrimination and actions taken**

During 2024, Getinge did not record any cases of discrimination that would be found substantiated as of the date of this reporting.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

**Social responsibility**

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**SOCIAL – Own employees**

**Employee metrics**

| FTEGender and Region    | Female       | Male         | Other      | of which Americas | of which APAC | of which EMEA | Total         |
|-------------------------|--------------|--------------|------------|-------------------|---------------|---------------|---------------|
| FTE Permanent employees | 4,250        | 7,059        | 115        | 3,254             | 1,533         | 6,637         | 11,423        |
| FTE Temporary employees | 195          | 170          | 3          | 71                | 49            | 248           | 368           |
| FTE Full Time           | 4,175        | 7,064        | 115        | 3,308             | 1,570         | 6,476         | 11,354        |
| FTE Part Time           | 270          | 165          | 2          | 17                | 11            | 409           | 437           |
| <b>Total FTEs 2024</b>  | <b>4,445</b> | <b>7,229</b> | <b>117</b> | <b>3,325</b>      | <b>1,581</b>  | <b>6,885</b>  | <b>11,791</b> |
| Total FTE 2023          | 4,277        | 7,100        | 9          | 3,027             | 1,607         | 6,752         | 11,386        |

| Difference to last period                         | FTEs | Comments   |
|---|------|--|
| Increase from Dec 2023 to Dec 2024                | +405 |  |
| Healthmark  | +346 | End of 2023 Healthmark was added to Getinge's system, however migration of the number of employees to the Human resources system was not finalized before the end of 2024. |
| Paragonix Technologies                            | +111 | Getinge acquired Paragonix Technologies.   |
| Other Changes excluding acquisitions of companies | -52  |  |

Changes from December 2023 to December 2024, including acquisitions of assets, split on Employee Cost Category. Only major changes are mentioned.

|                         |      |  |
|-------------------------|------|--|
| Manufacturing & Service | +44  | Changes in the number of Field Technicians in China, France, USA and Japan to match market demands. Applikon has down scaled production due to restructuring. HPNE also adjusted the capacity downwards. The DPTE Betabag® production capacity in Vendome has upscaled to accommodate the needs. Production has been increased in Türkiye, Germany and France to meet market demands. In USA there was a decrease due to efficiency and productivity programs. Insourcing of logistics activities in the USA led to an increase. |
| Sales                   | -114 | During 2024 there was a steady decrease of personnel involved in sales activities, in direct sales personnel, sales support and customer service functions.  |
| Administration          | +24  | The biggest change in administrative personnel comes from the insourcing of logistics project in US. Furthermore, the company increased the personnel in Getinge Shared Service Center to support increased task activity. Reduced employees in IT support and internal development in Germany.  |
| R&D                     | -6   | Personnel increased in Sweden at the same time as the R&D operations decreased in Germany and USA.   |

The number of employees at Getinge was 11,791 full-time equivalents (FTEs) at the end of the reporting period. All figures are rounded to the nearest whole number, but totals are calculated with decimals. Table "FTEGender and Region" shows the gender split across Permanent/Temporary, Full/Part time and the regional split. All numbers are in FTE.

The higher amount of "Other" compared to last reporting period comes from the acquired Paragonix Technologies where the gender of the employees was not captured adequately in the Human Resource Information System (HRIS). This will be corrected during 2025.

The table "Difference to last period" presents the most marked differences to last year, including acquisitions of companies and/or assets.

Development of the FTE throughout the year is characterized by a slight increase during first half and then a steeper decrease during second half (ranging from 11,130 - 11,541 FTE when excluding acquisitions of Healthmark and Paragonix).

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

**Social responsibility**

Governance

Reporting principles

GRI content index

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**SOCIAL – Own employees**

| Workers who are not employees | FTEs | Comments  |
|-------------------------------|------|---|
| Difference to last period     | -110 | Decrease from Dec 2023 to Dec 2024  |
| Manufacturing & Service       | +6   | The increase is primarily due to changes in various aspects of manufacturing. |
| Sales                         | -2   | Minor changes across the globe.   |
| Administration                | -123 | Decreases in Germany, Sweden and USA.   |
| R&D                           | +8   | Decrease in Sweden and increase in India and USA.                             |

| KPIs for different groupings | New hires       |               | Employee turnover |              |
|------------------------------|-----------------|---------------|-------------------|--------------|
|                              | Number (person) | Hire rate (%) | Number (person)   | Turnover (%) |
| Female                       | 405             | 9%            | 518               | 12%          |
| Male                         | 664             | 9%            | 794               | 11%          |
| Other                        | 144             | 65%           | 31                | 14%          |
| 15-30                        | 331             | 22%           | 211               | 14%          |
| 31-50                        | 692             | 11%           | 709               | 11%          |
| 51-70                        | 181             | 5%            | 405               | 12%          |
| Invalid data                 | 9               | 16%           | 18                | 31%          |
| Americas                     | 459             | 14%           | 488               | 15%          |
| APAC                         | 208             | 13%           | 228               | 15%          |
| EMEA                         | 546             | 8%            | 627               | 9%           |
| <b>Total 2024</b>            | <b>1,213</b>    | <b>10%</b>    | <b>1,343</b>      | <b>12%</b>   |
| Total 2023                   | 1,314           | 12%           | 1,278             | 11%          |

| Parental leave    | Started in 2024 | Ended in 2024 | Ended in 2023 and remained for at least 12 months |            |
|-------------------|-----------------|---------------|---|------------|
|                   |                 |               | Retention rate                                    |            |
| Female            | 137             | 89            | 75  | 86%        |
| Male              | 147             | 138           | 85  | 93%        |
| Other             | 0               | 0             | 0   | n.a        |
| <b>Total 2024</b> | <b>284</b>      | <b>227</b>    | <b>160</b>  | <b>90%</b> |
| Total 2023        | 225             | 178           | 194   | 94%        |

**Workers who are not employees**

External workers at Getinge account for 861 full-time equivalents (FTE). All numbers are rounded to nearest whole. 631 FTE were shorter term temporary workers joining the company for secondment or as project support, upscaling of production, etc. 230 full-time equivalents are consultants & technical accounts that support on a project or on a need-to-support basis. Development of all the external workers during the period and between periods was relatively stable, varying from 861 to 1,037 FTE, but with a slightly decline from second half of 2024 (see the table to the left).

**New employee hires and employee turnover**

The table to the left shows the hires (including rehires) and terminations (both voluntary and involuntary) split by region, age and gender. All numbers are rounded to nearest whole.

The increased hire rate of the "Other" category primarily came from the acquisition of Paragonix Technologies and secondarily the Healthmark Industries Inc. where gender was not recorded in the system at the time of acquisition.

**Parental leave**

Entitlement to parental leave is governed by local rules, regulations and individual contracts and there is no data recorded centrally to provide an overview. Under Getinge's benefit plan, a total of 10,546 FTEs are entitled to parental leave, of whom 3,961 are women, 6,505 men and 81 others. The table "Parental leave" shows the number of employees that started maternity/paternity/parental leave during 2024, the number that returned and the number that were still employed at Getinge, 12 months after their return from this leave split by gender. The company has no records on employees not returning from parental leave.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

**Social responsibility**

Governance

Reporting principles

GRI content index

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**SOCIAL**

# Workers in the value chain

**The big picture**

Ensuring good working conditions and protecting worker rights throughout the whole value chain is important as it safeguards the well-being of individuals. In the value chain there is a risk that workers are exposed to unsafe environments and excessive working hours. In addition, when workers are exposed to unfair treatment it can result in significant stress and lack of job security impacting the workers' quality of life.

By prioritizing fair labor practices, workers can get access to better working conditions fostering a healthier and more equitable workforce.<sup>1</sup>

**Relevant Sustainability Development Goals**



**Impacts**

The assessed impacts on workers in the value chain are limited to potential impacts. During the year a process has been implemented to better understand which of the potential impacts are actual impacts.

Getinge may contribute to poor working conditions in the value chain such as, but not limited to, excessive working hours, lack of health & safety, low wages, poor employment terms. In addition, workers' rights such as freedom of association or collective bargaining may be at risk. In the value chain there is also a potential risk of modern slavery and child labor or other human rights breaches.

**Policies**


The Business Partner Code of Conduct defines Getinge's ethical principles and requirements that stakeholders are expected to comply with when doing business with Getinge. The Business Partner Code of Conduct applies to suppliers, partners, contractors and subcontractors. Setting clear expectations on ethical business and responsible leadership is a prerequisite for a sustainable and fruitful collaboration. Responsible leadership is about daily decisions and as such it is critical that the Business Partner Code of Conduct is applied, that compliance is monitored, and continuous improvement undertaken. This monitoring is part of the auditing of suppliers.

**Strategic direction and actions**

During the year, Getinge initiated a comprehensive ESG due diligence process in the supply chain. The process is built around an analysis of ESG risks prevalent in the country of origin of the suppliers (human rights/anti-corruption) as well as ESG risks associated with the product, service or process purchased (health and safety/environment). The initiative has been launched in the majority of the company's legal entities.

**Targets, key figures & results**

The main objective of the ESG due diligence process is to ensure that supply chain partners work in line with the Getinge Business Partner Code of Conduct. To achieve this, the company conducts supplier due diligence by first classifying suppliers based on risk, assessing whether identified risks are actual, and then implementing measures to mitigate them. During 2024, 65 legal entities were onboarded and more than 300 employee users trained, each tasked with implementing and overseeing the due diligence measures.



<sup>1</sup>) <https://www.ilo.org/publications/value-chain-development-decent-work-0>

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

**Social responsibility**

Governance

Reporting principles

GRI content index

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**SOCIAL**

# Patient safety and quality

**The big picture**

Getinge's offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. This means most of the company's products contribute directly or indirectly to public health. Product quality is an essential aspect in ensuring the safety of patients. Regulatory conformance of all products is mandatory in the highly regulated healthcare and life science industry.

**Getinge's Targets**

In 2024, Getinge replaced the Quality Index with two focused KPIs that reflect its commitment to quality: audit findings per audit (targeting regulatory compliance) and field actions per billion SEK net sales (assessing product quality). While field actions are safety-related measures with no defined target, Getinge aims for audit findings per audit for quality systems to remain below or equal to 1.5.

**Relevant Sustainability Development Goals**



**Impacts**

Poor quality can have severe consequences spanning operational, financial, legal and reputational. The most significant being harm to patients as defective medical devices can lead to adverse health consequences.

When product quality fails, already manufactured products and parts are at risk of becoming obsolete, resulting in unnecessary use of materials and natural resources and increased waste streams with negative environmental consequences.

**Policies**


Getinge is committed to delivering safe, high-quality products for its customers and patients. The Quality Management Systems (QMS) at all sites are certified to ISO 9001 or ISO 13485 standards, with additional compliance with national standards like 21 CFR 820, depending on market requirements. QMS implementation is based on a unified Quality Policy and a global framework consisting of nine Quality Directives. This ensures alignment with regulatory standards across all locations, supporting both product quality and regulatory compliance.

Through a structured corporate approach, Getinge continuously monitors compliance and the effectiveness of local QMS implementations, enabling the company to conduct targeted improvements across all areas.

Comprehensive training ensures that all employees understand quality principles, their significance, and Getinge's unified approach toward achieving quality. The company's commitment includes regular audits, with a focus on maintaining an agile, purpose-driven QMS.

**Strategic direction and actions**

During 2024, Getinge continued to work on important initiatives to optimize the QMS and deliver improved end-to-end quality outcomes. These initiatives and the associated investments in the QMS have been prioritized to support the company's operations related



commitments to FDA and equivalent government monitoring bodies worldwide. In 2024 Getinge transformed key QMS processes across the company with a special focus on management review, complaints process, and the field action process. Expected results from these changes are, for example, early alerts on where to improve, strengthen the quality culture to increase customer satisfaction, improve patient and user safety, reduce business risks and continue to nurture a learning organization.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

**Social responsibility**

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**SOCIAL – Own employees**

**Targets, key figures & results**

In 2024, Getinge replaced the Quality Index with two focused KPIs that reflect its commitment to quality: audit findings per audit (targeting regulatory compliance) and field actions per billion SEK net sales (assessing product quality), where the KPI is based on number of initiated field actions. While field actions are safety-related measures with no defined target, Getinge aims for audit findings per audit to remain below or equal to 1.5.

**Getinge’s performance in 2024 included:**

- Field actions per billion SEK (assessing product quality): 1.2 (2023: 1.9)
- Audit findings per audit for quality systems : 2.5 (2023: 1.3)
- Online customer trainings: 48,486 (2023: 45,553)

Field actions, which include recalls, corrections, and safety notifications, are essential for ensuring patient safety and regulatory compliance. In 2023, a higher number of field actions was initiated, mainly linked to the Cardiosave product. At the beginning of 2024 the number normalized. The number and type of field actions should be monitored to improve product quality and safety over time. However, it’s important to clarify that the target should not be to reach a specific number of field actions but rather to reduce their occurrence. Getinge’s focus is on improving product design, manufacturing processes, and post-market surveillance to address the underlying root causes of the field actions and thereby resolve problems and prevent future issues.

Audit findings are documented observations of nonconformance identified during an external audit against regulatory, quality, or procedural requirements. Getinge undergoes audits in accordance with industry practices and the requirements set by the FDA and equivalent governmental oversight bodies worldwide. The KPI for compliance metric increased slightly in 2024 compared to 2023 following a number of intensive quality audits at the beginning of the year.


Online-customer training includes various activities designed to train hospital staff in the proper and safe use of Getinge equipment. The KPI shows the number of times a customer has finalized an eLearning course or joined a training webinar, held by Getinge. In addition, the company offers extensive online training opportunities via [getinge.com](https://getinge.com), simulations and workshops, and user trainings at customer site. The outcome for online customer training increased compared with 2023, mainly related to a customer activity in October 2024 – Getinge’s Respiratory Care Week.

**Incidents reported**

In 2024, Getinge reported zero incidents of regulatory non-compliance concerning the health and safety impacts of products and services resulting in penalties or fines and one incident resulting in warnings. Compliance with CE certification ensures that all relevant products are evaluated for health and safety impacts.

All of Getinge’s products are evaluated as regards to requirements for product and service information and labeling by either being subject to medical device market regulations or managed in Getinge’s QMS. In 2024, Getinge reported one incident of non-compliance concerning product and service information and labeling resulting in penalties or fines and zero incidents resulting in warnings. Getinge did not have any incidents of non-compliance with regulations and/or voluntary codes concerning marketing communications, including advertising, promotion, and sponsorship, in 2024.

Customer privacy remains a priority, and during 2024, Getinge received one complaint concerning a breach of customer privacy. The incident was caused by human error whereby e-mail addresses were added in the cc field rather than the blind cc field. Measures were taken to mitigate risks of similar incidents happening again. Getinge received no complaints in 2024 from regulatory bodies in relation to breaches of customer privacy. No leaks, theft or loss of customer data were detected in 2024.



**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

Social responsibility

**Governance**

Reporting principles

GRI content index

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**GOVERNANCE**

# Anti-corruption

**The big picture**

Corruption can divert financial resources away from healthcare services, leading to inadequate care and even loss of life<sup>1</sup>. Corruption increases inequalities in healthcare access and inefficient use of public funds. When resources are used wrongly, marginalized communities often suffer the most, as they rely heavily on public health services. Trust in healthcare systems is vital for effective public health. Corruption erodes this trust, making individuals less likely to seek care or follow medical advice. When patients believe that healthcare providers are corrupt, they may avoid necessary treatments, which can lead to worse health outcomes.

**Getinge's Targets**

**Business Ethics & Responsible Leadership:**

All employees are properly trained in Business ethics.

**Relevant Sustainability Development Goals**



<sup>1</sup> <https://www.who.int/activities/reducing-health-system-corruption/reducing-health-system-corruption>



**Impacts**

Corruption leads to inefficiencies in healthcare delivery. It can inflate costs and reduce the quality of services, as funds are not used effectively. Implementing anti-corruption, anti-trust and healthcare compliance programs are important to ensure Getinge advocates for fair and transparent business practices and fostering a culture of accountability in healthcare systems.

The risk of corruption is significant especially in public procurement processes in emerging markets or markets where the tendering process is less mature and involves several business partners and intermediaries.

Distorted public procurement could be a result of corrupt practices. Public procurement stands for an increased risk and impact as this type of corruption leads to:

- Negative impact on the welfare of societies
- Potential misuse of public funds
- Potential negative impact on health equity

**Policies**

Getinge's Code of Conduct is at the core of Getinge's business. The Code of Conduct describes the main principles for conducting business in line with both laws and stakeholder expectations. One of the principles in Getinge's Code of Conduct is to always act with honesty, fairness and integrity. The principle states that employees should never act in a way that could manipulate the market or unfairly disadvantage colleagues, business partners or competitors. It also states that there should be no bribes, no corruption and no insider trading without exceptions.

Getinge's Global Anti-Bribery & Corruption Policy provides an overview of Getinge's commitment and principles against bribery and corruption. The policy applies to all employees, Board members and business partners acting on behalf of Getinge. The implementation is driven by global and local management, supported by the global Ethics & Compliance function. Getinge's Anti-Bribery and Corruption Policy is communicated to business

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

Social responsibility

**Governance**

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

**GOVERNANCE – Anti-corruption**

partners during contracting and onboarding processes. The policy and the Business Partner Code of Conduct are also referred to in contract templates.

The Global Anti-bribery & Corruption (ABC) program serves as a method and tool for ensuring that Getinge has adequate procedures in place, aimed at preventing the company from taking part in any corrupt business practices, and ensuring that the company adheres to applicable laws and regulations as well as relevant ethical norms including the Code of Conduct and global policies and directives. In addition, specific ethics & compliance programs have been designed for Healthcare Compliance and Anti-Trust to provide a risk-based framework for managing the risk of undue influence and unfair business practices.

Internal Controls, relevant for the ethics & compliance programs, have been integrated into the Getinge Internal Controls framework as relevant. The Corporate Internal Audit function conducts risk-based audits on the local implementation and provides recommendations for improving the effectiveness of the ethics & compliance programs.

**Strategic direction and actions**

Getinge uses a risk-based methodology in implementing its ethics and compliance programs and concentrates its efforts on high-risk areas. One of the high-risk areas is the interaction with healthcare professionals and participation in public procurement. Getinge has developed a formal protocol for conducting risk assessments and uses forensic expertise when necessary. The risk assessment process includes an evaluation of various criteria and risk factors such as those related to location, business activity, third-party interactions, products or services, internal control and audit outcomes.

Regional risk assessments have been conducted, encompassing a thorough review of country risk analysis, past audits, investigation findings, and risk assessments from site visits and stakeholder interviews. Findings indicate that a continued focus is necessary on interactions with healthcare professionals and organizations. As a major mitigation step taken over the past year, a Global Educational Grants portal was launched, along with a tool to register all interactions with healthcare professionals and organizations. In response to these findings, a detailed plan at each regional level has been developed to advance the implementation of identified mitigation actions. This includes updating relevant policies and delivering training on third-party management and monitoring practices.

Training and communication are essential components of Getinge’s global ethics and compliance programs. The programs include targeted training for Anti-bribery and corruption at all levels of the company, including employees, the Board and all members of the Getinge Executive Team. The global Ethics and Compliance team monitors all training to ensure that all employees receive relevant training at least once a year.

A specialized program, titled Responsible Leadership #ItStartsWithMe, was deployed in 2022 aiming to enhance business ethics awareness and a culture of compliance at all levels in Getinge. In 2024, the program was complemented with modules that are aimed for colleagues working in the factories.

The company has an ethics ambassador program with around 70 Ethics Ambassadors globally promoting business ethics and Responsible Leadership. The ethics ambassador program is a key initiative with the aim of spreading knowledge and supporting the organization in business ethics and compliance including Anti-Bribery and Corruption.

**Targets, key figures & results**

**Business Ethics & Responsible Leadership:**

Getinge's target is that all employees are properly trained in business ethics. Percentage of employees who completed online training in business ethics 2024: 90% (2023: 89%).

**Confirmed incidents of corruption and actions taken**

During 2024, Getinge did not record any cases of corruption that would be found substantiated as of the date of this reporting. No public corruption cases were brought against the company or its employees.

**Legal actions for anti-competitive behavior, antitrust, and monopoly practices**

No legal actions for anti-competitive behavior, antitrust, and monopoly practices arose in 2024.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

Social responsibility

Governance

**Reporting principles**

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

# Reporting principles

**ENVIRONMENT**

**Climate and Energy**

Boundaries: All greenhouse gas emissions are consolidated from entities over which Getinge has operational control (see pages 118–119 and pages 179–181).

The base year for calculation has been set to 2021 emission values, if not stated otherwise. The base year is updated for the 2024 report and is aligned with the baseline year in SBTi. Apart from adding one acquired unit (HPNE) and restatements presented in page 128, no changes in calculation method have been made.

Carbon dioxide (CO<sub>2</sub>) is the predominant greenhouse gas included in the calculations. Emission factors applied to energy consumption for different energy resources are converted to MWh/CO<sub>2</sub>eq. Getinge uses CO<sub>2</sub>eq emission factors that may include small amounts of converted methane (CH<sub>4</sub>) and N<sub>2</sub>O, where applicable. Getinge does not report on other ozone depleting substances or greenhouse gases, neither on biogenic CO<sub>2</sub> emissions.

The inventory method has been used to account for reductions. Getinge strives to reach its targets to reduce GHG emissions without offsetting mechanisms to the extent possible. Getinge acknowledges that reducing CO<sub>2</sub> emissions with CO<sub>2</sub> offsetting is accepted by the GHG Protocol, but not by the SBTi.

**Scope 1 and 2**

GHG emissions are calculated based on the Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (Revised Edition).

**Scope 1**

*Fuel combustion*

Global Scope 1 emission factor for fuel combustion is from the Department for Business, Energy and Industrial Strategy 2021 Government GHG Conversion Factors for Company Reporting, in line with IPCC 2006 Guidelines for National Greenhouse Gas Inventories.

*Calculation of emissions from vehicles*

Getinge’s fleet consists of 100% leased vehicles. Emissions from leased vehicles under the operational control of Getinge are calculated by multiplying contracted annual mileage in km with CO<sub>2</sub>eq emission factors per vehicle from vehicle manufacturers (in gCO<sub>2</sub>eq / km). DEFRA’s “UK Government Conversion Factors for Company Reporting” for the respective years 2021-2024 was applied in estimates.

**Scope 2**

Country-specific (location based) factors are sourced for electricity from AIB (2023) and IEA (2023), and for heating from Werner (2017). In addition, supplier specific factors have been analyzed locally to report emissions based on the location and market based methodology. The most recent and internationally recognized schemes are preferred. Due to incomplete data from suppliers, Getinge does not report its market based GHG emissions in 2024 but strives to obtain such data in the future.

*Calculation of emissions from offices and warehouses*

Emissions from owned and leased offices and warehouses are calculated by multiplying workplace area in m<sup>2</sup> with an average factor of energy consumption per year (kWh/m<sup>2</sup> per yr). For offices, this factor is 242.19 kWh/yr and for warehouses 96.88 kWh/yr<sup>1</sup>. In the few cases in which data for consumption per office or warehouse is available, this has been used. The sum of calculated annual energy consumption per office/warehouse is then multiplied by country specific emission factors for the respective site. Emission factors: (IEA 2019) CO<sub>2</sub>eq emissions per kWh of electricity and heat (gCO<sub>2</sub>eq /kWh).

**Scope 3**

The calculation of the emissions from the three categories emitting the majority of the emissions – purchased goods and services (Category 3.1), upstream transportation and distribution (Category 3.4) and use of sold products (Category 3.11) are based on the Greenhouse Gas Protocol standards.

*Category 3.1 – Purchased goods and services*

The emissions represented in category 3.1 are based on the goods and services Getinge has purchased during the year. These purchases were divided into five different categories:

- Plastics
- Metals
- Electronics and Electrical
- Other
- Purchased services

For plastics, metals and electronics, the calculations are based on both spend data and weight of the materials where available. Material emission factors used are the following: US Commodities and Industries v1.1, DEFRA UK database, EPA database and from Zero carbon product database and Ecolivent.

*Category 3.4 Upstream transportation and distribution*

For inbound transport Getinge gathers and estimates the weight for each product bought. For each order the region of the supplier and the end location of the goods are gathered. The start and end destination are then used for distance estimation. For inbound transport the split between means of transport is estimated. For outbound goods transport Getinge receives emission or transport reports from the freight forwarder. Transportation mode emission factors from the DEFRA UK database have been used for the calculations.

*Category 3.11 – Use of sold products*

The emissions calculated for use of sold products are based on expected energy consumption from Getinge’s sold products during their lifetime. The activity data used has been the number of sold products that consume direct energy, that has been sold during the measurement period and the estimated energy profile for the sold products during its lifetime. Lifetime expectancy is calculated to be on average 10 years. The global electricity emission factor from “Our world in data” database has been used. Steam factors are from DEFRA UK. Please refer to Getinge Climate disclosure report 2023 for more details on calculations of other scope 3 emissions.

1) <https://www.altenergymag.com/article/2019/07/benchmarking-commercial-building-energy-use-per-square-foot/31381>  
[https://www.betterbuildingspartnership.co.uk/sites/default/files/media/attachment/REEB%202023%20Benchmarks\\_0.pdf](https://www.betterbuildingspartnership.co.uk/sites/default/files/media/attachment/REEB%202023%20Benchmarks_0.pdf)

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

Social responsibility

Governance

**Reporting principles**

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

Reporting principles cont.

**Circularity**

**Waste**

Waste data is measured quarterly and is based on invoices from suppliers or local data bases. Responsible use of resources and waste handling is in focus in all locations of operation. Getinge has ISO 14001 certifications at all production units (except for a small number of recently acquired units) to comply with all local regulation in this area and has set targets to increase recycling of its waste. The management of waste follows the principles set out in the environmental and sustainability policies and local environmental management systems. The development of generated waste volumes from production and modes of recycling are gathered quarterly in a central data management system for all production units.

**Water**

Water data is compiled monthly, either via supplier invoices or via local measuring equipment or meters. For assessing water risk and water stress level, the WRI Acqueduct database has been used.

**METHODOLOGIES TO REPORT EMPLOYEE DATA**

**Employees**

The presented data is extracted from the Getinge Global Human Resource Information System (HRIS). Data is reported as a snapshot of the end of the reporting period. Numbers are presented in full-time equivalents (FTE). FTE is defined as all employees that are either active or on paid leave, but excludes all employees on unpaid leave. Each relevant employee is then counted with their reported FTE value that represents their work time. Gender data is allowing for selecting other categories than “Male” or “Female”. These are here presented combined under “Other” due to the low number of employees in these categories. Governance on gender classification is that it should be recorded in the system as stated in the employee’s passport or any other country specific legal document. Region is defined based on the geographical place of the legal entity. Getinge doesn’t centrally collect data on employees with guaranteed vs non-guaranteed hours, nor is this necessarily collected locally. Managers are defined as employees who have management responsibility over other employees – internally or externally. Getinge has no other minority data collected globally.

**Workers who are not employees**

The presented data is extracted from Getinge HRIS. Data is reported as a snapshot at the end of the reporting period. Numbers are presented in full-time equivalents (FTE).

**New employee hires and employee turnover**

The presented data is extracted from Getinge HRIS. Data is reported over the period of a year for people who were hired during 2024 or had their last day of employment in 2024. For both terminations and new hires, the numbers are presented in FTE. The definition is similar to that described under Employees with the following exceptions:

1. Only permanent employees are included in the retention rate. It excludes the small number of temporary employees. This is standard company practice to avoid impacting the data with terminations due to planned end of contract.
2. Getinge includes both employees who are active and on paid leave (as for Employees), but people on unpaid leave are also included to ensure all employees who are on unpaid leave for some reason during their period of notice are counted.

For data on gender, see the definition under Employees. Age group uses the recorded date of birth to calculate the age at the end of the reporting period. If date of birth is missing or incorrect, it is recorded as invalid in the above.

**Parental leave**

The presented data is extracted from Getinge HRIS. Data is reported over the period of a year for people going on leave or returning from leave.

Any kind of parental leave is by default handled locally according to local rules, regulations and contracts, hence the global data on this is limited. Any parental leave is to be recorded in the global HRIS system if it is either expected to last or actually lasts more than 14 calendar days. Multiple parental leaves for the same person are counted only once during the period, but as two leaves across reporting periods (e.g. if the person changes from paid to unpaid, etc.).

For data on gender, see the definition under Employees.

**Diversity of governance bodies and employees**

The presented data is extracted from Getinge HRIS. Data is reported as a snapshot of the end of the reporting period. Numbers are presented in FTE.

For data on gender, see the definition under Employees.

As regards to age groups, the recorded date of birth is used to calculate the age at the end of the reporting period. If the date of birth is missing or the age is outside the interval of 15–70, it is recorded as invalid in the above.

**Health & Safety**

High consequence work-related accident is defined as: A work-related accident that results in an injury from which the worker cannot, does not, or is not expected to recover fully to pre-injury health status within six months.

Work-related ill health is defined as: Any negative impact, such as abnormal conditions or disorders with a clear causal relationship between the ill health and the specific work environment or activity, other than one resulting from occupational health injuries arising from exposure to hazards at work.

Recordable injury is defined as: Any occupational injury that requires medical treatment more than simple first aid and occurs within a Getinge site perimeter, or while on business travel and which includes an employee or a contractor normally based at that site.

Work-related accident rate (WRAR): The number of accidents that resulted in absence of more than one day per 200,000 hours worked. Number of total hours worked: employees: 25,002,684 hours, workers who are not employees: 2,380,596 hours.

**Contractors are defined as:**

- short term temporary workers who join the company as temporary cover or, for example, to support projects or scale up production.
- associated consultants and technical consultants who provide support on a project- or need basis.

Introduction

Strategy

Corporate Governance Report

Financial statements

Sustainability Report

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

Social responsibility

Governance

Reporting principles

GRI content index

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

Other information

# GRI Content Index

Statement of Use: Getinge has reported in accordance with the GRI Standards for the period from January 1 to December 31, 2024  
 GRI 1 used: GRI 1 Foundation 2021  
 Applicable GRI Sector standard: none

| GRI Standard   | Disclosure Title  | Pages             | Omission   |
|--|---|-------------------|--|
| <b>GENERAL DISCLOSURES</b>                             |   |                   |  |
| <b>GRI 2 General Disclosures 2021</b>                  |   |                   |  |
| <b>1. The organization and its reporting practices</b> |   |                   |  |
| 2-1  | Organizational details  | 34-35, 56         |  |
| 2-2  | Entities included in the organization’s sustainability reporting            | 118-119, 128      |  |
| 2-3  | Reporting period, frequency and contact point                               | 128               |  |
| 2-4  | Restatements of information   | 128               |  |
| 2-5  | External assurance  | 128, 168          |  |
| <b>2. Activities and workers</b>                       |   |                   |  |
| 2-6  | Activities, value chain and other business relationships                    | 3, 12-31, 56, 133 |  |
| 2-7  | Employees   | 155-156, 163      | <b>Not applicable.</b> Getinge does not report on GRI 2-7, b iii (non-guaranteed hours employees, and a breakdown by gender and by region) as such employee relations are not present. |
| 2-8  | Workers who are not employees   | 156, 163          |  |
| <b>3. Governance</b>                                   |   |                   |  |
| 2-9  | Governance structure and composition  | 32-46, 135-137    | <b>Not applicable.</b> GRI 2-9 c vi, Getinge’s highest governance body is not composed based on these parameters.  |
| 2-10   | Nomination and selection of the highest governance body                     | 35-37             |  |
| 2-11   | Chair of the highest governance body  | 39                |  |
| 2-12   | Role of the highest governance body in overseeing the management of impacts | 135-137           | <b>The information is incomplete.</b> GRI 2-12 b i, Getinge does not follow a formalized procedure for the engagement process between stakeholders and the highest governance body.    |
| 2-13   | Delegation of responsibility for managing impacts                           | 38, 135-137       |  |

| GRI Standard                               | Disclosure Title  | Pages              | Omission   |
|--|---|--------------------|--|
| <b>Governance, cont.</b>                   |   |                    |  |
| 2-14                                       | Role of the highest governance body in sustainability reporting | 135-137            |  |
| 2-15                                       | Conflicts of interest   | 36-37, 39-41       |  |
| 2-16                                       | Communication of critical concerns                              | 135-137            | <b>Information unavailable.</b> GRI 2-16 b, Getinge does not consolidate data about this specific type of communication.   |
| 2-17                                       | Collective knowledge of the highest governance body             | 36-37, 135-137     |  |
| 2-18                                       | Evaluation of the performance of the highest governance body    | 37                 | <b>Information unavailable.</b> The evaluation carried out does not specifically monitor the organization’s impact on the economy, environment or people.  |
| 2-19                                       | Remuneration policies   | 64-67, 105-106     |  |
| 2-20                                       | Process to determine remuneration                               | 38, 64-67, 105-106 |  |
| 2-21                                       | Annual total compensation ratio                                 | 64-67, 105-106     | <b>The information is incomplete.</b> Getinge does not yet consolidate this information at Group level.  |
| <b>4. Strategy, policies and practices</b> |   |                    |  |
| 2-22                                       | Statement on sustainable development strategy                   | 7, 13-16, 129      |  |
| 2-23                                       | Policy commitments  | 135-137            | <b>The information is incomplete.</b> GRI 2-23 a ii, iii and b ii, Reported information does not fully cover all requirements, but Getinge strives to obtain such information in future reports. |
| 2-24                                       | Embedding policy commitments                                    | 136-137            |  |
| 2-25                                       | Processes to remediate negative impacts                         | 137                |  |
| 2-26                                       | Mechanisms for seeking advice and raising concerns              | 137                |  |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

Social responsibility

Governance

Reporting principles

**GRI content index**

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

| GRI Standard   | Disclosure Title   | Pages            | Omission   |
|--|--|------------------|--|
| <b>Strategy, policies and practices, cont.</b>         |  |                  |  |
| 2-27   | Compliance with laws and regulations                                     | 56-60, 136-137   | <b>The information is incomplete.</b> GRI 2-27 a ii, b, d, Getinge does not yet consolidate this information at Group level.   |
| 2-28   | Membership associations  | 134, 137         |  |
| <b>5. Stakeholder engagement</b>                       |  |                  |  |
| 2-29   | Approach to stakeholder engagement                                       | 130-131          |  |
| 2-30   | Collective bargaining agreements   |                  | <b>Information unavailable.</b> Getinge complies with local regulation in all countries of operation but does not collect country specific information on collective bargaining agreements on a global level.  |
| <b>MATERIAL TOPICS</b>                                 |  |                  |  |
| <b>GRI 3 Material Topics 2021</b>                      |  |                  |  |
| <b>1. The organization and its reporting practices</b> |  |                  |  |
| 3-1  | Process to determine material topics                                     | 130-132          |  |
| 3-2  | Material topics  | 132              |  |
| <b>GRI Topic Specific Disclosures</b>                  |  |                  |  |
| <b>Governance</b>                                      |  |                  |  |
| <b>GRI 205 Anti-corruption 2016</b>                    |  |                  |  |
| GRI 3-3  | Management of material topics  | 130-132, 135-137 |  |
| 205-1  | Operations assessed for risks related to corruption                      | 160-161          | <b>The information is incomplete.</b> GRI 205-1 a, The percentage of operations assessed for corruption risks is not available for 2023.   |
| 205-2  | Communication and training about anti-corruption policies and procedures | 160-161          | <b>The information is unavailable.</b> Getinge does not currently measure the percentage of governance body members and business partners that have received training on anti-corruption, broken down by region (GRI 205-2 a,b,c,d). The percentage of employees who received anti-corruption training by category is not available for 2023 (GRI 205-2(e)). |
| 205-3  | Confirmed incidents of corruption and actions taken                      | 160-161          |  |

| GRI Standard                                       | Disclosure Title  | Pages            | Omission   |
|--|---|------------------|--|
| <b>Governance, cont.</b>                           |   |                  |  |
| <b>GRI 206 Anti-competitive behavior 2016</b>      |   |                  |  |
| GRI 3-3  | Management of material topics   | 130-132, 160-161 |  |
| 206-1  | Legal actions for anti-competitive behavior, anti-trust and monopoly practices          | 161              |  |
| Own  | Employee Training on Business Ethics  | 161              |  |
| <b>GRI Topic Specific Disclosures</b>              |   |                  |  |
| <b>Social</b>                                      |   |                  |  |
| <b>GRI 401 Employment 2016</b>                     |   |                  |  |
| GRI 3-3  | Management of material topics   | 130-132, 150-156 |  |
| 401-1  | New employee hires and employee turnover  | 155-156          |  |
| 401-3  | Parental leave  | 156              | <b>The information is incomplete.</b> 401-3 e. Getinge does not currently have records on employees not returning from parental leave.   |
| Own  | Sick Leave  | 150              |  |
| <b>GRI 403 Occupational Health and Safety 2018</b> |   |                  |  |
| GRI 3-3  | Management of material topics   | 130-132, 151-152 |  |
| 403-1  | Occupational health and safety management system  | 151-152          |  |
| 403-2  | Hazard identification, risk assessment, and incident investigation                      | 151-152          |  |
| 403-3  | Occupational health services  |                  | <b>Information unavailable.</b> Due to regional variances, Getinge doesn’t currently collect data on occupational health services at global level.                                     |
| 403-4  | Worker participation, consultation, and communication on occupational health and safety |                  | <b>Information unavailable.</b> Due to regional variances, Getinge currently doesn’t collect data on occupational health and safety jointed manager-worker committees at global level. |
| 403-5  | Worker training on occupational health and safety                                       | 151-152          |  |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

Social responsibility

Governance

Reporting principles

**GRI content index**

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

| GRI Standard  | Disclosure Title  | Pages                 | Omission  |
|---|---|-----------------------|---|
| <b>Social, cont.</b>                                |   |                       |   |
| 403-6   | Promotion of worker health  |                       | <b>Information unavailable.</b> Due to regional variances, Getinge currently does not collect data from all sites of operation on workers’ access to non-occupational medical and healthcare services, nor information on any voluntary health promotion services and programs. |
| 403-7   | Prevention and mitigation of occupational health and safety impacts directly linked by business relationships | 151-152               |   |
| 403-8   | Workers covered by an occupational health and safety management system  | 151-152, 163          | <b>The information is incomplete.</b> 403-8 a ii and iii. Getinge currently does not report on information from internal or external audits of the occupational health and safety management system at its workplaces.  |
| 403-9   | Work-related injuries   | 151-152, 163          | <b>The information is incomplete.</b> 403-9 a v, b v: Getinge does not currently report the local number of hours worked. 403-9 c ii, iii Getinge also does not report the actions taken or underway to eliminate work-related hazards and minimize risks.                      |
| 403-10  | Work-related ill health   | 151-152, 163          | <b>The information is incomplete.</b> Getinge does not collect data on work-related ill health from contractors as it is under external employer responsibility.  |
| <b>GRI 405 Diversity and Equal Opportunity 2016</b> |   |                       |   |
| GRI 3-3   | Management of material topics   | 130-132, 153-154      |   |
| 405-1   | Diversity of governance bodies and employees  | 39-41, 43-44, 153-154 |   |
| <b>GRI 406 Non-discrimination 2016</b>              |   |                       |   |
| GRI 3-3   | Management of material topics   | 130-132, 153-154      |   |
| 406-1   | Incidents of discrimination and corrective actions taken  | 154                   |   |

| GRI Standard                                   | Disclosure Title  | Pages            | Omission |
|--|---|------------------|----------|
| <b>Social, cont.</b>                           |   |                  |          |
| <b>GRI 416 Customer Health and Safety 2016</b> |   |                  |          |
| GRI 3-3  | Management of material topics   | 130-132, 158-159 |          |
| 416-1  | Assessment of the health and safety impacts of product and service categories                 | 158-159          |          |
| 416-2  | Incidents of non-compliance concerning the health and safety impacts of products and services | 158-159          |          |
| <b>GRI 417 Marketing and labeling 2016</b>     |   |                  |          |
| GRI 3-3  | Management of material topics   | 130-132, 158-159 |          |
| 417-1  | Requirements for product and service information and labeling                                 | 158-159          |          |
| 417-2  | Incidents of non-compliance concerning product and service information and labeling           | 158-159          |          |
| 417-3  | Incidents of non-compliance concerning marketing communications                               | 158-159          |          |
| <b>GRI 418 Customer privacy 2016</b>           |   |                  |          |
| GRI 3-3  | Management of material topics   | 130-132, 158-159 |          |
| 418-1  | Substantiated complaints concerning breaches of customer privacy and losses of customer data  | 158-159          |          |
| Own  | Regulatory compliance (audit findings/audit for quality systems)                              | 159              |          |
| Own  | Product quality (field actions per SEK billion in net revenue)                                | 159              |          |
| Own  | Customer Training   | 159              |          |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

Social responsibility

Governance

Reporting principles

**GRI content index**

Auditor’s Limited Assurance Report on Getinge AB (publ)’s Sustainability Report and statement on the Statutory Sustainability Report

**Other information**

| GRI Standard                          | Disclosure Title                           | Pages            | Omission   |
|---------------------------------------|--|------------------|--|
| <b>GRI Topic Specific Disclosures</b> |  |                  |  |
| <b>Environment</b>                    |  |                  |  |
| <b>GRI 302 Energy 2016</b>            |  |                  |  |
| GRI 3-3                               | Management of material topics              | 130-132, 138-141 |  |
| 302-1                                 | Energy consumption within the organization | 140-141, 162-163 |  |
| 302-3                                 | Energy intensity                           | 141              |  |
| 302-4                                 | Reduction of energy consumption            | 141, 162-163     |  |
| <b>GRI 305 Emissions 2016</b>         |  |                  |  |
| GRI 3-3                               | Management of material topics              | 130-132, 138-141 |  |
| 305-1                                 | Direct (Scope 1) GHG emissions             | 140, 162-163     | <b>The information is incomplete.</b> Getinge does not report on other ozone depleting substances or greenhouse gases (other than CO <sub>2</sub> e) or on biogenic carbon emissions.        |
| 305-2                                 | Indirect (Scope 2) GHG emissions           | 140, 162-163     | <b>The information is incomplete.</b> Due to incomplete data from suppliers, Getinge is not reporting its market-based GHG emissions in 2024, but strives to obtain such data in the future. |
| 305-3                                 | Other indirect (Scope 3) GHG emissions     | 140, 162-163     | <b>The information is incomplete.</b> Getinge reports on 3.1, 3.4 and 3.11. Detailed report on all scope 3 emissions is included in the Getinge Climate Disclosure report.                   |
| 305-4                                 | GHG emissions intensity                    | 140, 162-163     |  |
| 305-5                                 | Reduction of GHG emissions                 | 140, 162-163     |  |

| GRI Standard              | Disclosure Title  | Pages            | Omission   |
|---------------------------|---|------------------|--|
| <b>Environment, cont.</b> |   |                  |  |
| Own                       | Reduction of water consumption in sites with water scarcity | 143, 163         |  |
| <b>GRI 306 Waste 2020</b> |   |                  |  |
| GRI 3-3                   | Management of material topics                               | 130-132, 144-145 |  |
| 306-1                     | Waste generation and significant waste-related impacts      | 144-145          |  |
| 306-2                     | Management of significant waste-related impacts             | 144-145, 163     | <b>The information is incomplete.</b> GRI 306-2 b, c. Getinge does not consolidate data about this process.  |
| 306-3                     | Waste generated   | 144-145, 163     |  |
| 306-4                     | Waste diverted from disposal                                | 144-145, 163     | <b>The information is incomplete.</b> Getinge does not aggregate detailed data on local recycling schemes and treatments of waste at production sites on a global level, but complies with local legal environmental requirements in all countries of production.  |
| 306-5                     | Waste directed to disposal                                  | 144-145, 163     | <b>The information is incomplete.</b> GRI 306-5 a, b, c. Getinge reports incineration without energy recovery, landfilling and other disposal operations under the item not recycled. GRI 306-5 d. Getinge does not aggregate detailed data on local recycling schemes and treatments of waste at production sites on a global level, but complies with local legal environmental requirements in all countries of production. |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

Social responsibility

Governance

Reporting principles

GRI content index

**Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report**

**Other information**

# Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

To the annual general meeting of Getinge AB (publ), corporate identity number 556408-5032

**Introduction**

We have been engaged by the Board and Group Management of Getinge AB (publ) ("Getinge") to undertake a limited assurance of Getinge AB (publ)'s Sustainability Report for the year 2024. The company has defined the scope of its sustainability report on page 128. The statutory sustainability report is further defined on page 128.

**Responsibilities of the Board and Group Management**

The Board of Directors and Group Management are responsible for the preparation of the Sustainability Report, including the statutory sustainability report, in accordance with the applicable criteria and the Annual Accounts Act in the previous version that applied before 1 July 2024. The criteria are described on page 128 of the Sustainability Report and consists of the parts of the sustainability reporting framework issued by the GRI (Global Reporting Initiative) Sustainability Reporting Standards which are applicable to the Sustainability Report, as well as the accounting and calculation principles that the company has developed. This responsibility also includes the internal control which is deemed necessary to establish a sustainability report that does not contain material misstatement, whether due to fraud or error.

**Responsibilities of the auditor**

Our responsibility is to express a conclusion on the Sustainability Report based on the limited assurance procedures we have performed and to provide a statement on the statutory sustainability report. Our assignment is limited to the historical information that is presented and thus does not include future-oriented information.

We conducted our limited assurance engagement in accordance with ISAE 3000 (revised) *Assurance Engagements Other than Audits or Reviews of Historical Financial Information*. A limited assurance engagement consists of making inquiries, primarily of persons responsible for the preparation of the Sustainability Report and applying analytical and other limited assurance procedures. We have conducted our examination regarding the statutory sustainability report in accordance with FAR's recommendation RevR 12, *the Auditor's Opinion on the Statutory Sustainability Report*. A limited assurance engagement and an examination according to RevR 12 have a different focus and a considerably smaller scope compared to the focus and scope of an audit in accordance with International Standards on Auditing and generally accepted auditing standards in Sweden.

The audit firm applies ISQM 1 (International Standard on Quality Management), which requires the firm to design, implement and operate a system of quality management including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements. We are independent in relation to Getinge according to generally accepted auditing standards in Sweden and have fulfilled our professional ethics responsibility according to these requirements.

The procedures performed in a limited assurance engagement and an examination according to RevR 12 do not allow us to obtain such assurance that we become aware of all significant matters that could have been identified if an audit was performed. The conclusion based on a limited assurance engagement and an examination in accordance with RevR 12, therefore, does not provide the same level of assurance as a conclusion based on an audit has.

Our procedures are based on the criteria defined by the Board of Directors and the Group Management as described above. We consider these criteria as suitable for the preparation of the Sustainability Report.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our conclusion below.

**Conclusion**

Based on the limited assurance procedures we have performed, nothing has come to our attention that causes us to believe that the Sustainability Report is not prepared, in all material respects, in accordance with the criteria defined by the Board of Directors and Group Management.

A Statutory Sustainability Report has been prepared.

Gothenburg, March 27, 2025

Öhrlings PricewaterhouseCoopers AB

|                              |                              |
|------------------------------|------------------------------|
| Cecilia Andrén Dorselius     | Karin Olsson                 |
| Authorized Public Accountant | Authorized Public Accountant |
| Auditor in charge            |                              |

*This is a translation of the Swedish language original. In the event of any differences between this translation and the Swedish language original, the latter shall prevail.*

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

The Getinge share

Multi-year overview

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

# Other information

## Contents

|         |  |
|---------|--|
| 170–171 | The Getinge share                                  |
| 172–173 | Multi-year overview                                |
| 176–178 | Reconciliation of alternative performance measures |
| 179–181 | Group companies                                    |
| 182–183 | Definitions  |
| 184     | Annual General Meeting and Nomination Committee    |
| 184     | Financial information                              |
| 185     | Reading guide and distribution policy              |
| 185     | Contact  |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

**The Getinge share**

Multi-year overview

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

# The Getinge share

Getinge's Class B share has been listed on Nasdaq Stockholm since 1993. The share is included in the Nasdaq Nordic Large Cap segment and the OMXS30 index. On December 31, 2024, the number of shareholders was 59,381. The percentage of foreign-owned shares amounted to 30.1%. Institutional owners accounted for 62.9% of the share capital, of which Swedish institutional owners accounted for 37.7%.

### Share trend and liquidity

At year-end, Getinge's share was listed at SEK 181.55, which was a decrease by -19.1% (3.7) during the year. The highest price paid in 2024 was SEK 240.20 (April 29), the lowest was SEK 164.35 (November 21). At year-end, market capitalization amounted to SEK 49.4 billion. During the year, 211.9 million shares (203.3) were traded.

### Share capital

At year-end 2024, the share capital in Getinge totaled to SEK 136,184,786.50 distributed among 272,369,573 shares. All shares carry the same dividend entitlement. One Class A share carries ten votes and one Class B share carries one vote.

### Dividend policy

The Board of Directors of Getinge has adopted a dividend policy entailing that future dividends will be adjusted in line with Getinge's profit level, financial position and future development potential. The aim is for the dividend to correspond to 30–50% of net income. During the last five years, the dividend payout ratio has been an average of 46.9%, including the proposed dividend.

### Sell-side analysts covering Getinge

ABG Sundal Collier, Carnegie, DNB Markets, Equita, Handelsbanken, J.P. Morgan, Kepler Cheuvreux, Morgan Stanley, Morningstar, Nordea, Pareto Securities, Redburn and SEB Enskilda.

### Getinge's peers

Getinge's peers consist of the listed companies named in the section for each business area in this Annual Report.



Performance 2020–2024



Introduction

Strategy

Corporate Governance Report

Financial statements

Sustainability Report

Other information

The Getinge share

Multi-year overview

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

Development of share capital

| Transaction                                 | No. of shares after transaction | Share capital after transaction, SEK |
|---|---------------------------------|--------------------------------------|
| 1990 Formation                              | 500                             | 50,000                               |
| 1992 Split 50:1, par value SEK 100 to SEK 2 | 25,000                          | 50,000                               |
| 1992 Private placement                      | 5,088,400                       | 10,176,800                           |
| 1993 Private placement                      | 6,928,400                       | 13,856,800                           |
| 1995 Non-cash issue                         | 15,140,544                      | 30,281,088                           |
| 1996 Bonus issue 2:1                        | 45,421,632                      | 90,843,264                           |
| 2001 New issue 1:9 at SEK 100               | 50,468,480                      | 100,936,960                          |
| 2003 Split 4:1, par value SEK 2 to SEK 0.50 | 201,873,920                     | 100,936,960                          |
| 2008 New issue 1:16 at SEK 120              | 214,491,404                     | 107,245,520                          |
| 2009 New issue 1:9 at SEK 83.5              | 238,323,377                     | 119,161,689                          |
| 2017 New issue 1:7 at SEK 127               | 272,369,573                     | 136,184,787                          |

Ownership structure 2024

| Ägarfördelning efter innehav | Antal aktier       | % of capital   | % of votes     | Ownership     | Ownership (%)  |
|------------------------------|--------------------|----------------|----------------|---------------|----------------|
| 1 - 100                      | 1,087,307          | 0.40%          | 0.25%          | 32,098        | 54.05%         |
| 101 - 200                    | 1,159,683          | 0.43%          | 0.27%          | 7,633         | 12.85%         |
| 201 - 500                    | 2,955,648          | 1.09%          | 0.68%          | 8,766         | 14.76%         |
| 501 - 1 000                  | 3,663,731          | 1.35%          | 0.84%          | 4,952         | 8.34%          |
| 1 001 - 2 000                | 4,368,984          | 1.60%          | 1.00%          | 3,030         | 5.10%          |
| 2 001 - 5 000                | 5,677,916          | 2.08%          | 1.30%          | 1,797         | 3.03%          |
| 5 001 - 10 000               | 3,873,018          | 1.42%          | 0.89%          | 541           | 0.91%          |
| 10 001 - 20 000              | 3,472,650          | 1.27%          | 0.80%          | 247           | 0.42%          |
| 20 001 - 50 000              | 4,158,492          | 1.53%          | 0.95%          | 135           | 0.23%          |
| 50 001 - 100 000             | 3,927,489          | 1.44%          | 0.90%          | 53            | 0.09%          |
| 100 001 - 200 000            | 6,538,650          | 2.40%          | 1.50%          | 45            | 0.08%          |
| 200 001 - 500 000            | 10,335,753         | 3.79%          | 2.37%          | 34            | 0.06%          |
| 500 001 - 1 000 000          | 10,874,367         | 3.99%          | 2.49%          | 16            | 0.03%          |
| 1 000 001 - 2 000 000        | 18,558,122         | 6.81%          | 4.25%          | 14            | 0.02%          |
| 2 000 001 - 5 000 000        | 24,853,600         | 9.12%          | 5.70%          | 9             | 0.02%          |
| 5 000 001 - 10 000 000       | 55,412,264         | 20.34%         | 12.70%         | 7             | 0.01%          |
| 10 000 001 - 20 000 000      | 23,447,217         | 8.61%          | 5.37%          | 2             | 0.00%          |
| 20 000 001 -                 | 76,027,559         | 27.91%         | 55.00%         | 2             | 0.00%          |
| Anonymous ownership          | 11,977,123         | 4.40%          | 2.75%          | 0             | 0.00%          |
| <b>Total</b>                 | <b>272,369,573</b> | <b>100.00%</b> | <b>100.00%</b> | <b>59,381</b> | <b>100.00%</b> |

Getinge's largest shareholders on December 31, 2024

|                            | Class A shares    | Class B shares     | % of capital   | % of votes     |
|----------------------------|-------------------|--------------------|----------------|----------------|
| Carl Bennet AB             | 18,217,200        | 36,802,969         | 20.20%         | 50.19%         |
| Fjärde AP-fonden           |                   | 21,007,390         | 7.71%          | 4.81%          |
| AMF Pension & Fonder       |                   | 11,782,460         | 4.33%          | 2.70%          |
| Carnegie Fonder            |                   | 11,664,757         | 4.28%          | 2.67%          |
| Swedbank Robur Fonder      |                   | 9,659,015          | 3.55%          | 2.21%          |
| Vanguard                   |                   | 8,866,076          | 3.26%          | 2.03%          |
| Incentive AS               |                   | 8,830,666          | 3.24%          | 2.02%          |
| BlackRock                  |                   | 8,818,388          | 3.24%          | 2.02%          |
| Handelsbanken Fonder       |                   | 7,618,677          | 2.80%          | 1.75%          |
| Lannebo Kapitalförvaltning |                   | 6,053,120          | 2.22%          | 1.39%          |
| Other                      | 0                 | 123,048,855        | 45.18%         | 28.20%         |
| <b>Total</b>               | <b>18,217,200</b> | <b>25,4152,373</b> | <b>100.00%</b> | <b>100.00%</b> |


Share capital distribution

|               | Class A     | Class B     | Total       |
|---------------|-------------|-------------|-------------|
| No. of shares | 18,217,200  | 254,152,373 | 272,369,573 |
| No. of votes  | 182,172,000 | 254,152,373 | 436,324,373 |
| % of capital  | 7%          | 93%         | 100%        |
| % of votes    | 42%         | 58%         | 100%        |

Five largest countries – capital, %



Ownership by category – capital, %



Shareholder information

Financial information about Getinge is available on the company's website. Questions regarding this annual report and other financial communications can be directed to the investor relations function at the company, as indicated on the website.

Introduction

Strategy

Corporate Governance Report

Financial statements

Sustainability Report

Other information

The Getinge share

Multi-year overview

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

# Multi-year overview

## Group

| Amounts in SEK M unless otherwise stated             | 2024          | 2023          | 2022          | 2021          | 2020          |
|--|---------------|---------------|---------------|---------------|---------------|
| <b>Order situation</b>                               |               |               |               |               |               |
| Order intake   | 34,232        | 30,894        | 29,621        | 28,258        | 30,568        |
| Net sales  | 34,759        | 31,827        | 28,292        | 27,049        | 29,819        |
| <i>of which, international sales, %</i>              | 98.2          | 98.0          | 98.1          | 98.2          | 97.3          |
| EBITDA   | 5,275         | 5,829         | 5,653         | 6,185         | 7,251         |
| Adjusted EBITA                                       | 4,869         | 3,887         | 4,281         | 5,212         | 5,724         |
| Operating profit/loss (EBIT)                         | 2,854         | 3,736         | 3,626         | 4,371         | 4,784         |
| Net financial items                                  | -571          | -393          | -154          | -183          | -299          |
| Profit/loss after financial items                    | 2,282         | 3,343         | 3,472         | 4,188         | 4,485         |
| Taxes  | -628          | -915          | -956          | -1,187        | -1,213        |
| <b>Net profit/loss for the year</b>                  | <b>1,654</b>  | <b>2,428</b>  | <b>2,516</b>  | <b>3,000</b>  | <b>3,273</b>  |
| <b>Margin measures</b>                               |               |               |               |               |               |
| EBITDA margin, %                                     | 15.2          | 18.3          | 20.0          | 22.9          | 24.3          |
| Adjusted EBITA margin, %                             | 14.0          | 12.2          | 15.1          | 19.3          | 19.2          |
| Operating margin (EBIT), %                           | 8.2           | 11.7          | 12.8          | 16.2          | 16.0          |
| <b>Personnel</b>                                     |               |               |               |               |               |
| Number of employees, December 31                     | 11,791        | 11,739        | 11,082        | 10,729        | 10,818        |
| <b>Balance sheet</b>                                 |               |               |               |               |               |
| Intangible assets                                    | 39,242        | 30,670        | 27,010        | 24,148        | 22,085        |
| Tangible assets                                      | 3,902         | 3,723         | 3,532         | 3,060         | 2,956         |
| Right-of-use assets                                  | 1,795         | 1,486         | 1,336         | 1,060         | 1,017         |
| Financial assets                                     | 817           | 1,061         | 1,048         | 1,217         | 1,526         |
| Inventories  | 6,590         | 6,416         | 6,232         | 4,767         | 4,513         |
| Other receivables                                    | 8,610         | 7,503         | 7,198         | 6,227         | 6,862         |
| Cash and cash equivalents                            | 2,961         | 2,728         | 5,676         | 4,076         | 6,056         |
| <b>Total assets</b>                                  | <b>63,918</b> | <b>53,586</b> | <b>52,032</b> | <b>44,555</b> | <b>45,014</b> |
| Equity   | 33,210        | 30,403        | 30,453        | 25,176        | 21,486        |
| Provisions for pensions, interest-bearing            | 2,700         | 2,664         | 2,454         | 3,378         | 3,359         |
| Leasing liabilities                                  | 1,800         | 1,479         | 1,314         | 1,036         | 990           |
| Other interest-bearing liabilities                   | 12,207        | 6,597         | 4,510         | 3,270         | 9,216         |
| Other provisions <sup>1)</sup>                       | 4,502         | 3,245         | 4,539         | 3,782         | 3,077         |
| Other non-interest-bearing liabilities <sup>1)</sup> | 9,498         | 9,198         | 8,761         | 7,912         | 6,886         |
| <b>Total equity and liabilities</b>                  | <b>63,918</b> | <b>53,586</b> | <b>52,032</b> | <b>44,555</b> | <b>45,014</b> |

| Amounts in SEK M unless otherwise stated                      | 2024               | 2023   | 2022   | 2021   | 2020   |
|---|--------------------|--------|--------|--------|--------|
| Net debt, including pension liabilities                       | 10,467             | 8,012  | 2,602  | 3,609  | 7,509  |
| Net debt, excluding pension liabilities                       | 7,766              | 5,348  | 148    | 231    | 4,150  |
| <b>Cash flow</b>  |                    |        |        |        |        |
| Cash flow from operating activities                           | 4,577              | 2,957  | 3,367  | 6,560  | 7,199  |
| Cash flow per share, SEK                                      | 16.8               | 10.9   | 12.4   | 24.1   | 26.4   |
| Net investments in non-current assets                         | -1,294             | -1,334 | -1,106 | -614   | -993   |
| <b>Return indicators</b>                                      |                    |        |        |        |        |
| Return on operating capital, %                                | 11.1               | 10.2   | 13.0   | 17.3   | 16.3   |
| Return on equity, %   | 5.2                | 7.8    | 8.9    | 12.9   | 15.1   |
| <b>Financial indicators</b>                                   |                    |        |        |        |        |
| Equity/assets ratio, %  | 52.0               | 56.7   | 58.5   | 56.5   | 47.7   |
| Net debt/equity ratio, multiple                               | 0.32               | 0.26   | 0.09   | 0.14   | 0.35   |
| Operating capital, average                                    | 40,952             | 35,660 | 31,510 | 28,561 | 32,374 |
| Equity December 31  | 33,210             | 30,403 | 30,453 | 25,176 | 21,486 |
| <b>Data per share, amounts in SEK unless otherwise stated</b> |                    |        |        |        |        |
| Earnings per share  | 6.01               | 8.86   | 9.15   | 10.90  | 11.89  |
| Market price, December 31                                     | 181.55             | 224.30 | 216.30 | 395.10 | 192.10 |
| Dividend  | 4.60 <sup>2)</sup> | 4.40   | 4.25   | 4.00   | 3.00   |
| Dividend yield, %   | 2.53               | 1.96   | 1.96   | 1.01   | 1.56   |
| Price/earnings ratio  | 30.19              | 25.32  | 23.64  | 36.25  | 16.16  |
| Dividend as profit percentage, %                              | 76.50              | 49.68  | 46.45  | 36.70  | 25.23  |
| Equity per share, SEK   | 121.93             | 111.63 | 111.81 | 92.43  | 78.88  |
| Average number of shares (million)                            | 272.4              | 272.4  | 272.4  | 272.4  | 272.4  |
| Number of shares December 31 (million)                        | 272.4              | 272.4  | 272.4  | 272.4  | 272.4  |

1) As from 2024, contingent considerations have been reclassified from Other provisions to Other non-interest-bearing liabilities. Previous years have been restated.

2) Dividend proposed by the Board of Directors.

Introduction

Strategy

Corporate Governance Report

Financial statements

Sustainability Report

Other information

The Getinge share

Multi-year overview

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

## Business areas

| ACUTE CARE THERAPIES, SEK M  | 2024          | 2023          | 2022          | 2021          | 2020          |
|--|---------------|---------------|---------------|---------------|---------------|
| <b>Order intake</b>  | <b>17,719</b> | <b>16,375</b> | <b>16,108</b> | <b>15,335</b> | <b>19,208</b> |
| <b>Net sales</b>   | <b>17,948</b> | <b>16,529</b> | <b>15,285</b> | <b>15,527</b> | <b>18,719</b> |
| <b>Adjusted gross profit</b>   | <b>10,417</b> | <b>9,660</b>  | <b>9,174</b>  | <b>9,596</b>  | <b>11,536</b> |
| <i>Margin, %</i>   | <i>58.0</i>   | <i>58.4</i>   | <i>60.0</i>   | <i>61.8</i>   | <i>61.6</i>   |
| <b>Adjusted EBITDA</b>   | <b>4,474</b>  | <b>4,023</b>  | <b>4,274</b>  | <b>5,272</b>  | <b>6,833</b>  |
| <i>Margin, %</i>   | <i>24.9</i>   | <i>24.3</i>   | <i>28.0</i>   | <i>34.0</i>   | <i>36.5</i>   |
| Depreciation, amortization and write-downs of tangible and intangible assets | -920          | -905          | -872          | -828          | -1,002        |
| <b>Adjusted EBITA</b>  | <b>3,554</b>  | <b>3,117</b>  | <b>3,402</b>  | <b>4,444</b>  | <b>5,831</b>  |
| <i>Margin, %</i>   | <i>19.8</i>   | <i>18.9</i>   | <i>22.3</i>   | <i>28.6</i>   | <i>31.1</i>   |
| <b>LIFE SCIENCE, SEK M</b>   | <b>2024</b>   | <b>2023</b>   | <b>2022</b>   | <b>2021</b>   | <b>2020</b>   |
| <b>Order intake</b>  | <b>4,601</b>  | <b>4,148</b>  | <b>3,932</b>  | <b>4,120</b>  | <b>3,413</b>  |
| <b>Net sales</b>   | <b>4,552</b>  | <b>4,325</b>  | <b>4,026</b>  | <b>3,558</b>  | <b>2,854</b>  |
| <b>Adjusted gross profit</b>   | <b>1,808</b>  | <b>1,527</b>  | <b>1,548</b>  | <b>1,492</b>  | <b>1,176</b>  |
| <i>Margin, %</i>   | <i>39.7</i>   | <i>35.3</i>   | <i>38.5</i>   | <i>41.9</i>   | <i>41.2</i>   |
| <b>Adjusted EBITDA</b>   | <b>818</b>    | <b>620</b>    | <b>801</b>    | <b>870</b>    | <b>522</b>    |
| <i>Margin, %</i>   | <i>18.0</i>   | <i>14.3</i>   | <i>19.9</i>   | <i>24.5</i>   | <i>18.3</i>   |
| Depreciation, amortization and write-downs of tangible and intangible assets | -211          | -190          | -151          | -141          | -128          |
| <b>Adjusted EBITA</b>  | <b>608</b>    | <b>430</b>    | <b>650</b>    | <b>729</b>    | <b>393</b>    |
| <i>Margin, %</i>   | <i>13.4</i>   | <i>9.9</i>    | <i>16.1</i>   | <i>20.5</i>   | <i>13.8</i>   |
| <b>SURGICAL WORKFLOWS, SEK M</b>   | <b>2024</b>   | <b>2023</b>   | <b>2022</b>   | <b>2021</b>   | <b>2020</b>   |
| <b>Order intake</b>  | <b>11,912</b> | <b>10,371</b> | <b>9,581</b>  | <b>8,803</b>  | <b>7,948</b>  |
| <b>Net sales</b>   | <b>12,258</b> | <b>10,974</b> | <b>8,981</b>  | <b>7,965</b>  | <b>8,246</b>  |
| <b>Adjusted gross profit</b>   | <b>5,185</b>  | <b>4,346</b>  | <b>3,639</b>  | <b>3,304</b>  | <b>3,163</b>  |
| <i>Margin, %</i>   | <i>42.3</i>   | <i>39.6</i>   | <i>40.5</i>   | <i>41.5</i>   | <i>38.4</i>   |
| <b>Adjusted EBITDA</b>   | <b>1,728</b>  | <b>1,304</b>  | <b>1,127</b>  | <b>949</b>    | <b>495</b>    |
| <i>Margin, %</i>   | <i>14.1</i>   | <i>11.9</i>   | <i>12.5</i>   | <i>11.9</i>   | <i>6.0</i>    |
| Depreciation, amortization and write-downs of tangible and intangible assets | -638          | -583          | -577          | -559          | -622          |
| <b>Adjusted EBITA</b>  | <b>1,090</b>  | <b>721</b>    | <b>549</b>    | <b>390</b>    | <b>-127</b>   |
| <i>Margin, %</i>   | <i>8.9</i>    | <i>6.6</i>    | <i>6.1</i>    | <i>4.9</i>    | <i>-1.5</i>   |

## The group's 20 largest markets

| Net sales      | 2024   |       | 2023   |       | 2022   |       |
|----------------|--------|-------|--------|-------|--------|-------|
|                | SEK M  | %     | SEK M  | %     | SEK M  | %     |
| US             | 13,929 | 40.1% | 11,697 | 36.8% | 10,143 | 35.9% |
| China          | 2,844  | 8.2%  | 2,836  | 8.9%  | 2,610  | 9.2%  |
| Germany        | 1,904  | 5.5%  | 1,859  | 5.8%  | 1,631  | 5.8%  |
| France         | 1,611  | 4.6%  | 1,483  | 4.7%  | 1,251  | 4.4%  |
| Japan          | 1,207  | 3.5%  | 1,241  | 3.9%  | 1,254  | 4.4%  |
| United Kingdom | 1,177  | 3.4%  | 1,100  | 3.5%  | 949    | 3.4%  |
| Italy          | 1,041  | 3.0%  | 980    | 3.1%  | 849    | 3.0%  |
| Spain          | 771    | 2.2%  | 738    | 2.3%  | 649    | 2.3%  |
| Canada         | 770    | 2.2%  | 731    | 2.3%  | 606    | 2.1%  |
| Australia      | 715    | 2.1%  | 643    | 2.0%  | 582    | 2.1%  |
| Sweden         | 617    | 1.8%  | 632    | 2.0%  | 549    | 1.9%  |
| India          | 561    | 1.6%  | 491    | 1.5%  | 534    | 1.9%  |
| Netherlands    | 544    | 1.6%  | 518    | 1.6%  | 496    | 1.8%  |
| Switzerland    | 440    | 1.3%  | 423    | 1.3%  | 284    | 1.0%  |
| Denmark        | 400    | 1.2%  | 345    | 1.1%  | 265    | 0.9%  |
| Brazil         | 395    | 1.1%  | 305    | 1.0%  | 274    | 1.0%  |
| Belgium        | 363    | 1.0%  | 342    | 1.1%  | 296    | 1.0%  |
| Hong Kong      | 346    | 1.0%  | 377    | 1.2%  | 354    | 1.2%  |
| Austria        | 302    | 0.9%  | 283    | 0.9%  | 228    | 0.8%  |
| Saudi Arabia   | 286    | 0.8%  | 182    | 0.6%  | 175    | 0.6%  |

Introduction

Strategy

Corporate Governance Report

Financial statements

Sustainability Report

Other information

The Getinge share

Multi-year overview

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and

Nomination Committee

Financial information

Reading guide and distribution policy

Contact

# The ten largest markets by business area

|                             | 2024  |       |    | 2023  |       |    | 2022  |       |    |
|-----------------------------|-------|-------|----|-------|-------|----|-------|-------|----|
|                             | SEK M | %     | #  | SEK M | %     | #  | SEK M | %     | #  |
| <b>ACUTE CARE THERAPIES</b> |       |       |    |       |       |    |       |       |    |
| US                          | 8,377 | 46.7% | 1  | 7,517 | 45.5% | 1  | 6,846 | 44.8% | 1  |
| China                       | 2,040 | 11.4% | 2  | 1,830 | 11.1% | 2  | 1,592 | 10.4% | 2  |
| Germany                     | 848   | 4.7%  | 3  | 797   | 4.8%  | 3  | 720   | 4.7%  | 3  |
| Japan                       | 541   | 3.0%  | 4  | 578   | 3.5%  | 4  | 628   | 4.1%  | 4  |
| Italy                       | 525   | 2.9%  | 5  | 534   | 3.2%  | 5  | 485   | 3.2%  | 5  |
| France                      | 485   | 2.7%  | 6  | 467   | 2.8%  | 6  | 422   | 2.8%  | 6  |
| Canada                      | 454   | 2.5%  | 7  | 421   | 2.5%  | 7  | 373   | 2.4%  | 7  |
| Spain                       | 396   | 2.2%  | 8  | 393   | 2.4%  | 8  | 350   | 2.3%  | 8  |
| India                       | 372   | 2.1%  | 9  | 314   | 1.9%  | 10 | 344   | 2.2%  | 9  |
| United Kingdom              | 364   | 2.0%  | 10 | 317   | 1.9%  | 9  | 314   | 2.1%  | 10 |
|                             |       |       |    |       |       |    |       |       |    |
|                             |       |       |    |       |       |    |       |       |    |
| <b>LIFE SCIENCE</b>         |       |       |    |       |       |    |       |       |    |
| US                          | 1,738 | 38.2% | 1  | 1,470 | 34.0% | 1  | 1,343 | 33.4% | 1  |
| France                      | 517   | 11.3% | 2  | 455   | 10.5% | 2  | 379   | 9.4%  | 3  |
| Germany                     | 290   | 6.4%  | 3  | 291   | 6.7%  | 4  | 316   | 7.8%  | 4  |
| United Kingdom              | 275   | 6.0%  | 4  | 219   | 5.1%  | 5  | 203   | 5.0%  | 5  |
| China                       | 210   | 4.6%  | 5  | 408   | 9.4%  | 3  | 433   | 10.8% | 2  |
| Denmark                     | 172   | 3.8%  | 6  | 121   | 2.8%  | 9  | 69    | 1.7%  | 11 |
| Ireland                     | 132   | 2.9%  | 7  | 151   | 3.5%  | 6  | 105   | 2.6%  | 8  |
| Belgium                     | 129   | 2.8%  | 8  | 125   | 2.9%  | 8  | 108   | 2.7%  | 7  |
| Italy                       | 115   | 2.5%  | 9  | 96    | 2.2%  | 11 | 67    | 1.7%  | 12 |
| Japan                       | 114   | 2.5%  | 10 | 94    | 2.2%  | 12 | 103   | 2.6%  | 9  |
|                             |       |       |    |       |       |    |       |       |    |
|                             |       |       |    |       |       |    |       |       |    |
| <b>SURGICAL WORKFLOWS</b>   |       |       |    |       |       |    |       |       |    |
| US                          | 3,813 | 31.1% | 1  | 2,710 | 24.7% | 1  | 1,954 | 21.8% | 1  |
| Germany                     | 765   | 6.2%  | 2  | 771   | 7.0%  | 2  | 595   | 6.6%  | 2  |
| France                      | 609   | 5.0%  | 3  | 561   | 5.1%  | 6  | 450   | 5.0%  | 5  |
| China                       | 594   | 4.8%  | 4  | 599   | 5.5%  | 3  | 585   | 6.5%  | 3  |
| Japan                       | 552   | 4.5%  | 5  | 569   | 5.2%  | 4  | 524   | 5.8%  | 4  |
| United Kingdom              | 538   | 4.4%  | 6  | 563   | 5.1%  | 5  | 432   | 4.8%  | 6  |
| Australia                   | 456   | 3.7%  | 7  | 388   | 3.5%  | 8  | 339   | 3.8%  | 8  |
| Sweden                      | 414   | 3.4%  | 8  | 429   | 3.9%  | 7  | 363   | 4.0%  | 7  |
| Italy                       | 401   | 3.3%  | 9  | 350   | 3.2%  | 9  | 296   | 3.3%  | 9  |
| Spain                       | 351   | 2.9%  | 10 | 325   | 3.0%  | 10 | 253   | 2.8%  | 10 |

Introduction

Strategy

Corporate Governance Report

Financial statements

Sustainability Report

Other information

The Getinge share

Multi-year overview

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

# Acquisition history

| Year | Company   | Business   | Country | Sales       | Year | Company  | Business   | Country | Sales       |
|------|---|--|---------|-------------|------|--|--|---------|-------------|
| 2024 | Paragonix Technologies, Inc   | Organ transport products and services  | US      | SEK 826 M   | 2008 | Boston Scientific's Cardiac and Vascular surgery divisions | Endoscopic vessel harvesting (EVH), anastomosis, stabilizers and instruments for surgery on beating hearts and vascular implants   | US      | SEK 1,733 M |
| 2024 | Technology and intellectual property rights from Intact Solutions LLC | Technology aseptic processing, bioprocessing   | US      | -           | 2007 | NS Nielsen Equipment A/S                                   | Distributor  | DK      | -           |
| 2023 | Healthmark Industries Co. Inc.  | Provider of innovative instrument care and infection control consumables   | US      | SEK 1,321 M | 2006 | Huntleigh Technology                                       | Special mattresses for pressure-ulcer treatment, beds for intensive, specialist and elderly care vein thrombosis prophylaxis and equipment for fetal and vascular diagnostics. | UK      | SEK 2,675 M |
| 2023 | High Purity New England Inc.  | Company in the areas of custom single-use solutions for bioprocessing applications   | US      | SEK 389 M   | 2006 | Comercio E Industria Medicia OTY GmbH                      | Consumables for open-heart surgery<br>Telemedicine specializing in products and solutions for hospitals' IT infrastructure focused on the operating room.                      | BR      | SEK 25 M    |
| 2023 | Ultra Clean Systems Inc.  | Manufacturer of ultrasonic cleaning technologies used in hospitals and surgery centers to decontaminate surgical instruments | US      | SEK 90 M    | 2006 | Getinge Czech Republic                                     | Distributor  | DE      | SEK 20 M    |
| 2022 | Fluooptics SAS  | Leader in fluorescence imaging   | FR      | SEK 45 M    | 2006 | Lancer UK  | Distributor  | CZ      | SEK 10 M    |
| 2022 | Irasun GmbH   | Develops products for venous drainage and temperature control  | DE      | -           | 2005 | La Cahléne   | Isolator technology and electron sterilization technology  | UK      | SEK 104 M   |
| 2021 | Talis Clinical LLC  | High Acuity cloud-based software solutions   | US      | SEK 57 M    | 2005 | Dynamed  | Distributor  | FR      | EUR 40 M    |
| 2021 | Development assets from Verrix  | Biological indicators  | US      | -           | 2004 | BHM Medical Inc.   | Patient management products for the care and elderly care segments   | CA      | SEK 206 M   |
| 2020 | Applikon Biotechnology BV   | Life Science bioreactor system   | NL      | SEK 350 M   | 2004 | MAQUET AG  | Distributor  | CH      | CHF 4.9 M   |
| 2020 | Quadralene Holdings Ltd   | Disinfection   | GB      | SEK 75 M    | 2003 | Siemens LSS  | Ventilators and anesthesia equipment for the hospital market   | SE      | EUR 230 M   |
| 2017 | Carus HMS GmbH  | Integrated workflow solutions  | DE      | SEK 20 M    | 2003 | Jostra GmbH  | Equipment and consumables for cardiac surgery  | DE      | EUR 90 M    |
| 2017 | Simm Company and Surgeon Aids   | Distributor  | TH      | SEK 75 M    | 2003 | Copharm B.V.   | Distributor  | NL      | EUR 10 M    |
| 2016 | AccuMed   | Production facility for medical textiles   | DR      | SEK 100 M   | 2002 | Heraeus Medical  | Surgical lamps, ceiling service units and therapy accessories and gas distribution for operating rooms   | DE      | EUR 52 M    |
| 2016 | 1st Call Mobility Ltd   | Medical-device solutions for bariatric patients  | GB      | SEK 100 M   | 2001 | ALM  | Surgical lamps   | FR      | FRF 490 M   |
| 2015 | GOA Teknoloji Danismanlik Elektronik                                  | Low temperature sterilization technology   | TR      | SEK 20 M    | 2000 | Maquet   | Surgical tables  | DE      | EUR 155 M   |
| 2014 | Pulsion AG  | Systems for hemodynamic monitoring   | DE      | SEK 300 M   | 2000 | Parker Bath  | Bathing systems for the semi-institutional care market   | UK      | SEK 150 M   |
| 2014 | Altrax Group Ltd  | Systems for traceability and quality assurance for sterilization   | GB      | SEK 35 M    | 2000 | Lenken Healthcare  | Distributor  | IE      | SEK 65 M    |
| 2014 | Cetrea A/S  | Systems for resource planning  | DK      | SEK 30 M    | 2000 | Gestion Techno-Medic                                       | Patient lifting systems  | CA      | SEK 22 M    |
| 2014 | Austmel Pty Ltd   | Sterilization and thermal processes  | AU      | SEK 80 M    | 1999 | Lunatronics Aps  | Comprehensive IT solutions for the maintenance of sterilization departments  | DK      | DKK 15 M    |
| 2013 | LAAX Inc.   | Cardiac and vascular surgery   | US      | SEK 8 M     | 1999 | MPT Corp.  | Washer disinfectors for the life science market  | US      | SEK 35 M    |
| 2013 | Trans Medikal Devices Inc.  | Manufacture of sterilizers and distribution of disinfectors  | TR      | SEK 55 M    | 1998 | Egerton Hospital Equipment                                 | Specialist beds and anti-decubitus mattresses for hospitals and care facilities  | UK      | SEK 45 M    |
| 2013 | STS East LLC  | Service  | US      | SEK 25 M    | 1998 | Royal Linden B.V.  | Infection control  | NL      | SEK 60 M    |
| 2012 | Product rights from Avalon Laboratories                               | Cardiopulmonary  | US      | -           | 1998 | Medibo   | Patient lifting and pressure-ulcer treatments  | BE      | SEK 28 M    |
| 2012 | Eirus Medical   | Critical Care  | SE      | -           | 1998 | OMASA  | Infection control  | IT      | SEK 100 M   |
| 2012 | Acare Medical Science Ltd   | Healthcare beds  | CH      | SEK 135 M   | 1998 | SMI/BBC  | Infection control  | FR      | SEK 75 M    |
| 2012 | USCI  | Distributor  | JP      | SEK 150 M   | 1998 | Kemitem  | Water distillers pure-steam generators for pharmaceutical industry   | DK      | DKK 25 M    |
| 2012 | Tecno Hospitalia  | Distributor  | CO      | SEK 4 M     | 1998 | Pegasus  | Anti-decubitus products for hospitals and elderly care   | UK      | SEK 350 M   |
| 2012 | Therapeutic Support Systems (TSS)                                     | Wound care   | US      | SEK 1,600 M | 1996 | MDT/Castle   | Infection control  | US      | -           |
| 2012 | Steritec Products Mfg Inc.  | Consumables  | US      | SEK 70 M    | 1996 | Van Dijk Medizintechnik GmbH                               | Infection control  | DE      | SEK 30 M    |
| 2011 | Blanchet Medical Service  | Service  | FR      | SEK 3 M     | 1995 | Arjo   | Products for aging care related to hygiene and patient management  | SE      | SEK 1,538 M |
| 2011 | Atrium Medical Inc  | Products for the cardiovascular market   | US      | USD 200 M   | 1994 | Lancer   | Disinfection products  | FR      | FRF 70 M    |
| 2011 | Combimobil AB   | Rehabilitation aids  | SE      | SEK 2 M     |      |  |  |         |             |
| 2011 | Fumedica  | Distributor  | CH      | SEK 70 M    |      |  |  |         |             |
| 2011 | IDS Medical Equipment   | Distributor  | SG      | SEK 25 M    |      |  |  |         |             |
| 2011 | Mak Saglik  | Distributor  | TR      | SEK 20 M    |      |  |  |         |             |
| 2011 | STS Holding West  | Service  | US      | SEK 20 M    |      |  |  |         |             |
| 2010 | Odelga  | Service  | AT      | SEK 25 M    |      |  |  |         |             |
| 2008 | Datascope   | Cardiac assist and vascular surgery  | US      | USD 231 M   |      |  |  |         |             |
| 2008 | Cardio Research Pty Ltd.  | Distributor  | AU      | AUD 5.1 M   |      |  |  |         |             |
| 2008 | Subtil Crepieux   | Service  | FR      | EUR 8 M     |      |  |  |         |             |
| 2008 | Getus Services Ltd  | Service  | NZ      | NZD 1.1 M   |      |  |  |         |             |
| 2008 | Olmed AB  | Distributor  | SE      | SEK 70 M    |      |  |  |         |             |

Introduction

Strategy

Corporate Governance Report

Financial statements

Sustainability Report

Other information

The Getinge share

Multi-year overview

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

# Reconciliation of alternative performance measures

Alternative performance measures refer to financial measures used by the company's management and investors to evaluate the group's earnings and financial position and that cannot be directly read or derived from the financial statements. These financial measures are intended to facilitate analysis of the group's performance. The alternative performance measures are not to be considered a substitute for, but rather a supplement to, the financial statements prepared in accordance with IFRS.

The alternative performance measures recognized are not calculated in accordance with IFRS but are provided since Getinge believes that they are important to investors' assessments of the group and the Getinge share. These performance measures are widely used by investors, securities analysts and other stakeholders as supplementary measures of the earnings trend and financial position. Getinge's performance measures that are not defined in accordance with IFRS are not necessary comparable with similar measures presented by other companies and have certain limitations as analysis tools.

## THE GROUP'S PRIMARY PERFORMANCE MEASURES

| Adjusted gross profit, SEK M   | 2024          | 2023          |
|--|---------------|---------------|
| <b>Gross profit</b>  | <b>16,153</b> | <b>14,495</b> |
| <i>Add-back of:</i>  |               |               |
| Depreciation, amortization and write-downs of tangible and non-acquired intangible assets          | 960           | 1,029         |
| Other items affecting comparability  | 297           | 154           |
| Adjustment for write-downs included in other items affecting comparability                         | –             | -146          |
| <b>Adjusted gross profit</b>   | <b>17,409</b> | <b>15,533</b> |
| <b>Adjusted EBITDA, SEK M</b>  | <b>2024</b>   | <b>2023</b>   |
| <b>Operating profit/loss (EBIT)</b>  | <b>2,854</b>  | <b>3,736</b>  |
| <i>Add-back of:</i>  |               |               |
| Depreciation, amortization and write-downs of tangible and non-acquired intangible assets          | 1,823         | 1,859         |
| Amortization and write-down of acquired intangible assets  | 320           | 234           |
| Other items affecting comparability  | 797           | -325          |
| Acquisition and restructuring costs  | 898           | 242           |
| Adjustment for write-downs included in other items affecting comparability and restructuring costs | -46           | -172          |
| <b>Adjusted EBITDA</b>   | <b>6,646</b>  | <b>5,574</b>  |
| <b>EBITA, SEK M</b>  | <b>2024</b>   | <b>2023</b>   |
| <b>Operating profit/loss (EBIT)</b>  | <b>2,854</b>  | <b>3,736</b>  |
| <i>Add-back of:</i>  |               |               |
| Amortization and write-down of acquired intangible assets  | 320           | 234           |
| <b>EBITA</b>   | <b>3,174</b>  | <b>3,970</b>  |
| <b>Adjusted EBITA, SEK M</b>   | <b>2024</b>   | <b>2023</b>   |
| <b>Operating profit/loss (EBIT)</b>  | <b>2,854</b>  | <b>3,736</b>  |
| <i>Add-back of:</i>  |               |               |
| Amortization and write-down of acquired intangible assets  | 320           | 234           |
| Other items affecting comparability  | 797           | -325          |
| Acquisition and restructuring costs  | 898           | 242           |
| <b>Adjusted EBITA</b>  | <b>4,869</b>  | <b>3,887</b>  |
| <b>Adjusted EBIT, SEK M</b>  | <b>2024</b>   | <b>2023</b>   |
| <b>Operating profit/loss (EBIT)</b>  | <b>2,854</b>  | <b>3,736</b>  |
| <i>Add-back of:</i>  |               |               |
| Other items affecting comparability  | 797           | -325          |
| Acquisition and restructuring costs  | 898           | 242           |
| <b>Adjusted EBIT</b>   | <b>4,549</b>  | <b>3,653</b>  |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

The Getinge share

Multi-year overview

**Reconciliation of alternative performance measures**

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

| <b>Adjusted net profit for the year, SEK M</b>  | <b>2024</b>  | <b>2023</b>  |
|---|--------------|--------------|
| <b>Net profit for the year</b>  | <b>1,654</b> | <b>2,428</b> |
| <i>Add-back of:</i>   |              |              |
| Amortization and write-down of acquired intangible assets   | 320          | 234          |
| Other items affecting comparability   | 797          | -325         |
| Acquisition and restructuring costs   | 898          | 242          |
| Tax items affecting comparability   | -            | -            |
| Tax on add-back items   | -459         | -60          |
| <b>Adjusted net profit for the year</b>   | <b>3,211</b> | <b>2,519</b> |
| <br>  |              |              |
| <b>The calculation of adjusted earnings per share, before and after dilution, attributable to the Parent Company's shareholders, is based on the following information:</b> |              |              |
| <br>  |              |              |
| <b>Earnings (numerator), SEK M</b>  | <b>2024</b>  | <b>2023</b>  |
| <b>Adjusted net profit for the year</b>   | <b>3,211</b> | <b>2,519</b> |
| Adjusted net profit for the year attributable to non-controlling interest   | -16          | -16          |
| <b>Adjusted net profit for the year attributable to the Parent Company shareholders, which form the basis for calculation of adjusted earnings per share</b>                | <b>3,195</b> | <b>2,503</b> |
| <br>  |              |              |
| <b>Number of shares (denominator)</b>   |              |              |
| Weighted average number of ordinary shares for calculation of adjusted earnings per share (thousands)   | 272,370      | 272,370      |
| <b>Adjusted earnings per share, SEK</b>   | <b>11.73</b> | <b>9.19</b>  |
| <br>  |              |              |
| <b>Net debt/equity ratio, multiple</b>  | <b>2024</b>  | <b>2023</b>  |
| Net interest-bearing debt, SEK M  | 10,467       | 8,012        |
| Equity, SEK M   | 33,210       | 30,403       |
| <b>Net debt/equity ratio<sup>1)</sup></b>   | <b>0.32</b>  | <b>0.26</b>  |

1) Net interest-bearing debt in relation to equity.

**Introduction**
**Strategy**
**Corporate Governance Report**
**Financial statements**
**Sustainability Report**
**Other information**

The Getinge share

Multi-year overview

**Reconciliation of alternative performance measures**

Group companies

Definitions

 Annual General Meeting and  
Nomination Committee

Financial information

Reading guide and distribution policy

Contact

**ADJUSTED EBITA PER SEGMENT**

|   | Acute Care Therapies | Life Science | Surgical Workflows | Group functions and other | Total        |
|---|----------------------|--------------|--------------------|---------------------------|--------------|
| <b>Adjusted EBITA, 2024, SEK M</b>                        |                      |              |                    |                           |              |
| <b>Operating profit (EBIT)</b>                            | <b>2,065</b>         | <b>526</b>   | <b>703</b>         | <b>-440</b>               | <b>2,854</b> |
| <i>Add back of:</i>                                       |                      |              |                    |                           |              |
| Amortization and write-down of acquired intangible assets | 170                  | 46           | 104                | –                         | 320          |
| Other items affecting comparability                       | 604                  | –            | 193                | –                         | 797          |
| Acquisition and restructuring costs                       | 715                  | 35           | 91                 | 57                        | 898          |
| <b>Adjusted EBITA</b>                                     | <b>3,554</b>         | <b>608</b>   | <b>1,090</b>       | <b>-383</b>               | <b>4,869</b> |

|   | Acute Care Therapies | Life Science | Surgical Workflows | Group functions and other | Total        |
|---|----------------------|--------------|--------------------|---------------------------|--------------|
| <b>Adjusted EBITA, 2023, SEK M</b>                        |                      |              |                    |                           |              |
| <b>Operating profit (EBIT)</b>                            | <b>3,215</b>         | <b>395</b>   | <b>675</b>         | <b>-549</b>               | <b>3,736</b> |
| <i>Add back of:</i>                                       |                      |              |                    |                           |              |
| Amortization and write-down of acquired intangible assets | 145                  | 32           | 56                 | –                         | 234          |
| Other items affecting comparability                       | -279                 | –            | -46                | –                         | -325         |
| Acquisition and restructuring costs                       | 36                   | 3            | 35                 | 167                       | 242          |
| <b>Adjusted EBITA</b>                                     | <b>3,117</b>         | <b>430</b>   | <b>721</b>         | <b>-381</b>               | <b>3,887</b> |

|   | Acute Care Therapies | Life Science | Surgical Workflows | Group functions and other | Total      |
|---|----------------------|--------------|--------------------|---------------------------|------------|
| <b>Other items affecting comparability, 2024, SEK M</b>               |                      |              |                    |                           |            |
| Provision for investigations with CGU in Brazil, Acute Care Therapies | 289                  | –            | –                  | –                         | 289        |
| Provision for investigations with CGU in Brazil, Surgical Workflows   | –                    | –            | 193                | –                         | 193        |
| Provision for field actions for Cardiosave, Acute Care Therapies      | 297                  | –            | –                  | –                         | 297        |
| Other   | 18                   | –            | –                  | –                         | 18         |
| <b>Total</b>  | <b>604</b>           | <b>–</b>     | <b>193</b>         | <b>–</b>                  | <b>797</b> |

|   | Acute Care Therapies | Life Science | Surgical Workflows | Group functions and other | Total       |
|---|----------------------|--------------|--------------------|---------------------------|-------------|
| <b>Other items affecting comparability, 2023, SEK M</b> |                      |              |                    |                           |             |
| Write down of R&D                                       | 146                  | –            | –                  | –                         | 146         |
| Insurance compensation                                  | -450                 | –            | –                  | –                         | -450        |
| Dissolution of provision for contingent consideration   | –                    | –            | -46                | –                         | -46         |
| Other   | 25                   | –            | –                  | –                         | 25          |
| <b>Total</b>  | <b>-279</b>          | <b>–</b>     | <b>-46</b>         | <b>–</b>                  | <b>-325</b> |

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

The Getinge share

Multi-year overview

Reconciliation of alternative performance measures

**Group companies**

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

# Group companies

**HEAD OFFICE**

**Getinge AB (publ)**

Lindholmspiren 7A  
SE-417 56 Göteborg  
Tel: +46 10 335 0000  
President: Mattias Perjos

**Australia**

**Getinge Australia Pty Ltd**

Suite 701, Level 7, 11 Help St  
AU-Chatswood, NSW 2067  
Tel: +61 18 0043 8464  
President: Kartik Natarajan

**Austria**

**Getinge Österreich GmbH**

Lemböckgasse 49 Haus 2,  
Stiege D, EG  
AT-1230 Wien  
Tel: +43 1 8651 4870  
President: Raghed Hanna

**Belgium**

**Getinge Belgium NV**

Alfons Gossetlaan 17  
BE-1702 Groot-Bijgaarden  
Tel: +32 24 67 8585  
President: Raghed Hanna

**Brazil**

**Getinge do Brasil**

**Equipamentos Médicos Ltda**  
Avenida Manuel Bandeira, 291 –  
Bloco B – Conjunto 33 e 34  
BR-05317-020 São Paulo  
Tel: +55 11 2608 7400  
President: Aurélio Carmona

**Canada**

**Getinge Canada Ltd**

90 Matheson Blvd. W, Suite 300  
CA-L5R 3R3, Mississauga, ON  
Tel: +1 905 752 3300  
President: Dave Blair

**China**

**Maquet (Shanghai) Medical Equipment Co., Ltd**

20F, Building 1, 188 Ruby Road,  
Changning District  
CN-201 103 Shanghai  
Tel: +86 21 6197 3999  
President: Echo Mao

**Maquet (Suzhou) Co., Ltd**

No 158 Fangzhou Road, SIP  
CN-215 024 Suzhou  
Tel: +86 512 6283 9880  
President: Shukun Liu

**Colombia**

**Getinge Colombia SAS**

Carrera 16 # 95 70  
CO-110221 Bogotá, D.C.  
Tel: +571 743 8124  
President: Rodrigo Aurelio Garcia

**Czech Republic**

**Getinge Czech Republic, s.r.o.**

Na Strži 1702/65  
CZ-140 00 Praha 4-Nusle  
Tel: +420 225 092 302  
President: Jiri Lacina

**Denmark**

**Getinge Cetrea A/S**

Brendstrupgårdsvej 21 F  
DK-8200 Aarhus N  
Tel: +45 26 397 990  
President: Charlotte Enlund

**Getinge IT Solutions ApS**

Dampfærgevej 21, 2.  
DK- 2100 Copenhagen  
Tel: +45 33 338 855  
President: Charlotte Enlund

**Getinge Danmark A/S**

Tonsbakken 16-18,  
DK-2740 Skovlunde  
Tel: +45 45 932 727  
President: Magnus Back

**Finland**

**Getinge Finland Oy**

Vuoritontuntie 22  
FI-02200 Espoo  
Tel: +35 896 824 120  
President: Magnus Back

**France**

**Getinge France SAS**

Carnot Plaza,  
14/16 avenue Carnot  
FR-91300 Massy  
Tel: +33 238 258 888  
President: Sylvain Touron

**Getinge Infection Control SAS**

30 Boulevard De L'Industrie  
FR-31170 Tournefeuille  
Tel: +33 561 151 111  
President: Sebastien Blanche

**Getinge Life Science**

**France SAS**

1 Rue du Comté de Donegal  
FR-41100 Vendome  
Tel: +33 561 151 111  
President: Julien Albuy-Meyer & Michael Raphael

**LTA Medical**

27 rue Albert Einstein  
FR-93 000 Bobigny  
Tel: +33 766 152 048  
President: Jérôme Polenne

**Intervascular SAS**

270 Voie Ariane - ZI Athélia 1  
FR-13600 La Ciotat  
Tel: +33 442 084 646  
President: Jocelyn Lebrun

**Maquet SAS**

Parc de Limère – Avenue de la Pomme de Pin  
FR-45074 Orléans  
Tel: +33 238 258 888  
President: Jèrome Baron

**Fluoptics SAS**

44 Rue Des Berges  
FR-38000 Grenoble  
Tel: +33 485 870 660  
President: Laurence Baudel-Vanbeek

**Germany**

**Getinge IT Solutions GmbH**

Südportal 5  
DE-22848 Norderstedt  
Tel: +49 4051 435 0  
President: Dr. Matthias Rath

**Getinge Deutschland GmbH**

Kehler Str. 31  
DE-76437 Rastatt  
Tel: +49 7222 932 0  
President: Raghed Hanna

**Irasun GmbH**

Lichtenbergstr. 8  
DE-85748 Garching bei München  
Tel: +49 176 43 6663 46  
President: Fabian König & Florian Altinger

**Maquet Cardiopulmonary GmbH**

Kehler Str. 31  
DE-76437 Rastatt  
Tel: +49 7222 932 0  
President: Dr. Dieter Engel

**Maquet GmbH**

Kehler Str. 31  
DE-76437 Rastatt  
Tel: +49 7222 932 0  
President: Sebastian Hügli

**Getinge Holding B.V. & Co KG**

Kehler Str. 31  
DE-76437 Rastatt  
Tel: +49 7222 932 0  
President: Matthias Gelsok

**Pulsion Medical Systems SE**

Hans-Riedl-Str. 21  
DE-85622 Feldkirchen  
Tel: +49 894 599 140  
President: Stephan Haft

**MediKomp GmbH**

Kehler Str. 31  
DE-76437 Rastatt  
Tel: +49 7222 932 0  
President: Özgür Yildiz

**Getinge Financial Services GmbH**

Kehler Str. 31  
DE-76437 Rastatt  
Tel: +49 7222 932 0  
President: Matthias Gelsok

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

The Getinge share

Multi-year overview

Reconciliation of alternative performance measures

**Group companies**

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

**Hong Kong**

**Getinge Group Hong Kong Ltd**

26/F, Port 33, 33 Tseuk Luk Street  
HK-San Po Kong, Kowloon, Hong Kong  
Tel: +852 2207 6111  
President: CM Leung

**India**

**Getinge Medical India Pvt Ltd**

Times Square Building, 9th floor, E Wing, Mathuradas VasANJI Road, Marol, Andheri East  
IN-400059 Mumbai  
Tel: +91 22 6233 2100  
President: Aruna Nayak

**Getinge India Pvt Ltd**

Times Square Building, 9th floor, E Wing, Mathuradas VasANJI Road, Marol, Andheri East  
IN-400059 Mumbai  
Tel: +91 74 0009 4775  
President: Sunil Dinanath Joshi

**Ireland**

**Getinge Ireland Ltd.**

B6 Calmount Park, Ballymount, Dublin 12  
IE-D12NA03 Dublin  
Tel: +353 1 426 0032  
President: Amy Rothwell

**Italy**

**Getinge Italia Srl**

Via Guido Gozzano, 14  
IT-20092 Cinisello Balsamo (MI)  
Tel: +39 02 611 135 1  
President: Roberto Chareun

**Japan**

**Getinge Group Japan KK**

Sphere Tower Tennoz 7F, 2-2-8 Higashi-shinagawa, Shinagawa-ku  
JP-140-0002 Tokyo  
Tel: +81 3 5463 8310  
President: Yuko Nagasawa

**Mexico**

**Maquet Mexicana, S. de R.L. de C.V.**

Montecito 38, piso 10 ofna 33, Col Nápoles, Alcaldía Benito Juárez  
MX-03810 Mexico City  
Tel: +52 55 9000 8970  
President: Rodrigo Aurelio Garcia

**Netherlands**

**Getinge Netherlands B.V.**

Olympia 4  
NL-1213 NT Hilversum  
Tel: +31 35 303 5000  
President: Raghed Hanna

**Applikon Biotechnology B.V.**

Heertjeslaan 2  
NL-2629 JG Delft  
Tel: +31 10 20 83 555  
President: Eric Goossens

**New Zealand**

**Maquet New Zealand Pty Ltd (Branch)**

Level 2, Building B, 600 Great South Road  
NZ-Auckland 1051  
Tel: +61 1800 438 464  
President: Kartik Natarajan

**Norway**

**Getinge Norge AS**

Enebakkveien 150  
NO-0680 Oslo  
Tel: +47 230 35 200  
President: Magnus Back

**Poland**

**Getinge IC Production Poland Sp. z o.o.**

ul. Szkolna 30  
PL-62-064 Plewiska  
Tel: +48 61 630 99 00  
President: Jakub Cegiela

**Getinge Polska Sp. z o.o.**

ul. Żwirki i Wigury 18  
PL-02-092 Warszawa  
Tel: +48 22 882 06 44  
President: Szymon Kawałko

**Getinge Shared Service Sp. z o.o.**

Powstańców Wielkopolskich 13 F (Budynek D)  
PL-30-707 Kraków  
Tel: +48 12 385 42 22  
President: Agnieszka Obuchowska

**Portugal**

**Getinge Group Portugal Unipessoal Lda**

Edificio Zenith, Rua Dr. Antonio Loureiro Borges nº 9/9ª - 3º andar  
PT-1495-131 Alges Miraflares  
Tel: +351 214 189 815  
President: Marcio Mazon

**Russia**

**Maquet LLC**

Office Park Comcity, 22nd km Kievskoe highway, 6 bld 1  
RU-108811 Moscow  
Tel: +7 495 514 0055  
President: Anna Mednikova

**Saudi Arabia**

**Getinge Regional Headquarter**

Building No: 7793, West Umm Al Hamam District  
SA-12329 Riyadh  
Tel: +966 563 333 417  
President: Georges El Obeid

**Serbia**

**Getinge Group South East Europe d.o.o. Beograd**

Bulevar Vojvode Bojovica 6-8  
RS-11000 Belgrade  
Tel: +420 225 092 302  
President: Jiri Lacina

**Singapore**

**Getinge Singapore Pte. Ltd.**

20 Bendemeer Road #06-04  
BS Bendemeer Centre  
SG-339914 Singapore  
Tel: +65 6 296 1992  
President: Marimuthu Anbuechezian

**Getinge South East Asia Pte. Ltd.**

20 Bendemeer Road #06-01/02  
BS Bendemeer Centre  
SG-339914 Singapore  
Tel: +65 6 296 1992  
President: Teodor Johansson

**South Africa**

**Maquet Southern Africa (Pty) Ltd**

4 Bridle Close, Woodmead  
Office Park, Van Reenen Ave  
ZA-2196 Sandton, Johannesburg  
Tel: +27 11 656 3306  
President: Salah Malek

**South Korea**

**Getinge Medical Korea Co., Ltd.**

13F KeumKang Building, 304, Bongeunsa-ro, Gangnam-gu  
KR-06143 Seoul  
Tel: +82 25 58 2271  
President: Hyun Dong Kim

**Spain**

**Getinge Group Spain SL**

C/Marie Curie 5, edificio Alfa  
Planta 6 Of 6.2  
ES-28521 Rivas Vacia Madrid  
Tel: +34 91 678 1652  
President: Marcio Mazon

**Sweden**

**Getinge AB (publ)**

Lindholmspiren 7A  
SE-417 56 Göteborg  
Tel: +46 10 335 0000  
President: Mattias Perjos

**Getinge Disinfection AB**

Ljungadalsgatan 11  
SE-352 46 Växjö  
Tel: +46 10 335 9800  
President: Jonas Andersson, interim

**Getinge Finance Holding AB**

Lindholmspiren 7A  
SE-417 56 Göteborg  
Tel: +46 10 335 0000  
President: Daniel Bengtsson Iremán

**Getinge Logistics AB**

Ekebergsvägen 26  
SE-305 75 Getinge  
Tel: +46 10 335 0000  
President: Christian Lambrant

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

The Getinge share

Multi-year overview

Reconciliation of alternative performance measures

**Group companies**

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

**Getinge Business Support Services AB**

Lindholmspiren 7A  
SE-417 56 Göteborg  
Tel: +46 10 335 0000  
President: Pelle Nilsson

**Getinge Sterilization AB**

Ekebergsvägen 26  
SE-305 75 Getinge  
Tel: +46 10 335 0000  
President: Maria Ek

**Getinge Sverige AB**

Ekebergsvägen 26  
SE-305 75 Getinge  
Tel: +46 10 335 0000  
President: Magnus Back

**Getinge Treasury AB**

Lindholmspiren 7A  
SE-417 56 Göteborg  
Tel: +46 10 335 0000  
President: Mimmi Lykken Ljungdahl

**Maquet Critical Care AB**

Röntgenvägen 2  
SE-171 54 Solna  
Tel: +46 10 335 7300  
President: Cecilia Sjöstedt

**Switzerland**

**Getinge Schweiz AG**

Quellenstr. 41b  
CH-4310 Rheinfelden  
Tel: +41 61 836 47 70  
President: Raghed Hanna

**Taiwan**

**Getinge Group Taiwan Co., Ltd.**

Rm. 08, 6F., No. 288, Sec. 6, Civic Blvd., Xinyi Dist.  
TW-110417 Taipei City  
Tel: +886 2 8161 6588  
President: Tina Wang

**Thailand**

**Getinge (Thailand) Co., Ltd.**

5 Soi Krungthepkreetha 4 (B.Grimm)  
Huamark, Bangkok  
TH-10240 Bangkok  
Tel: +66 02 704 4388  
President: Kulissara Tunyong

**Türkiye**

**Getinge Medikal Sistemler San. Ve Tic. A.Ş.**

Allianz Plaza Küçükbakkalköy Mah. Kayışdağı Cad. No:1 Kapı no:96  
TR-34752 Ataşehir / Istanbul  
Tel: +90 216 444 66 78  
President: Vecihe Özek

**Maquet Cardiopulmonary**

**Medikal Teknik San.Tic.Ltd.Şti**

Serbest Bölge R  
Ada,108/1,109/1,110/1,111/1  
Parseller 1 Cadde Dış Kapı No:8  
TR-07070 Antalya  
Tel: +90 242 249 90 30  
President: Murat Calik

**United Arab Emirates**

**Getinge Group Middle East FZ-LLC**

1901N, 19th Floor, Dubai Science Park (DSP) Towers-North  
AE-214742 Dubai  
Tel: +971 4 447 0963  
President: Salah Malek

**United Kingdom**

**Getinge IT Solutions Ltd**

Unit 3 St Modwen Park, Andresseway Way, Chaddesden  
GB-DE61 6YH Derby  
Tel: +44 1773 814730  
President: Stéphane Le Roy

**Getinge Ltd**

Unit 3 St Modwen Park, Andresseway Way, Chaddesden  
GB-DE61 6YH Derby  
Tel: +44 1773 814730  
President: Amy Rothwell

**Applikon Biotechnology B.V. (UK Branch)**

Unit 3 St Modwen Park, Andresseway Way, Chaddesden  
GB-DE61 6YH Derby  
Tel: +44 345 337 3306  
President: Eric Goossens

**Quadralene Ltd**

Unit 3 St Modwen Park, Andresseway Way, Chaddesden  
GB-DE61 6YH Derby  
Tel: +44 133 229 2500  
President: Robert Newsome

**US**

**Atrium Medical Corporation**

40 Continental Blvd.  
US-03054, Merrimack, NH  
Tel: +1 603 880 1433  
President: Chad Carlton

**Datascope Corp.**

45 Barbour Pond Drive  
US-07470 Wayne, NJ  
Tel: +1 888 627 8383  
President: Cynthia Hougum

**Steritec Products Mfg. Co., Inc.**

74 Inverness Drive East  
US-80112 Englewood, CO  
Tel: +1 303 660 4201  
President: Bryan Leo

**Getinge Group Logistics Americas, LLC**

45 Barbour Pond Drive  
US-07470 Wayne, NJ  
Tel: +1 551 427 1052  
President: Frank Kozar

**Getinge Aseptic Solutions, LCC**

201 Housatonic Avenue  
US-06776 Milford, CT  
Tel: +1 860 350 1900  
President: Benoit Portier

**Paragonix Technologies, Inc.**

950 Winter Street, 2nd Floor  
US-02451 Waltham, MA  
Tel: +1 781 428 4153  
President: Lisa Anderson

**Talis Clinical LLC**

650 Mondial Parkway  
US-44241 Streetsboro, OH  
Tel: +1 234 284 2400  
President: Gary Colister

**Getinge USA Sales, LLC**

45 Barbour Pond Drive  
US-07470 Wayne, NJ  
Tel: +1 973 709 7000  
President: Patricia Fitch

**Maquet Cardiovascular LLC**

45 Barbour Pond Drive  
US-07470 Wayne, NJ  
Tel: +1 973 709 7000  
President: Cynthia Hougum

**Ultra Clean Systems Inc.**

110 Douglas Road East  
US-34677 Oldsmar, FL  
Tel: +1 727 512 9576  
President: Christopher Devlin

**High Purity New England Inc.,**

2 Thurber Blvd.  
US-02917 Smithfield, RI  
Tel: +1 401 349 4477  
President: Sean Herdlein

**Healthmark Industries Co., Inc.**

18600 Maylyn Blvd.  
US-48026-3496 Fraser, MI  
Tel: +1 800 521 6224  
President: Steven Basile

**Vietnam**

**Getinge Vietnam Company Ltd**

Floor 6, Yoco Building,  
41 Nguyen Thi Minh Khai,  
Ben Nghe Ward, District 1  
VN-Ho Chi Minh City  
Tel: +84 28 3824 3391  
President: Teodor Johansson

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

The Getinge share

Multi-year overview

Reconciliation of alternative performance measures

Group companies

**Definitions**

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

# Definitions

**Financial terms**

**Adjusted EBIT:** Operating profit (EBIT) with add-back of acquisition and restructuring costs and other items affecting comparability.

**Adjusted EBITA:** EBITA with add-back of acquisition and restructuring costs and other items affecting comparability.

**Adjusted EBITDA:** EBITDA with add-back of acquisition and restructuring costs and other items affecting comparability.

**Adjusted earnings per share:** Adjusted net profit for the year attributable to Parent Company's shareholders in relation to average number of outstanding shares.

**Adjusted gross profit:** Gross profit with add-back of depreciation, amortization and write-downs and other items affecting comparability.

**Adjusted net profit:** Net profit for the year with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs, other items affecting comparability and tax effect of add-back of income statement items.

**Adjusted profit before tax:** Profit before tax with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs and other items affecting comparability.

**Capital goods:** Durable products that are not consumed when used.

**Cash flow per share:** Cash flow from operating activities divided by the average number of outstanding shares.

**Currency transaction effect:** Exchange of current year's volumes of foreign currency at this year's exchange rates, compared with the exchange rates in the preceding year.

**Dividend yield:** Dividend in relation to the market share price on December 31.

**Earnings per share:** Net profit for the year attributable to Parent Company's shareholders in relation to average number of outstanding shares.

**EBIT:** Operating profit.

**EBITA:** Operating profit (EBIT) with add-back of amortization and write-down of acquired intangible assets.

**EBITA margin:** EBITA in relation to net sales.

**EBITDA:** Operating profit (EBIT) with add-back of amortization, depreciation and write-downs.

**EBITDA margin:** EBITDA in relation to net sales.

**Equity/assets ratio:** Equity in relation to total assets.

**Equity per share:** Equity in relation to the number of outstanding shares at the end of the period.

**Gross margin:** Gross profit in relation to net sales.

**Interest-coverage ratio:** Adjusted EBITDA in relation to net interest.

**Items affecting comparability:** Comprises acquisition and restructuring costs and other items affecting comparability. Other items affecting comparability are significant revenue/expenses that impact comparability between accounting periods. These items include, but are not limited to, write-downs, disputes and major gains and losses attributable to divestments of assets or businesses.

**Net debt/equity ratio:** Net interest-bearing debt in relation to equity.

**Operating capital:** Average total assets with add-back of cash and cash equivalents, other provisions, accounts payable and other non-interest-bearing liabilities.

**Operating liabilities:** Accounts payable, other provisions and other non-interestbearing liabilities (contract liabilities, non-interest-bearing provisions for pensions, accrued expenses and deferred income as well as other liabilities).

**Operating margin:** Operating profit (EBIT) in relation to net sales.

**Operating receivables:** Accounts receivable and other current receivables (contract assets, prepaid expenses and accrued income, and other receivables).

**Organic change:** A financial change adjusted for currency, acquisitions and divestment of operations.

**P/E ratio:** Share price (final price) in relation to earnings per share.

**Recurring revenue:** Products that are continuously consumed as well as service, spare parts and similar items.

**Return on equity:** Profit after tax in relation to average equity.

**Return on operating capital:** Adjusted EBIT in relation to operating capital.

**Introduction**

**Strategy**

**Corporate Governance Report**

**Financial statements**

**Sustainability Report**

**Other information**

The Getinge share

Multi-year overview

Reconciliation of alternative performance measures

Group companies

**Definitions**

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

**Sustainability terms**

**Double materiality assessment:** The process of identifying an organization's impacts on people and the environment and the sustainability-related financial risks and opportunities for the organization. The results are also used to determine whether a sustainability topic is to be included in the company's sustainability report.

**ESRS:** European Sustainability Reporting Standards.

**Employee engagement:** The engagement score in Getinge's employee survey.

**Online customer training:** The number of training courses held for customers. The total number of times a customer has completed an e-learning course or participated in a training webinar.

**REC (Renewable Energy Certificates):** Used to certify that electricity was generated from renewable sources.

**Scope 1 & 2:** Carbon emissions from production (in ton CO<sub>2</sub> equivalents). Scope 1 includes emissions from oil and gas consumption and emissions from Getinge's vehicle fleet. Scope 2 includes emissions from electricity, heating, cooling and emissions from leased spaces.

**Medical terms**

**Anesthesia:** A procedure where patients are put into a state of unconsciousness so that they do not feel pain during, for example, surgery.

**Aseptic handling:** Refers to a controlled process where a product undergoes disinfection in a washer and is stored and handled as to maintain its level of purity.

**Bioreactor:** A container used for the development and production of biopharmaceuticals and food.

**Cardiopulmonary:** Something that relates to or belongs to both the heart and lungs.

**Cardiovascular:** Pertaining or belonging to both heart and blood vessels.

**DPTE-BetaBag:** A bag that ensures contamination-free transfer of components.

**ECMO:** Extracorporeal membrane oxygenation, meaning oxygenation outside the body through a membrane. Put simply, a modified cardiac and respiratory machine that exchanges oxygen and carbon dioxide, like an artificial lung.

**Endoscope:** Equipment for visual examination of the body's cavities, such as the stomach.

**Endovascular:** Vascular treatment using catheter technologies.

**GMP:** Good Manufacturing Practice is an international guideline for production and quality assurance in the pharmaceutical industry.

**Graft:** Artificial vascular implant.

**Hemodynamic monitoring:** Monitoring the balance between blood pressure and blood flow.

**Isolator:** Sterile space for antiseptic handling of, for example, pharmaceuticals.

**Low-temperature sterilization:** A device used to sterilize surgical instruments which cannot be sterilized with high temperature steam. It is mainly used for instruments used in minimal invasive surgery.

**Monoclonal antibodies:** Identical antibodies derived from a single cell.

**Stent:** A tube for endovascular widening of blood vessels.

**Sterilizer:** A device to eliminate microorganisms on surgical instruments, usually by high temperature with steam.

**Vascular intervention:** A medical procedure conducted through vascular puncturing instead of using an open surgery method.

**Ventilator:** Medical device to help patients breathe.

**Washer:** Machine that cleans and disinfects medical equipment.

**Geographic areas**

**Americas:** North, South and Central America.

**APAC:** Asia and Pacific (excluding Middle East).

**EMEA:** Europe, Middle East and Africa.

Introduction

Strategy

Corporate Governance Report

Financial statements

Sustainability Report

Other information

The Getinge share

Multi-year overview

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

# Annual General Meeting and Nomination Committee

## Annual General Meeting

The Annual General Meeting will be held on April 22, 2025, in Kongresshallen at Hotel Tylösand, Halmstad, Sweden. Detailed information about participation and postal voting is available on the company's website, <https://www.getinge.com/int/company/corporate-governance/general-meetings/annual-general-meeting-2025/>.

## Registration

Shareholders wishing to participate at the Annual General Meeting must:

- be recorded in the share register kept by Euroclear Sweden AB on April 10, 2025, and
- notify the company of their intention to participate not later than April 14, 2025

Shareholders who wish to participate in person may register in the following ways:

- On Getinge's website: <https://www.getinge.com/int/company/corporate-governance/general-meetings/annual-general-meeting-2025/>.
- By post to:  
Getinge AB (publ)  
"AGM 2025"  
c/o Euroclear Sweden AB  
PO Box 191, SE-101 23 Stockholm, Sweden
- By telephone: +46 (0) 10 335 08 18  
(weekdays between 9:00 a.m.–4:00 p.m.)

Shareholders who wish to participate in the Annual General Meeting by postal vote should cast their postal vote in accordance with instructions available on Getinge's website, <https://www.getinge.com/int/company/corporate-governance/general-meetings/annual-general-meeting-2025/>.

## Nominee-registered shares

Shareholders whose shares are registered in the name of a nominee through a bank or other nominee must be entered in their own name in the share register maintained by Euroclear Sweden AB on April 10, 2025 in order to be entitled to participate in the AGM. Shareholder must inform the nominee well in advance of this date.

For shareholders represented by proxy, power of attorney must be issued, which should be sent before the AGM. A proxy form can be downloaded from <https://www.getinge.com/int/company/corporate-governance/general-meetings/annual-general-meeting-2025/>. Anyone representing a legal entity must show a certified copy of the registration certificate or equivalent authorization documents stating the authorized signatory.

## Nomination Committee

Getinge AB's interim report for the third quarter of 2024 contained instructions for shareholders on how to proceed to submit proposals to Getinge's Nomination Committee and how to propose motions to be addressed at the Annual General Meeting.

## Dividend

The Board of Directors and CEO propose that a dividend of SEK 4.60 (4.40) per share, a combined total of SEK 1,253 M (1,198), shall be paid for 2024.

The proposed record date is April 24, 2025. Euroclear Sweden AB expects to distribute the dividend to shareholders on April 29, 2025.

# Financial information

Updated information on, for example, the Getinge share and corporate governance is available on Getinge's website [www.getinge.com](http://www.getinge.com).

The Annual Report, year-end report and interim reports are published in Swedish and English and are available for download at [www.getinge.com](http://www.getinge.com). A printed copy of the Annual Report can also be ordered at [www.getinge.com](http://www.getinge.com).

## Financial information

Preliminary dates for financial information are as follows:

- April 22, 2025: Q1 Report 2025
- April 22, 2025: Annual General Meeting
- July 18, 2025: Q2 Report 2025
- October 21, 2025: Q3 Report 2025
- January 27, 2026: Q4 Report 2025
- March 2026: 2025 Annual Report

**Introduction****Strategy****Corporate Governance Report****Financial statements****Sustainability Report****Other information**

The Getinge share

Multi-year overview

Reconciliation of alternative  
performance measures

Group companies

Definitions

Annual General Meeting and  
Nomination Committee

Financial information

**Reading guide and distribution policy****Contact**

# Reading guide and distribution policy

**Reading guide**

- The Getinge Group is referred to as Getinge in the Annual Report.
- Figures in parentheses pertain to operations in 2023, unless otherwise specified.
- Swedish kronor (SEK) is used throughout (sometimes abbreviated as SEK or kr).
- Millions of Swedish kronor are abbreviated SEK M.
- All figures pertain to SEK M, unless otherwise specified.
- For practical reasons, numbers are rounded off in the Annual Report, therefore it can occur that notes and tables do not sum up.
- Information provided in the Annual Report concerning markets, competition and future growth constitutes Getinge's assessment based on both external information and material compiled internally.

**Distribution policy**

The Annual Report is available for download at [www.getinge.com](http://www.getinge.com). A printed version of the report can also be ordered from the website. The decision not to automatically send a printed version to the company's shareholders is based on the ambition to reduce Getinge's negative impact on the environment.

# Contact

Getinge AB (publ)  
Lindholmspiren 7A  
P.O. Box 8861  
SE-402 72, Gothenburg  
Sweden

Tel: +46 (0)10 335 00 00  
E-mail: [info@getinge.com](mailto:info@getinge.com)  
[www.getinge.com](http://www.getinge.com)



Getinge AB (publ)  
Lindholmspiren 7A  
P.O. Box 8861  
SE-402 72, Gothenburg  
Sweden

Tel: +46 (0)10 335 00 00  
E-mail: [info@getinge.com](mailto:info@getinge.com)  
[www.getinge.com](http://www.getinge.com)